CATH Search:   
       by CATH code, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Mainly Beta (13760)
(-)
Architecture: Sandwich (5577)
(-)
Topology: Immunoglobulin-like (3897)
(-)
Homologous Superfamily: Immunoglobulins (2282)
(-)
[unclassified] (54)
1A02N:570-678STRUCTURE OF THE DNA BINDING DOMAINS OF NFAT, FOS AND JUN BOUND TO DNA
1A3QA:225-322; B:225-322HUMAN NF-KAPPA-B P52 BOUND TO DNA
1EHLL:110-209; H:1-113; L:1-108; H:114-22664M-2 ANTIBODY FAB COMPLEXED WITH D(5HT)(6-4)T
1F3RB:1-123; B:124-222COMPLEX BETWEEN FV ANTIBODY FRAGMENT AND AN ANALOGUE OF THE MAIN IMMUNOGENIC REGION OF THE ACETYLCHOLINE RECEPTOR
1GJIA:182-275; B:182-275CRYSTAL STRUCTURE OF C-REL BOUND TO DNA
1HYSC:108-211; D:1-123; C:1-107; D:124-220CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH A POLYPURINE TRACT RNA:DNA
1I8MA:109-213; B:1-113; H:1-113; A:1-108; L:1-108; L:109-213; B:114-212; H:114-212CRYSTAL STRUCTURE OF A RECOMBINANT ANTI-SINGLE-STRANDED DNA ANTIBODY FRAGMENT COMPLEXED WITH DT5
1IKFL:109-211; H:1-127; L:1-108; H:128-227A CONFORMATION OF CYCLOSPORIN A IN AQUEOUS ENVIRONMENT REVEALED BY THE X-RAY STRUCTURE OF A CYCLOSPORIN-FAB COMPLEX
1IMHC:363-468; D:363-468TONEBP/DNA COMPLEX
1J5OL:108-211; H:1-123; L:1-107; H:124-220CRYSTAL STRUCTURE OF MET184ILE MUTANT OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DOUBLE STRANDED DNA TEMPLATE-PRIMER
1KEGL:110-209; H:1-113; L:1-108; H:114-226ANTIBODY 64M-2 FAB COMPLEXED WITH DTT(6-4)TT
1LE5A:191-285; E:191-285; B:246-350; F:246-350CRYSTAL STRUCTURE OF A NF-KB HETERODIMER BOUND TO AN IFNB-KB
1LE9A:191-285; E:191-285; B:246-350; F:246-350CRYSTAL STRUCTURE OF A NF-KB HETERODIMER BOUND TO THE IG/HIV-KB SITI
1LEIA:191-285; B:246-350THE KB DNA SEQUENCE FROM THE HLV-LTR FUNCTIONS AS AN ALLOSTERIC REGULATOR OF HIV TRANSCRIPTION
1N5YL:108-211; H:1-123; L:1-107; H:124-220HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO POST-TRANSLOCATION AZTMP-TERMINATED DNA (COMPLEX P)
1N6QL:108-211; H:1-123; L:1-107; H:124-220HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO PRE-TRANSLOCATION AZTMP-TERMINATED DNA (COMPLEX N)
1NEZB:1-99; H:1-120; G:4-125; A:182-274THE CRYSTAL STRUCTURE OF A TL/CD8AA COMPLEX AT 2.1A RESOLUTION:IMPLICATIONS FOR MEMORY T CELL GENERATION, CO-RECEPTOR PREFERENCE AND AFFINITY
1NFKA:246-350; B:246-350STRUCTURE OF THE NUCLEAR FACTOR KAPPA-B (NF-KB) P50 HOMODIMER
1OOAA:246-350; B:246-350CRYSTAL STRUCTURE OF NF-KB(P50)2 COMPLEXED TO A HIGH-AFFINITY RNA APTAMER
1OWRM:570-678; N:570-678; P:570-678; Q:570-678CRYSTAL STRUCTURE OF HUMAN NFAT1 BOUND MONOMERICALLY TO DNA
1P7HL:570-676; N:570-676; M:570-678; O:570-678STRUCTURE OF NFAT1 BOUND AS A DIMER TO THE HIV-1 LTR KB ELEMENT
1PZUB:570-678; D:570-678; I:570-678; L:570-678; M:570-678; H:570-676AN ASYMMETRIC NFAT1-RHR HOMODIMER ON A PSEUDO-PALINDROMIC, KAPPA-B SITE
1R0AL:108-211; H:1-123; L:1-107; H:124-220CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COVALENTLY TETHERED TO DNA TEMPLATE-PRIMER SOLVED TO 2.8 ANGSTROMS
1RAMA:191-285; B:191-285A NOVEL DNA RECOGNITION MODE BY NF-KB P65 HOMODIMER
1S9KC:570-678CRYSTAL STRUCTURE OF HUMAN NFAT1 AND FOS-JUN ON THE IL-2 ARRE1 SITE
1SVCP:249-353NFKB P50 HOMODIMER BOUND TO DNA
1T03L:108-211; H:1-123; L:1-107; H:124-220HIV-1 REVERSE TRANSCRIPTASE CROSSLINKED TO TENOFOVIR TERMINATED TEMPLATE-PRIMER (COMPLEX P)
1TTUA:563-660CRYSTAL STRUCTURE OF CSL BOUND TO DNA
1VKXA:191-285; B:546-650CRYSTAL STRUCTURE OF THE NFKB P50/P65 HETERODIMER COMPLEXED TO THE IMMUNOGLOBULIN KB DNA
1XCQA:115-217; A:1-114; C:1-114; E:1-114; G:1-114; B:1-118; D:1-118; F:1-118; H:1-118; C:115-217; E:115-217; G:115-217; B:119-217; D:119-217; F:119-217; H:119-217COMPLEX HCV CORE-FAB 19D9D6-PROTEIN L MUTANT (D55A,L57H,Y64W) IN SPACE GROUP P21
1XCTA:115-217; A:1-114; C:1-114; B:1-118; D:1-118; C:115-217; B:119-217; D:119-217COMPLEX HCV CORE-FAB 19D9D6-PROTEIN L MUTANT (D55A, L57H, Y64W) IN SPACE GROUP P21212
1XF5A:115-217; A:1-114; C:1-114; C:115-217; B:1-118; D:1-118; B:119-217; D:119-217COMPLEX HCV CORE-FAB 19D9D6-PROTEIN L MUTANT (H74C, Y64W)IN SPACE GROUP P21212
1ZA3A:108-213; B:114-214; H:114-214; B:1-113; H:1-113; L:108-213; A:1-107; L:1-107THE CRYSTAL STRUCTURE OF THE YSD1 FAB BOUND TO DR5
2AS5M:570-678; N:570-678STRUCTURE OF THE DNA BINDING DOMAINS OF NFAT AND FOXP2 BOUND SPECIFICALLY TO DNA.
2BDNL:109-211; H:1-117; L:1-108; H:118-214CRYSTAL STRUCTURE OF HUMAN MCP-1 BOUND TO A BLOCKING ANTIBODY, 11K2
2C4FU:91-210; T:6-80CRYSTAL STRUCTURE OF FACTOR VII.STF COMPLEXED WITH PD0297121
2F8XC:341-434CRYSTAL STRUCTURE OF ACTIVATED NOTCH, CSL AND MAML ON HES-1 PROMOTER DNA SEQUENCE
2FO1A:563-663CRYSTAL STRUCTURE OF THE CSL-NOTCH-MASTERMIND TERNARY COMPLEX BOUND TO DNA
2FR4A:109-213; B:1-113; H:1-113; L:109-213; L:2-108; A:1-108; B:114-212; H:114-212STRUCTURE OF FAB DNA-1 COMPLEXED WITH A STEM-LOOP DNA LIGAND
2HMIC:108-211; D:1-123; C:1-107; D:124-220HIV-1 REVERSE TRANSCRIPTASE/FRAGMENT OF FAB 28/DNA COMPLEX
2HWZL:108-213; H:114-212; H:1-113; L:4-107FAB FRAGMENT OF HUMANIZED ANTI-VIRAL ANTIBODY MEDI-493 (SYNAGIS TM)
2I9TA:191-285; B:546-650STRUCTURE OF NF-KB P65-P50 HETERODIMER BOUND TO PRDII ELEMENT OF B-INTERFERON PROMOTER
2J8UB:0-99; I:0-99; F:3-117; M:3-117; F:118-245; M:118-245; E:1-116; L:1-116; A:182-270; H:182-270LARGE CDR3A LOOP ALTERATION AS A FUNCTION OF MHC MUTATION.
2O61B:246-350CRYSTAL STRUCTURE OF NFKB, IRF7, IRF3 BOUND TO THE INTERFERON-B ENHANCER
2O93L:570-676; M:570-678; O:570-678CRYSTAL STRUCTURE OF NFAT BOUND TO THE HIV-1 LTR TANDEM KAPPAB ENHANCER ELEMENT
2R0LL:109-214; H:114-216; H:1-113; L:1-108SHORT FORM HGFA WITH INHIBITORY FAB75
2R8SL:109-214; H:122-221; H:1-121; L:1-108HIGH RESOLUTION STRUCTURE OF A SPECIFIC SYNTHETIC FAB BOUND TO P4-P6 RNA RIBOZYME DOMAIN
2RAMA:191-285; B:191-283A NOVEL DNA RECOGNITION MODE BY NF-KB P65 HOMODIMER
2V7NA:150-253; B:150-249; D:150-249; F:150-249; H:150-249; B:2-149; F:2-149; H:2-149; D:1-149; E:150-253; C:150-252; G:150-252; A:1-149; C:1-149; E:1-149; G:1-149UNUSUAL TWINNING IN CRYSTALS OF THE CITS BINDING ANTIBODY FAB FRAGMENT F3P4
2WLYA:24-130CHITINASE A FROM SERRATIA MARCESCENS ATCC990 IN COMPLEX WITH CHITOTRIO-THIAZOLINE.
3IAGC:381-474CSL (RBP-JK) BOUND TO HES-1 NONCONSENSUS SITE
3IU3B:106-208; A:116-215; C:116-215; H:116-215; D:106-208; L:106-208; A:1-115; C:1-115; H:1-115CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THERAPEUTIC ANTIBODY BASILIXIMAB IN COMPLEX WITH IL-2RA (CD25) ECTODOMAIN
3L95A:109-212; B:114-214; H:114-213; B:1-113; H:1-113; L:109-212CRYSTAL STRUCTURE OF THE HUMAN NOTCH1 NEGATIVE REGULATORY REGION (NRR) BOUND TO THE FAB FRAGMENT OF AN ANTAGONIST ANTIBODY
(-)
1011 (Bacillus sp) (10)
1D7FA:583-685; A:496-582; B:496-582; B:583-685CRYSTAL STRUCTURE OF ASPARAGINE 233-REPLACED CYCLODEXTRIN GLUCANOTRANSFERASE FROM ALKALOPHILIC BACILLUS SP. 1011 DETERMINED AT 1.9 A RESOLUTION
1DEDA:583-685; A:496-582; B:496-582; B:583-685CRYSTAL STRUCTURE OF ALKALOPHILIC ASPARAGINE 233-REPLACED CYCLODEXTRIN GLUCANOTRANSFERASE COMPLEXED WITH AN INHIBITOR, ACARBOSE, AT 2.0 A RESOLUTION
1PAMA:583-685; B:583-685; A:496-582; B:496-582CYCLODEXTRIN GLUCANOTRANSFERASE
1UKQA:583-685; A:496-582; B:496-582; B:583-685CRYSTAL STRUCTURE OF CYCLODEXTRIN GLUCANOTRANSFERASE COMPLEXED WITH A PSEUDO-MALTOTETRAOSE DERIVED FROM ACARBOSE
1UKSA:583-685; A:496-582; B:496-582; B:583-685CRYSTAL STRUCTURE OF F183L/F259L MUTANT CYCLODEXTRIN GLUCANOTRANSFERASE COMPLEXED WITH A PSEUDO-MALTOTETRAOSE DERIVED FROM ACARBOSE
1UKTA:583-685; B:583-685; A:496-582; B:496-582CRYSTAL STRUCTURE OF Y100L MUTANT CYCLODEXTRIN GLUCANOTRANSFERASE COMPEXED WITH AN ACARBOSE
1V3JA:583-685; B:583-685; A:496-582; B:496-582CRYSTAL STRUCTURE OF F283L MUTANT CYCLODEXTRIN GLYCOSYLTRANSFERASE
1V3KA:583-685; B:583-685; A:496-582; B:496-582CRYSTAL STRUCTURE OF F283Y MUTANT CYCLODEXTRIN GLYCOSYLTRANSFERASE
1V3LA:583-685; B:583-685; A:496-582; B:496-582CRYSTAL STRUCTURE OF F283L MUTANT CYCLODEXTRIN GLYCOSYLTRANSFERASE COMPLEXED WITH A PSEUDO-TETRAOSE DERIVED FROM ACARBOSE
1V3MA:583-685; B:583-685; A:496-582; B:496-582CRYSTAL STRUCTURE OF F283Y MUTANT CYCLODEXTRIN GLYCOSYLTRANSFERASE COMPLEXED WITH A PSEUDO-TETRAOSE DERIVED FROM ACARBOSE
(-)
2457t (Shigella flexneri 2a str) (4)
2B20A:3-144CRYSTAL STRUCTURE OF ENTEROCHELIN ESTERASE FROM SHIGELLA FLEXNERI ENTEROCHELIN ESTERASE
3C87B:4-144; A:4-144CRYSTAL STRUCTURE OF THE ENTEROBACTIN ESTERASE FES FROM SHIGELLA FLEXNERI IN THE PRESENCE OF ENTEROBACTIN
3C8DA:6-144; B:7-144; C:6-144; D:6-144CRYSTAL STRUCTURE OF THE ENTEROBACTIN ESTERASE FES FROM SHIGELLA FLEXNERI IN THE PRESENCE OF 2,3-DI-HYDROXY-N-BENZOYL-GLYCINE
3C8HA:6-144; B:6-144; C:6-144; D:6-144CRYSTAL STRUCTURE OF THE ENTEROBACTIN ESTERASE FES FROM SHIGELLA FLEXNERI IN THE PRESENCE OF 2,3-DI-HYDROXY-N-BENZOYL-SERINE
(-)
2_ (6)
1B2WL:108-211; L:1-107; H:2-117; H:118-215COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF A HUMANIZED AND A CHIMERIC FAB OF AN ANTI-GAMMA-INTERFERON ANTIBODY
1FGVL:1-107; H:1-124X-RAY STRUCTURES OF FRAGMENTS FROM BINDING AND NONBINDING VERSIONS OF A HUMANIZED ANTI-CD18 ANTIBODY: STRUCTURAL INDICATIONS OF THE KEY ROLE OF VH RESIDUES 59 TO 65
1MCLA:2-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
2FGWL:109-211; H:1-125; L:1-108; H:126-227X-RAY STRUCTURES OF FRAGMENTS FROM BINDING AND NONBINDING VERSIONS OF A HUMANIZED ANTI-CD18 ANTIBODY: STRUCTURAL INDICATIONS OF THE KEY ROLE OF VH RESIDUES 59 TO 65
(-)
92 (Flavobacterium sp) (5)
3EDDA:3-92; B:3-92STRUCTURAL BASE FOR CYCLODEXTRIN HYDROLYSIS
3EDEA:3-92; B:3-92STRUCTURAL BASE FOR CYCLODEXTRIN HYDROLYSIS
3EDFA:3-92; B:3-92STRUCTURAL BASE FOR CYCLODEXTRIN HYDROLYSIS
3EDJA:3-92; B:3-92STRUCTURAL BASE FOR CYCLODEXTRIN HYDROLYSIS
3EDKA:3-92; B:3-92STRUCTURAL BASE FOR CYCLODEXTRIN HYDROLYSIS
(-)
A/viet nam/1203/2004(h5n1) (Influenza a virus (a/viet nam/1203/2004(h5n1))) (1)
3GBMH:114-227; I:114-223; H:1-113; I:1-113; L:108-213; M:106-211CRYSTAL STRUCTURE OF FAB CR6261 IN COMPLEX WITH A H5N1 INFLUENZA VIRUS HEMAGGLUTININ.
(-)
Aequorea victoria. Organism_taxid: 6100. (1)
3K1KC:1-112; D:1-113GREEN FLUORESCENT PROTEIN BOUND TO ENHANCER NANOBODY
(-)
Aeropyrum pernix. Organism_taxid: 56636. (1)
2A0LC:1-105; E:1-105; D:1-116; F:1-116CRYSTAL STRUCTURE OF KVAP-33H1 FV COMPLEX
(-)
Arabian camel (Camelus dromedarius) (15)
1F2XK:801-926; L:1002-1127STRUCTURE OF THE SINGLE-DOMAIN CAMELID ANTIBODY CAB-CA05
1JTOA:2-133; B:2-133DEGENERATE INTERFACES IN ANTIGEN-ANTIBODY COMPLEXES
1JTPB:1-133; A:1-135DEGENERATE INTERFACES IN ANTIGEN-ANTIBODY COMPLEXES
1JTTA:1-133DEGENERATE INTERFACES IN ANTIGEN-ANTIBODY COMPLEXES
1MELA:2-133; B:2-133CRYSTAL STRUCTURE OF A CAMEL SINGLE-DOMAIN VH ANTIBODY FRAGMENT IN COMPLEX WITH LYSOZYME
1MVFB:3-126; A:1-127MAZE ADDICTION ANTIDOTE
1OP9A:1-121COMPLEX OF HUMAN LYSOZYME WITH CAMELID VHH HL6 ANTIBODY FRAGMENT
1RI8A:2-125CRYSTAL STRUCTURE OF THE CAMELID SINGLE DOMAIN ANTIBODY 1D2L19 IN COMPLEX WITH HEN EGG WHITE LYSOZYME
1RJCA:2-127CRYSTAL STRUCTURE OF THE CAMELID SINGLE DOMAIN ANTIBODY CAB-LYS2 IN COMPLEX WITH HEN EGG WHITE LYSOZYME
1XFPA:2-132CRYSTAL STRUCTURE OF THE CDR2 GERMLINE REVERSION MUTANT OF CAB-LYS3 IN COMPLEX WITH HEN EGG WHITE LYSOZYME
1YC7A:2-117; B:2-118CABAN33 VHH FRAGMENT AGAINST VSG
1YC8B:2-117; A:1-117CABAN33- Y37V/E44G/R45L TRIPLE MUTANT
1YZZA:1-117; B:1-117HUMANIZED CABAN33 AT ROOM TEMPERATURE
1ZMYA:1-133CABBCII-10 VHH FRAMEWORK WITH CDR LOOPS OF CABLYS3 GRAFTED ON IT AND IN COMPLEX WITH HEN EGG WHITE LYSOZYME
1ZVYA:1-125CRYSTAL STRUCTURE OF THE VHH D3-L11 IN COMPLEX WITH HEN EGG WHITE LYSOZYME
(-)
Archaeoglobus fulgidus dsm 4304. Organism_taxid: 224325. Strain: dsm 4304, vc-16, jcm 9628, nbrc 100126. (1)
3BUTA:0-125CRYSTAL STRUCTURE OF PROTEIN AF_0446 FROM ARCHAEOGLOBUS FULGIDUS
(-)
Aspergillus niger. Organism_taxid: 5061. Strain: ab4.1. (2)
1KULA:509-616GLUCOAMYLASE, GRANULAR STARCH-BINDING DOMAIN, NMR, 5 STRUCTURES
1KUMA:509-616GLUCOAMYLASE, GRANULAR STARCH-BINDING DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
(-)
Aspergillus niger. Organism_taxid: 5061. Strain: ab4.1. (2)
1AC0A:509-616GLUCOAMYLASE, GRANULAR STARCH-BINDING DOMAIN COMPLEX WITH CYCLODEXTRIN, NMR, MINIMIZED AVERAGE STRUCTURE
1ACZA:509-616GLUCOAMYLASE, GRANULAR STARCH-BINDING DOMAIN COMPLEX WITH CYCLODEXTRIN, NMR, 5 STRUCTURES
(-)
Aureus nctc 8325 (Staphylococcus aureus subsp) (1)
1FC2D:338-443; D:238-337CRYSTALLOGRAPHIC REFINEMENT AND ATOMIC MODELS OF A HUMAN FC FRAGMENT AND ITS COMPLEX WITH FRAGMENT B OF PROTEIN A FROM STAPHYLOCOCCUS AUREUS AT 2.9-AND 2.8-ANGSTROMS RESOLUTION
(-)
Bacillus cereus. Organism_taxid: 1396. (7)
1B90A:417-516BACILLUS CEREUS BETA-AMYLASE APO FORM
1B9ZA:417-516BACILLUS CEREUS BETA-AMYLASE COMPLEXED WITH MALTOSE
1CQYA:418-516STARCH BINDING DOMAIN OF BACILLUS CEREUS BETA-AMYLASE
1VEMA:417-516CRYSTAL STRUCTURE ANALYSIS OF BACILLUS CEREUS BETA-AMYLASE AT THE OPTIMUM PH (6.5)
1VENA:417-516CRYSTAL STRUCTURE ANALYSIS OF Y164E/MALTOSE OF BACILUS CEREUS BETA-AMYLASE AT PH 4.6
1VEOA:417-516CRYSTAL STRUCTURE ANALYSIS OF Y164F/MALTOSE OF BACILLUS CEREUS BETA-AMYLASE AT PH 4.6
1VEPA:417-516CRYSTAL STRUCTURE ANALYSIS OF TRIPLE (T47M/Y164E/T328N) /MALTOSE OF BACILLUS CEREUS BETA-AMYLASE AT PH 6.5
(-)
Bacillus cereus. Organism_taxid: 1396. Strain: bacillus cereus. Variant: mycoides. (1)
5BCAA:417-516; B:417-516; C:417-516; D:417-516BETA-AMYLASE FROM BACILLUS CEREUS VAR. MYCOIDES
(-)
Bacillus cereus. Organism_taxid: 1396. Strain: var. Mycoides (5)
1J0YA:417-516; B:417-516; C:417-516; D:417-516BETA-AMYLASE FROM BACILLUS CEREUS VAR. MYCOIDES IN COMPLEX WITH GLUCOSE
1J0ZA:417-516; B:417-516; C:417-516; D:417-516BETA-AMYLASE FROM BACILLUS CEREUS VAR. MYCOIDES IN COMPLEX WITH MALTOSE
1J10A:417-516; C:417-516; D:417-516; B:417-516BETA-AMYLASE FROM BACILLUS CEREUS VAR. MYCOIDES IN COMPLEX WITH GGX
1J11A:417-516; B:417-516; C:417-516; D:417-516BETA-AMYLASE FROM BACILLUS CEREUS VAR. MYCOIDES IN COMPLEX WITH ALPHA-EPG
1J12A:417-516; B:417-516; C:417-516; D:417-516BETA-AMYLASE FROM BACILLUS CEREUS VAR. MYCOIDES IN COMPLEX WITH ALPHA-EBG
(-)
Bacillus cereus. Organism_taxid: 1396. Strain: var. Mycoides. (1)
1J18A:417-516CRYSTAL STRUCTURE OF A BETA-AMYLASE FROM BACILLUS CEREUS VAR. MYCOIDES COCRYSTALLIZED WITH MALTOSE
(-)
Bacillus cereus. Organism_taxid: 1396. Strain: var.mycoides. (1)
1ITCA:417-516BETA-AMYLASE FROM BACILLUS CEREUS VAR. MYCOIDES COMPLEXED WITH MALTOPENTAOSE
(-)
Bacillus circulans. Organism_taxid: 1397 (7)
1CDGA:583-685; A:496-582NUCLEOTIDE SEQUENCE AND X-RAY STRUCTURE OF CYCLODEXTRIN GLYCOSYLTRANSFERASE FROM BACILLUS CIRCULANS STRAIN 251 IN A MALTOSE-DEPENDENT CRYSTAL FORM
1CGTA:581-684; A:495-580STRUCTURE OF CYCLODEXTRIN GLYCOSYLTRANSFERASE REFINED AT 2.0 ANGSTROMS RESOLUTION
1CGUA:581-684; A:495-580CATALYTIC CENTER OF CYCLODEXTRIN GLYCOSYLTRANSFERASE DERIVED FROM X-RAY STRUCTURE ANALYSIS COMBINED WITH SITE-DIRECTED MUTAGENESIS
1CGVA:583-685; A:496-582SITE DIRECTED MUTATIONS OF THE ACTIVE SITE RESIDUE TYROSINE 195 OF CYCLODEXTRIN GLYCOSYLTRANSFERASE FROM BACILLUS CIRCULANS STRAIN 251 AFFECTING ACTIVITY AND PRODUCT SPECIFICITY
1CGWA:583-685; A:496-582SITE DIRECTED MUTATIONS OF THE ACTIVE SITE RESIDUE TYROSINE 195 OF CYCLODEXTRIN GLYCOSYLTRANSFERASE FROM BACILLUS CIRCULANS STRAIN 251 AFFECTING ACTIVITY AND PRODUCT SPECIFICITY
1CGXA:583-685; A:496-582SITE DIRECTED MUTATIONS OF THE ACTIVE SITE RESIDUE TYROSINE 195 OF CYCLODEXTRIN GLYXOSYLTRANSFERASE FROM BACILLUS CIRCULANS STRAIN 251 AFFECTING ACTIVITY AND PRODUCT SPECIFICITY
1CGYA:583-685; A:496-582SITE DIRECTED MUTATIONS OF THE ACTIVE SITE RESIDUE TYROSINE 195 OF CYCLODEXTRIN GLYXOSYLTRANSFERASE FROM BACILLUS CIRCULANS STRAIN 251 AFFECTING ACTIVITY AND PRODUCT SPECIFICITY
(-)
Bacillus circulans. Organism_taxid: 1397. (1)
1K85A:557-644SOLUTION STRUCTURE OF THE FIBRONECTIN TYPE III DOMAIN FROM BACILLUS CIRCULANS WL-12 CHITINASE A1.
(-)
Bacillus circulans. Organism_taxid: 1397. Strain: 251 (4)
1CXEA:583-685; A:496-582COMPLEX OF CGTASE WITH MALTOTETRAOSE AT ROOM TEMPERATURE AND PH 9.1 BASED ON DIFFRACTION DATA OF A CRYSTAL SOAKED WITH ALPHA-CYCLODEXTRIN
1CXHA:583-685; A:496-582COMPLEX OF CGTASE WITH MALTOTETRAOSE AT ROOM TEMPERATURE AND PH 9.6 BASED ON DIFFRACTION DATA OF A CRYSTAL SOAKED WITH MALTOHEPTAOSE
1CXIA:583-685; A:496-582WILD-TYPE CGTASE FROM BACILLUS CIRCULANS STRAIN 251 AT 120 K AND PH 7.55
2CXGA:583-685; A:496-582CYCLODEXTRIN GLYCOSYLTRANSFERASE COMPLEXED TO THE INHIBITOR ACARBOSE
(-)
Bacillus circulans. Organism_taxid: 1397. Strain: 251. (4)
1D3CA:583-685; A:496-582MICHAELIS COMPLEX OF BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYLTRANSFERASE WITH GAMMA-CYCLODEXTRIN
1DTUA:583-685; A:496-582BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYLTRANSFERASE: A MUTANT Y89D/S146P COMPLEXED TO AN HEXASACCHARIDE INHIBITOR
1EO5A:583-685; A:496-582BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYLTRANSFERASE IN COMPLEX WITH MALTOHEPTAOSE
1EO7A:583-685; A:496-582BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYLTRANSFERASE IN COMPLEX WITH MALTOHEXAOSE
(-)
Bacillus circulans. Organism_taxid: 1397. Strain: 251. (11)
1CXFA:583-685; A:496-582COMPLEX OF A (D229N/E257Q) DOUBLE MUTANT CGTASE FROM BACILLUS CIRCULANS STRAIN 251 WITH MALTOTETRAOSE AT 120 K AND PH 9.1 OBTAINED AFTER SOAKING THE CRYSTAL WITH ALPHA-CYCLODEXTRIN
1CXKA:583-685; A:496-582COMPLEX BETWEEN A MALTONONAOSE SUBSTRATE AND BACILLUS CIRCULANS STRAIN 251 CGTASE E257Q/D229N
1CXLA:583-685; A:496-582COMPLEX BETWEEN A COVALENT INTERMEDIATE AND BACILLUS CIRCULANS STRAIN 251 CGTASE E257Q
1KCKA:583-685; A:496-582BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYL TRANSFERASE MUTANT N193G
1KCLA:583-685; A:496-582BACILLUS CIRUCLANS STRAIN 251 CYCLODEXTRIN GLYCOSYL TRANSFERASE MUTANT G179L
1OT1A:583-685; A:496-582BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYL TRANSFERASE MUTANT D135A
1OT2A:583-685; A:496-582BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYL TRANSFERASE MUTANT D135N
1PEZA:583-685; A:496-582BACILLUS CIRCULANS STRAIN 251 MUTANT A230V
1PJ9A:583-685; A:496-582BACILLUS CIRCULANS STRAIN 251 LOOP MUTANT 183-195
1TCMA:583-685; B:583-685; A:496-582; B:496-582CYCLODEXTRIN GLYCOSYLTRANSFERASE W616A MUTANT FROM BACILLUS CIRCULANS STRAIN 251
2DIJA:583-685; A:496-582COMPLEX OF A Y195F MUTANT CGTASE FROM B. CIRCULANS STRAIN 251 COMPLEXED WITH A MALTONONAOSE INHIBITOR AT PH 9.8 OBTAINED AFTER SOAKING THE CRYSTAL WITH ACARBOSE AND MALTOHEXAOSE
(-)
Bacillus circulans. Organism_taxid: 1397. Strain: 8. (7)
3CGTA:581-684; A:495-580STRUCTURE OF CYCLODEXTRIN GLYCOSYLTRANSFERASE COMPLEXED WITH ITS MAIN PRODUCT BETA-CYCLODEXTRIN
4CGTA:581-684; A:495-580DELETION MUTANT DELTA(145-150), F151D OF CYCLODEXTRIN GLYCOSYLTRANSFERASE
5CGTA:581-684; A:495-580MALTOTRIOSE COMPLEX OF PRECONDITIONED CYCLODEXTRIN GLYCOSYLTRANSFERASE MUTANT
6CGTA:581-684; A:495-580HOXA COMPLEX OF CYCLODEXTRIN GLYCOSYLTRANSFERASE MUTANT
7CGTA:581-684; A:495-580RAMEB COMPLEX OF CYCLODEXTRIN GLYCOSYLTRANSFERASE MUTANT
8CGTA:581-684; A:495-580STRUCTURE OF CYCLODEXTRIN GLYCOSYLTRANSFERASE COMPLEXED WITH A THIO-MALTOHEXAOSE
9CGTA:581-684; A:495-580STRUCTURE OF CYCLODEXTRIN GLYCOSYLTRANSFERASE COMPLEXED WITH A THIO-MALTOPENTAOSE
(-)
Bacillus sp.. Organism_taxid: 1409 (1)
1EA9C:1-121; D:1-121CYCLOMALTODEXTRINASE
(-)
Bacillus sp.. Organism_taxid: 1409. (1)
1I75A:583-685; B:583-685; A:496-582; B:496-582CRYSTAL STRUCTURE OF CYCLODEXTRIN GLUCANOTRANSFERASE FROM ALKALOPHILIC BACILLUS SP.#1011 COMPLEXED WITH 1-DEOXYNOJIRIMYCIN
(-)
Baker's yeast (Saccharomyces cerevisiae) (5)
1EZVY:1-107; X:1-127STRUCTURE OF THE YEAST CYTOCHROME BC1 COMPLEX CO-CRYSTALLIZED WITH AN ANTIBODY FV-FRAGMENT
1KB9K:1-107; J:1-127YEAST CYTOCHROME BC1 COMPLEX
1KYOK:1-107; J:1-127; U:1-127; V:1-107YEAST CYTOCHROME BC1 COMPLEX WITH BOUND SUBSTRATE CYTOCHROME C
1P84K:1-107; J:1-127HDBT INHIBITED YEAST CYTOCHROME BC1 COMPLEX
2IBZY:1-107; X:1-127YEAST CYTOCHROME BC1 COMPLEX WITH STIGMATELLIN
(-)
Bantam,chickens (Gallus gallus) (1)
3JVGC:1-98; D:1-98; B:180-277; A:180-277CRYSTAL STRUCTURE OF CHICKEN CD1-1
(-)
Black rat (Rattus rattus) (2)
1BFOA:109-211; C:109-211; F:122-216; H:122-216; B:1-121; D:1-121; F:1-121; H:1-121; G:109-211; E:109-210; A:1-108; C:1-108; E:1-108; G:1-108; B:122-216; D:122-216CAMPATH-1G IGG2B RAT MONOCLONAL FAB
1HNGA:2-98; B:2-98; A:99-176; B:99-176CRYSTAL STRUCTURE AT 2.8 ANGSTROMS RESOLUTION OF A SOLUBLE FORM OF THE CELL ADHESION MOLECULE CD2
(-)
Black rat, roof rat (Rattus rattus) (7)
1OAQH:1-120; L:1-110FREE CONFORMATION AB1 OF THE IGE SPE-7
1OARH:1-122; O:3-109; M:3-109; L:2-109; N:2-109; J:1-122; I:14-116; K:14-116FV IGE SPE-7 IN COMPLEX WITH ALIZARIN RED
1OAUH:1-122; L:2-109; N:2-109; O:6-109; M:6-109; J:1-122FV STRUCTURE OF THE IGE SPE-7 IN COMPLEX WITH DNP-SER (IMMUNISING HAPTEN)
1OAXH:1-122; J:1-122; O:2-109; L:2-109; M:2-109; N:2-109FV STRUCTURE OF THE IGE SPE-7 IN COMPLEX WITH ACENAPHTHENEQUINONE
1OAYH:2-122; J:2-122; N:2-109; L:2-109; O:2-109; M:2-104ANTIBODY MULTISPECIFICITY MEDIATED BY CONFORMATIONAL DIVERSITY
1OAZH:1-122; L:2-109; N:2-109; J:1-122IGE FV SPE7 COMPLEXED WITH A RECOMBINANT THIOREDOXIN
1OCWH:1-120; L:1-110FREE CONFORMATION AB2 OF THE IGE SPE-7
(-)
Bovine,cow,domestic cattle,domestic cow (Bos taurus) (1)
3L9RD:1-98; F:1-98; H:1-98; B:1-97; A:183-278; E:183-278; G:183-278; C:183-278CRYSTAL STRUCTURE OF BOVINE CD1B3 WITH ENDOGENOUSLY BOUND LIGANDS
(-)
Caenorhabditis elegans. Organism_taxid: 6239. (4)
1WITA:1-93TWITCHIN IMMUNOGLOBULIN SUPERFAMILY DOMAIN (IGSF MODULE) (IG 18'), NMR, MINIMIZED AVERAGE STRUCTURE
1WIUA:1-93TWITCHIN IMMUNOGLOBULIN SUPERFAMILY DOMAIN (IGSF MODULE) (IG 18'), NMR, 30 STRUCTURES
3BRDA:563-661CSL (LAG-1) BOUND TO DNA WITH LIN-12 RAM PEPTIDE, P212121
3BRFA:563-660CSL (LAG-1) BOUND TO DNA WITH LIN-12 RAM PEPTIDE, C2221
(-)
Caenorhabditis elegans. Organism_taxid: 6239. (1)
1KOAA:6266-6361TWITCHIN KINASE FRAGMENT (C.ELEGANS), AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
(-)
Camel (Camelus dromedarius) (1)
3DWTA:2-129; B:2-129; C:2-129; D:2-129; E:2-129; F:2-129; G:2-129; H:2-129STRUCTURE OF CABBCII-10 NANOBODY
(-)
Camelus dromedarius. Organism_taxid: 9838. (2)
3EAKA:1-127; B:1-127NBBCII10 HUMANIZED (FGLA MUTANT)
3EBAA:1-122CABHUL6 FGLW MUTANT (HUMANIZED) IN COMPLEX WITH HUMAN LYSOZYME
(-)
Canine adenovirus 2. Organism_taxid: 10514. (2)
2J1KB:17-138; A:19-135; P:17-139; X:17-139; Z:19-135; O:19-139; T:19-137; Y:19-137; V:17-137; G:17-139; J:17-139; K:16-138CAV-2 FIBRE HEAD IN COMPLEX WITH CAR D1
2W9LA:19-135; B:20-136; Z:19-135; O:19-139; T:19-137; Y:19-137; V:17-137; G:17-139; J:17-139; K:16-138; P:17-139; X:17-139CANINE ADENOVIRUS TYPE 2 FIBRE HEAD IN COMPLEX WITH CAR DOMAIN D1 AND SIALIC ACID
(-)
Cattle (Bos taurus) (13)
1BMGA:1-98CRYSTAL STRUCTURE OF BOVINE BETA2-MICROGLOBULIN
1BZQK:801-924; L:1001-1124; M:1201-1324; N:1401-1524COMPLEX OF A DROMEDARY SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A
1G6VK:801-926COMPLEX OF THE CAMELID HEAVY-CHAIN ANTIBODY FRAGMENT CAB-CA05 WITH BOVINE CARBONIC ANHYDRASE
2P42B:1-121; D:1-121COMPLEX OF A CAMELID SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A AT 1.8A RESOLUTION: SE3-MONO-2 CRYSTAL FORM WITH THREE SE-MET SITES (M34, M51, M83) IN VHH SCAFFOLD
2P43B:-1-121COMPLEX OF A CAMELID SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A AT 1.65A RESOLUTION: SE3-MONO-1 CRYSTAL FORM WITH THREE SE-MET SITES (M34, M51, M83) IN VHH SCAFFOLD
2P44B:-1-121COMPLEX OF A CAMELID SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A AT 1.8A RESOLUTION: SE5A-MONO-1 CRYSTAL FORM WITH FIVE SE-MET SITES (M34, M51, F68M, M83, L86M) IN VHH SCAFFOLD
2P45B:1-121COMPLEX OF A CAMELID SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A AT 1.1A RESOLUTION: SE5B-ORTHO-1 CRYSTAL FORM WITH FIVE SE-MET SITES (L4M, M34, M51, F68M, M83) IN VHH SCAFFOLD.
2P46B:1-121; D:1-121COMPLEX OF A CAMELID SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A AT 2.5A RESOLUTION: SE5B-ORTHO-2 CRYSTAL FORM WITH FIVE SE-MET SITES (L4M, M34, M51, F68M, M83) IN VHH SCAFFOLD.
2P47B:1-121COMPLEX OF A CAMELID SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A AT 2.5A RESOLUTION: SE5B-TRI CRYSTAL FORM WITH FIVE SE-MET SITES (L4M, M34, M51, F68M, M83) IN VHH SCAFFOLD.
2P48B:1-121COMPLEX OF A CAMELID SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A AT 2.3A RESOLUTION: SE5B-TETRA CRYSTAL FORM WITH FIVE SE-MET SITES (L4M, M34, M51, F68M, M83) IN VHH SCAFFOLD.
2P49B:-1-121COMPLEX OF A CAMELID SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A AT 1.4A RESOLUTION: NATIVE MONO_1 CRYSTAL FORM
2P4AB:1-121; D:1-121X-RAY STRUCTURE OF A CAMELID AFFINITY MATURED SINGLE-DOMAIN VHH ANTIBODY FRAGMENT IN COMPLEX WITH RNASE A
2R56L:108-211; M:108-211; H:122-221; I:122-221; H:1-121; I:1-121; L:1-107; M:1-107CRYSTAL STRUCTURE OF A RECOMBINANT IGE FAB FRAGMENT IN COMPLEX WITH BOVINE BETA-LACTOGLOBULIN ALLERGEN
(-)
Cecropia moth (Hyalophora cecropia) (1)
1BIHA:102-207; B:102-207; A:208-307; B:208-307; A:5-101; B:5-101; A:308-395; B:308-395CRYSTAL STRUCTURE OF THE INSECT IMMUNE PROTEIN HEMOLIN: A NEW DOMAIN ARRANGEMENT WITH IMPLICATIONS FOR HOMOPHILIC ADHESION
(-)
Chicken (Gallus gallus) (9)
1CS6A:105-209; A:7-104; A:299-388; A:210-298N-TERMINAL FRAGMENT OF AXONIN-1 FROM CHICKEN
1IE5A:1-107NMR STRUCTURE OF THE THIRD IMMUNOGLOBULIN DOMAIN FROM THE NEURAL CELL ADHESION MOLECULE.
1QR4A:88-175; B:88-175; A:1-87; B:1-87TWO FIBRONECTIN TYPE-III DOMAIN SEGMENT FROM CHICKEN TENASCIN
1ZV5A:2-120CRYSTAL STRUCTURE OF THE VARIABLE DOMAIN OF THE CAMELID HEAVY-CHAIN ANTIBODY D2-L29 IN COMPLEX WITH HEN EGG WHITE LYSOZYME
1ZVHA:1-124CRYSTAL STRUCTURE OF THE VHH DOMAIN D2-L24 IN COMPLEX WITH HEN EGG WHITE LYSOZYME
3BEVB:0-98; A:179-26811MER STRUCTURE OF AN MHC CLASS I MOLECULE FROM B21 CHICKENS ILLUSTRATE PROMISCUOUS PEPTIDE BINDING
3BEWB:0-98; A:179-268; D:179-268; E:0-9810MER CRYSTAL STRUCTURE OF CHICKEN MHC CLASS I HAPLOTYPE B21
3D9AL:109-211; L:1-108; H:301-413; H:414-510HIGH RESOLUTION CRYSTAL STRUCTURE STRUCTURE OF HYHEL10 FAB COMPLEXED TO HEN EGG LYSOZYME
3DBXB:1-99; A:187-285STRUCTURE OF CHICKEN CD1-2 WITH BOUND FATTY ACID
(-)
Clostridium botulinum. Organism_taxid: 1491. Strain: type a1 (hall strain). Clostridium botulinum. Organism_taxid: 1491. Cell_line: cho dg44cells. (2)
2NYYC:113-216; C:1-112; D:119-218; D:2-118CRYSTAL STRUCTURE OF BOTULINUM NEUROTOXIN TYPE A COMPLEXED WITH MONOCLONAL ANTIBODY CR1
2NZ9C:113-216; D:2-118; F:2-118; E:113-216; C:1-112; E:1-112; D:119-218; F:119-218CRYSTAL STRUCTURE OF BOTULINUM NEUROTOXIN TYPE A COMPLEXED WITH MONOCLONAL ANTIBODY AR2
(-)
Clostridium cellulolyticum. Organism_taxid: 1521 (1)
1EHXA:1-94NMR SOLUTION STRUCTURE OF THE LAST UNKNOWN MODULE OF THE CELLULOSOMAL SCAFFOLDIN PROTEIN CIPC OF CLOSTRIDUM CELLULOLYTICUM
(-)
Clostridium thermocellum. Organism_taxid: 1515. (2)
1RQ5A:208-305STRUCTURAL BASIS FOR THE EXOCELLULASE ACTIVITY OF THE CELLOBIOHYDROLASE CBHA FROM C. THERMOCELLUM
1UT9A:208-305STRUCTURAL BASIS FOR THE EXOCELLULASE ACTIVITY OF THE CELLOBIOHYDROLASE CBHA FROM C. THERMOCELLUM
(-)
Clostridium thermocellum. Organism_taxid: 1515. Strain: ncib 10682. (1)
1CLCA:35-136THREE-DIMENSIONAL STRUCTURE OF ENDOGLUCANASE D AT 1.9 ANGSTROMS RESOLUTION
(-)
Common timothy (Phleum pratense) (1)
2VXQL:108-211; H:118-214; H:1-117CRYSTAL STRUCTURE OF THE MAJOR GRASS POLLEN ALLERGEN PHL P 2 IN COMPLEX WITH ITS SPECIFIC IGE-FAB
(-)
Dengue virus 2 thailand/16681/84. Organism_taxid: 31634. Strain: 16681. (2)
2R29L:113-211; H:1-116; L:1-112; H:117-213NEUTRALIZATION OF DENGUE VIRUS BY A SEROTYPE CROSS-REACTIVE ANTIBODY ELUCIDATED BY CRYOELECTRON MICROSCOPY AND X-RAY CRYSTALLOGRAPHY
2R69L:113-209; H:1-116; L:1-112; H:117-213CRYSTAL STRUCTURE OF FAB 1A1D-2 COMPLEXED WITH E-DIII OF DENGUE VIRUS AT 3.8 ANGSTROM RESOLUTION
(-)
Dictyostelium discoideum. Organism_taxid: 44689. (1)
1WLHA:757-857; B:757-857; A:655-756; B:655-756; A:547-654; B:549-654MOLECULAR STRUCTURE OF THE ROD DOMAIN OF DICTYOSTELIUM FILAMIN
(-)
Dictyostelium discoideum. Organism_taxid: 44689. (1)
1QFHA:757-857; B:757-857; A:646-756; B:646-756DIMERIZATION OF GELATION FACTOR FROM DICTYOSTELIUM DISCOIDEUM: CRYSTAL STRUCTURE OF ROD DOMAINS 5 AND 6
(-)
Dictyostelium discoideum. Organism_taxid: 44689. Strain: ax3. Cell_line: bl21. (1)
1KSRA:1-100THE REPEATING SEGMENTS OF THE F-ACTIN CROSS-LINKING GELATION FACTOR (ABP-120) HAVE AN IMMUNOGLOBULIN FOLD, NMR, 20 STRUCTURES
(-)
Domestic guinea pig (Cavia porcellus) (1)
1PFCA:334-446MOLECULAR-REPLACEMENT STRUCTURE OF GUINEA PIG IGG1 P*FC(PRIME) REFINED AT 3.1 ANGSTROMS RESOLUTION
(-)
Dromedary (Camelus dromedarius) (1)
2X6MA:2-127STRUCTURE OF A SINGLE DOMAIN CAMELID ANTIBODY FRAGMENT IN COMPLEX WITH A C-TERMINAL PEPTIDE OF ALPHA-SYNUCLEIN
(-)
Enterica serovar typhimurium (Salmonella enterica subsp) (1)
3HQK  [entry was replaced by entry 3NCY without any CATH domain information]
(-)
Epstein-barr virus (Human herpesvirus 4) (2)
1Y6MR:104-206; R:3-103CRYSTAL STRUCTURE OF EPSTEIN-BARR VIRUS IL-10 COMPLEXED WITH THE SOLUBLE IL-10R1 CHAIN
1Y6NR:104-203; R:2-103CRYSTAL STRUCTURE OF EPSTEIN-BARR VIRUS IL-10 MUTANT (A87I) COMPLEXED WITH THE SOLUBLE IL-10R1 CHAIN
(-)
Erwinia chrysanthemi. Organism_taxid: 556. (2)
3B4NA:20-107; B:20-107CRYSTAL STRUCTURE ANALYSIS OF PECTATE LYASE PELI FROM ERWINIA CHRYSANTHEMI
3B8YA:20-118; B:20-106CRYSTAL STRUCTURE OF PECTATE LYASE PELI FROM ERWINIA CHRYSANTHEMI IN COMPLEX WITH TETRAGALACTURONIC ACID
(-)
Escherichia coli. Organism_taxid: 316401. Strain: h10407. (1)
3EZJB:1-120; D:1-120; F:1-120; H:1-120CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAIN OF THE SECRETIN GSPD FROM ETEC DETERMINED WITH THE ASSISTANCE OF A NANOBODY
(-)
Escherichia coli. Organism_taxid: 562. (17)
1OTSD:108-210; F:107-210; F:1-106; D:1-107; C:122-220; E:122-220; C:2-121; E:2-121STRUCTURE OF THE ESCHERICHIA COLI CLC CHLORIDE CHANNEL AND FAB COMPLEX
1OTTF:108-210; C:2-121; E:2-121; D:107-210; D:1-106; F:1-107; C:122-220; E:122-220STRUCTURE OF THE ESCHERICHIA COLI CLC CHLORIDE CHANNEL E148A MUTANT AND FAB COMPLEX
1OTUD:107-210; C:2-121; E:2-121; F:107-210; D:1-106; F:1-106; C:122-220; E:122-220STRUCTURE OF THE ESCHERICHIA COLI CLC CHLORIDE CHANNEL E148Q MUTANT AND FAB COMPLEX
2FECL:108-210; I:2-121; J:2-121; O:108-210; L:1-107; O:1-107; I:122-220; J:122-220STRUCTURE OF THE E203Q MUTANT OF THE CL-/H+ EXCHANGER CLC-EC1 FROM E.COLI
2FEDD:108-210; C:2-121; E:2-121; F:108-210; D:1-107; F:1-107; C:122-220; E:122-220STRUCTURE OF THE E203Q MUTANT OF THE CL-/H+ EXCHANGER CLC-EC1 FROM E.COLI
2FEEL:108-210; O:108-210; I:2-121; J:2-121; L:1-107; O:1-107; I:122-220; J:122-220STRUCTURE OF THE CL-/H+ EXCHANGER CLC-EC1 FROM E.COLI IN NABR
2H2PD:108-210; C:2-121; E:2-121; D:1-107; F:1-107; F:108-210; C:122-220; E:122-220CRYSTAL STRUCTURE OF CLC-EC1 IN COMPLEX WITH FAB FRAGMENT IN SECN-
2H2SD:108-210; C:2-121; E:2-121; D:1-107; F:1-107; F:108-210; C:122-220; E:122-220CRYSTAL STRUCTURE OF E148A MUTANT OF CLC-EC1 IN SECN-
2HLFD:108-210; C:2-121; E:2-121; F:108-210; D:1-107; F:1-107; C:122-220; E:122-220STRUCTURE OF THE ESCHERICHIS COLI CLC CHLORIDE CHANNEL Y445E MUTANT AND FAB COMPLEX
2HT2D:108-210; C:2-121; E:2-121; F:108-210; D:1-107; F:1-107; C:122-220; E:122-220STRUCTURE OF THE ESCHERICHIA COLI CLC CHLORIDE CHANNEL Y445H MUTANT AND FAB COMPLEX
2HT3D:108-210; C:2-121; E:2-121; F:108-210; D:1-107; F:1-107; C:122-220; E:122-220STRUCTURE OF THE ESCHERICHIA COLI CLC CHLORIDE CHANNEL Y445L MUTANT AND FAB COMPLEX
2HT4D:108-210; C:2-121; E:2-121; F:108-210; D:1-107; F:1-107; C:122-220; E:122-220STRUCTURE OF THE ESCHERICHIA COLI CLC CHLORIDE CHANNEL Y445W MUTANT AND FAB COMPLEX
2HTKD:108-210; C:2-121; E:2-121; F:108-210; D:1-107; F:1-107; C:122-220; E:122-220STRUCTURE OF THE ESCHERICHIA COLI CLC CHLORIDE CHANNEL Y445A MUTANT AND FAB COMPLEX
2HTLD:108-210; C:2-121; E:2-121; F:108-210; D:1-107; F:1-107; C:122-220; E:122-220STRUCTURE OF THE ESCHERICHIA COLI CLC CHLORIDE CHANNEL Y445F MUTANT AND FAB COMPLEX
2R9HD:108-210; C:2-121; E:2-121; D:1-107; F:1-107; C:122-220; E:122-220; F:108-210CRYSTAL STRUCTURE OF Q207C MUTANT OF CLC-EC1 IN COMPLEX WITH FAB
3EJYD:108-210; C:2-121; E:2-121; F:108-210; C:122-220; E:122-220STRUCTURE OF E203H MUTANT OF E.COLI CL-/H+ ANTIPORTER, CLC-EC1
3EJZD:108-210; C:2-121; E:2-121; F:108-210; C:122-220; E:122-220STRUCTURE OF E203V MUTANT E.COLI CL-/H+ EXCHANGER, CLC-EC1
(-)
Escherichia coli. Organism_taxid: 562. (10)
1CE1L:109-211; L:1-108; H:122-220; H:1-1211.9A STRUCTURE OF THE THERAPEUTIC ANTIBODY CAMPATH-1H FAB IN COMPLEX WITH A SYNTHETIC PEPTIDE ANTIGEN
1M7XB:117-223; D:117-223; A:117-223; C:118-223THE X-RAY CRYSTALLOGRAPHIC STRUCTURE OF BRANCHING ENZYME
1XGRA:109-211; A:0-108; B:114-210; B:1-113STRUCTURE FOR ANTIBODY HYHEL-63 Y33I MUTANT COMPLEXED WITH HEN EGG LYSOZYME
1XGTA:109-211; A:0-108; B:114-210; B:1-113STRUCTURE FOR ANTIBODY HYHEL-63 Y33L MUTANT COMPLEXED WITH HEN EGG LYSOZYME
1XGUA:109-211; A:1-108; B:114-210; B:1-113STRUCTURE FOR ANTIBODY HYHEL-63 Y33F MUTANT COMPLEXED WITH HEN EGG LYSOZYME
2BX5A:1-106; B:1-106; C:1-106; D:1-106; E:1-106; F:1-106; G:1-106; I:1-106; J:1-106; K:1-106; L:1-106; M:1-106; N:1-106; O:1-106; H:2-106IS FR1 THE ANTIBODY'S ACHILLIES HEEL
2EXWD:108-210; D:1-107; F:1-107; C:122-220; E:122-220; F:108-210; C:2-121; E:2-121CRYSTAL STRUCTURE OF A ECCLC-FAB COMPLEX IN THE ABSENCE OF BOUND IONS
2EXYD:108-210; D:1-107; F:1-107; F:108-210; C:122-220; E:122-220; C:2-121; E:2-121CRYSTAL STRUCTURE OF THE E148Q MUTANT OF ECCLC, FAB COMPLEXED IN ABSENCE OF BOUND IONS
2EZ0D:108-210; D:1-107; F:1-107; C:122-220; E:122-220; C:2-121; E:2-121; F:108-210CRYSTAL STRUCTURE OF THE S107A/E148Q/Y445A MUTANT OF ECCLC, IN COMPLEX WITH A FAB FRAGMENT
2JIXA:109-214; G:109-214; L:109-214; A:1-108; G:1-108; L:1-108; D:117-215; F:117-215; H:117-215; D:1-116; F:1-116; H:1-116; B:119-220; C:119-220; E:119-220; B:22-118; C:22-118; E:22-118CRYSTAL STRUCTURE OF ABT-007 FAB FRAGMENT WITH THE SOLUBLE DOMAIN OF EPO RECEPTOR
(-)
Escherichia coli. Organism_taxid: 562. Strain: dr/afa. (1)
2VERN:1-110STRUCTURAL MODEL FOR THE COMPLEX BETWEEN THE DR ADHESINS AND CARCINOEMBRYONIC ANTIGEN (CEA)
(-)
Escherichia coli. Organism_taxid: 83333. Strain: k12. (1)
2ZUQB:134-236; E:134-236; C:121-221; F:121-215; C:1-119; F:1-119CRYSTAL STRUCTURE OF DSBB-FAB COMPLEX
(-)
Escherichia coli. Strain: k12. (1)
3DETD:108-210; F:108-210; D:1-107; F:1-107; C:122-220; E:122-220; C:2-121; E:2-121STRUCTURE OF THE E148A, Y445A DOUBLY UNGATED MUTANT OF E.COLI CLC_EC1, CL-/H+ ANTIPORTER
(-)
European white birch (Betula pendula) (1)
1FSKE:109-211; K:109-211; I:119-217; L:119-217; C:1-118; F:1-118; I:1-118; L:1-118; B:108-211; H:108-211; H:3-107; B:1-107; E:1-108; K:1-108; C:119-217; F:119-217COMPLEX FORMATION BETWEEN A FAB FRAGMENT OF A MONOCLONAL IGG ANTIBODY AND THE MAJOR ALLERGEN FROM BIRCH POLLEN BET V 1
(-)
Fervidobacterium pennivorans. Organism_taxid: 93466. (1)
1R6VA:452-563CRYSTAL STRUCTURE OF FERVIDOLYSIN FROM FERVIDOBACTERIUM PENNIVORANS, A KERATINOLYTIC ENZYME RELATED TO SUBTILISIN
(-)
Flavobacterium sp.. Flavobacterium. Organism_taxid: 239. Strain: no 92. (1)
1H3GA:3-92; B:3-92CYCLOMALTODEXTRINASE FROM FLAVOBACTERIUM SP. NO. 92: FROM DNA SEQUENCE TO PROTEIN STRUCTURE
(-)
Fruit fly (Drosophila melanogaster) (1)
1CFBA:709-814; A:610-708CRYSTAL STRUCTURE OF TANDEM TYPE III FIBRONECTIN DOMAINS FROM DROSOPHILA NEUROGLIAN AT 2.0 ANGSTROMS
(-)
Fusarium sp.. Organism_taxid: 29916. (1)
1T2XA:542-639GLACTOSE OXIDASE C383S MUTANT IDENTIFIED BY DIRECTED EVOLUTION
(-)
Fusarium sp.. Organism_taxid: 29916. (1)
1K3IA:542-638CRYSTAL STRUCTURE OF THE PRECURSOR OF GALACTOSE OXIDASE
(-)
Geobacillus stearothermophilus. Organism_taxid: 1422 (1)
1CYGA:576-679; A:492-575CYCLODEXTRIN GLUCANOTRANSFERASE (E.C.2.4.1.19) (CGTASE)
(-)
Geobacillus stearothermophilus. Organism_taxid: 1422. (6)
1J0HA:1-125; B:1-125CRYSTAL STRUCTURE OF BACILLUS STEAROTHERMOPHILUS NEOPULLULANASE
1J0IA:1-125; B:1-125CRYSTAL STRUCTURE OF NEOPULLULANASE COMPLEX WITH PANOSE
1J0JA:1-125; B:1-125CRYSTAL STRUCTURE OF NEOPULLULANASE E357Q COMPLEX WITH MALTOTETRAOSE
1J0KA:1-125; B:1-125CRYSTAL STRUCTURE OF NEOPULLULANASE E357Q COMPLEX WITH ISOPANOSE
1QHOA:578-685; A:496-577FIVE-DOMAIN ALPHA-AMYLASE FROM BACILLUS STEAROTHERMOPHILUS, MALTOSE/ACARBOSE COMPLEX
1QHPA:578-685; A:496-577FIVE-DOMAIN ALPHA-AMYLASE FROM BACILLUS STEAROTHERMOPHILUS, MALTOSE COMPLEX
(-)
German cockroach (Blattella germanica) (1)
2NR6C:109-211; E:109-211; C:1-108; E:1-108; D:1-116; F:1-116; D:117-213; F:117-213CRYSTAL STRUCTURE OF THE COMPLEX OF ANTIBODY AND THE ALLERGEN BLA G 2
(-)
Gibberella zeae. Organism_taxid: 5518. (2)
2EIBA:542-639CRYSTAL STRUCTURE OF GALACTOSE OXIDASE, W290H MUTANT
2EICA:542-639CRYSTAL STRUCTURE OF GALACTOSE OXIDASE MUTANT W290F
(-)
Gibberella zeae. Organism_taxid: 5518. (6)
2EIDA:542-639GALACTOSE OXIDASE W290G MUTANT
2EIEA:542-639CRYSTAL STRUCTURE OF GALACTOSE OXIDASE COMPLEXED WITH AZIDE
2JKXA:542-639GALACTOSE OXIDASE. MATGO. COPPER FREE, EXPRESSED IN PICHIA PASTORIS.
2VZ1A:542-639PREMAT-GALACTOSE OXIDASE
2VZ3A:542-639BLEACHED GALACTOSE OXIDASE
2WQ8A:542-639GLYCAN LABELLING USING ENGINEERED VARIANTS OF GALACTOSE OXIDASE OBTAINED BY DIRECTED EVOLUTION
(-)
Grass carp (Ctenopharyngodon idella) (1)
3GBLA:1-97CRYSTAL STRUCTURE OF GRASS CARP BETA2-MICROGLOBULIN
(-)
Harbor seal (Phoca vitulina) (1)
1MCBA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
(-)
Hiv-1 (Human immunodeficiency virus type 1) (1)
3HI1A:109-211; L:109-211; B:114-212; H:114-212; B:1-113; H:1-113STRUCTURE OF HIV-1 GP120 (CORE WITH V3) IN COMPLEX WITH CD4-BINDING-SITE ANTIBODY F105
(-)
Homo sapiens (Homo sapiens) (1)
3BQUC:108-209; A:108-211; A:1-107; C:1-104; D:123-224; B:133-231; D:1-122; B:1-132CRYSTAL STRUCTURE OF THE 2F5 FAB'-3H6 FAB COMPLEX
(-)
Homo sapiens. Organism_taxid: 9606. (8)
3CDCA:-1-107; B:-1-107KI O18/O8 N34I/Y87H IMMUNOGLOBULIN LIGHT CHAIN VARIABLE DOMAIN
3CDFA:0-107; B:-1-107; D:-1-107; F:-1-107; C:0-107; E:0-107KI O18/O8 Y87H IMMUNOGLOBULIN LIGHT CHAIN VARIABLE DOMAIN
3D39B:0-99; A:182-270; E:1-117; E:118-243; D:1-116THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE MODIFIED HTLV-1 TAX (Y5(4-FLUOROPHENYLALANINE)) PEPTIDE
3D3VB:0-99; A:182-270; E:1-117; E:118-243; D:1-116THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE MODIFIED HTLV-1 TAX (Y5(3,4-DIFLUOROPHENYLALANINE)) PEPTIDE
3DO3A:338-443; B:338-443; A:238-337; B:238-337HUMAN 1GG1 FC FRAGMENT, 2.5 ANGSTROM STRUCTURE
3EO9L:109-213; H:122-219; H:1-121CRYSTAL STRUCTURE THE FAB FRAGMENT OF EFALIZUMAB
3EOAA:109-214; B:122-220; H:122-220; B:1-121; H:1-121; L:109-214CRYSTAL STRUCTURE THE FAB FRAGMENT OF EFALIZUMAB IN COMPLEX WITH LFA-1 I DOMAIN, FORM I
3EOBA:109-214; B:122-220; H:122-220; B:1-121; H:1-121; L:109-214CRYSTAL STRUCTURE THE FAB FRAGMENT OF EFALIZUMAB IN COMPLEX WITH LFA-1 I DOMAIN, FORM II
(-)
Homo sapiens. Organism_taxid: 9606. (14)
1OLLA:96-188; A:1-95EXTRACELLULAR REGION OF THE HUMAN RECEPTOR NKP46
2K9UA:1-119SOLUTION NMR STRUCTURE OF THE FILAMIN-MIGFILIN COMPLEX
3CZFB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE GLUCAGON RECEPTOR (GR) PEPTIDE (RESIDUES 412-420)
3DGGA:111-214; D:120-216; B:120-216; A:6-110; C:111-214; C:6-110; B:1-119; D:1-119CRYSTAL STRUCTURE OF FABOX108
3DIFA:109-211; C:109-211; A:1-108; C:1-108; B:1-119; D:1-119; B:120-216; D:120-216CRYSTAL STRUCTURE OF FABOX117
3EYFA:110-212; A:0-109; C:0-109; B:126-225; D:126-224; B:1-125; D:1-125; C:110-212CRYSTAL STRUCTURE OF ANTI-HUMAN CYTOMEGALOVIRUS ANTIBODY 8F9 PLUS GB PEPTIDE
3EYOA:110-212; C:110-212; A:1-109; C:1-109; B:126-225; D:126-225; B:1-125; D:1-125CRYSTAL STRUCTURE OF ANTI-HUMAN CYTOMEGALOVIRUS ANTIBODY 8F9
3EYQC:110-212; C:1-109; D:126-224; D:1-125CRYSTAL STRUCTURE OF MJ5 FAB, A GERMLINE ANTIBODY VARIANT OF ANTI-HUMAN CYTOMEGALOVIRUS ANTIBODY 8F9
3F12C:111-214; A:111-212; D:126-224; B:128-224; B:2-124; D:1-125GERMLINE V-GENES SCULPT THE BINDING SITE OF A FAMILY OF ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS
3FN0L:109-211; H:114-223; H:1-113CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB Z13E1 IN COMPLEX WITH A 12-RESIDUE PEPTIDE CONTAINING THE Z13E1 EPITOPE ON GP41
3H3PH:1-127; I:1-128CRYSTAL STRUCTURE OF HIV EPITOPE-SCAFFOLD 4E10 FV COMPLEX
3INUL:108-211; N:108-211; H:114-228; M:114-227; H:1-113; M:1-113CRYSTAL STRUCTURE OF AN UNBOUND KZ52 NEUTRALIZING ANTI-EBOLAVIRUS ANTIBODY.
3KDMA:113-218; B:123-222; H:123-222; L:113-218; B:2-122; H:2-122CRYSTAL STRUCTURE OF HUMAN ANTI-STEROID FAB 5F2 IN COMPLEX WITH TESTOSTERONE
3KYMC:109-213; E:109-213; G:109-213; I:109-213; O:109-213; A:109-211; M:109-208; K:109-209; B:120-220; D:120-220; F:120-219; H:120-219; J:120-219; L:120-219; N:120-219; P:120-219; B:1-119; D:1-119; F:1-119; H:1-119; J:1-119; L:1-119; N:1-119; P:1-119CRYSTAL STRUCTURE OF LI33 IGG2 DI-FAB
(-)
Homo sapiens. Organism_taxid: 9606. Homo sapiens. Organism_taxid: 9606. (6)
3EGSA:108-211; B:134-233; B:1-133CRYSTAL STRUCTURE OF THE HIV-1 BROADLY NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH THE GP41 SCRAMBLEDFP-MPER SCRHYB3K CONSTRUCT GIGAFGLLGFLAAGSKK-AHX-K656NEQELLELDKWASLWN671 SOAKED IN AMMONIUM SULFATE
3IDGA:108-211; B:1-113; B:114-216CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ALDKWD
3IDIA:108-211; B:1-113; B:114-213CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 FAB' FRAGMENT IN COMPLEX WITH GP41 PEPTIDE ALDKWNQ
3IDJA:108-211; B:1-113; B:114-216CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 FAB' FRAGMENT IN COMPLEX WITH GP41 PEPTIDE ANALOG ELD(ORN)WAS
3IDMA:108-211; B:1-113; B:114-216CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 FAB' FRAGMENT IN COMPLEX WITH GP41 PEPTIDE ANALOG ELD(NRG)WAS
3IDNA:108-211; B:114-213; B:1-113CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 FAB' FRAGMENT IN COMPLEX WITH GP41 PEPTIDE ANALOG ELD(PAF)WAS
(-)
Homo sapiens. Organism_taxid: 9606. Strain: hxbc2. (1)
3JWOL:108-210; H:110-214; H:1-109; C:1000-1098; C:1099-1173STRUCTURE OF HIV-1 GP120 WITH GP41-INTERACTIVE REGION: LAYERED ARCHITECTURE AND BASIS OF CONFORMATIONAL MOBILITY
(-)
Honey bee (Apis mellifera) (1)
2J88L:109-205; L:1-108; H:2-112; H:113-180HYALURONIDASE IN COMPLEX WITH A MONOCLONAL IGG FAB FRAGMENT
(-)
House mouse (Mus musculus) (616)
12E8L:108-211; H:114-212; P:114-212; M:108-211; L:1-107; M:1-107; H:1-113; P:1-1132E8 FAB FRAGMENT
15C8L:109-211; H:114-226; H:1-113; L:1-108CATALYTIC ANTIBODY 5C8, FREE FAB
1A0QL:108-211; H:114-209; H:2-113; L:2-10729G11 COMPLEXED WITH PHENYL [1-(1-N-SUCCINYLAMINO)PENTYL] PHOSPHONATE
1A2YA:1-107; B:1-116HEN EGG WHITE LYSOZYME, D18A MUTANT, IN COMPLEX WITH MOUSE MONOCLONAL ANTIBODY D1.3
1A3LL:109-211; H:114-227; L:1-108; H:1-113CATALYSIS OF A DISFAVORED REACTION: AN ANTIBODY EXO DIELS-ALDERASE-TSA-INHIBITOR COMPLEX AT 1.95 A RESOLUTION
1A3RL:109-211; H:114-223; L:1-108; H:2-113FAB FRAGMENT (ANTIBODY 8F5) COMPLEXED WITH PEPTIDE FROM HUMAN RHINOVIRUS (SEROTYPE 2) VIRAL CAPSID PROTEIN VP2 (RESIDUES 156-170)
1A4JL:114-214; B:120-217; H:120-217; A:1-112; L:1-113; B:1-119; H:1-119; A:113-216DIELS ALDER CATALYTIC ANTIBODY GERMLINE PRECURSOR
1A4KL:109-211; B:114-213; H:114-211; A:1-107; L:1-108; B:1-113; H:1-113; A:108-211DIELS ALDER CATALYTIC ANTIBODY WITH TRANSITION STATE ANALOGUE
1A5FL:115-217; H:121-216; L:1-114; H:1-120FAB FRAGMENT OF A MONOCLONAL ANTI-E-SELECTIN ANTIBODY
1A6TC:109-211; B:114-212; D:114-212; B:1-113; D:1-113; A:109-210; A:1-108; C:1-108FAB FRAGMENT OF MAB1-IA MONOCLONAL ANTIBODY TO HUMAN RHINOVIRUS 14 NIM-IA SITE
1A6UH:301-420; L:2-109B1-8 FV FRAGMENT
1A6VH:301-418; M:1-109; N:1-109; L:1-110; I:301-419; J:301-420B1-8 FV FRAGMENT COMPLEXED WITH A (4-HYDROXY-3-NITROPHENYL) ACETATE COMPOUND
1A6WH:301-420; L:2-110B1-8 FV FRAGMENT COMPLEXED WITH A (4-HYDROXY-5-IODO-3-NITROPHENYL) ACETATE COMPOUND
1A7NL:1-107; H:201-316FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) VARIANT FOR CHAIN L GLU81->ASP AND CHAIN H LEU312->VAL
1A7OL:1-107; H:201-316FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) R96L DELETION MUTANT ON VARIANT FOR CHAIN L GLU81->ASP AND CHAIN H LEU312->VAL
1A7PL:1-107; H:201-316FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) ENGINEERED MUTANT PRO95L->SER ON VARIANT CHAIN L GLU81->ASP AND CHAIN H LEU312->VAL
1A7QL:1-106; H:201-316FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) HIGH AFFINITY EXPRESSED VARIANT CONTAINING SER26L->GLY, ILE29L->THR, GLU81L->ASP, THR97L->SER, PRO240H->LEU, ASP258H->ALA, LYS281H->GLU, ASN283H->ASP AND LEU312H->VAL
1A7RL:1-107; H:201-316FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) VARIANT CHAIN L GLU81->ASP
1AC6A:1-112; B:1-112CRYSTAL STRUCTURE OF A VARIABLE DOMAIN MUTANT OF A T-CELL RECEPTOR ALPHA CHAIN
1ACYL:109-211; L:1-108; H:114-225; H:1-113CRYSTAL STRUCTURE OF THE PRINCIPAL NEUTRALIZING SITE OF HIV-1
1AE6L:108-210; L:1-107; H:115-211; H:1-114IGG-FAB FRAGMENT OF MOUSE MONOCLONAL ANTIBODY CTM01
1AHWD:109-211; B:118-214; E:118-214; C:4-105; F:4-105; C:106-210; F:106-210; A:109-210; B:1-117; E:1-117; A:1-108; D:1-108A COMPLEX OF EXTRACELLULAR DOMAIN OF TISSUE FACTOR WITH AN INHIBITORY FAB (5G9)
1AI1L:109-211; L:1-108; H:114-225; H:1-113HIV-1 V3 LOOP MIMIC
1AIFA:110-215; B:122-218; H:122-218; B:1-121; H:1-121; L:110-215; A:1-109; L:1-109ANTI-IDIOTYPIC FAB 409.5.3 (IGG2A) FAB FROM MOUSE
1AP2B:1-120; A:1-112; C:1-113; D:1-123SINGLE CHAIN FV OF C219
1AXTL:109-211; H:114-227; L:1-108; H:1-113IMMUNE VERSUS NATURAL SELECTION: ANTIBODY ALDOLASES WITH THE RATES OF NATURAL ENZYMES
1AY1L:109-211; H:116-208; H:1-115; L:1-108ANTI TAQ FAB TP7
1B88A:1-114; B:201-314V-ALPHA 2.6 MOUSE T CELL RECEPTOR (TCR) DOMAIN
1BAFL:109-211; H:116-213; H:1-115; L:1-1082.9 ANGSTROMS RESOLUTION STRUCTURE OF AN ANTI-DINITROPHENYL-SPIN-LABEL MONOCLONAL ANTIBODY FAB FRAGMENT WITH BOUND HAPTEN
1BBDL:115-217; H:119-215; L:1-114; H:1-118THREE DIMENSIONAL STRUCTURE OF THE FAB FRAGMENT OF A NEUTRALIZING ANTIBODY TO HUMAN RHINOVIRUS SEROTYPE 2
1BECA:3-117; A:118-246BETA CHAIN OF A T CELL ANTIGEN RECEPTOR
1BFSA:245-350STRUCTURE OF NF-KB P50 HOMODIMER BOUND TO A KB SITE
1BFTA:191-291; B:191-291STRUCTURE OF NF-KB P50 HOMODIMER BOUND TO A KB SITE
1BFVL:1-113; H:1-119MONOCLONAL ANTIBODY FRAGMENT FV4155 FROM E. COLI
1BIIB:301-399; A:182-272THE CRYSTAL STRUCTURE OF H-2DD MHC CLASS I IN COMPLEX WITH THE HIV-1 DERIVED PEPTIDE P18-110
1BJ1J:109-211; H:124-223; K:124-223; H:1-123; K:1-123; L:109-211; J:1-108; L:1-108VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH A NEUTRALIZING ANTIBODY
1BLNC:109-211; A:1-108; C:1-108; B:114-226; D:114-226; B:1-113; D:1-113; A:109-212ANTI-P-GLYCOPROTEIN FAB MRK-16
1BM3L:109-211; H:126-223; H:1-125; L:1-108IMMUNOGLOBULIN OPG2 FAB-PEPTIDE COMPLEX
1BOGA:109-211; B:113-211; B:1-112; A:1-108ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-HOMOLOGOUS PEPTIDE
1BQHB:1-99; A:182-272; D:182-272; E:1-99; G:1-122; I:4-125; H:1-125; K:1-125MURINE CD8AA ECTODOMAIN FRAGMENT IN COMPLEX WITH H-2KB/VSV8
1BQLL:107-209; H:117-215; H:2-116; L:1-106STRUCTURE OF AN ANTI-HEL FAB FRAGMENT COMPLEXED WITH BOBWHITE QUAIL LYSOZYME
1BWMA:3-201; A:202-392A SINGLE-CHAIN T CELL RECEPTOR
1BZ7A:108-206; B:123-217; B:1-122; A:1-107FAB FRAGMENT FROM MURINE ASCITES
1BZ9B:0-99; A:182-271CRYSTAL STRUCTURE OF MURINE CLASS I MHC H2-DB COMPLEXED WITH A SYNTHETIC PEPTIDE P1027
1C08A:1-107; B:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV-HEN LYSOZYME COMPLEX
1C12A:108-211; B:414-511; B:301-413; A:1-107INSIGHT IN ODORANT PERCEPTION: THE CRYSTAL STRUCTURE AND BINDING CHARACTERISTICS OF ANTIBODY FRAGMENTS DIRECTED AGAINST THE MUSK ODORANT TRASEOLIDE
1C16B:1-99; A:180-276; C:180-276; E:180-276; G:180-276; D:1-99; F:1-99; H:1-99CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/DELTA T CELL LIGAND T22
1C1EL:113-211; H:120-218; L:1-112; H:1-119CRYSTAL STRUCTURE OF A DIELS-ALDERASE CATALYTIC ANTIBODY 1E9 IN COMPLEX WITH ITS HAPTEN
1CBVL:114-216; H:122-219; L:1-113; H:1-121AN AUTOANTIBODY TO SINGLE-STRANDED DNA: COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF THE UNLIGANDED FAB AND A DEOXYNUCLEOTIDE-FAB COMPLEX
1CD1B:1-99; A:185-279; C:185-279; D:1-99CD1(MOUSE) ANTIGEN PRESENTING MOLECULE
1CE6B:1-99; A:182-272MHC CLASS I H-2DB COMPLEXED WITH A SENDAI VIRUS NUCLEOPROTEIN PEPTIDE
1CF8L:109-211; H:114-212; H:1-113; L:1-108CONVERGENCE OF CATALYTIC ANTIBODY AND TERPENE CYCLASE MECHANISMS: POLYENE CYCLIZATION DIRECTED BY CARBOCATION-PI INTERACTIONS
1CFNA:109-211; B:113-211; B:1-112; A:1-108ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-RELATED PEPTIDE
1CFQA:108-211; B:113-211; B:1-112; A:2-107ANTI-P24 (HIV-1) FAB FRAGMENT CB41
1CFSA:109-211; B:113-211; B:1-112; A:1-108ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-UNRELATED PEPTIDE
1CFTA:109-211; B:113-211; B:1-112; A:1-108ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-UNRELATED D-PEPTIDE
1CFVL:1-113; H:1-119MONOCLONAL ANTIBODY FRAGMENT FV4155 FROM E. COLI
1CGSL:114-216; H:117-214; L:1-113; H:1-116LOCAL AND TRANSMITTED CONFORMATIONAL CHANGES ON COMPLEXATION OF AN ANTI-SWEETENER FAB
1CICA:109-211; B:118-216; D:117-215; B:1-117; D:1-116; C:109-211; A:1-108; C:1-108IDIOTOPE-ANTI-IDIOTOPE FAB-FAB COMPLEX; D1.3-E225
1CK0L:108-210; H:118-215; L:1-107; H:1-117ANTI-ANTI-IDIOTYPIC ANTIBODY AGAINST HUMAN ANGIOTENSIN II, UNLIGANDED FORM
1CL7L:109-211; L:1-108; H:1-128; I:141-222ANTI HIV1 PROTEASE FAB
1CLOL:109-214; H:114-212; H:1-113; L:1-108ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY A5B7
1CLZL:109-211; H:115-230; L:1-108; H:1-113IGG FAB (IGG3, KAPPA) FRAGMENT (MBR96) COMPLEXED WITH LEWIS Y NONOATE METHYL ESTER
1CQKA:4-104; B:204-304CRYSTAL STRUCTURE OF THE CH3 DOMAIN FROM THE MAK33 ANTIBODY
1CR9L:109-214; L:1-108; H:111-209; H:1-110CRYSTAL STRUCTURE OF THE ANTI-PRION FAB 3F4
1CT8C:109-214; B:114-212; D:114-212; B:1-113; D:1-113; A:109-211; A:1-108; C:1-108CATALYTIC ANTIBODY 7C8 COMPLEX
1CTOA:1-109NMR STRUCTURE OF THE C-TERMINAL DOMAIN OF THE LIGAND-BINDING REGION OF MURINE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR, MINIMIZED AVERAGE STRUCTURE
1CU4L:109-214; L:1-108; H:111-209; H:3-110CRYSTAL STRUCTURE OF THE ANTI-PRION FAB 3F4 IN COMPLEX WITH ITS PEPTIDE EPITOPE
1D9KB:3-116C; F:3-116C; C:82-181; G:82-181; D:93-190; H:93-190; A:2-117; E:2-117CRYSTAL STRUCTURE OF COMPLEX BETWEEN D10 TCR AND PMHC I-AK/CA
1DBAL:109-211; H:114-227; L:1-108; H:1-113THREE-DIMENSIONAL STRUCTURE OF AN ANTI-STEROID FAB' AND PROGESTERONE-FAB' COMPLEX
1DBBL:109-210; H:114-227; L:1-108; H:1-113THREE-DIMENSIONAL STRUCTURE OF AN ANTI-STEROID FAB' AND PROGESTERONE-FAB' COMPLEX
1DBJL:109-211; H:114-227; L:1-108; H:1-113MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
1DBKL:109-211; H:114-227; L:1-108; H:1-113MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
1DBML:109-211; H:114-227; L:1-108; H:1-113MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
1DDHB:1-99; A:182-272MHC CLASS I H-2DD HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND AN IMMUNODOMINANT PEPTIDE P18-I10 FROM THE HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEIN 120
1DLFL:1-108; H:1-114HIGH RESOLUTION CRYSTAL STRUCTURE OF THE FV FRAGMENT FROM AN ANTI-DANSYL SWITCH VARIANT ANTIBODY IGG2A(S) CRYSTALLIZED AT PH 5.25
1DQDL:108-209; H:123-220; H:1-122; L:1-107CRYSTAL STRUCTURE OF FAB HGR-2 F6, A COMPETITIVE ANTAGONIST OF THE GLUCAGON RECEPTOR
1DQJA:109-211; B:114-221; B:1-113; A:1-108CRYSTAL STRUCTURE OF THE ANTI-LYSOZYME ANTIBODY HYHEL-63 COMPLEXED WITH HEN EGG WHITE LYSOZYME
1DQML:109-211; H:114-221; H:2-113; L:1-108CRYSTAL STRUCTURE OF ANTI-LYSOZYME ANTIBODY
1DQQA:109-211; B:114-221; D:114-221; C:109-211; B:1-113; D:1-113; A:1-108; C:1-108CRYSTAL STRUCTURE OF ANTI-LYSOZYME ANTIBODY HYHEL-63
1DQTA:1-117; B:1-117; C:1-117; D:1-117THE CRYSTAL STRUCTURE OF MURINE CTLA4 (CD152)
1DSFL:1-107; H:3-113THE CRYSTAL STRUCTURE OF THE DISULFIDE-STABILIZED FV FRAGMENT OF ANTICANCER ANTIBODY B1: CONFORMATIONAL INFLUENCE OF AN ENGINEERED DISULFIDE BOND
1DVFD:1-112; B:1-116; A:1-107; C:1-107IDIOTOPIC ANTIBODY D1.3 FV FRAGMENT-ANTIIDIOTOPIC ANTIBODY E5.2 FV FRAGMENT COMPLEX
1DZBA:1-116; B:1-116; A:201-299; B:201-299CRYSTAL STRUCTURE OF PHAGE LIBRARY-DERIVED SINGLE-CHAIN FV FRAGMENT 1F9 IN COMPLEX WITH TURKEY EGG-WHITE LYSOZYME
1E4WL:109-211; H:111-209; H:1-110; L:1-108CROSSREACTIVE BINDING OF A CIRCULARIZED PEPTIDE TO AN ANTI-TGFALPHA ANTIBODY FAB-FRAGMENT
1E4XM:108-211; H:111-209; I:111-209; L:109-211; H:1-110; I:1-110; M:1-107; L:1-108CROSSREACTIVE BINDING OF A CIRCULARIZED PEPTIDE TO AN ANTI-TGFALPHA ANTIBODY FAB-FRAGMENT
1E6JL:107-209; H:121-218; H:1-120; L:1-106CRYSTAL STRUCTURE OF HIV-1 CAPSID PROTEIN (P24) IN COMPLEX WITH FAB13B5
1E6OL:107-209; H:121-219; H:1-120; L:1-106CRYSTAL STRUCTURE OF FAB13B5 AGAINST HIV-1 CAPSID PROTEIN P24
1EAPA:108-211; B:125-221; B:1-124; A:1-107CRYSTAL STRUCTURE OF A CATALYTIC ANTIBODY WITH A SERINE PROTEASE ACTIVE SITE
1EJOL:2113-2215; L:2001-2112; H:2620-2718; H:2501-2619FAB FRAGMENT OF NEUTRALISING MONOCLONAL ANTIBODY 4C4 COMPLEXED WITH G-H LOOP FROM FMDV.
1EMTL:109-211; H:117-215; H:1-116; L:1-108FAB ANTIBODY FRAGMENT OF AN C60 ANTIFULLERENE ANTIBODY
1ES0A:82-180; B:94-189CRYSTAL STRUCTURE OF THE MURINE CLASS II ALLELE I-A(G7) COMPLEXED WITH THE GLUTAMIC ACID DECARBOXYLASE (GAD65) PEPTIDE 207-220
1ETZB:127-225; H:127-225; A:1-110; L:1-110; B:1-126; H:1-126; A:111-210; L:111-210THE THREE-DIMENSIONAL STRUCTURE OF AN ANTI-SWEETENER FAB, NC10.14, SHOWS THE EXTENT OF STRUCTURAL DIVERSITY IN ANTIGEN RECOGNITION BY IMMUNOGLOBULINS
1F11A:109-212; A:1-108; C:1-108; B:114-227; D:114-227; B:1-113; D:1-113; C:109-211F124 FAB FRAGMENT FROM A MONOCLONAL ANTI-PRES2 ANTIBODY
1F3DL:108-211; H:122-220; K:122-220; L:1-107; J:1-108; H:1-121; K:1-121; J:109-207CATALYTIC ANTIBODY 4B2 IN COMPLEX WITH ITS AMIDINIUM HAPTEN.
1F3JA:82-181; D:82-181; B:93-191; E:93-191HISTOCOMPATIBILITY ANTIGEN I-AG7
1F4WH:118-216; L:1-110; L:111-209; H:1-117CRYSTAL STRUCTURE OF AN ANTI-CARBOHYDRATE ANTIBODY DIRECTED AGAINST VIBRIO CHOLERAE O1 IN COMPLEX WITH ANTIGEN
1F4XH:118-216; L:1-110; L:111-209; H:1-117CRYSTAL STRUCTURE OF AN ANTI-CARBOHYDRATE ANTIBODY DIRECTED AGAINST VIBRIO CHOLERAE O1 IN COMPLEX WITH ANTIGEN
1F4YH:118-216; L:1-110; L:111-209; H:1-117CRYSTAL STRUCTURE OF AN ANTI-CARBOHYDRATE ANTIBODY DIRECTED AGAINST VIBRIO CHOLERAE O1 IN COMPLEX WITH ANTIGEN
1F58L:109-211; L:1-108; H:114-227; H:1-113IGG1 FAB FRAGMENT (58.2) COMPLEX WITH 24-RESIDUE PEPTIDE (RESIDUES 308-333 OF HIV-1 GP120 (MN ISOLATE) WITH ALA TO AIB SUBSTITUTION AT POSITION 323
1F8TL:109-214; L:1-108; H:114-227; H:1-113FAB (LNKB-2) OF MONOCLONAL ANTIBODY, CRYSTAL STRUCTURE
1F90L:109-214; L:1-108; H:114-227; H:1-113FAB FRAGMENT OF MONOCLONAL ANTIBODY (LNKB-2) AGAINST HUMAN INTERLEUKIN-2 IN COMPLEX WITH ANTIGENIC PEPTIDE
1F97A:129-238; A:27-128SOLUBLE PART OF THE JUNCTION ADHESION MOLECULE FROM MOUSE
1FAIL:108-211; H:125-221; H:1-124; L:1-107THREE-DIMENSIONAL STRUCTURE OF TWO CRYSTAL FORMS OF FAB R19.9, FROM A MONOCLONAL ANTI-ARSONATE ANTIBODY
1FBIL:109-214; H:123-221; Q:123-221; P:108-211; H:1-122; Q:1-122; P:1-107; L:1-108CRYSTAL STRUCTURE OF A CROSS-REACTION COMPLEX BETWEEN FAB F9.13.7 AND GUINEA-FOWL LYSOZYME
1FDLL:109-211; H:117-215; H:1-116; L:1-108CRYSTALLOGRAPHIC REFINEMENT OF THE THREE-DIMENSIONAL STRUCTURE OF THE FAB D1.3-LYSOZYME COMPLEX AT 2.5-ANGSTROMS RESOLUTION
1FFNB:0-99; A:182-271; D:182-271; E:0-99CRYSTAL STRUCTURE OF MURINE CLASS I H-2DB COMPLEXED WITH PEPTIDE GP33(C9M)
1FFOB:0-99; A:182-271; D:182-271; E:0-99CRYSTAL STRUCTURE OF MURINE CLASS I H-2DB COMPLEXED WITH SYNTHETIC PEPTIDE GP33 (C9M/K1A)
1FFPB:0-99; A:181-271; D:181-271; E:0-99CRYSTAL STRUCTURE OF MURINE CLASS I H-2DB COMPLEXED WITH PEPTIDE GP33 (C9M/K1S)
1FG2B:1-99; A:182-272; E:1-99; D:182-272; G:182-272; J:182-272; H:1-99; K:1-99CRYSTAL STRUCTURE OF THE LCMV PEPTIDIC EPITOPE GP33 IN COMPLEX WITH THE MURINE CLASS I MHC MOLECULE H-2DB
1FGNL:109-211; H:118-214; H:1-117; L:1-108MONOCLONAL MURINE ANTIBODY 5G9-ANTI-HUMAN TISSUE FACTOR
1FIGL:109-211; H:115-223; H:1-114; L:1-108ROUTES TO CATALYSIS: STRUCTURE OF A CATALYTIC ANTIBODY AND COMPARISON WITH ITS NATURAL COUNTERPART
1FJ1A:109-211; B:114-212; D:114-212; B:1-113; D:1-113; C:109-211; A:1-108; C:1-108LYME DISEASE ANTIGEN OSPA IN COMPLEX WITH NEUTRALIZING ANTIBODY FAB LA-2
1FL3B:114-215; A:117-214; H:117-214; B:2-113; L:2-113; A:2-116; H:2-116; L:114-215CRYSTAL STRUCTURE OF THE BLUE FLUORESCENT ANTIBODY (19G2) IN COMPLEX WITH STILBENE HAPTEN AT 277K
1FL5A:109-211; A:3-108; L:3-108; B:114-213; H:114-213; B:1-113; H:1-113; L:109-211THE UNLIGANDED GERMLINE PRECURSOR TO THE SULFIDE OXIDASE CATALYTIC ANTIBODY 28B4.
1FL6A:109-211; A:3-108; L:3-108; B:114-213; H:114-213; B:1-113; H:1-113; L:109-211THE HAPTEN COMPLEXED GERMLINE PRECURSOR TO SULFIDE OXIDASE CATALYTIC ANTIBODY 28B4
1FLRL:114-219; H:119-216; L:1-113; H:1-1184-4-20 FAB FRAGMENT
1FNEA:82-181; C:82-181; B:94-188; D:94-188HISTOCOMPATIBILITY ANTIGEN
1FNGA:82-181; C:82-181; B:94-188; D:94-188HISTOCOMPATIBILITY ANTIGEN
1FNSL:108-211; H:337-435; H:215-336; L:1-107CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR (VWF) A1 DOMAIN I546V MUTANT IN COMPLEX WITH THE FUNCTION BLOCKING FAB NMC4
1FO0L:1-99; B:1-116; A:2-116; H:182-274MURINE ALLOREACTIVE SCFV TCR-PEPTIDE-MHC CLASS I MOLECULE COMPLEX
1FORL:108-210; H:121-219; H:1-120; L:1-107STRUCTURE DETERMINATION OF AN FAB FRAGMENT THAT NEUTRALIZES HUMAN RHINOVIRUS AND ANALYSIS OF THE FAB-VIRUS COMPLEX
1FRGL:115-217; H:338-436; L:1-114; H:218-337CRYSTAL STRUCTURE, SEQUENCE, AND EPITOPE MAPPING OF A PEPTIDE COMPLEX OF AN ANTI-INFLUENZA HA PEPTIDE ANTIBODY FAB 26(SLASH)9: FINE-TUNING ANTIBODY SPECIFICITY
1FZJB:1-99; A:182-273MHC CLASS I NATURAL MUTANT H-2KBM1 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND VESICULAR STOMATITIS VIRUS NUCLEOPROTEIN
1FZKB:1-99; A:182-273MHC CLASS I NATURAL MUTANT H-2KBM1 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND SENDAI VIRUS NUCLEOPROTEIN
1FZMB:1-99; A:182-273MHC CLASS I NATURAL MUTANT H-2KBM8 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND VESICULAR STOMATITIS VIRUS NUCLEOPROTEIN
1FZOB:1-99; A:182-273MHC CLASS I NATURAL MUTANT H-2KBM8 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND SENDAI VIRUS NUCLEOPROTEIN
1G6RL:1-99; H:182-274; I:182-274; M:1-99; B:3-117; D:3-117; A:117-213; C:117-213; B:118-246; D:118-246; A:1-116; C:1-116A FUNCTIONAL HOT SPOT FOR ANTIGEN RECOGNITION IN A SUPERAGONIST TCR/MHC COMPLEX
1G7HA:1-107; B:1-116CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME (HEL) COMPLEXED WITH THE MUTANT ANTI-HEL MONOCLONAL ANTIBODY D1.3(VLW92A)
1G7IA:1-107; B:1-116CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME (HEL) COMPLEXED WITH THE MUTANT ANTI-HEL MONOCLONAL ANTIBODY D1.3 (VLW92F)
1G7JA:1-107; B:1-116CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME (HEL) COMPLEXED WITH THE MUTANT ANTI-HEL MONOCLONAL ANTIBODY D1.3 (VLW92H)
1G7LA:1-107; B:1-114CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME (HEL) COMPLEXED WITH THE MUTANT ANTI-HEL MONOCLONAL ANTIBODY D1.3 (VLW92S)
1G7MA:1-107; B:1-116CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME (HEL) COMPLEXED WITH THE MUTANT ANTI-HEL MONOCLONAL ANTIBODY D1.3 (VLW92V)
1G7PB:1-99; A:182-274CRYSTAL STRUCTURE OF MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND YEAST ALPHA-GLUCOSIDASE
1G7QB:1-99; A:182-274CRYSTAL STRUCTURE OF MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND MUC1 VNTR PEPTIDE SAPDTRPA
1GCFA:1-109NMR STRUCTURE OF THE C-TERMINAL DOMAIN OF THE LIGAND-BINDING REGION OF MURINE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR, 12 STRUCTURES
1GGBL:109-211; L:1-108; H:114-227; H:1-113MAJOR ANTIGEN-INDUCED DOMAIN REARRANGEMENTS IN AN ANTIBODY
1GGCL:109-210; L:1-108; H:114-228; H:1-113MAJOR ANTIGEN-INDUCED DOMAIN REARRANGEMENTS IN AN ANTIBODY
1GGIL:108-211; L:1-107; M:1-108; J:114-227; H:114-226; H:1-113; J:1-113; M:109-211CRYSTAL STRUCTURE OF AN HIV-1 NEUTRALIZING ANTIBODY 50.1 IN COMPLEX WITH ITS V3 LOOP PEPTIDE ANTIGEN
1GHFL:108-211; H:116-213; H:1-115; L:1-107ANTI-ANTI-IDIOTYPE GH1002 FAB FRAGMENT
1GIGH:124-221; L:1-110; H:1-123; L:111-210REFINED THREE-DIMENSIONAL STRUCTURE OF THE FAB FRAGMENT OF A MURINE IGG1, LAMBDA ANTIBODY
1GPOL:114-216; H:1-113; I:1-113; H:114-212; I:114-212; M:114-216; L:1-113; M:1-113CRYSTAL STRUCTURE OF THE RATIONALLY DESIGNED ANTIBODY M41 AS A FAB FRAGMENT
1HH6A:109-211; B:113-211; B:1-112; A:1-108ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH A PEPTIDE
1HH9A:109-211; B:113-211; B:1-112; A:1-108ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH A PEPTIDE
1HI6A:109-211; B:113-211; B:1-112; A:1-108ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH A PEPTIDE
1HILC:109-211; B:114-227; D:114-226; A:1-108; C:1-108; A:109-210; B:1-113; D:1-113STRUCTURAL EVIDENCE FOR INDUCED FIT AS A MECHANISM FOR ANTIGEN-ANTIBODY RECOGNITION
1HIMH:109-211; L:114-226; M:114-226; H:1-108; J:1-108; L:1-113; M:1-113; J:109-211STRUCTURAL EVIDENCE FOR INDUCED FIT AS A MECHANISM FOR ANTIBODY-ANTIGEN RECOGNITION
1HINL:109-210; H:114-227; L:1-108; H:1-113STRUCTURAL EVIDENCE FOR INDUCED FIT AS A MECHANISM FOR ANTIBODY-ANTIGEN RECOGNITION
1HOCB:1-99; A:182-272THE THREE-DIMENSIONAL STRUCTURE OF H-2DB AT 2.4 ANGSTROMS RESOLUTION: IMPLICATIONS FOR ANTIGEN-DETERMINANT SELECTION
1HQ4A:109-211; B:114-212; D:114-212; B:1-113; D:1-113; C:109-211; A:1-108; C:1-108STRUCTURE OF NATIVE CATALYTIC ANTIBODY HA5-19A4
1I3GL:1-147; H:1-148CRYSTAL STRUCTURE OF AN AMPICILLIN SINGLE CHAIN FV, FORM 1, FREE
1I3RA:82-181; C:82-181; E:82-181; G:82-181; B:120-216; D:120-216; F:120-216; H:120-216CRYSTAL STRUCTURE OF A MUTANT IEK CLASS II MHC MOLECULE
1I8IA:1-106; B:301-419CRYSTAL STRUCTURE OF DSFV MR1 IN COMPLEX WITH THE PEPTIDE ANTIGEN OF THE MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR, EGFRVIII, AT ROOM TEMPERATURE
1I8KA:1-106; B:301-419CRYSTAL STRUCTURE OF DSFV MR1 IN COMPLEX WITH THE PEPTIDE ANTIGEN OF THE MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR, EGFRVIII, AT LIQUID NITROGEN TEMPERATURE
1I9EA:1-115TCR DOMAIN
1I9IL:115-214; H:119-217; L:1-113; H:1-118NATIVE CRYSTAL STRUCTURE OF THE RECOMBINANT MONOCLONAL WILD TYPE ANTI-TESTOSTERONE FAB FRAGMENT
1I9JL:115-214; H:119-217; L:1-113; H:1-118TESTOSTERONE COMPLEX STRUCTURE OF THE RECOMBINANT MONOCLONAL WILD TYPE ANTI-TESTOSTERONE FAB FRAGMENT
1IAIL:109-211; H:122-219; I:122-218; H:1-121; I:1-121; M:110-212; L:1-108; M:1-109IDIOTYPE-ANTI-IDIOTYPE FAB COMPLEX
1IAKA:82-181; B:93-190HISTOCOMPATIBILITY ANTIGEN I-AK
1IAOA:82-178; B:94-2TCLASS II MHC I-AD IN COMPLEX WITH OVALBUMIN PEPTIDE 323-339
1IBGL:109-211; H:115-223; L:2-108; H:2-114STRUCTURE AND SPECIFICITY OF THE ANTI-DIGOXIN ANTIBODY 40-50
1IC4L:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT(HD32A)-HEN LYSOZYME COMPLEX
1IC5L:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT(HD99A)-HEN LYSOZYME COMPLEX
1IC7L:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT(HD32A99A)-HEN LYSOZYME COMPLEX
1IEAA:82-181; C:82-181; B:94-188; D:94-188HISTOCOMPATIBILITY ANTIGEN
1IEBA:82-181; C:82-181; B:94-188; D:94-188HISTOCOMPATIBILITY ANTIGEN
1IFHL:109-211; H:114-227; L:1-108; H:1-113A DETAILED ANALYSIS OF THE FREE AND BOUND CONFORMATION OF AN ANTIBODY: X-RAY STRUCTURES OF ANTI-PEPTIDE FAB 17(SLASH)9 AND THREE DIFFERENT FAB-PEPTIDE COMPLEXES
1IGCL:109-210; L:1-108; H:122-222; H:1-121IGG1 FAB FRAGMENT (MOPC21) COMPLEX WITH DOMAIN III OF PROTEIN G FROM STREPTOCOCCUS
1IGFL:109-211; L:1-108; M:1-108; H:114-226; J:114-226; H:1-113; J:1-113; M:109-211CRYSTAL STRUCTURES OF AN ANTIBODY TO A PEPTIDE AND ITS COMPLEX WITH PEPTIDE ANTIGEN AT 2.8 ANGSTROMS
1IGIL:109-211; H:114-227; L:1-108; H:2-11326-10 FAB:DIGOXIN COMPLEX-AFFINITY AND SPECIFICITY DUE TO SURFACE COMPLEMENTARITY
1IGJA:109-211; B:114-227; D:114-227; A:1-108; C:1-108; B:2-113; D:2-113; C:109-21026-10 FAB:DIGOXIN COMPLEX-AFFINITY AND SPECIFICITY DUE TO SURFACE COMPLEMENTARITY
1IGTA:109-211; B:115-236; D:115-236; B:361-474; D:361-474; B:250-360; D:250-360; B:1-114; D:1-114; C:109-211; A:1-108; C:1-108STRUCTURE OF IMMUNOGLOBULIN
1IGYA:109-211; A:2-108; C:2-108; B:114-239; D:114-239; D:358-474; B:361-474; D:240-357; B:240-360; C:109-211; B:2-113; D:2-113STRUCTURE OF IMMUNOGLOBULIN
1IKNA:187-289; C:245-357IKAPPABALPHA/NF-KAPPAB COMPLEX
1IL1B:114-212; A:122-220; B:1-113; A:3-121CRYSTAL STRUCTURE OF G3-519, AN ANTI-HIV MONOCLONAL ANTIBODY
1INDH:115-212; L:2-110; L:111-211; H:1-114HOW THE ANTI-(METAL CHELATE) ANTIBODY CHA255 IS SPECIFIC FOR THE METAL ION OF ITS ANTIGEN: X-RAY STRUCTURES FOR TWO FAB'(SLASH)HAPTEN COMPLEXES WITH DIFFERENT METALS IN THE CHELATE
1INEH:115-212; L:2-110; L:111-211; H:1-114HOW THE ANTI-(METAL CHELATE) ANTIBODY CHA255 IS SPECIFIC FOR THE METAL ION OF ITS ANTIGEN: X-RAY STRUCTURES FOR TWO FAB'(SLASH)HAPTEN COMPLEXES WITH DIFFERENT METALS IN THE CHELATE
1INQB:1001-1099; A:182-272STRUCTURE OF MINOR HISTOCOMPATIBILITY ANTIGEN PEPTIDE, H13A, COMPLEXED TO H2-DB
1IQWL:113-215; L:1-112; H:122-220; H:1-121CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THE MOUSE ANTI-HUMAN FAS ANTIBODY HFE7A
1J05B:1-113; A:1-107; L:1-107; H:1-113THE CRYSTAL STRUCTURE OF ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY T84.66 FV FRAGMENT
1J1OL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT LY50F COMPLEXED WITH HEN EGG WHITE LYSOZYME
1J1PL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT LS91A COMPLEXED WITH HEN EGG WHITE LYSOZYME
1J1XL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT LS93A COMPLEXED WITH HEN EGG WHITE LYSOZYME
1JBJA:112-186; A:1-89CD3 EPSILON AND GAMMA ECTODOMAIN FRAGMENT COMPLEX IN SINGLE-CHAIN CONSTRUCT
1JCKA:3-117; C:3-117; A:118-246; C:118-246T-CELL RECEPTOR BETA CHAIN COMPLEXED WITH SEC3 SUPERANTIGEN
1JFQL:108-210; H:422-521; H:302-421; L:1-107ANTIGEN-BINDING FRAGMENT OF THE MURINE ANTI-PHENYLARSONATE ANTIBODY 36-71, "FAB 36-71"
1JGLL:109-211; H:114-210; H:1-113; L:1-108CRYSTAL STRUCTURE OF IMMUNOGLOBULIN FAB FRAGMENT COMPLEXED WITH 17-BETA-ESTRADIOL
1JGUL:110-209; H:114-212; L:1-108; H:1-113STRUCTURAL BASIS FOR DISFAVORED ELIMINATION REACTION IN CATALYTIC ANTIBODY 1D4
1JGVL:110-209; H:114-212; L:1-108; H:1-113STRUCTURAL BASIS FOR DISFAVORED ELIMINATION REACTION IN CATALYTIC ANTIBODY 1D4
1JHKL:109-211; H:114-210; H:2-113; L:1-108CRYSTAL STRUCTURE OF THE ANTI-ESTRADIOL ANTIBODY 57-2
1JHLL:1-108; H:1-116THREE-DIMENSIONAL STRUCTURE OF A HETEROCLITIC ANTIGEN-ANTIBODY CROSS-REACTION COMPLEX
1JN6B:1-121; B:122-216; A:1-113; A:114-209CRYSTAL STRUCTURE OF FAB-ESTRADIOL COMPLEXES
1JNHB:2-116; B:117-216; D:117-216; F:117-216; H:117-216; A:1-112; C:1-112; E:1-112; G:1-112; A:113-210; C:113-210; E:113-210; G:113-210; H:2-116; D:1-116; F:1-116CRYSTAL STRUCTURE OF FAB-ESTRADIOL COMPLEXES
1JNLL:109-211; H:115-228; H:1-114; L:1-108CRYSTAL STRUCTURE OF FAB-ESTRADIOL COMPLEXES
1JNNL:109-211; H:115-228; H:1-114; L:1-108CRYSTAL STRUCTURE OF FAB-ESTRADIOL COMPLEXES
1JP5A:1-128; B:1-128; A:129-227; B:129-227CRYSTAL STRUCTURE OF THE SINGLE-CHAIN FV FRAGMENT 1696 IN COMPLEX WITH THE EPITOPE PEPTIDE CORRESPONDING TO N-TERMINUS OF HIV-1 PROTEASE
1JPFB:1-99; A:182-272CRYSTAL STRUCTURE OF THE LCMV PEPTIDIC EPITOPE GP276 IN COMPLEX WITH THE MURINE CLASS I MHC MOLECULE H-2DB
1JPGB:1-99; A:182-271CRYSTAL STRUCTURE OF THE LCMV PEPTIDIC EPITOPE NP396 IN COMPLEX WITH THE MURINE CLASS I MHC MOLECULE H-2DB
1JRHL:109-204; H:114-217; H:1-113; I:11-105; L:1-108COMPLEX (ANTIBODY/ANTIGEN)
1JUFB:1001-1099; A:182-272STRUCTURE OF MINOR HISTOCOMPATIBILITY ANTIGEN PEPTIDE, H13B, COMPLEXED TO H2-DB
1K2DA:82-181; B:93-190CRYSTAL STRUCTURE OF THE AUTOIMMUNE MHC CLASS II I-AU COMPLEXED WITH MYELIN BASIC PROTEIN 1-11 AT 2.2A
1K3ZB:191-308; A:191-320X-RAY CRYSTAL STRUCTURE OF THE IKBB/NF-KB P65 HOMODIMER COMPLEX
1K4CB:109-211; A:119-217; A:1-118; B:1-108POTASSIUM CHANNEL KCSA-FAB COMPLEX IN HIGH CONCENTRATION OF K+
1K4DB:109-211; A:119-217; A:1-118; B:1-108POTASSIUM CHANNEL KCSA-FAB COMPLEX IN LOW CONCENTRATION OF K+
1K6QL:109-209; H:118-214; H:1-117; L:1-108CRYSTAL STRUCTURE OF ANTIBODY FAB FRAGMENT D3
1K8DB:1-99; A:182-272CRYSTAL STRUCTURE OF THE NON-CLASSICAL MHC CLASS IB QA-2 COMPLEXED WITH A SELF PEPTIDE
1K8IB:92-190; A:88-191CRYSTAL STRUCTURE OF MOUSE H2-DM
1KB5L:109-214; H:114-212; H:1-113; A:1-120; B:1-116A; L:1-108MURINE T-CELL RECEPTOR VARIABLE DOMAIN/FAB COMPLEX
1KBGL:1-99; H:182-274MHC CLASS I H-2KB PRESENTED GLYCOPEPTIDE RGY8-6H-GAL2
1KC5L:108-211; L:5-107; H:117-215; H:1-116CRYSTAL STRUCTURE OF ANTIBODY PC287 IN COMPLEX WITH PS1 PEPTIDE
1KCRL:108-210; L:1-107; H:117-215; H:1-116CRYSTAL STRUCTURE OF ANTIBODY PC283 IN COMPLEX WITH PS1 PEPTIDE
1KCSL:109-212; H:117-215; L:1-108; H:1-116CRYSTAL STRUCTURE OF ANTIBODY PC282 IN COMPLEX WITH PS1 PEPTIDE
1KCUL:109-211; L:1-108; H:117-215; H:1-116CRYSTAL STRUCTURE OF ANTIBODY PC287
1KCVL:109-211; H:117-215; L:1-108; H:1-116CRYSTAL STRUCTURE OF ANTIBODY PC282
1KELL:114-216; L:1-113; H:120-218; H:1-119CATALYTIC ANTIBODY 28B4 FAB FRAGMENT COMPLEXED WITH HAPTEN (1-[N-4'-NITROBENZYL-N-4'-CARBOXYBUTYLAMINO] METHYLPHOSPHONIC ACID)
1KEML:114-216; L:1-113; H:120-218; H:1-119CATALYTIC ANTIBODY 28B4 FAB FRAGMENT
1KIPA:1-107; B:1-116FV MUTANT Y(B 32)A (VH DOMAIN) OF MOUSE MONOCLONAL ANTIBODY D1.3 COMPLEXED WITH HEN EGG WHITE LYSOZYME
1KIQA:1-107; B:1-116FV MUTANT Y(B 101)F (VH DOMAIN) OF MOUSE MONOCLONAL ANTIBODY D1.3 COMPLEXED WITH HEN EGG WHITE LYSOZYME
1KIRA:1-107; B:1-116FV MUTANT Y(A 50)S (VL DOMAIN) OF MOUSE MONOCLONAL ANTIBODY D1.3 COMPLEXED WITH HEN EGG WHITE LYSOZYME
1KJ2L:1-99; M:1-99; A:1-116; D:1-116; B:1-116A; E:1-116A; H:182-274; I:182-274MURINE ALLOREACTIVE SCFV TCR-PEPTIDE-MHC CLASS I MOLECULE COMPLEX
1KJ3L:1-99; M:1-99; H:182-274; I:182-274MHC CLASS I H-2KB MOLECULE COMPLEXED WITH PKB1 PEPTIDE
1KN2L:109-214; L:1-108; H:114-223; H:1-113CATALYTIC ANTIBODY D2.3 COMPLEX
1KN4L:109-214; L:1-108; H:114-223; H:1-113CATALYTIC ANTIBODY D2.3 COMPLEX
1KNOA:109-211; B:121-235; D:121-235; F:121-235; B:1-120; D:1-120; F:1-120; C:109-211; E:109-211; A:1-108; C:1-108; E:1-108CRYSTAL STRUCTURE OF THE COMPLEX OF A CATALYTIC ANTIBODY FAB WITH A TRANSITION STATE ANALOG: STRUCTURAL SIMILARITIES IN ESTERASE-LIKE ABZYMES
1KPUB:1-99; A:182-274HIGH RESOLUTION CRYSTAL STRUCTURE OF THE MHC CLASS I COMPLEX H-2KB/VSV8
1KPVB:2-99; A:182-273HIGH RESOLUTION CRYSTAL STRUCTURE OF THE MHC CLASS I COMPLEX H-2KB/SEV9
1KT2A:82-181; C:82-181; B:119-215; D:119-215CRYSTAL STRUCTURE OF CLASS II MHC MOLECULE IEK BOUND TO MOTH CYTOCHROME C PEPTIDE
1KTDA:82-181; C:82-181; B:119-215; D:119-215CRYSTAL STRUCTURE OF CLASS II MHC MOLECULE IEK BOUND TO PIGEON CYTOCHROME C PEPTIDE
1KTRL:1-149; H:1-149CRYSTAL STRUCTURE OF THE ANTI-HIS TAG ANTIBODY 3D5 SINGLE-CHAIN FRAGMENT (SCFV) IN COMPLEX WITH A OLIGOHISTIDINE PEPTIDE
1L0XA:3-117; C:3-117; A:118-244; C:118-244TCR BETA CHAIN COMPLEXED WITH STREPTOCOCCAL SUPERANTIGEN SPEA
1L0YA:3-117; C:3-117; A:118-244; C:118-244T CELL RECEPTOR BETA CHAIN COMPLEXED WITH SUPERANTIGEN SPEA SOAKED WITH ZINC
1L6ZA:1-107; A:108-203CRYSTAL STRUCTURE OF MURINE CEACAM1A[1,4]: A CORONAVIRUS RECEPTOR AND CELL ADHESION MOLECULE IN THE CEA FAMILY
1L7TL:114-215; H:119-217; L:1-113; H:1-118CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-TESTOSTERONE FAB FRAGMENT
1LD9B:1-99; A:182-268; D:182-268; E:1-99THE THREE-DIMENSIONAL STRUCTURE OF AN H-2LD PEPTIDE COMPLEX EXPLAINS THE UNIQUE INTERACTION OF LD WITH BETA2M AND PEPTIDE
1LDPL:1-99; H:182-268CRYSTAL STRUCTURE OF MURINE MHC CLASS I H-2LD WITH A MIXTURE OF BOUND PEPTIDES
1LEGB:1-99; A:182-273CRYSTAL STRUCTURE OF H-2KB BOUND TO THE DEV8 PEPTIDE
1LEKB:1-99; A:182-273CRYSTAL STRUCTURE OF H-2KBM3 BOUND TO DEV8
1LK2B:1-99; A:182-2741.35A CRYSTAL STRUCTURE OF H-2KB COMPLEXED WITH THE GNYSFYAL PEPTIDE
1LMKA:2-123; A:124-312; C:124-312; E:124-312; G:124-312; C:2-123; E:2-123; G:2-123THE STRUCTURE OF A BIVALENT DIABODY
1LNUA:83-182; C:83-182; E:83-182; G:83-182; B:119-217; D:119-217; F:119-217; H:119-217CRYSTAL STRUCTURE OF CLASS II MHC MOLECULE IAB BOUND TO EALPHA3K PEPTIDE
1LO0L:114-216; H:120-218; Y:120-218; L:1-113; X:1-113; X:114-216; H:1-119; Y:1-119CATALYTIC RETRO-DIELS-ALDERASE TRANSITION STATE ANALOGUE COMPLEX
1LO2L:114-216; H:120-218; Y:120-218; L:1-113; X:1-113; X:114-216; H:1-119; Y:1-119RETRO-DIELS-ALDERASE CATALYTIC ANTIBODY
1LO3L:114-216; H:120-218; Y:120-218; L:1-113; X:1-113; H:1-119; Y:1-119; X:114-216RETRO-DIELS-ALDERASE CATALYTIC ANTIBODY: PRODUCT ANALOGUE
1LO4L:115-214; H:119-217; L:1-113; H:1-118RETRO-DIELS-ALDERASE CATALYTIC ANTIBODY 9D9
1M71A:110-209; B:114-212; A:1-108; B:1-113CRYSTAL STRUCTURE OF A MONOCLONAL FAB SPECIFIC FOR SHIGELLA FLEXNERI Y LIPOPOLYSACCHARIDE
1M7DA:110-209; B:114-212; A:1-108; B:1-113CRYSTAL STRUCTURE OF A MONOCLONAL FAB SPECIFIC FOR SHIGELLA FLEXNERI Y LIPOPOLYSACCHARIDE COMPLEXED WITH A TRISACCHARIDE
1M7IA:110-209; B:114-212; A:1-108; B:1-113CRYSTAL STRUCTURE OF A MONOCLONAL FAB SPECIFIC FOR SHIGELLA FLEXNERI Y LIPOPOLYSACCHARIDE COMPLEXED WITH A PENTASACCHARIDE
1MAJA:1-113SOLUTION STRUCTURE OF AN ISOLATED ANTIBODY VL DOMAIN
1MAKA:1-113SOLUTION STRUCTURE OF AN ISOLATED ANTIBODY VL DOMAIN
1MAML:109-211; H:121-217; H:1-120; L:1-108CRYSTAL STRUCTURE TO 2.45 A RESOLUTION OF A MONOCLONAL FAB SPECIFIC FOR THE BRUCELLA A CELL WALL POLYSACCHARIDE ANTIGEN
1MCPL:115-217; L:1-114; H:1-123; H:124-222PHOSPHOCHOLINE BINDING IMMUNOGLOBULIN FAB MC/PC603. AN X-RAY DIFFRACTION STUDY AT 2.7 ANGSTROMS
1MEXL:109-211; H:114-224; L:1-108; H:1-113ANTIBODY CATALYSIS OF A BIMOLECULAR CYCLOADDITION REACTION
1MF2M:109-211; L:1-108; M:1-108; H:114-207; N:114-207; H:1-113; N:1-113; L:109-208ANTI HIV1 PROTEASE FAB COMPLEX
1MFAL:1-110; H:251-347STRUCTURE OF A SINGLE-CHAIN FV FRAGMENT COMPLEXED WITH A CARBOHYDRATE ANTIGEN AT 1.7 ANGSTROMS RESOLUTION
1MFBH:369-467; L:1-110; L:111-212; H:251-368HIGH RESOLUTION STRUCTURES OF ANTIBODY FAB FRAGMENT COMPLEXED WITH CELL-SURFACE OLIGOSACCHARIDE OF PATHOGENIC SALMONELLA
1MFCH:369-467; L:1-110; L:111-212; H:251-368HIGH RESOLUTION STRUCTURES OF ANTIBODY FAB FRAGMENT COMPLEXED WITH CELL-SURFACE OLIGOSACCHARIDE OF PATHOGENIC SALMONELLA
1MFDH:369-467; L:1-110; L:111-211; H:251-368THE SOLUTION STRUCTURE OF A TRISACCHARIDE-ANTIBODY COMPLEX: COMPARISON OF NMR MEASUREMENTS WITH A CRYSTAL STRUCTURE
1MFEH:369-466; L:2-110; L:111-211; H:251-368RECOGNITION OF A CELL-SURFACE OLIGO-SACCHARIDE OF PATHOGENIC SALMONELLA BY AN ANTIBODY FAB FRAGMENT
1MFNA:92-184; A:1-91SOLUTION NMR STRUCTURE OF LINKED CELL ATTACHMENT MODULES OF MOUSE FIBRONECTIN CONTAINING THE RGD AND SYNERGY REGIONS, 20 STRUCTURES
1MH5L:109-211; A:1-108; L:1-108; H:114-212; B:2-113; H:2-113; B:114-191; A:109-207THE STRUCTURE OF THE COMPLEX OF THE FAB FRAGMENT OF THE ESTEROLYTIC ANTIBODY MS6-164 AND A TRANSITION-STATE ANALOG
1MHCB:1-99; A:182-276; D:182-276; E:1-99MODEL OF MHC CLASS I H2-M3 WITH NONAPEPTIDE FROM RAT ND1 REFINED AT 2.3 ANGSTROMS RESOLUTION
1MHHA:109-211; B:114-211; D:114-211; A:1-108; C:1-108; B:1-113; D:1-113; C:109-211ANTIBODY-ANTIGEN COMPLEX
1MIEL:109-211; L:1-108; H:114-223; H:5-113CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ESTEROLYTIC ANTIBODY MS5-393
1MJ7L:109-211; L:1-108; H:114-222; H:4-113CRYSTAL STRUCTURE OF THE COMPLEX OF THE FAB FRAGMENT OF ESTEROLYTIC ANTIBODY MS5-393 AND A TRANSITION-STATE ANALOG
1MJ8L:109-211; L:1-108; H:114-227; H:2-113HIGH RESOLUTION CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THE ESTEROLYTIC ANTIBODY MS6-126
1MJJA:109-211; A:1-108; L:1-108; B:114-227; H:114-226; B:2-113; H:2-113; L:109-211HIGH RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX OF THE FAB FRAGMENT OF ESTEROLYTIC ANTIBODY MS6-12 AND A TRANSITION-STATE ANALOG
1MJUL:109-211; L:1-108; H:114-227; H:2-1131.22 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ESTEROLYTIC ANTIBODY MS6-12
1MLBA:109-211; B:117-215; A:1-108; B:1-116MONOCLONAL ANTIBODY FAB D44.1 RAISED AGAINST CHICKEN EGG-WHITE LYSOZYME
1MLCA:109-211; B:117-215; D:117-214; C:109-211; A:1-108; C:1-108; B:1-116; D:1-116MONOCLONAL ANTIBODY FAB D44.1 RAISED AGAINST CHICKEN EGG-WHITE LYSOZYME COMPLEXED WITH LYSOZYME
1MNUL:114-216; H:122-220; L:1-113; H:1-121UNLIGANDED BACTERICIDAL ANTIBODY AGAINST NEISSERIA MENINGITIDIS
1MOEA:1-112; B:1-112; A:113-211; B:113-211THE THREE-DIMENSIONAL STRUCTURE OF AN ENGINEERED SCFV T84.66 DIMER OR DIABODY IN VL TO VH LINKAGE.
1MPAL:114-216; H:122-220; L:1-113; H:1-121BACTERICIDAL ANTIBODY AGAINST NEISSERIA MENINGITIDIS
1MQKL:1-109; H:1-123CRYSTAL STRUCTURE OF THE UNLIGANDED FV-FRAGMENT OF THE ANTI-CYTOCHROME C OXIDASE ANTIBODY 7E2
1MRCL:108-211; H:114-222; L:1-107; H:1-113PREPARATION, CHARACTERIZATION AND CRYSTALLIZATION OF AN ANTIBODY FAB FRAGMENT THAT RECOGNIZES RNA. CRYSTAL STRUCTURES OF NATIVE FAB AND THREE FAB-MONONUCLEOTIDE COMPLEXES
1MRDL:108-211; H:114-223; L:1-107; H:2-113PREPARATION, CHARACTERIZATION AND CRYSTALLIZATION OF AN ANTIBODY FAB FRAGMENT THAT RECOGNIZES RNA. CRYSTAL STRUCTURES OF NATIVE FAB AND THREE FAB-MONONUCLEOTIDE COMPLEXES
1MREL:109-211; H:114-223; L:1-108; H:1-113PREPARATION, CHARACTERIZATION AND CRYSTALLIZATION OF AN ANTIBODY FAB FRAGMENT THAT RECOGNIZES RNA. CRYSTAL STRUCTURES OF NATIVE FAB AND THREE FAB-MONONUCLEOTIDE COMPLEXES
1MRFL:109-211; H:114-223; L:1-108; H:2-113PREPARATION, CHARACTERIZATION AND CRYSTALLIZATION OF AN ANTIBODY FAB FRAGMENT THAT RECOGNIZES RNA. CRYSTAL STRUCTURES OF NATIVE FAB AND THREE FAB-MONONUCLEOTIDE COMPLEXES
1MUJA:82-181; B:95-192CRYSTAL STRUCTURE OF MURINE CLASS II MHC I-AB IN COMPLEX WITH A HUMAN CLIP PEPTIDE
1MVUB:1-121; A:1-112SINGLE CHAIN FV OF C219 HEAVY CHAIN V101L MUTANT IN COMPLEX WITH SYNTHETIC EPITOPE PEPTIDE
1MWAL:1-99; H:182-274; I:182-274; B:3-117; D:3-117; A:117-213; C:117-213; B:118-246; D:118-246; A:1-116; C:1-116; M:1-992C/H-2KBM3/DEV8 ALLOGENEIC COMPLEX
1MY5A:191-297; B:191-291NF-KAPPAB P65 SUBUNIT DIMERIZATION DOMAIN HOMODIMER
1MY7A:191-297; B:191-292NF-KAPPAB P65 SUBUNIT DIMERIZATION DOMAIN HOMODIMER N202R MUTATION
1N3NB:1-99; A:182-272; C:182-272; E:182-272; G:182-272; D:1-99; F:1-99; H:1-99CRYSTAL STRUCTURE OF A MYCOBACTERIAL HSP60 EPITOPE WITH THE MURINE CLASS I MHC MOLECULE H-2DB
1N4XL:0-112; M:0-112; I:301-419; H:301-420STRUCTURE OF SCFV 1696 AT ACIDIC PH
1N59B:1-99; A:182-274; C:182-274; D:1-99CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX OF H-2KB, B2-MICROGLOBULIN, AND A 9-RESIDUE IMMUNODOMINANT PEPTIDE EPITOPE GP33 DERIVED FROM LCMV
1N5AE:1-99; A:182-272; D:182-272; G:182-272; J:182-272; H:1-99; K:1-99; B:1-98CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX OF H-2DB, B2-MICROGLOBULIN, AND A 9-RESIDUE IMMUNODOMINANT PEPTIDE EPITOPE GP33 DERIVED FROM LCMV
1N64L:109-211; H:114-212; L:1-108; H:1-113CRYSTAL STRUCTURE ANALYSIS OF THE IMMUNODOMINANT ANTIGENIC SITE ON HEPATITIS C VIRUS PROTEIN BOUND TO MAB 19D9D6
1NAKL:110-209; H:114-226; I:114-226; L:1-108; M:1-108; H:1-113; I:1-113; M:110-209IGG1 FAB FRAGMENT (83.1) COMPLEX WITH 16-RESIDUE PEPTIDE (RESIDUES 304-321 OF HIV-1 GP120 (MN ISOLATE))
1NAML:0-99; B:1-116A; A:1-116; H:182-274MURINE ALLOREACTIVE SCFV TCR-PEPTIDE-MHC CLASS I MOLECULE COMPLEX
1NANI:1-99; P:1-99; H:182-274; L:182-274MCH CLASS I H-2KB MOLECULE COMPLEXED WITH PBM1 PEPTIDE
1NBVL:115-214; H:122-219; L:1-113; H:1-121AN AUTOANTIBODY TO SINGLE-STRANDED DNA: COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF THE UNLIGANDED FAB AND A DEOXYNUCLEOTIDE-FAB COMPLEX
1NBYA:109-211; B:414-510; B:301-413; A:1-108CRYSTAL STRUCTURE OF HYHEL-63 COMPLEXED WITH HEL MUTANT K96A
1NBZA:109-211; B:414-509; B:301-413; A:1-108CRYSTAL STRUCTURE OF HYHEL-63 COMPLEXED WITH HEL MUTANT K97A
1NC2B:120-218; D:120-218; A:1-110; C:1-110; B:2-119; D:1-119; A:111-210; C:111-210CRYSTAL STRUCTURE OF MONOCLONAL ANTIBODY 2D12.5 FAB COMPLEXED WITH Y-DOTA
1NC4B:120-218; D:120-218; A:1-110; C:1-110; D:1-119; B:2-119; A:111-210; C:111-210CRYSTAL STRUCTURE OF MONOCLONAL ANTIBODY 2D12.5 FAB COMPLEXED WITH GD-DOTA
1NCWL:109-214; L:1-108; H:114-227; H:1-113CATIONIC CYCLIZATION ANTIBODY 4C6 IN COMPLEX WITH BENZOIC ACID
1ND0A:109-214; A:1-108; C:1-108; E:1-108; G:1-108; B:114-227; D:114-227; F:114-227; H:114-227; B:1-113; D:1-113; F:1-113; H:1-113; C:109-214; E:109-214; G:109-214CATIONIC CYCLIZATION ANTIBODY 4C6 COMPLEX WITH TRANSITION STATE ANALOG
1NDGA:109-211; B:301-413; B:414-520; A:1-108CRYSTAL STRUCTURE OF FAB FRAGMENT OF ANTIBODY HYHEL-8 COMPLEXED WITH ITS ANTIGEN LYSOZYME
1NDMA:109-211; B:414-521; B:301-413; A:1-108CRYSTAL STRUCTURE OF FAB FRAGMENT OF ANTIBODY HYHEL-26 COMPLEXED WITH LYSOZYME
1NFDF:114-226; H:114-226; E:2-107; G:2-107; B:3-117; D:3-117; E:108-215; G:108-215; F:1-113; H:1-113; A:117-213; C:117-213; B:118-246; D:118-246; A:1-116; C:1-116AN ALPHA-BETA T CELL RECEPTOR (TCR) HETERODIMER IN COMPLEX WITH AN ANTI-TCR FAB FRAGMENT DERIVED FROM A MITOGENIC ANTIBODY
1NGPH:1-120; H:121-219; L:1-110; L:111-210N1G9 (IGG1-LAMBDA) FAB FRAGMENT COMPLEXED WITH (4-HYDROXY-3-NITROPHENYL) ACETATE
1NGQH:1-120; H:121-219; L:1-110; L:111-210N1G9 (IGG1-LAMBDA) FAB FRAGMENT
1NJ9H:114-212; B:114-211; A:1-109; L:1-109; B:1-113; H:1-113; A:110-208; L:110-208COCAINE HYDROLYTIC ANTIBODY 15A10
1NLBL:109-211; H:114-212; L:1-108; H:1-113CRYSTAL STRUCTURE OF ANTI-HCV MONOCLONAL ANTIBODY 19D9D6
1NLDL:109-214; L:1-108; H:114-212; H:1-113FAB FRAGMENT OF A NEUTRALIZING ANTIBODY DIRECTED AGAINST AN EPITOPE OF GP41 FROM HIV-1
1NPUA:1-116CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF MURINE PD-1
1NQBA:3-120; A:121-219; C:121-219; C:3-120TRIVALENT ANTIBODY FRAGMENT
1NSNL:109-211; L:1-108; H:114-223; H:1-113THE CRYSTAL STRUCTURE OF ANTIBODY N10-STAPHYLOCOCCAL NUCLEASE COMPLEX AT 2.9 ANGSTROMS RESOLUTION
1OAKL:108-211; H:337-435; H:215-336; L:1-107CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR (VWF) A1 DOMAIN IN COMPLEX WITH THE FUNCTION BLOCKING NMC-4 FAB
1ORQA:110-212; B:119-217; B:1-118; A:1-109X-RAY STRUCTURE OF A VOLTAGE-DEPENDENT POTASSIUM CHANNEL IN COMPLEX WITH AN FAB
1ORSA:109-211; B:119-217; B:1-118; A:1-108X-RAY STRUCTURE OF THE KVAP POTASSIUM CHANNEL VOLTAGE SENSOR IN COMPLEX WITH AN FAB
1OSPL:109-211; H:1-120; H:121-218; L:1-108CRYSTAL STRUCTURE OF OUTER SURFACE PROTEIN A OF BORRELIA BURGDORFERI COMPLEXED WITH A MURINE MONOCLONAL ANTIBODY FAB
1OSZB:1-99; A:182-274MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND AN (L4V) MUTANT OF THE VESICULAR STOMATITIS VIRUS NUCLEOPROTEIN
1OY3C:191-325; B:191-302CRYSTAL STRUCTURE OF AN IKBBETA/NF-KB P65 HOMODIMER COMPLEX
1P1ZB:1-99; A:182-274X-RAY CRYSTAL STRUCTURE OF THE LECTIN-LIKE NATURAL KILLER CELL RECEPTOR LY-49C BOUND TO ITS MHC CLASS I LIGAND H-2KB
1P2CA:109-211; B:417-515; E:1317-1415; D:1009-1111; A:1-108; D:901-1008; B:301-416; E:1201-1316CRYSTAL STRUCTURE ANALYSIS OF AN ANTI-LYSOZYME ANTIBODY
1P4BL:0-148; H:1-148THREE-DIMENSIONAL STRUCTURE OF A SINGLE CHAIN FV FRAGMENT COMPLEXED WITH THE PEPTIDE GCN4(7P-14P).
1P4IL:0-148; H:1-148CRYSTAL STRUCTURE OF SCFV AGAINST PEPTIDE GCN4
1P4LB:1-99; A:182-274CRYSTAL STRUCTURE OF NK RECEPTOR LY49C MUTANT WITH ITS MHC CLASS I LIGAND H-2KB
1P7KL:109-212; H:114-211; B:114-211; A:109-211; H:2-113; B:1-113; A:1-108; L:1-108CRYSTAL STRUCTURE OF AN ANTI-SSDNA ANTIGEN-BINDING FRAGMENT (FAB) BOUND TO 4-(2-HYDROXYETHYL)PIPERAZINE-1-ETHANESULFONIC ACID (HEPES)
1PKQA:109-211; B:114-213; G:114-212; A:1-108; F:1-108; J:1-118; E:1A-119; F:109-210; B:1-113; G:1-113MYELIN OLIGODENDROCYTE GLYCOPROTEIN-(8-18C5) FAB-COMPLEX
1PLGL:114-215; H:118-215; L:1-113; H:1-117EVIDENCE FOR THE EXTENDED HELICAL NATURE OF POLYSACCHARIDE EPITOPES. THE 2.8 ANGSTROMS RESOLUTION STRUCTURE AND THERMODYNAMICS OF LIGAND BINDING OF AN ANTIGEN BINDING FRAGMENT SPECIFIC FOR ALPHA-(2->8)-POLYSIALIC ACID
1PSKL:108-210; H:115-207; H:1-114; L:1-107THE CRYSTAL STRUCTURE OF AN FAB FRAGMENT THAT BINDS TO THE MELANOMA-ASSOCIATED GD2 GANGLIOSIDE
1PY9A:2-117THE CRYSTAL STRUCTURE OF AN AUTOANTIGEN IN MULTIPLE SCLEROSIS
1PZ5A:110-209; B:114-212; A:1-108; B:1-113STRUCTURAL BASIS OF PEPTIDE-CARBOHYDRATE MIMICRY IN AN ANTIBODY COMBINING SITE
1Q0XH:1-113; H:114-227; L:1-107; L:108-210ANTI-MORPHINE ANTIBODY 9B1 UNLIGANDED FORM
1Q0YH:1-113; H:114-227; L:1-107; L:108-210ANTI-MORPHINE ANTIBODY 9B1 COMPLEXED WITH MORPHINE
1Q72L:109-213; L:1-108; H:1-113; H:114-216ANTI-COCAINE ANTIBODY M82G2 COMPLEXED WITH COCAINE
1Q9KA:108-210; B:112-210; A:1-107; B:1-111S25-2 FAB UNLIGANDED 1
1Q9LA:108-210; B:112-210; D:112-210; A:1-107; C:1-107; B:1-111; D:1-111; C:108-210S25-2 FAB UNLIGANDED 2
1Q9OA:108-210; D:112-213; B:112-210; C:108-210; A:1-107; C:1-107; B:1-111; D:1-111S45-18 FAB UNLIGANDED
1Q9Q  [entry was replaced by entry 3SY0 without any CATH domain information]
1Q9R  [entry was replaced by entry 3T65 without any CATH domain information]
1Q9T  [entry was replaced by entry 3T77 without any CATH domain information]
1Q9V  [entry was replaced by entry 3T4Y without any CATH domain information]
1Q9WA:108-210; B:112-210; D:112-209; C:108-210; A:1-107; C:1-107; B:1-111; D:1-111S45-18 FAB PENTASACCHARIDE BISPHOSPHATE COMPLEX
1QBLL:109-211; H:118-216; H:1-117; L:1-108FAB E8 (FABE8A) X-RAY STRUCTURE AT 2.26 ANGSTROM RESOLUTION
1QBML:109-211; H:118-216; H:1-117; L:1-108FAB E8B ANTIBODY, X-RAY STRUCTURE AT 2.37 ANGSTROMS RESOLUTION
1QFOC:1-119; A:1-118; B:1-118N-TERMINAL DOMAIN OF SIALOADHESIN (MOUSE) IN COMPLEX WITH 3'SIALYLLACTOSE
1QFPA:1-119N-TERMINAL DOMAIN OF SIALOADHESIN (MOUSE)
1QYGL:109-205; L:1-108; H:1-113; H:114-216ANTI-COCAINE ANTIBODY M82G2 COMPLEXED WITH BENZOYLECGONINE
1R24A:109-206; B:123-217; D:123-217; B:1-122; D:1-122; C:109-206; A:1-108; C:1-108FAB FROM MURINE IGG3 KAPPA
1R3HB:2001-2099; A:1184-1276; C:3184-3276; G:7184-7274; E:5184-5273; D:4001-4099; F:6001-6099; H:8001-8099CRYSTAL STRUCTURE OF T10
1R3IL:109-211; H:119-217; H:1-118; L:1-108POTASSIUM CHANNEL KCSA-FAB COMPLEX IN RB+
1R3JA:109-211; B:119-217; B:1-118; A:1-108POTASSIUM CHANNEL KCSA-FAB COMPLEX IN HIGH CONCENTRATION OF TL+
1R3KA:109-211; B:119-217; B:1-118; A:1-108POTASSIUM CHANNEL KCSA-FAB COMPLEX IN LOW CONCENTRATION OF TL+
1R3LA:109-211; B:119-217; B:1-118; A:1-108POTASSIUM CHANNEL KCSA-FAB COMPLEX IN CS+
1R5VA:82-181; C:82-181; B:120-215; D:120-215EVIDENCE THAT STRUCTURAL REARRANGEMENTS AND/OR FLEXIBILITY DURING TCR BINDING CAN CONTRIBUTE TO T-CELL ACTIVATION
1R5WA:82-181; C:82-181; B:120-215; D:120-215EVIDENCE THAT STRUCTURAL REARRANGEMENTS AND/OR FLEXIBILITY DURING TCR BINDING CAN CONTRIBUTE TO T-CELL ACTIVATION
1RFDL:109-205; L:1-108; H:1-113; H:114-216ANTI-COCAINE ANTIBODY M82G2
1RIHL:109-211; H:114-211; L:1-108; H:1-113CRYSTAL STRUCTURE OF FAB 14F7, A UNIQUE ANTI-TUMOR ANTIBODY SPECIFIC FOR N-GLYCOLYL GM3
1RIUL:109-205; L:1-108; H:1-113; H:114-216ANTI-COCAINE ANTIBODY M82G2 COMPLEXED WITH NORBENZOYLECGONINE
1RIVL:109-205; L:1-108; H:1-113; H:114-216ANTI-COCAINE ANTIBODY M82G2 COMPLEXED WITH META-OXYBENZOYLECGONINE
1RJLA:109-211; B:121-219; B:1-120; A:1-108STRUCTURE OF THE COMPLEX BETWEEN OSPB-CT AND BACTERICIDAL FAB-H6831
1RJYB:0-99; E:0-99; A:182-274; D:182-274MHC CLASS I NATURAL MUTANT H-2KBM8 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND HERPES SIMPLEX VIRUS GLYCOPROTEIN B PEPTIDE
1RJZB:0-99; E:0-99; A:182-274; D:182-274MHC CLASS I NATURAL MUTANT H-2KBM8 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND HERPIES SIMPLEX VIRUS MUTANT GLYCOPROTEIN B PEPTIDE
1RK0B:1-99; A:184-272MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND HERPES SIMPLEX VIRUS GLYCOPROTEIN B PEPTIDE
1RK1B:1-99; A:184-272MHC CLASS I NATURAL H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND HERPES SIMPLEX VIRUS MUTANT GLYCOPROTEIN B PEPTIDE
1RMFL:114-217; H:120-216; L:1-113; H:1-119STRUCTURES OF A MONOCLONAL ANTI-ICAM-1 ANTIBODY R6.5 FRAGMENT AT 2.8 ANGSTROMS RESOLUTION
1RU9L:109-214; L:1-108; H:114-227; H:1-113CRYSTAL STRUCTURE (A) OF U.V.-IRRADIATED CATIONIC CYCLIZATION ANTIBODY 4C6 FAB AT PH 4.6 WITH A DATA SET COLLECTED IN-HOUSE.
1RUAL:109-214; L:1-108; H:114-227; H:1-113CRYSTAL STRUCTURE (B) OF U.V.-IRRADIATED CATIONIC CYCLIZATION ANTIBODY 4C6 FAB AT PH 4.6 WITH A DATA SET COLLECTED AT SSRL BEAMLINE 11-1.
1RUKL:109-214; L:1-108; H:114-227; H:1-113CRYSTAL STRUCTURE (C) OF NATIVE CATIONIC CYCLIZATION ANTIBODY 4C6 FAB AT PH 4.6 WITH A DATA SET COLLECTED AT SSRL BEAMLINE 9-1
1RULL:109-214; L:1-108; H:114-227; H:1-113CRYSTAL STRUCTURE (D) OF U.V.-IRRADIATED CATIONIC CYCLIZATION ANTIBODY 4C6 FAB AT PH 5.6 WITH A DATA SET COLLECTED AT SSRL BEAMLINE 11-1.
1RUML:109-214; L:1-108; H:114-227; H:1-113CRYSTAL STRUCTURE (F) OF H2O2-SOAKED CATIONIC CYCLIZATION ANTIBODY 4C6 FAB AT PH 8.5 WITH A DATA SET COLLECTED AT SSRL BEAMLINE 9-1.
1RUPL:109-214; L:1-108; H:114-227; H:1-113CRYSTAL STRUCTURE (G) OF NATIVE CATIONIC CYCLIZATION ANTIBODY 4C6 FAB AT PH 8.5 WITH A DATA SET COLLECTED AT APS BEAMLINE 19-ID
1RUQL:109-211; H:114-227; L:1-108; H:1-113CRYSTAL STRUCTURE (H) OF U.V.-IRRADIATED DIELS-ALDER ANTIBODY 13G5 FAB AT PH 8.0 WITH A DATA SET COLLECTED IN HOUSE.
1RURL:109-211; H:114-227; L:1-108; H:1-113CRYSTAL STRUCTURE (I) OF NATIVE DIELS-ALDER ANTIBODY 13G5 FAB AT PH 8.0 WITH A DATA SET COLLECTED AT SSRL BEAMLINE 9-1.
1S5HA:109-211; B:119-217; B:1-118; A:1-108POTASSIUM CHANNEL KCSA-FAB COMPLEX T75C MUTANT IN K+
1S5IL:109-214; L:1-108; H:114-227; H:1-113FAB (LNKB-2) OF MONOCLONAL ANTIBODY TO HUMAN INTERLEUKIN-2, CRYSTAL STRUCTURE
1S7QB:1-99; A:182-274CRYSTAL STRUCTURES OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2KB IN COMPLEX WITH LCMV-DERIVED GP33 INDEX PEPTIDE AND THREE OF ITS ESCAPE VARIANTS
1S7RB:1-99; A:182-274; D:182-274; E:1-99CRYSTAL STRUCTURES OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2KB IN COMPLEX WITH LCMV-DERIVED GP33 INDEX PEPTIDE AND THREE OF ITS ESCAPE VARIANTS
1S7SB:1-99; A:182-274CRYSTAL STRUCTURES OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2KB IN COMPLEX WITH LCMV-DERIVED GP33 INDEX PEPTIDE AND THREE OF ITS ESCAPE VARIANTS
1S7TB:1-99; E:1-99; A:182-274; D:182-274CRYSTAL STRUCTURES OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2KB IN COMPLEX WITH LCMV-DERIVED GP33 INDEX PEPTIDE AND THREE OF ITS ESCAPE VARIANTS
1S7UB:1-99; A:182-272; D:182-272; G:182-272; J:182-272; E:1-99; H:1-99; K:1-99CRYSTAL STRUCTURES OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH LCMV-DERIVED GP33 INDEX PEPTIDE AND THREE OF ITS ESCAPE VARIANTS
1S7VB:1-99; A:182-272; D:182-272; E:1-99CRYSTAL STRUCTURES OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH LCMV-DERIVED GP33 INDEX PEPTIDE AND THREE OF ITS ESCAPE VARIANTS
1S7WE:1-99; A:182-272; D:182-272; G:182-272; J:182-272; H:1-99; K:1-99; B:1-98CRYSTAL STRUCTURES OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH LCMV-DERIVED GP33 INDEX PEPTIDE AND THREE OF ITS ESCAPE VARIANTS
1S7XB:1-99; A:182-272; D:182-272; G:182-272; J:182-272; E:1-99; H:1-99; K:1-99CRYSTAL STRUCTURES OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX H-2DB IN COMPLEX WITH LCMV-DERIVED GP33 INDEX PEPTIDE AND THREE OF ITS ESCAPE VARIANTS
1SBBA:3-117; C:3-117; A:118-246; C:118-246T-CELL RECEPTOR BETA CHAIN COMPLEXED WITH SUPERANTIGEN SEB
1SBSL:115-213; H:124-222; L:1-114; H:1-123CRYSTAL STRUCTURE OF AN ANTI-HCG FAB
1SEQL:108-210; H:1-113; H:114-213; L:1-107FAB MNAC13
1SM3H:114-212; L:3-107; L:108-207; H:1-113CRYSTAL STRUCTURE OF THE TUMOR SPECIFIC ANTIBODY SM3 COMPLEX WITH ITS PEPTIDE EPITOPE
1SVZA:1-128; B:1-128; A:129-227; B:129-227CRYSTAL STRUCTURE OF THE SINGLE-CHAIN FV FRAGMENT 1696 IN COMPLEX WITH THE EPITOPE PEPTIDE CORRESPONDING TO N-TERMINUS OF HIV-2 PROTEASE
1SY6L:108-210; H:120-219; A:118-203; A:0-81; H:1-119; L:1-107CRYSTAL STRUCTURE OF CD3GAMMAEPSILON HETERODIMER IN COMPLEX WITH OKT3 FAB FRAGMENT
1T0MB:1-99; E:1-99; A:182-274; D:182-274CONFORMATIONAL SWITCH IN POLYMORPHIC H-2K MOLECULES CONTAINING AN HSV PEPTIDE
1T0NB:1-99; E:1-99; A:182-274; D:182-274CONFORMATIONAL SWITCH IN POLYMORPHIC H-2K MOLECULES CONTAINING AN HSV PEPTIDE
1T2QL:116-215; H:120-218; L:2-114; H:1-119THE CRYSTAL STRUCTURE OF AN NNA7 FAB THAT RECOGNIZES AN N-TYPE BLOOD GROUP ANTIGEN
1T4KA:109-211; B:114-228; D:114-228; A:1-108; C:1-108; B:1-113; D:1-113; C:109-211CRYSTAL STRUCTURE OF UNLIGANDED ALDOLASE ANTIBODY 93F3 FAB
1T66C:114-216; D:119-216; H:119-216; C:1-113; L:1-113; D:1-118; H:1-118; L:114-216THE STRUCTURE OF FAB WITH INTERMEDIATE AFFINITY FOR FLUORESCEIN.
1TCRB:3-117; A:117-213; B:118-246; A:1-116MURINE T-CELL ANTIGEN RECEPTOR 2C CLONE
1TETL:109-211; L:1-108; H:114-212; H:1-113CRYSTAL STRUCTURE OF AN ANTICHOLERA TOXIN PEPTIDE COMPLEX AT 2.3 ANGSTROMS
1TZIA:109-211; B:114-213; B:1-113; A:1-108CRYSTAL STRUCTURE OF THE FAB YADS2 COMPLEXED WITH H-VEGF
1U2CA:58-160CRYSTAL STRUCTURE OF A-DYSTROGLYCAN
1U36A:247-350CRYSTAL STRUCTURE OF WLAC MUTANT OF DIMERISATION DOMAIN OF NF-KB P50 TRANSCRIPTION FACTOR
1U3HB:3-117; F:3-117; C:82-181; G:82-181; D:93-190; H:93-190; A:2-116; E:2-116CRYSTAL STRUCTURE OF MOUSE TCR 172.10 COMPLEXED WITH MHC CLASS II I-AU MOLECULE AT 2.4 A
1U3JA:247-350CRYSTAL STRUCTURE OF MLAV MUTANT OF DIMERISATION DOMAIN OF NF-KB P50 TRANSCRIPTION FACTOR
1U3YA:247-350CRYSTAL STRUCTURE OF ILAC MUTANT OF DIMERISATION DOMAIN OF NF-KB P50 TRANSCRIPTION FACTOR
1U3ZA:247-350CRYSTAL STRUCTURE OF MLAC MUTANT OF DIMERISATION DOMAIN OF NF-KB P50 TRANSCRIPTION FACTOR
1U41A:247-350; D:245-350; B:247-350; C:248-350CRYSTAL STRUCTURE OF YLGV MUTANT OF DIMERISATION DOMAIN OF NF-KB P50 TRANSCRIPTION FACTOR
1U42A:246-350CRYSTAL STRUCTURE OF MLAM MUTANT OF DIMERISATION DOMAIN OF NF-KB P50 TRANSCRIPTION FACTOR
1U9KA:25-134; B:25-134CRYSTAL STRUCTURE OF MOUSE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 (TREM-1) AT 1.76
1UA6L:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT SFSF COMPLEXED WITH HEN EGG WHITE LYSOZYME COMPLEX
1UACL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT SFSF COMPLEXED WITH TURKEY WHITE LYSOZYME
1UB5B:114-214; A:117-214; H:117-214; B:2-113; L:2-113; A:2-116; H:2-116; L:114-214CRYSTAL STRUCTURE OF ANTIBODY 19G2 WITH HAPTEN AT 100K
1UB6B:114-214; A:117-214; H:117-214; B:2-113; L:2-113; A:2-116; H:2-116; L:114-214CRYSTAL STRUCTURE OF ANTIBODY 19G2 WITH SERA LIGAND
1UM4L:111-213; H:120-219; H:3-119; L:3-110CATALYTIC ANTIBODY 21H3 WITH HAPTEN
1UM5L:111-213; H:120-219; H:3-119; L:3-110CATALYTIC ANTIBODY 21H3 WITH ALCOHOL SUBSTRATE
1UM6L:111-213; H:120-219; H:3-119; L:3-110CATALYTIC ANTIBODY 21H3
1V7ML:108-209; H:117-205; I:117-205; H:1-116; I:1-116; M:108-209; L:1-107; M:1-107HUMAN THROMBOPOIETIN FUNCTIONAL DOMAIN COMPLEXED TO NEUTRALIZING ANTIBODY TN1 FAB
1V7NL:108-209; H:117-205; I:117-205; J:117-205; K:117-205; H:1-116; I:1-116; J:1-116; K:1-116; N:108-209; M:108-208; O:108-208; L:1-107; M:1-107; N:1-107; O:1-107HUMAN THROMBOPOIETIN FUNCTIONAL DOMAIN COMPLEXED TO NEUTRALIZING ANTIBODY TN1 FAB
1VACB:1-99; A:182-274MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND CHICKEN OVALBUMIN
1VADB:1-99; A:182-274MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND YEAST ALPHA-GLUCOSIDASE
1VFAA:1-108; B:1-116BOUND WATER MOLECULES AND CONFORMATIONAL STABILIZATION HELP MEDIATE AN ANTIGEN-ANTIBODY ASSOCIATION
1VFBA:1-107; B:1-116BOUND WATER MOLECULES AND CONFORMATIONAL STABILIZATION HELP MEDIATE AN ANTIGEN-ANTIBODY ASSOCIATION
1VGKB:1-99; A:182-272THE CRYSTAL STRUCTURE OF CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX, H-2KD AT 2.0 A RESOLUTION
1VPOL:114-216; H:119-217; L:1-113; H:1-118CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-TESTOSTERONE FAB IN COMPLEX WITH TESTOSTERONE
1WEJL:109-211; H:118-216; H:1-117; L:1-108IGG1 FAB FRAGMENT (OF E8 ANTIBODY) COMPLEXED WITH HORSE CYTOCHROME C AT 1.8 A RESOLUTION
1WZ1L:1-113; H:1-123CRYSTAL STRUCTURE OF THE FV FRAGMENT COMPLEXED WITH DANSYL-LYSINE
1XAUA:11-114STRUCTURE OF THE BTLA ECTODOMAIN
1XF3A:109-213; B:114-212; H:114-212; H:3-113; B:1-113; L:109-213; A:1-108; L:1-108STRUCTURE OF LIGAND-FREE FAB DNA-1 IN SPACE GROUP P65
1XF4A:109-213; B:114-212; H:114-212; B:1-113; H:1-113; L:109-213; A:1-108; L:1-108STRUCTURE OF LIGAND-FREE FAB DNA-1 IN SPACE GROUP P321 SOLVED FROM CRYSTALS WITH PERFECT HEMIHEDRAL TWINNING
1XGPA:109-211; B:114-210; B:1-113; A:0-108STRUCTURE FOR ANTIBODY HYHEL-63 Y33A MUTANT COMPLEXED WITH HEN EGG LYSOZYME
1XGQA:109-211; B:114-210; B:1-113; A:0-108STRUCTURE FOR ANTIBODY HYHEL-63 Y33V MUTANT COMPLEXED WITH HEN EGG LYSOZYME
1XGYL:109-211; H:115-214; I:115-214; L:1-108; M:1-108; M:109-211; H:1-114; I:1-114CRYSTAL STRUCTURE OF ANTI-META I RHODOPSIN FAB FRAGMENT K42-41L
1YECL:109-214; L:1-108; H:114-223; H:1-113STRUCTURE OF A CATALYTIC ANTIBODY IGG2A FAB FRAGMENT (D2.3)
1YEDA:112-222; A:1-111; L:1-111; B:116-214; H:116-214; L:112-222; B:1-113; H:1-113STRUCTURE OF A CATALYTIC ANTIBODY IGG2A FAB FRAGMENT (D2.4)
1YEEL:109-214; L:1-108; H:114-223; H:1-113STRUCTURE OF A CATALYTIC ANTIBODY, IGG2A FAB FRAGMENT (D2.5)
1YEFL:109-214; L:1-108; H:114-223; H:1-113STRUCTURE OF IGG2A FAB FRAGMENT (D2.3) COMPLEXED WITH SUBSTRATE ANALOGUE
1YEGL:109-214; L:1-108; H:114-223; H:1-113STRUCTURE OF IGG2A FAB FRAGMENT (D2.3) COMPLEXED WITH REACTION PRODUCT
1YEIL:109-214; L:1-108; H:114-223; H:1-113CATALYTIC ANTIBODY D2.3 COMPLEX
1YEJL:109-214; L:1-108; H:114-223; H:1-113CATALYTIC ANTIBODY COMPLEX
1YEKL:109-214; L:1-108; H:114-223; H:1-113CATALYTIC ANTIBODY D2.3 COMPLEX
1YJDL:109-211; H:122-218; H:2-121; L:1-108CRYSTAL STRUCTURE OF HUMAN CD28 IN COMPLEX WITH THE FAB FRAGMENT OF A MITOGENIC ANTIBODY (5.11A1)
1YMHA:109-211; B:114-212; D:114-212; A:1-108; C:1-108; B:1-113; D:1-113; C:109-211ANTI-HCV FAB 19D9D6 COMPLEXED WITH PROTEIN L (PPL) MUTANT A66W
1YN6B:0-99; A:182-271CRYSTAL STRUCTURE OF A MOUSE MHC CLASS I PROTEIN, H2-DB, IN COMPLEX WITH A PEPTIDE FROM THE INFLUENZA A ACID POLYMERASE
1YN7B:0-99; A:182-271CRYSTAL STRUCTURE OF A MOUSE MHC CLASS I PROTEIN, H2-DB, IN COMPLEX WITH A MUTATED PEPTIDE (R7A) OF THE INFLUENZA A ACID POLYMERASE
1YNKL:109-211; H:113-215; L:1-108; H:1-112IDENTIFICATION OF KEY RESIDUES OF THE NC6.8 FAB ANTIBODY FRAGMENT BINDING TO SYNTHETIC SWEETENERS: CRYSTAL STRUCTURE OF NC6.8 CO-CRYSTALIZED WITH HIGH POTENCY SWEETENER COMPOUND SC45647
1YNLL:109-211; H:113-215; L:1-108; H:1-112IDENTIFICATION OF KEY RESIDUES OF THE NC6.8 FAB ANTIBODY FRAGMENT BINDING TO SYNTHETIC SWEETERNERS: CRYSTAL STRUCTURE OF NC6.8 CO-CRYSTALIZED WITH HIGH POTENCY SWEETENER COMPOUND SC45647
1YNTA:108-211; B:619-718; D:1619-1718; B:501-618; D:1501-1618; C:1108-1211; A:1-107; C:1001-1107STRUCTURE OF THE IMMUNODOMINANT EPITOPE DISPLAYED BY THE SURFACE ANTIGEN 1 (SAG1) OF TOXOPLASMA GONDII COMPLEXED TO A MONOCLONAL ANTIBODY
1YPZB:-2-99; A:180-276; C:180-276; D:-2-99; E:1-120; G:1-120; F:124-230; H:124-230; E:121-207; G:121-207; F:1-123; H:1-123IMMUNE RECEPTOR
1YQVL:109-211; H:114-225; H:1-113; L:0-108THE CRYSTAL STRUCTURE OF THE ANTIBODY FAB HYHEL5 COMPLEX WITH LYSOZYME AT 1.7A RESOLUTION
1YUHB:1-118; H:119-217; B:119-213; A:2-110; L:2-110; L:111-210; A:111-209; H:1-118FAB FRAGMENT
1Z3GL:108-210; H:116-214; I:116-214; H:3-115; I:3-115; M:108-210; L:1-107; M:1-107CRYSTAL STRUCTURE OF COMPLEX BETWEEN PVS25 AND FAB FRAGMENT OF MALARIA TRANSMISSION BLOCKING ANTIBODY 2A8
1Z5LB:2-99; D:2-99; C:185-279; A:185-279STRUCTURE OF A HIGHLY POTENT SHORT-CHAIN GALACTOSYL CERAMIDE AGONIST BOUND TO CD1D
1ZEAL:109-211; L:1-108; H:114-212; H:1-113STRUCTURE OF THE ANTI-CHOLERA TOXIN ANTIBODY FAB FRAGMENT TE33 IN COMPLEX WITH A D-PEPTIDE
1ZHBB:1-99; H:1-99; K:1-99; A:182-272; D:182-272; G:182-272; J:182-272; E:1-99CRYSTAL STRUCTURE OF THE MURINE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX OF H-2DB, B2-MICROGLOBULIN, AND A 9-RESIDUE PEPTIDE DERIVED FROM RAT DOPAMINE BETA-MONOOXIGENASE
1ZHNB:1-99; A:185-279CRYSTAL STRUCTURE OF MOUSE CD1D BOUND TO THE SELF LIGAND PHOSPHATIDYLCHOLINE
1ZK9A:269-378NF-KB RELB FORMS AN INTERTWINED HOMODIMER
1ZKAA:269-378NF-KB RELB FORMS AN INTERTWINED HOMODIMER, Y300S MUTANT
1ZOXA:1-110CLM-1 MOUSE MYELOID RECEPTOR EXTRACELLULAR DOMAIN
1ZS8B:1-99; H:1-99; A:181-274; C:181-274; E:181-274; G:181-274; I:181-274; J:1-99; D:1-99; F:1-99CRYSTAL STRUCTURE OF THE MURINE MHC CLASS IB MOLECULE M10.5
1ZT1B:2-99; A:182-274CRYSTAL STRUCTURE OF CLASS I MHC H-2KK IN COMPLEX WITH AN OCTAPEPTIDE
1ZT7B:1-99; A:182-274; C:182-274; D:1-99CRYSTAL STRUCTURE OF CLASS I MHC H-2KK IN COMPLEX WITH A NONAPEPTIDE
1ZWIB:109-211; A:119-217; A:1-118; B:1-108STRUCTURE OF MUTANT KCSA POTASSIUM CHANNEL
25C8L:109-208; H:114-226; H:1-113; L:1-108CATALYTIC ANTIBODY 5C8, FAB-HAPTEN COMPLEX
2A1WL:115-214; H:124-224; I:124-224; L:1-113; M:1-113; H:1-123; I:1-123; M:115-214ANTI-COCAINE ANTIBODY 7.5.21, CRYSTAL FORM I
2A6DA:108-211; B:122-221; H:122-221; L:108-211; B:1-121; H:1-121; A:1-107; L:1-107CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-ARSONATE GERMLINE ANTIBODY 36-65 IN COMPLEX WITH A PHAGE DISPLAY DERIVED DODECAPEPTIDE RLLIADPPSPRE
2A6IA:108-211; B:122-221; B:1-121; A:1-107CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-ARSONATE GERMLINE ANTIBODY 36-65 IN COMPLEX WITH A PHAGE DISPLAY DERIVED DODECAPEPTIDE KLASIPTHTSPL
2A6JA:108-211; B:122-221; H:122-221; L:108-211; B:1-121; H:1-121; A:1-107; L:1-107CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-ARSONATE GERMLINE ANTIBODY 36-65
2A6KA:108-211; B:122-221; H:122-221; L:108-211; B:1-121; H:1-121; A:1-107; L:1-107CRYSTAL STRUCTURE ANALYSIS OF THE GERMLINE ANTIBODY 36-65 FAB IN COMPLEX WITH THE DODECAPEPTIDE SLGDNLTNHNLR
2A77L:115-214; H:124-223; L:1-113; H:1-123ANTI-COCAINE ANTIBODY 7.5.21, CRYSTAL FORM II
2AABL:109-213; H:114-212; L:1-108; H:1-113STRUCTURAL BASIS OF ANTIGEN MIMICRY IN A CLINICALLY RELEVANT MELANOMA ANTIGEN SYSTEM
2ADGA:108-211; B:114-211; B:1-113; A:1-107CRYSTAL STRUCTURE OF MONOCLONAL ANTI-CD4 ANTIBODY Q425
2ADIA:108-211; B:114-211; B:1-113; A:1-107CRYSTAL STRUCTURE OF MONOCLONAL ANTI-CD4 ANTIBODY Q425 IN COMPLEX WITH BARIUM
2ADJA:108-211; B:114-211; B:1-113; A:1-107CRYSTAL STRUCTURE OF MONOCLONAL ANTI-CD4 ANTIBODY Q425 IN COMPLEX WITH CALCIUM
2AI0L:115-214; H:124-224; I:124-223; J:124-223; K:124-223; L:1-113; M:1-113; N:1-113; O:1-113; H:1-123; K:1-123; I:1-123; J:1-123; N:115-214; O:115-214; M:115-214ANTI-COCAINE ANTIBODY 7.5.21, CRYSTAL FORM III
2AJSL:109-211; H:114-228; L:1-108; H:1-113CRYSTAL STRUCTURE OF COCAINE CATALYTIC ANTIBODY 7A1 FAB' IN COMPLEX WITH HEPTAETHYLENE GLYCOL
2AJUL:109-211; H:114-228; L:1-108; H:1-113CYRSTAL STRUCTURE OF COCAINE CATALYTIC ANTIBODY 7A1 FAB'
2AJVL:109-211; H:114-228; L:1-108; H:1-113CRYSTAL STRUCTURE OF COCAINE CATALYTIC ANTIBODY 7A1 FAB' IN COMPLEX WITH COCAINE
2AJXL:109-211; H:114-228; L:1-108; H:1-113CRYSTAL STRUCTURE OF COCAINE CATALYTIC ANTIBODY 7A1 FAB' IN COMPLEX WITH TRANSITION STATE ANALOG
2AJYL:109-211; H:114-228; L:1-108; H:1-113CRYSTAL STRUCTURE OF COCAINE CATALYTIC ANTIBODY 7A1 FAB' IN COMPLEX WITH ECGONINE METHYL ESTER AND BENZOIC ACID
2AJZA:109-211; B:114-228; H:114-228; A:1-108; L:1-108; B:1-113; H:1-113; L:109-211CRYSTAL STRUCTURE OF COCAINE CATALYTIC ANTIBODY 7A1 FAB' IN COMPLEX WITH ECGONINE METHYL ESTER
2AK1L:109-211; H:114-228; L:1-108; H:1-113CRYSTAL STRUCTURE OF COCAINE CATALYTIC ANTIBODY 7A1 FAB' IN COMPLEX WITH BENZOIC ACID
2AKRB:2-99; D:2-99; A:185-279; C:185-279STRUCTURAL BASIS OF SULFATIDE PRESENTATION BY MOUSE CD1D
2AP2B:1-122; A:-2-112; C:-2-112; D:1-122SINGLE CHAIN FV OF C219 IN COMPLEX WITH SYNTHETIC EPITOPE PEPTIDE
2AQ1A:2-117; C:2-117; E:2-117; G:2-117CRYSTAL STRUCTURE OF T-CELL RECEPTOR V BETA DOMAIN VARIANT COMPLEXED WITH SUPERANTIGEN SEC3 MUTANT
2AQ2A:1-117CRYSTAL STRUCTURE OF T-CELL RECEPTOR V BETA DOMAIN VARIANT COMPLEXED WITH SUPERANTIGEN SEC3 MUTANT
2AQ3A:2-117; C:2-117; E:2-117; G:2-117CRYSTAL STRUCTURE OF T-CELL RECEPTOR V BETA DOMAIN VARIANT COMPLEXED WITH SUPERANTIGEN SEC3
2ATKB:109-211; A:119-217; A:1-118; B:1-108STRUCTURE OF A MUTANT KCSA K+ CHANNEL
2ATPA:4-121; C:4-122CRYSTAL STRUCTURE OF A CD8AB HETERODIMER
2BFVL:1-112; H:1-119MONOCLONAL ANTIBODY FRAGMENT FV4155 FROM E. COLI
2CGRL:114-216; H:117-214; L:1-113; H:1-116LOCAL AND TRANSMITTED CONFORMATIONAL CHANGES ON COMPLEXATION OF AN ANTI-SWEETENER FAB
2CK0L:108-210; H:118-215; L:1-107; H:1-117ANTI-ANTI-IDIOTYPIC ANTIBODY AGAINST HUMAN ANGIOTENSIN II, COMPLEX WITH A SYNTHETIC CYCLIC PEPTIDE
2CKBL:1-99; H:182-274; I:182-274; M:1-99; B:3-117; D:3-117; A:117-213; C:117-213; B:118-246; D:118-246; A:1-116; C:1-116STRUCTURE OF THE 2C/KB/DEV8 COMPLEX
2D03L:116-215; H:120-218; L:2-114; H:3-119CRYSTAL STRUCTURE OF THE G91S MUTANT OF THE NNA7 FAB
2DBLL:109-210; H:114-227; L:1-108; H:1-113MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
2DDQL:115-214; L:1-113; H:114-213; H:1-113CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF A R310 ANTIBODY COMPLEXED WITH (R)-HNE-HISTIDINE ADDUCT
2DLFL:1-108; H:1-112HIGH RESOLUTION CRYSTAL STRUCTURE OF THE FV FRAGMENT FROM AN ANTI-DANSYL SWITCH VARIANT ANTIBODY IGG2A(S) CRYSTALLIZED AT PH 6.75
2DQCL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT(HY33F) COMPLEXED WITH HEN EGG LYSOZYME
2DQDL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT (HY50F) COMPLEXED WITH HEN EGG LYSOZYME
2DQEL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT (HY53A) COMPLEXED WITH HEN EGG LYSOZYME
2DQFA:1-107; B:1-114; E:1-114; D:1-107CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT (Y33AY53A) COMPLEXED WITH HEN EGG LYSOZYME
2DQGL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT (HY53F) COMPLEXED WITH HEN EGG LYSOZYME
2DQHL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT (HY58A) COMPLEXED WITH HEN EGG LYSOZYME
2DQIL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT (LY50A) COMPLEXED WITH HEN EGG LYSOZYME
2DQJL:1-107; H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV (WILD-TYPE) COMPLEXED WITH HEN EGG LYSOZYME AT 1.8A RESOLUTION
2DQTL:109-214; H:114-212; L:1-108; H:2-113HIGH RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX OF THE HYDROLYTIC ANTIBODY FAB 6D9 AND A TRANSITION-STATE ANALOG
2DQUL:109-214; H:114-212; L:1-108; H:1-113CRYSTAL FORM II: HIGH RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX OF THE HYDROLYTIC ANTIBODY FAB 6D9 AND A TRANSITION-STATE ANALOG
2DTG  [entry was replaced by entry 4ZXB without any CATH domain information]
2DTML:109-213; H:114-215; L:1-108; H:1-113THERMODYNAMIC AND STRUCTURAL ANALYSES OF HYDROLYTIC MECHANISM BY CATALYTIC ANTIBODIES
2DWDB:109-211; A:119-217; A:1-118; B:1-108CRYSTAL STRUCTURE OF KCSA-FAB-TBA COMPLEX IN TL+
2DWEB:109-211; A:119-217; A:1-118; B:1-108CRYSTAL STRUCTURE OF KCSA-FAB-TBA COMPLEX IN RB+
2E27H:1-113; L:2-108CRYSTAL STRUCTURE OF FV FRAGMENT OF ANTI-CIGUATOXIN ANTIBODY COMPLEXED WITH ABC-RING OF CIGUATOXIN
2E7LC:1-119; D:1-119; B:2-116; A:1-117STRUCTURE OF A HIGH-AFFINITY MUTANT OF THE 2C TCR IN COMPLEX WITH LD/QL9
2EH7L:108-214; L:1-107; H:114-212; H:1-113CRYSTAL STRUCTURE OF HUMANIZED KR127 FAB
2EH8L:108-213; L:1-107; H:114-212; H:1-113CRYSTAL STRUCTURE OF THE COMPLEX OF HUMANIZED KR127 FAB AND PRES1 PEPTIDE EPITOPE
2F19L:109-211; H:125-221; H:1-124; L:1-108THREE-DIMENSIONAL STRUCTURE OF TWO CRYSTAL FORMS OF FAB R19.9, FROM A MONOCLONAL ANTI-ARSONATE ANTIBODY
2F58L:109-210; L:1-108; H:114-227; H:1-113IGG1 FAB FRAGMENT (58.2) COMPLEX WITH 12-RESIDUE CYCLIC PEPTIDE (INCLUDING RESIDUES 315-324 OF HIV-1 GP120) (MN ISOLATE)
2F74B:0-99; A:182-272; D:182-272; E:1-99MURINE MHC CLASS I H-2DB IN COMPLEX WITH HUMAN B2-MICROGLOBULIN AND LCMV-DERIVED IMMUNODMINANT PEPTIDE GP33
2FBJL:108-210; H:1-118; H:119-191; L:1-107REFINED CRYSTAL STRUCTURE OF THE GALACTAN-BINDING IMMUNOGLOBULIN FAB J539 AT 1.95-ANGSTROMS RESOLUTION
2FIKB:2-98; A:185-279STRUCTURE OF A MICROBIAL GLYCOSPHINGOLIPID BOUND TO MOUSE CD1D
2FO4B:1-99; A:182-272ENHANCED MHC CLASS I BINDING AND IMMUNE RESPONSES THROUGH ANCHOR MODIFICATION OF THE NON-CANONICAL TUMOR ASSOCIATED MUC1-8 PEPTIDE
2FWOB:1-99; A:182-272MHC CLASS I H-2KD HEAVY CHAIN IN COMPLEX WITH BETA-2MICROGLOBULIN AND PEPTIDE DERIVED FROM INFLUENZA NUCLEOPROTEIN
2G2RA:109-214; A:1-108; L:1-108; B:114-227; H:114-227; B:1-113; H:1-113; L:109-214GREEN-FLUORESCENT ANTIBODY 11G10 IN COMPLEX WITH ITS HAPTEN (NITRO-STILBENE DERIVATIVE)
2G5BA:108-210; B:112-210; D:112-210; F:112-210; H:112-210; A:1-107; C:1-107; E:1-107; G:1-107; B:1-111; D:1-111; F:1-111; H:1-111; C:108-210; E:108-210; G:108-210CRYSTAL STRUCTURE OF THE ANTI-BAX MONOCLONAL ANTIBODY 6A7 AND A BAX PEPTIDE.
2G60L:109-208; L:1-108; H:114-224; H:1-113STRUCTURE OF ANTI-FLAG M2 FAB DOMAIN
2GAZB:2-99; A:185-279MYCOBACTERIAL LIPOGLYCAN PRESENTATION BY CD1D
2GCYA:113-216; A:1-112; B:119-218; B:1-118HUMANIZED ANTIBODY C25 FAB FRAGMENT
2GFBA:109-211; B:115-227; D:115-227; F:115-227; H:115-227; J:115-227; L:115-227; N:115-227; P:115-219; B:1-113; D:1-113; F:1-113; H:1-113; J:1-113; L:1-113; N:1-113; P:1-113; C:109-211; E:109-211; G:109-211; I:109-211; K:109-211; M:109-211; O:109-211; A:1-108; C:1-108; E:1-108; G:1-108; I:1-108; K:1-108; M:1-108; O:1-108CRYSTAL STRUCTURE OF A CATALYTIC FAB HAVING ESTERASE-LIKE ACTIVITY
2GJJB:1-137; A:1-137; A:138-244; B:138-244CRYSTAL STRUCTURE OF A SINGLE CHAIN ANTIBODY SCA21 AGAINST HER2/ERBB2
2GJZA:110-209; B:115-228; H:115-228; A:1-108; L:1-108; B:1-114; H:1-114; L:110-209STRUCTURE OF CATALYTIC ELIMINATION ANTIBODY 13G5 FROM A CRYSTAL IN SPACE GROUP P2(1)
2GK0A:110-209; B:115-228; H:115-228; A:1-108; L:1-108; B:1-114; H:1-114; L:110-209STRUCTURE OF CATALYTIC ELIMINATION ANTIBODY 13G5 FROM A TWINNED CRYSTAL IN SPACE GROUP C2
2GKIB:157-274; A:23-159; B:23-157HEAVY AND LIGHT CHAIN VARIABLE SINGLE DOMAINS OF AN ANTI-DNA BINDING ANTIBODY HYDROLYZE BOTH DOUBLE- AND SINGLE-STRANDED DNAS WITHOUT SEQUENCE SPECIFICITY
2GSGB:1-118; D:1-118; A:1-116; C:1-116CRYSTAL STRUCTURE OF THE FV FRAGMENT OF A MONOCLONAL ANTIBODY SPECIFIC FOR POLY-GLUTAMINE
2GSIA:108-211; A:6-107; C:6-107; E:6-107; G:6-107; D:114-226; F:114-226; B:114-226; H:114-226; C:108-211; E:108-211; G:108-211; B:2-113; F:2-113; D:2-113; H:2-113CRYSTAL STRUCTURE OF A MURINE FAB IN COMPLEX WITH AN 11 RESIDUE PEPTIDE DERIVED FROM STAPHYLOCOCCAL NUCLEASE
2H1PL:114-216; H:421-519; L:1-113; H:301-420THE THREE-DIMENSIONAL STRUCTURES OF A POLYSACCHARIDE BINDING ANTIBODY TO CRYPTOCOCCUS NEOFORMANS AND ITS COMPLEX WITH A PEPTIDE FROM A PHAGE DISPLAY LIBRARY: IMPLICATIONS FOR THE IDENTIFICATION OF PEPTIDE MIMOTOPES
2H8PB:109-211; A:119-217; A:1-118; B:1-108STRUCTURE OF A K CHANNEL WITH AN AMIDE TO ESTER SUBSTITUTION IN THE SELECTIVITY FILTER
2HFEB:109-211; A:119-217; A:1-118; B:1-108RB+ COMPLEX OF A K CHANNEL WITH AN AMIDE TO ESTER SUBSTITUTION IN THE SELECTIVITY FILTER
2HG5B:109-211; A:119-217; A:1-118; B:1-108CS+ COMPLEX OF A K CHANNEL WITH AN AMIDE TO ESTER SUBSTITUTION IN THE SELECTIVITY FILTER
2HJFB:109-211; A:119-217; A:1-118; B:1-108POTASSIUM CHANNEL KCSA-FAB COMPLEX WITH TETRABUTYLAMMONIUM (TBA)
2HKFL:114-216; H:120-218; L:1-113; H:1-119CRYSTAL STRUCTURE OF THE COMPLEX FAB M75- PEPTIDE
2HKHL:114-216; H:120-218; L:1-113; H:2-119CRYSTAL STRUCTURE OF THE FAB M75
2HRPL:109-211; L:1-108; M:1-108; H:114-212; N:114-211; H:1-113; N:1-113; M:109-211ANTIGEN-ANTIBODY COMPLEX
2HVJB:109-212; A:119-217; A:2-118; B:1-108CRYSTAL STRUCTURE OF KCSA-FAB-TBA COMPLEX IN LOW K+
2HVKB:109-212; A:119-217; A:1-118; B:1-108CRYSTAL STRUCTURE OF THE KCSA-FAB-TBA COMPLEX IN HIGH K+
2I9LA:114-216; B:120-219; D:120-219; F:120-219; H:120-219; A:1-113; C:1-113; E:1-113; G:1-113; C:114-216; E:114-216; G:114-216; B:1-119; D:1-119; F:1-119; H:1-119STRUCTURE OF FAB 7D11 FROM A NEUTRALIZING ANTIBODY AGAINST THE POXVIRUS L1 PROTEIN
2IFFL:107-209; H:117-214; H:2-116; L:1-106STRUCTURE OF AN ANTIBODY-LYSOZYME COMPLEX: EFFECT OF A CONSERVATIVE MUTATION
2IGFL:109-211; L:1-108; H:114-226; H:1-113CRYSTAL STRUCTURES OF AN ANTIBODY TO A PEPTIDE AND ITS COMPLEX WITH PEPTIDE ANTIGEN AT 2.8 ANGSTROMS
2IH1B:109-211; A:119-217; A:1-118; B:1-108ION SELECTIVITY IN A SEMI-SYNTHETIC K+ CHANNEL LOCKED IN THE CONDUCTIVE CONFORMATION
2IH3B:109-211; A:119-217; A:1-118; B:1-108ION SELECTIVITY IN A SEMI-SYNTHETIC K+ CHANNEL LOCKED IN THE CONDUCTIVE CONFORMATION
2IMMA:1-108REFINED CRYSTAL STRUCTURE OF A RECOMBINANT IMMUNOGLOBULIN DOMAIN AND A COMPLEMENTARITY-DETERMINING REGION 1-GRAFTED MUTANT
2IMNA:1-108REFINED CRYSTAL STRUCTURE OF A RECOMBINANT IMMUNOGLOBULIN DOMAIN AND A COMPLEMENTARITY-DETERMINING REGION 1-GRAFTED MUTANT
2IPTL:109-208; L:1-107; H:114-212; H:1-113PFA1 FAB FRAGMENT
2IPUK:109-208; K:1-107; L:1-107; H:114-213; G:114-213; L:109-208; G:1-113; H:1-113PFA1 FAB FRAGMENT COMPLEXED WITH ABETA 1-8 PEPTIDE
2IQ9L:109-208; L:1-107; H:114-212; H:1-113PFA2 FAB FRAGMENT, TRICLINIC APO FORM
2IQAA:109-208; A:1-107; L:1-107; H:114-212; B:114-212; B:1-113; H:1-113; L:109-208PFA2 FAB FRAGMENT, MONOCLINIC APO FORM
2ITCB:109-211; A:119-217; A:1-118; B:1-108POTASSIUM CHANNEL KCSA-FAB COMPLEX IN SODIUM CHLORIDE
2ITDB:109-211; A:119-217; A:1-118; B:1-108POTASSIUM CHANNEL KCSA-FAB COMPLEX IN BARIUM CHLORIDE
2JELL:109-211; L:1-108; H:114-225; H:1-113JEL42 FAB/HPR COMPLEX
2MCPL:115-217; L:1-114; H:1-123; H:124-222REFINED CRYSTAL STRUCTURE OF THE MC/PC603 FAB-PHOSPHOCHOLINE COMPLEX AT 3.1 ANGSTROMS RESOLUTION
2MFNA:92-184; A:1-91SOLUTION NMR STRUCTURE OF LINKED CELL ATTACHMENT MODULES OF MOUSE FIBRONECTIN CONTAINING THE RGD AND SYNERGY REGIONS, 10 STRUCTURES
2MHAB:1-99; A:182-270; C:182-270; D:1-99CRYSTAL STRUCTURE OF THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I H-2KB MOLECULE CONTAINING A SINGLE VIRAL PEPTIDE: IMPLICATIONS FOR PEPTIDE BINDING AND T-CELL RECEPTOR RECOGNITION
2MPAL:115-214; H:122-220; L:1-113; H:1-121BACTERICIDAL ANTIBODY AGAINST NEISSERIA MENINGITIDIS
2NCMA:1-99NEURAL CELL ADHESION MOLECULE, NMR, 20 STRUCTURES
2NLJA:109-211; B:119-217; B:1-118; A:1-108POTASSIUM CHANNEL KCSA(M96V)-FAB COMPLEX IN KCL
2NTFB:115-228; H:115-228; B:1-114; H:1-114; A:1-107; L:1-107; A:108-211; L:108-211CRYSTAL STRUCTURE OF A QUORUM-QUENCHING ANTIBODY IN COMPLEX WITH AN N-ACYL-L-HOMOSERINE LACTONE ANALOG
2OI9C:1-118; B:1-115STRUCTURE OF THE 2C/LD/QL9 ALLOGENEIC COMPLEX
2OJZL:110-209; H:115-228; I:115-228; L:1-108; M:1-108; M:110-209; H:1-114; I:1-114ANTI-DNA ANTIBODY ED10
2OL3L:0-99; H:182-274; B:1-117; A:1-118CRYSTAL STRUCTURE OF BM3.3 SCFV TCR IN COMPLEX WITH PBM8-H-2KBM8 MHC CLASS I MOLECULE
2OP4H:115-228; H:1-114; L:1-107; L:108-212CRYSTAL STRUCTURE OF QUORUM-QUENCHING ANTIBODY 1G9
2OR9M:109-214; I:114-211; H:114-211; L:1-108; M:1-108; H:1-113; I:1-113; L:109-212THE STRUCTURE OF THE ANTI-C-MYC ANTIBODY 9E10 FAB FRAGMENT/EPITOPE PEPTIDE COMPLEX REVEALS A NOVEL BINDING MODE DOMINATED BY THE HEAVY CHAIN HYPERVARIABLE LOOPS
2ORBM:109-213; H:114-211; I:114-211; M:1-108; L:1-108; I:1-113; H:1-113; L:109-212THE STRUCTURE OF THE ANTI-C-MYC ANTIBODY 9E10 FAB FRAGMENT
2OTUB:1-118; D:1-118; F:1-118; H:1-118; A:0-114; C:0-114; E:0-114; G:0-114CRYSTAL STRUCTURE OF FV POLYGLUTAMINE COMPLEX
2OTWB:1-118; D:1-118; A:0-114; C:0-114CRYSTAL STRUCTURE OF FV POLYGLUTAMINE COMPLEX
2P1YA:3-116; A:302-4121.B2.D9, A BISPECIFIC ALPHA/BETA TCR
2P24A:82-181; B:193-293I-AU/MBP125-135
2P7TB:109-211; A:119-217; A:1-118; B:1-108CRYSTAL STRUCTURE OF KCSA MUTANT
2PCPA:109-211; A:1-108; C:1-108; B:114-226; D:114-226; B:1-113; D:1-113; C:109-211ANTIBODY FAB COMPLEXED WITH PHENCYCLIDINE
2PXYB:3-117; C:82-180; D:93-191; A:-1-116CRYSTAL STRUCTURES OF IMMUNE RECEPTOR COMPLEXES
2Q76A:109-211; B:117-215; D:117-215; C:109-211; A:1-108; C:1-108; B:1-116; D:1-116MOUSE ANTI-HEN EGG WHITE LYSOZYME ANTIBODY F10.6.6 FAB FRAGMENT
2Q7YB:2-99; D:2-99; A:185-279; C:185-279STRUCTURE OF THE ENDOGENOUS INKT CELL LIGAND IGB3 BOUND TO MCD1D
2Q86A:0-109; C:0-109STRUCTURE OF THE MOUSE INVARIANT NKT CELL RECEPTOR VALPHA14
2QHRH:114-212; L:109-208; H:1-113; L:2-108CRYSTAL STRUCTURE OF THE 13F6-1-2 FAB FRAGMENT BOUND TO ITS EBOLA VIRUS GLYCOPROTEIN PEPTIDE EPITOPE.
2QRIA:1B-99B; B:1B-99B; A:182H-276H; B:182H-276HCRYSTAL STRUCTURE OF A SINGLE CHAIN TRIMER COMPOSED OF THE MHC I HEAVY CHAIN H-2KB WT, BETA-2MICROGLOBULIN, AND OVALBUMIN-DERIVED PEPTIDE.
2QRSA:1B-99B; B:1B-99B; A:182H-276H; B:182H-276HCRYSTAL STRUCTURE OF A SINGLE CHAIN TRIMER COMPOSED OF THE MHC I HEAVY CHAIN H-2KB Y84A, BETA-2MICROGLOBULIN, AND OVALBUMIN-DERIVED PEPTIDE.
2QRTA:1B-99B; B:1B-99B; A:182H-276H; B:182H-276HCRYSTAL STRUCTURE OF A DISULFIDE TRAPPED SINGLE CHAIN TRIMER COMPOSED OF THE MHC I HEAVY CHAIN H-2KB Y84C, BETA-2MICROGLOBULIN, AND OVALBUMIN-DERIVED PEPTIDE.
2R0WL:109-208; L:1-107; H:114-212; H:1-113PFA2 FAB COMPLEXED WITH ABETA1-8
2R0ZL:109-208; L:1-107; H:114-212; H:1-113PFA1 FAB COMPLEXED WITH GRIPI PEPTIDE FRAGMENT
2VAAB:1-99; A:182-274MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND VESICULAR STOMATITIS VIRUS NUCLEOPROTEIN
2VABB:1-99; A:182-274MHC CLASS I H-2KB HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND SENDAI VIRUS NUCLEOPROTEIN
2VIRB:124-221; A:1-110; B:1-123; A:111-210INFLUENZA VIRUS HEMAGGLUTININ COMPLEXED WITH A NEUTRALIZING ANTIBODY
2VISB:124-221; A:1-110; B:1-123; A:111-210INFLUENZA VIRUS HEMAGGLUTININ, (ESCAPE) MUTANT WITH THR 131 REPLACED BY ILE, COMPLEXED WITH A NEUTRALIZING ANTIBODY
2VITB:124-221; A:1-110; B:1-123; A:111-210INFLUENZA VIRUS HEMAGGLUTININ, MUTANT WITH THR 155 REPLACED BY ILE, COMPLEXED WITH A NEUTRALIZING ANTIBODY
2Z31B:3-117; C:82-180; D:93-190; A:1-116CRYSTAL STRUCTURE OF IMMUNE RECEPTOR COMPLEX
2Z35B:3-117; A:1-116CRYSTAL STRUCTURE OF IMMUNE RECEPTOR
2Z4QA:114-219; B:119-218; A:1-113; B:1-118CRYSTAL STRUCTURE OF A MURINE ANTIBODY FAB 528
32C2A:111-214; A:6-110; B:120-218; B:1-119STRUCTURE OF AN ACTIVITY SUPPRESSING FAB FRAGMENT TO CYTOCHROME P450 AROMATASE
35C8L:109-208; H:114-226; H:1-113; L:1-108CATALYTIC ANTIBODY 5C8, FAB-INHIBITOR COMPLEX
3A67H:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT LN31D COMPLEXED WITH HEN EGG WHITE LYSOZYME
3A6BH:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT LN32D COMPLEXED WITH HEN EGG WHITE LYSOZYME
3A6CH:1-114CRYSTAL STRUCTURE OF HYHEL-10 FV MUTANT LN92D COMPLEXED WITH HEN EGG WHITE LYSOZYME
3BAEL:109-208; L:1-107; H:114-212; H:2-113CRYSTAL STRUCTURE OF FAB WO2 BOUND TO THE N TERMINAL DOMAIN OF AMYLOID BETA PEPTIDE (1-28)
3BD3A:160-271; B:160-271CRYSTAL STRUCTURE OF SINGLE DOMAIN VL OF AN ANTI-DNA BINDING ANTIBODY 3D8 SCFV AND ITS ACTIVE SITE REVEALED BY COMPLEX STRUCTURES OF A SMALL MOLECULE AND METALS
3BD4B:160-271; A:160-271CRYSTAL STRUCTURE OF SINGLE DOMAIN VL OF AN ANTI-DNA BINDING ANTIBODY 3D8 SCFV AND ITS ACTIVE SITE REVEALED BY COMPLEX STRUCTURES OF A SMALL MOLECULE AND METALS
3BD5A:160-271; B:160-271CRYSTAL STRUCTURE OF SINGLE DOMAIN VL OF AN ANTI-DNA BINDING ANTIBODY 3D8 SCFV AND ITS ACTIVE SITE REVEALED BY COMPLEX STRUCTURES OF A SMALL MOLECULE AND METALS
3BKCL:109-208; L:1-107; H:114-212; H:2-113CRYSTAL STRUCTURE OF ANTI-AMYLOID BETA FAB WO2 (P21, FORMB)
3BKJL:109-208; L:1-107; H:114-212; H:2-113CRYSTAL STRUCTURE OF FAB WO2 BOUND TO THE N TERMINAL DOMAIN OF AMYLOID BETA PEPTIDE (1-16)
3BKML:109-208; L:1-107; H:114-212; H:2-113STRUCTURE OF ANTI-AMYLOID-BETA FAB WO2 (FORM A, P212121)
3BRGC:381-474CSL (RBP-JK) BOUND TO DNA
3BUYB:1-99; A:182-272MHC-I IN COMPLEX WITH PEPTIDE
3C5ZB:1-111; F:1-111; C:83-182; G:83-182; B:112-240; F:112-240; D:119-217; H:119-217; A:1-110; E:1-110CRYSTAL STRUCTURE OF MOUSE MHC CLASS II I-AB/3K PEPTIDE COMPLEXED WITH MOUSE TCR B3K506
3C60B:1-111; F:1-111; C:83-182; G:83-182; B:112-236; F:112-236; D:119-217; H:119-217; A:1-110; E:1-110CRYSTAL STRUCTURE OF MOUSE MHC CLASS II I-AB/3K PEPTIDE COMPLEXED WITH MOUSE TCR YAE62
3C6LB:1-111; F:1-111; C:83-182; G:83-182; B:112-236; F:112-236; D:119-217; H:119-217; A:1-111; E:1-111CRYSTAL STRUCTURE OF MOUSE MHC CLASS II I-AB/3K PEPTIDE COMPLEXED WITH MOUSE TCR 2W20
3C8KB:1-99; A:182-272THE CRYSTAL STRUCTURE OF LY49C BOUND TO H-2KB
3CFBA:109-211; B:114-227; H:114-227; A:1-108; L:1-108; L:109-211; B:2-113; H:2-113HIGH-RESOLUTION STRUCTURE OF BLUE FLUORESCENT ANTIBODY EP2-19G2 IN COMPLEX WITH STILBENE HAPTEN AT 100K
3CFCL:109-211; H:114-227; L:1-108; H:2-113HIGH-RESOLUTION STRUCTURE OF BLUE FLUORESCENT ANTIBODY EP2-19G2
3CFDA:108-211; H:114-228; B:114-227; B:1-113; H:1-113; L:108-211; A:1-107; L:1-107PURPLE-FLUORESCENT ANTIBODY EP2-25C10 IN COMPLEX WITH ITS STILBENE HAPTEN
3CFEA:108-211; B:114-227; H:114-227; B:1-113; H:1-113; L:108-211; A:1-107; L:1-107CRYSTAL STRUCTURE OF PURPLE-FLUORESCENT ANTIBODY EP2-25C10
3CK0L:108-210; H:118-215; L:1-107; H:1-117ANTI-ANTI-IDIOTYPIC ANTIBODY AGAINST HUMAN ANGIOTENSIN II, COMPLEX WITH HUMAN ANGIOTENSIN II
3CLEL:108-211; H:114-224; L:1-107; H:1-113HIV NEUTRALIZING MONOCLONAL ANTIBODY YZ23
3CLFL:108-211; H:114-226; L:1-107; H:1-113HIV NEUTRALIZING MONOCLONAL ANTIBODY YZ23
3F58L:109-211; L:1-108; H:114-227; H:1-113IGG1 FAB FRAGMENT (58.2) COMPLEX WITH 12-RESIDUE CYCLIC PEPTIDE (INCLUDING RESIDUES 315-324 OF HIV-1 GP120 (MN ISOLATE); H315S MUTATION
3HFML:109-211; H:1-113; H:114-211; L:1-108STRUCTURE OF AN ANTIBODY-ANTIGEN COMPLEX. CRYSTAL STRUCTURE OF THE HY/HEL-10 FAB-LYSOZYME COMPLEX
43C9A:1-107; C:1-107; E:1-107; G:1-107; B:0-112; D:0-112; F:0-112; H:0-112CRYSTALLOGRAPHIC STRUCTURE OF THE ESTEROLYTIC AND AMIDOLYTIC 43C9 ANTIBODY
43CAA:1-107; C:1-107; E:1-107; G:1-107; B:1-112; D:1-112; F:1-112; H:1-112CRYSTALLOGRAPHIC STRUCTURE OF THE ESTEROLYTIC AND AMIDOLYTIC 43C9 ANTIBODY WITH BOUND P-NITROPHENOL
4FABL:114-215; H:119-216; L:1-113; H:1-118THREE-DIMENSIONAL STRUCTURE OF A FLUORESCEIN-FAB COMPLEX CRYSTALLIZED IN 2-METHYL-2,4-PENTANEDIOL
6FABL:108-210; H:122-221; H:1-121; L:1-107THREE-DIMENSIONAL STRUCTURE OF MURINE ANTI-P-AZOPHENYLARSONATE FAB 36-71. 1. X-RAY CRYSTALLOGRAPHY, SITE-DIRECTED MUTAGENESIS, AND MODELING OF THE COMPLEX WITH HAPTEN
(-)
House mouse (mus musculus) (4)
1AJ7L:109-211; H:114-213; H:1-113; L:1-108IMMUNOGLOBULIN 48G7 GERMLINE FAB ANTIBODY COMPLEXED WITH HAPTEN 5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID. AFFINITY MATURATION OF AN ESTEROLYTIC ANTIBODY
1YEHL:109-214; H:1-113; L:1-108; H:114-223STRUCTURE OF IGG2A FAB FRAGMENT
2IADA:82-181; B:94-190CLASS II MHC I-AD IN COMPLEX WITH AN INFLUENZA HEMAGGLUTININ PEPTIDE 126-138
2RCSL:109-211; H:114-213; H:1-113; L:1-108IMMUNOGLOBULIN 48G7 GERMLINE FAB-AFFINITY MATURATION OF AN ESTEROLYTIC ANTIBODY
(-)
House mouse, human (Mus musculus, homo sapiens) (20)
1C5BL:109-211; H:1-113; L:1-108; H:114-227DECARBOXYLASE CATALYTIC ANTIBODY 21D8 UNLIGANDED FORM
1C5CL:109-211; H:1-113; L:1-108; H:114-227DECARBOXYLASE CATALYTIC ANTIBODY 21D8-HAPTEN COMPLEX
1D5BA:109-211; L:109-211; B:1-113; H:1-113; A:1-108; L:1-108; B:114-213; H:114-213UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY
1D5IL:109-211; H:1-113; L:1-108; H:114-214UNLIGANDED GERMLINE PRECURSOR OF AN OXY-COPE CATALYTIC ANTIBODY
1D6VL:109-211; H:1-113; L:1-108; H:114-211CONFORMATION EFFECTS IN BIOLOGICAL CATALYSIS INTRODUCED BY OXY-COPE ANTIBODY MATURATION
1I7ZA:109-211; B:1-113; D:1-113; A:1-108; C:1-108; B:114-225; D:114-225; C:109-211ANTIBODY GNC92H2 BOUND TO LIGAND
1IT9L:113-214; H:1-121; L:1-112; H:122-219CRYSTAL STRUCTURE OF AN ANTIGEN-BINDING FRAGMENT FROM A HUMANIZED VERSION OF THE ANTI-HUMAN FAS ANTIBODY HFE7A
1N7MH:109-213; H:1-108; L:1-114; L:115-214GERMLINE 7G12 WITH N-METHYLMESOPORPHYRIN
1NGWA:109-213; L:109-213; A:1-108; L:1-108; B:1-114; H:1-114; B:115-214; H:115-214CHIMERIC AFFINITY MATURED FAB 7G12 COMPLEXED WITH MESOPORPHYRIN
1NGXA:109-213; L:109-213; A:1-108; L:1-108; B:1-114; H:1-114; B:115-214; H:115-214CHIMERIC GERMLINE FAB 7G12 WITH JEFFAMINE FRAGMENT BOUND
1NGYA:109-213; A:1-108; B:1-114; B:115-214CHIMERIC MATURE FAB 7G12-APO
1NGZA:109-213; A:1-108; B:1-114; B:115-214CHIMERIC GERMLINE FAB 7G12-APO
1Y0LA:109-214; C:109-214; A:1-108; E:109-214; C:1-108; E:1-108; L:1-108; L:109-214; B:1-113; D:1-113; F:1-113; H:1-113; B:114-233; D:114-233; F:114-233; H:114-233CATALYTIC ELIMINATION ANTIBODY 34E4 IN COMPLEX WITH HAPTEN
1Y18A:109-214; A:1-108; C:1-108; E:1-108; L:1-108; B:1-113; D:1-113; F:1-113; H:1-113; C:109-214; E:109-214; L:109-214; B:114-233; D:114-233; F:114-233; H:114-233FAB FRAGMENT OF CATALYTIC ELIMINATION ANTIBODY 34E4 E(H50)D MUTANT IN COMPLEX WITH HAPTEN
1YY8A:109-213; B:1-118; D:1-118; C:109-213; A:1-108; C:1-108; B:122-219; D:122-219CRYSTAL STRUCTURE OF THE FAB FRAGMENT FROM THE MONOCLONAL ANTIBODY CETUXIMAB/ERBITUX/IMC-C225
2HH0L:153-271; H:152-271; H:1-149; L:2-149STRUCTURE OF AN ANTI-PRP FAB, P-CLONE, IN COMPLEX WITH ITS COGNATE BOVINE PEPTIDE EPITOPE.
2O5XL:108-211; H:114-227; L:1-107; H:1-113CRYSTAL STRUCTURE OF 1E9 LEUH47TRP/ARGH100TRP, AN ENGINEERED DIELS-ALDERASE FAB WITH NM STEROID-BINDING AFFINITY
2O5YL:108-211; H:114-227; L:1-107; H:1-113CRYSTAL STRUCTURE OF THE 1E9 LEUH47TRP/ARGH100TRP FAB PROGESTERONE COMPLEX
2O5ZL:108-211; H:114-227; L:1-107; H:1-113CRYSTAL STRUCTURE OF THE 1E9 LEUH47TRP/ARGH100TRP FAB 5-BETA-ANDROSTANE-3,17-DIONE COMPLEX
3CFKA:109-213; H:114-228; I:114-228; K:114-228; N:114-228; P:114-228; A:1-108; C:1-108; E:1-108; G:1-108; J:1-108; L:1-108; M:1-108; O:1-108; B:1-113; C:109-213; D:1-113; F:1-113; H:1-113; I:1-113; K:1-113; N:1-113; P:1-113; E:109-213; G:109-213; J:109-213; L:109-213; M:109-213; O:109-213; B:114-228; D:114-228; F:114-228CRYSTAL STRUCTURE OF CATALYTIC ELIMINATION ANTIBODY 34E4, TRICLINIC CRYSTAL FORM
(-)
House mouse, sheep (Mus musculus, ovis aries) (1)
1XMWA:114-178; A:1-79CD3 EPSILON AND DELTA ECTODOMAIN FRAGMENT COMPLEX IN SINGLE-CHAIN CONSTRUCT
(-)
Human (Homo sapiens) (912)
1A1MB:1-99; A:182-272MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE TPYDINQML FROM GAG PROTEIN OF HIV2
1A1NB:1-99; A:182-272MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTY FROM THE NEF PROTEIN (75-82) OF HIV1
1A1OB:1-99; A:182-272MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) FROM THE MALARIA PARASITE P. FALCIPARUM
1A22B:332-432; B:233-331HUMAN GROWTH HORMONE BOUND TO SINGLE RECEPTOR
1A6AA:82-180; B:94-191THE STRUCTURE OF AN INTERMEDIATE IN CLASS II MHC MATURATION: CLIP BOUND TO HLA-DR3
1A6ZB:1-99; D:1-99; A:183-273; C:183-273HFE (HUMAN) HEMOCHROMATOSIS PROTEIN
1A8JH:2-111; L:2-111; H:112-212; L:112-212IMMUNOGLOBULIN LAMBDA LIGHT CHAIN DIMER (MCG) COMPLEX WITH ASPARTAME
1A9BB:1-100; E:1-100; A:182-272; D:182-272DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
1A9EB:1-100; A:182-272DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
1AD0A:108-210; B:114-211; D:114-211; B:1-113; D:1-113; C:108-210; A:1-107; C:1-107FAB FRAGMENT OF ENGINEERED HUMAN MONOCLONAL ANTIBODY A5B7
1AD9A:108-208; B:114-212; H:114-212; B:1-113; H:1-113; L:107-210; L:1-106; A:1-107IGG-FAB FRAGMENT OF ENGINEERED HUMAN MONOCLONAL ANTIBODY CTM01
1ADQA:338-443; L:2-107; L:108-211; A:238-337; H:1-113; H:114-223BCRYSTAL STRUCTURE OF A HUMAN IGM RHEUMATOID FACTOR FAB IN COMPLEX WITH ITS AUTOANTIGEN IGG FC
1AGBB:1-99; A:182-272ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MUTATION)
1AGCB:1-99; A:182-272ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MUTATION)
1AGDB:1-99; A:182-272ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX PEPTIDE)
1AGEB:1-99; A:182-272ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MUTATION)
1AGFB:1-99; A:182-272ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKRYKL-5R MUTATION)
1AH1A:1A-131CTLA-4, NMR, 20 STRUCTURES
1AKJB:2-99; A:182-270; D:1-114; E:1-114COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 AND THE T CELL CORECEPTOR CD8
1AO7B:0-99; A:182-270; E:3-117; E:118-243; D:1-121COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201
1AQDA:82-181; D:82-179; G:82-179; J:82-179; K:93-191; B:93-190; E:93-190; H:93-190HLA-DR1 (DRA, DRB1 0101) HUMAN CLASS II HISTOCOMPATIBILITY PROTEIN (EXTRACELLULAR DOMAIN) COMPLEXED WITH ENDOGENOUS PEPTIDE
1AQKH:124-223; L:2-111; L:112-212; H:2-123THREE-DIMENSIONAL STRUCTURE OF A HUMAN FAB WITH HIGH AFFINITY FOR TETANUS TOXOID
1AR2A:1-109DISULFIDE-FREE IMMUNOGLOBULIN FRAGMENT
1AXIB:132-232; B:32-131STRUCTURAL PLASTICITY AT THE HGH:HGHBP INTERFACE
1B0GB:0-99; A:182-270; D:182-270; E:0-99CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX
1B0RB:400-499; A:182-270CRYSTAL STRUCTURE OF HLA-A*0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUTED BY A METHYL GROUP
1B0WA:1-108; B:1-108; C:1-108STRUCTURAL COMPARISON OF AMYLOIDOGENIC LIGHT CHAIN DIMER IN TWO CRYSTAL FORMS WITH NONAMYLOIDOGENIC COUNTERPARTS
1B3JA:181-274STRUCTURE OF THE MHC CLASS I HOMOLOG MIC-A, A GAMMADELTA T CELL LIGAND
1B4JL:108-211; L:1-107; H:2-117; H:118-217COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF A HUMANIZED AND A CHIMERIC FAB OF AN ANTI-GAMMA-INTERFERON ANTIBODY
1B6DA:108-211; B:108-211; A:1-107; B:1-107BENCE JONES PROTEIN DEL: AN ENTIRE IMMUNOGLOBULIN KAPPA LIGHT-CHAIN DIMER
1B6UA:103-203; A:5-102CRYSTAL STRUCTURE OF THE HUMAN KILLER CELL INHIBITORY RECEPTOR (KIR2DL3) SPECIFIC FOR HLA-CW3 RELATED ALLELES
1BBJA:109-211; B:115-212; H:115-212; L:109-211; B:2-114; H:2-114; A:1-108; L:1-108CRYSTAL STRUCTURE OF A CHIMERIC FAB' FRAGMENT OF AN ANTIBODY BINDING TUMOUR CELLS
1BD2B:1-99; A:182-270; E:3-118; D:117-201; E:119-244; D:1-116COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201
1BEYL:109-211; H:122-219; H:1-121; L:1-108ANTIBODY TO CAMPATH-1H HUMANIZED FAB
1BJ8A:1-109THIRD N-TERMINAL DOMAIN OF GP130, NMR, MINIMIZED AVERAGE STRUCTURE
1BJMA:2-111; B:2-111; A:112-212; B:112-212LOC NAKS, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN NAKSO4
1BOYA:3-105; A:106-213EXTRACELLULAR REGION OF HUMAN TISSUE FACTOR
1BP3B:202-301; B:302-404THE XRAY STRUCTURE OF A GROWTH HORMONE-PROLACTIN RECEPTOR COMPLEX
1BPVA:0-103TITIN MODULE A71 FROM HUMAN CARDIAC MUSCLE, NMR, 50 STRUCTURES
1BQSA:91-209; A:1-90THE CRYSTAL STRUCTURE OF MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1)
1BQUA:105-214; B:105-213; A:5-104; B:5-104CYTOKYNE-BINDING REGION OF GP130
1BREA:1-107; B:1-107; C:1-107; D:1-107; E:1-107; F:1-107IMMUNOGLOBULIN LIGHT CHAIN PROTEIN
1BVKA:1-108; B:1-116; E:1-116; D:1-108HUMANIZED ANTI-LYSOZYME FV COMPLEXED WITH LYSOZYME
1BWWA:1-109; B:1-109BENCE-JONES IMMUNOGLOBULIN REI VARIABLE PORTION, T39K MUTANT
1BX2A:82-181; D:82-181; B:92-193; E:92-191CRYSTAL STRUCTURE OF HLA-DR2 (DRA*0101,DRB1*1501) COMPLEXED WITH A PEPTIDE FROM HUMAN MYELIN BASIC PROTEIN
1C8PA:1-102NMR STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE COMMON BETA-CHAIN IN THE GM-CSF, IL-3 AND IL-5 RECEPTORS
1CCZA:1-93; A:94-171CRYSTAL STRUCTURE OF THE CD2-BINDING DOMAIN OF CD58 (LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 3) AT 1.8-A RESOLUTION
1CD0B:1-107; A:1-108STRUCTURE OF HUMAN LAMDA-6 LIGHT CHAIN DIMER JTO
1CD8A:1-114CRYSTAL STRUCTURE OF A SOLUBLE FORM OF THE HUMAN T CELL CO-RECEPTOR CD8 AT 2.6 ANGSTROMS RESOLUTION
1CD9D:2-108; B:1-108; B:109-213; D:109-2122:2 COMPLEX OF G-CSF WITH ITS RECEPTOR
1CDBA:1-105STRUCTURE OF THE GLYCOSYLATED ADHESION DOMAIN OF HUMAN T LYMPHOCYTE GLYCOPROTEIN CD2
1CDHA:1-98; A:99-173STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES
1CDIA:1-98; A:99-173STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES
1CDJA:1-98; A:99-173STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4
1CDUA:1-98; A:99-173STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH PHE 43 REPLACED BY VAL
1CDYA:1-98; A:99-173STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH GLY 47 REPLACED BY SER
1CG9B:1-100; A:182-272COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6
1CI5A:1-95GLYCAN-FREE MUTANT ADHESION DOMAIN OF HUMAN CD58 (LFA-3)
1CN4A:119-220; B:119-220; A:22-118; B:22-118ERYTHROPOIETIN COMPLEXED WITH EXTRACELLULAR DOMAINS OF ERYTHROPOIETIN RECEPTOR
1CVSC:149-249; D:149-249; C:250-359; D:250-358CRYSTAL STRUCTURE OF A DIMERIC FGF2-FGFR1 COMPLEX
1CZ8L:109-211; H:124-223; Y:124-223; H:1-123; Y:1-123; X:109-211; L:1-108; X:1-108VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH AN AFFINITY MATURED ANTIBODY
1D5MA:82-181; B:92-190X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH PEPTIDE AND SEB
1D5XA:82-181; B:92-190X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH DIPEPTIDE MIMETIC AND SEB
1D5ZA:82-180; B:92-190X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH PEPTIDOMIMETIC AND SEB
1D6EA:82-180; B:92-190CRYSTAL STRUCTURE OF HLA-DR4 COMPLEX WITH PEPTIDOMIMETIC AND SEB
1DANU:91-210; T:6-80COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR
1DCLA:1-111; B:1-111; A:112-212; B:112-212MCG, A LAMBDA V TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN), CRYSTALLIZED FROM AMMONIUM SULFATE
1DE4B:1-99; E:1-99; H:1-99; A:183-273; D:183-273; G:183-273HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRIN RECEPTOR
1DEEC:1109-1211; B:501-621; D:1501-1621; F:2501-2621; B:622-723; D:1622-1723; F:2622-2723; A:108-211; E:2108-2211; A:1-107; E:2001-2107; C:1001-1108CRYSTAL STRUCTURE AT 2.7A RESOLUTION OF A COMPLEX BETWEEN A STAPHYLOCOCCUS AUREUS DOMAIN AND A FAB FRAGMENT OF A HUMAN IGM ANTIBODY
1DFBL:108-209; H:127-226; H:1-126; L:1-106STRUCTURE OF A HUMAN MONOCLONAL ANTIBODY FAB FRAGMENT AGAINST GP41 OF HUMAN IMMUNODEFICIENCY VIRUS TYPE I
1DJSA:147-250; A:251-362LIGAND-BINDING PORTION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 IN COMPLEX WITH FGF1
1DL7L:1-109; H:1-112THE STRUCTURAL BASIS OF REPERTOIRE SHIFT IN AN IMMUNE RESPONSE TO PHOSPHOCHOLINE
1DLHA:82-181; D:82-181; B:93-190; E:93-190CRYSTAL STRUCTURE OF THE HUMAN CLASS II MHC PROTEIN HLA-DR1 COMPLEXED WITH AN INFLUENZA VIRUS PEPTIDE
1DN0A:110-212; A:1-109; C:1-109; B:1-120; D:1-120; D:121-222; B:121-222; C:110-212STRUCTURE OF THE FAB FRAGMENT FROM A HUMAN IGM COLD AGGLUTININ
1DN2A:338-443; B:338-443; A:238-337; B:238-337FC FRAGMENT OF HUMAN IGG1 IN COMPLEX WITH AN ENGINEERED 13 RESIDUE PEPTIDE DCAWHLGELVWCT-NH2
1DQLL:1-106; H:2-123CRYSTAL STRUCTURE OF AN UNLIGANDED (NATIVE) FV FROM A HUMAN IGM ANTI-PEPTIDE ANTIBODY
1DR9A:1-105; A:106-200CRYSTAL STRUCTURE OF A SOLUBLE FORM OF B7-1 (CD80)
1DUYB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF HLA-A*0201/OCTAMERIC TAX PEPTIDE COMPLEX
1DUZB:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) IN COMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN
1E0OB:149-250; D:149-250; B:251-359; D:251-359CRYSTAL STRUCTURE OF A TERNARY FGF1-FGFR2-HEPARIN COMPLEX
1E27B:1-99; A:182-272NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM1(LPPVVAKEI)
1E28B:1-99; A:182-272NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM2(TAFTIPSI)
1E4JA:87-172; A:2-86CRYSTAL STRUCTURE OF THE SOLUBLE HUMAN FC-GAMMA RECEPTOR III
1E4KA:338-443; B:338-443; A:238-337; B:238-337; C:87-172; C:2-86CRYSTAL STRUCTURE OF SOLUBLE HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR III COMPLEX
1EAJB:20-139; A:16-139DIMERIC STRUCTURE OF THE COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR D1 DOMAIN AT 1.35 ANGSTROM RESOLUTION
1EBAA:119-220; B:119-218; A:22-118; B:22-118COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN INACTIVE PEPTIDE [EMP33] CONTAINS 3,5-DIBROMOTYROSINE IN POSITION 4 (DENOTED DBY)
1EBPA:119-220; B:119-220; A:22-118; B:22-118COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN AGONIST PEPTIDE [EMP1]
1EEQA:1-107; B:301-407M4L/Y(27D)D/T94H MUTANT OF LEN
1EERB:119-220; C:119-220; C:22-118; B:24-118CRYSTAL STRUCTURE OF HUMAN ERYTHROPOIETIN COMPLEXED TO ITS RECEPTOR AT 1.9 ANGSTROMS
1EEUA:1-106; B:301-407M4L/Y(27D)D/Q89D/T94H MUTANT OF LEN
1EEYB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE DETERMINATION OF HLA A2 COMPLEXED TO PEPTIDE GP2 WITH THE SUBSTITUTION (I2L/V5L/L9V)
1EEZB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE DETERMINATION OF HLA-A2.1 COMPLEXED TO GP2 PEPTIDE VARIANT(I2L/V5L)
1EFQA:1-107Q38D MUTANT OF LEN
1EFXB:0-99; A:182-272; D:103-200; E:103-200; D:5-102; E:5-102STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3
1EGJL:109-211; L:1-108; H:114-223; H:1-113; A:338-438DOMAIN 4 OF THE BETA COMMON CHAIN IN COMPLEX WITH AN ANTIBODY
1EK3A:1-108; B:301-408KAPPA-4 IMMUNOGLOBULIN VL, REC
1ERNB:119-220; A:119-218; A:19-118; B:19-118NATIVE STRUCTURE OF THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP]
1EV2E:150-250; F:150-250; G:151-250; H:151-250; H:251-357; G:251-357; F:251-357; E:251-357CRYSTAL STRUCTURE OF FGF2 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 (FGFR2)
1EVTC:149-249; D:149-249; D:250-357; C:250-357CRYSTAL STRUCTURE OF FGF1 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1)
1EVUA:517-630; B:517-630; A:631-725; B:631-725; A:8-192; B:8-192HUMAN FACTOR XIII WITH CALCIUM BOUND IN THE ION SITE
1EX0A:517-630; B:517-630; A:631-725; B:631-725; A:8-192; B:8-192HUMAN FACTOR XIII, MUTANT W279F ZYMOGEN
1EXUB:1-99; A:176-266CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR
1F13A:516-630; B:516-630; A:631-727; B:631-727; B:8-192; A:8-192RECOMBINANT HUMAN CELLULAR COAGULATION FACTOR XIII
1F2QA:4-84; A:85-174CRYSTAL STRUCTURE OF THE HUMAN HIGH-AFFINITY IGE RECEPTOR
1F42A:103-210; A:1-84; A:214-304THE P40 DOMAIN OF HUMAN INTERLEUKIN-12
1F45A:103-210; A:1-84; A:214-302HUMAN INTERLEUKIN-12
1F5WB:19-139; A:16-139DIMERIC STRUCTURE OF THE COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR D1 DOMAIN
1F6AB:436-543; D:436-543; A:4-84; B:336-435; D:336-435; A:85-173STRUCTURE OF THE HUMAN IGE-FC BOUND TO ITS HIGH AFFINITY RECEPTOR FC(EPSILON)RI(ALPHA)
1F6LL:1-106VARIABLE LIGHT CHAIN DIMER OF ANTI-FERRITIN ANTIBODY
1FAKT:6-105; T:106-206HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT
1FC1A:338-443; B:338-443; A:238-337; B:238-337CRYSTALLOGRAPHIC REFINEMENT AND ATOMIC MODELS OF A HUMAN FC FRAGMENT AND ITS COMPLEX WITH FRAGMENT B OF PROTEIN A FROM STAPHYLOCOCCUS AUREUS AT 2.9-AND 2.8-ANGSTROMS RESOLUTION
1FCCA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE C2 FRAGMENT OF STREPTOCOCCAL PROTEIN G IN COMPLEX WITH THE FC DOMAIN OF HUMAN IGG
1FCGA:90-174; A:4-89ECTODOMAIN OF HUMAN FC GAMMA RECEPTOR, FCGRIIA
1FE8L:108-211; H:116-214; I:116-214; J:116-214; H:1-115; I:1-115; J:1-115; M:108-211; N:109-211; L:1-107; M:1-107; N:1-108CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR A3 DOMAIN IN COMPLEX WITH A FAB FRAGMENT OF IGG RU5 THAT INHIBITS COLLAGEN BINDING
1FG9D:109-220; E:109-219; C:109-224; C:12-108; D:12-108; E:13-1083:1 COMPLEX OF INTERFERON-GAMMA RECEPTOR WITH INTERFERON-GAMMA DIMER
1FH5L:110-212; H:121-213; H:4-120; L:2-109CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THE MONOCLONAL ANTIBODY MAK33
1FIEA:516-630; B:516-630; A:631-725; B:631-724; A:9-192; B:10-192RECOMBINANT HUMAN COAGULATION FACTOR XIII
1FLTX:132-226; Y:132-225VEGF IN COMPLEX WITH DOMAIN 2 OF THE FLT-1 RECEPTOR
1FNAA:6-96CRYSTAL STRUCTURE OF THE TENTH TYPE III CELL ADHESION MODULE OF HUMAN FIBRONECTIN
1FNFA:1416-1508; A:1142-1235; A:1327-1415; A:1239-1325FRAGMENT OF HUMAN FIBRONECTIN ENCOMPASSING TYPE-III REPEATS 7 THROUGH 10
1FNHA:3-92; A:93-182; A:183-271CRYSTAL STRUCTURE OF HEPARIN AND INTEGRIN BINDING SEGMENT OF HUMAN FIBRONECTIN
1FNLA:90-175; A:5-89CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF A HUMAN FCGRIII
1FP5A:436-543; A:336-435CRYSTAL STRUCTURE ANALYSIS OF THE HUMAN IGE-FC CEPSILON3-CEPSILON4 FRAGMENT.
1FQ9C:149-249; D:149-249; C:250-359; D:250-358CRYSTAL STRUCTURE OF A TERNARY FGF2-FGFR1-HEPARIN COMPLEX
1FV1A:82-181; D:82-181; B:93-190; E:93-190STRUCTURAL BASIS FOR THE BINDING OF AN IMMUNODOMINANT PEPTIDE FROM MYELIN BASIC PROTEIN IN DIFFERENT REGISTERS BY TWO HLA-DR2 ALLELES
1FVCC:1-108; B:1-120; D:1-120; A:1-109X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING
1FVDA:109-211; B:121-220; D:121-220; B:1-120; D:1-120; C:109-211; A:1-108; C:1-108X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING
1FVEA:109-211; B:121-220; D:121-220; B:1-120; D:1-120; C:109-211; A:1-108; C:1-108X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING
1FYHB:109-222; E:109-221; B:12-108; E:12-1081:1 COMPLEX BETWEEN AN INTERFERON GAMMA SINGLE-CHAIN VARIANT AND ITS RECEPTOR
1FYTE:3-118; D:117-202; A:82-181; E:119-246; B:93-190; D:1-116CRYSTAL STRUCTURE OF A COMPLEX OF A HUMAN ALPHA/BETA-T CELL RECEPTOR, INFLUENZA HA ANTIGEN PEPTIDE, AND MHC CLASS II MOLECULE, HLA-DR1
1G0XA:97-198; A:2-96CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF LIR-1 (ILT2)
1G0YR:98-203; R:204-315; R:6-97IL-1 RECEPTOR TYPE 1 COMPLEXED WITH ANTAGONIST PEPTIDE AF10847
1G1CA:2-99; B:2-99I1 DOMAIN FROM TITIN
1G84A:1-105THE SOLUTION STRUCTURE OF THE C EPSILON2 DOMAIN FROM IGE
1GGTA:516-630; B:516-630; A:631-729; B:631-725; A:8-192; B:8-192THREE-DIMENSIONAL STRUCTURE OF A TRANSGLUTAMINASE: HUMAN BLOOD COAGULATION FACTOR XIII
1GGUA:517-630; B:517-630; A:631-724; B:631-724; A:8-192; B:8-192HUMAN FACTOR XIII WITH CALCIUM BOUND IN THE ION SITE
1GGYA:517-630; B:517-630; A:631-724; B:631-724; A:8-192; B:8-192HUMAN FACTOR XIII WITH YTTERBIUM BOUND IN THE ION SITE
1GH7A:109-215; B:109-215; A:320-416; B:320-416; A:1-95; B:1-95; A:218-308; B:218-308CRYSTAL STRUCTURE OF THE COMPLETE EXTRACELLULAR DOMAIN OF THE BETA-COMMON RECEPTOR OF IL-3, IL-5, AND GM-CSF
1GSMA:91-206; A:1-90A REASSESSMENT OF THE MADCAM-1 STRUCTURE AND ITS ROLE IN INTEGRIN RECOGNITION.
1GXEA:1-130CENTRAL DOMAIN OF CARDIAC MYOSIN BINDING PROTEIN C
1GYAA:1-105N-GLYCAN AND POLYPEPTIDE NMR SOLUTION STRUCTURES OF THE ADHESION DOMAIN OF HUMAN CD2
1GZPB:0-99; A:183-278CD1B IN COMPLEX WITH GM2 GANGLIOSIDE
1GZQB:0-99; A:183-278CD1B IN COMPLEX WITH PHOPHATIDYLINOSITOL
1H0DA:108-203; A:1-107; B:114-212; B:1-113CRYSTAL STRUCTURE OF HUMAN ANGIOGENIN IN COMPLEX WITH FAB FRAGMENT OF ITS MONOCLONAL ANTIBODY MAB 26-2F
1H15A:82-181; D:82-181; B:93-190; E:93-190X-RAY CRYSTAL STRUCTURE OF HLA-DRA1*0101/DRB5*0101 COMPLEXED WITH A PEPTIDE FROM EPSTEIN BARR VIRUS DNA POLYMERASE
1H3TA:338-443; B:338-433; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (MN2F)2
1H3UA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (M3N2F)2
1H3VA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G2F)2,SG P212121
1H3WM:338-443; M:238-337STRUCTURAL ANALYSIS OF HUMAN IGG-FC GLYCOFORMS REVEALS A CORRELATION BETWEEN GLYCOSYLATION AND STRUCTURAL INTEGRITY
1H3XA:338-443; B:338-443; A:238-337; B:239-337CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G0F)2
1H9VA:87-171; A:1-86HUMAN FC-GAMMA-RECEPTOR IIA (FCGRIIA), MONOCLINIC
1HCFX:283-383; Y:283-383CRYSTAL STRUCTURE OF TRKB-D5 BOUND TO NEUROTROPHIN-4/5
1HDMB:87-185; A:84-195HISTOCOMPATIBILITY ANTIGEN HLA-DM
1HE7A:282-388HUMAN NERVE GROWTH FACTOR RECEPTOR TRKA
1HEZA:108-211; B:1-121; D:1-121; D:122-222; B:122-222; C:108-211; A:1-107; C:1-107ANTIBODY-ANTIGEN COMPLEX
1HHGB:0-99; A:182-275; D:182-275; E:0-99THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHHB:0-99; A:182-275THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHIB:0-99; A:182-275; D:182-275; E:0-99THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHJB:0-99; A:182-275; D:182-275; E:0-99THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHKB:0-99; A:182-275; D:182-275; E:0-99THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HKFA:5-112THE THREE DIMENSIONAL STRUCTURE OF NK CELL RECEPTOR NKP44, A TRIGGERING PARTNER IN NATURAL CYTOTOXICITY
1HNFA:4-103; A:104-182CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE HUMAN CELL ADHESION MOLECULE CD2 AT 2.5 ANGSTROMS RESOLUTION
1HQRA:82-180; B:293-390CRYSTAL STRUCTURE OF A SUPERANTIGEN BOUND TO THE HIGH-AFFINITY, ZINC-DEPENDENT SITE ON MHC CLASS II
1HSAB:1-99; E:1-99; A:182-276; D:182-276THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC
1HSBB:1-99; A:182-270DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE
1HWGB:132-232; C:132-232; B:32-131; C:32-1311:2 COMPLEX OF HUMAN GROWTH HORMONE WITH ITS SOLUBLE BINDING PROTEIN
1HWHB:132-232; B:32-1311:1 COMPLEX OF HUMAN GROWTH HORMONE MUTANT G120R WITH ITS SOLUBLE BINDING PROTEIN
1HXMB:126-230; D:126-230; F:126-230; H:126-230; A:1-121; C:1-121; E:1-121; G:1-121; B:1-125; D:1-125; F:1-125; H:1-125; A:122-206; C:122-206; E:122-206; G:122-206CRYSTAL STRUCTURE OF A HUMAN VGAMMA9/VDELTA2 T CELL RECEPTOR
1HXYA:82-181; B:93-190CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN H IN COMPLEX WITH HUMAN MHC CLASS II
1HYRC:181-273CRYSTAL STRUCTURE OF HUMAN MICA IN COMPLEX WITH NATURAL KILLER CELL RECEPTOR NKG2D
1HZHL:108-211; L:1-107; M:1-108; K:105-230; H:361-474; K:361-473; K:1-104; H:250-360; K:250-360; H:129-236; H:24-128; M:109-211CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROAD AND POTENT ACTIVITY AGAINST PRIMARY HIV-1 ISOLATES: A TEMPLATE FOR HIV VACCINE DESIGN
1I1FB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
1I1RA:202-302; A:102-201; A:2-101CRYSTAL STRUCTURE OF A CYTOKINE/RECEPTOR COMPLEX
1I1YB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
1I4FB:0-99; A:182-270CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4-PEPTIDE COMPLEX
1I7RB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1058
1I7TB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-5V
1I7UB:0-99; E:0-99; A:182-270; D:182-270CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-6V
1I85D:3-120; C:3-120; B:1-109; A:0-109CRYSTAL STRUCTURE OF THE CTLA-4/B7-2 COMPLEX
1I8LC:3-120; D:3-120; A:1-105; B:1-105; A:106-199; B:106-199HUMAN B7-1/CTLA-4 CO-STIMULATORY COMPLEX
1I9RL:113-215; L:1-112; M:1-112; Y:1-112; H:113-219; K:113-219; X:113-219; H:1-112; K:1-112; X:1-112; M:113-215; Y:113-215STRUCTURE OF CD40L IN COMPLEX WITH THE FAB FRAGMENT OF HUMANIZED 5C8 ANTIBODY
1IAMA:84-185; A:1-83STRUCTURE OF THE TWO AMINO-TERMINAL DOMAINS OF HUMAN INTERCELLULAR ADHESION MOLECULE-1, ICAM-1
1IARB:1-96; B:97-197INTERLEUKIN-4 / RECEPTOR ALPHA CHAIN COMPLEX
1IC1A:84-190; B:84-190; A:1-83; B:1-83THE CRYSTAL STRUCTURE FOR THE N-TERMINAL TWO DOMAINS OF ICAM-1
1IGML:1-115; H:1-129THREE DIMENSIONAL STRUCTURE OF AN FV FROM A HUMAN IGM IMMUNOGLOBULIN
1II4E:150-250; F:150-250; G:150-250; H:150-250; E:251-357; F:251-357; G:251-357; H:251-357CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2
1IILE:150-250; F:150-250; G:150-250; H:150-250; G:251-357; H:251-357; E:251-357; F:251-357CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2
1IJ9A:90-196; A:1-89HIGHLY HYDRATED HUMAN VCAM-1 FRAGMENT
1IM3B:0-99; A:182-270; E:182-270; I:182-270; M:182-270; F:0-99; J:0-99; N:0-99CRYSTAL STRUCTURE OF THE HUMAN CYTOMEGALOVIRUS PROTEIN US2 BOUND TO THE MHC CLASS I MOLECULE HLA-A2/TAX
1IM9B:0-99; A:182-272; E:182-272; D:103-200; D:6-102; F:0-99CRYSTAL STRUCTURE OF THE HUMAN NATURAL KILLER CELL INHIBITORY RECEPTOR KIR2DL1 BOUND TO ITS MHC LIGAND HLA-CW4
1IQDA:110-211; A:2-109; B:115-210; B:1-114HUMAN FACTOR VIII C2 DOMAIN COMPLEXED TO HUMAN MONOCLONAL BO2C11 FAB.
1IRAY:95-200; Y:201-311; Y:3-94COMPLEX OF THE INTERLEUKIN-1 RECEPTOR WITH THE INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL1RA)
1ITBB:98-203; B:204-315; B:6-97TYPE-1 INTERLEUKIN-1 RECEPTOR COMPLEXED WITH INTERLEUKIN-1 BETA
1J7VR:104-206; R:2-103HUMAN IL-10 / IL-10R1 COMPLEX
1J86A:4-84; B:4-84; A:85-174; B:85-173HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), MONOCLINIC CRYSTAL FORM 2
1J87A:4-84; A:85-171HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), HEXAGONAL CRYSTAL FORM 1
1J88A:4-84; B:4-84; C:4-84; D:4-84; E:4-84; A:85-171; B:85-171; C:85-171; D:85-171; E:85-171HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), TETRAGONAL CRYSTAL FORM 1
1J8HE:3-118; D:117-202; A:82-181; E:119-246; B:92-190; D:1-116CRYSTAL STRUCTURE OF A COMPLEX OF A HUMAN ALPHA/BETA-T CELL RECEPTOR, INFLUENZA HA ANTIGEN PEPTIDE, AND MHC CLASS II MOLECULE, HLA-DR4
1J8KA:1-94NMR STRUCTURE OF THE FIBRONECTIN EDA DOMAIN, NMR, 20 STRUCTURES
1J9CT:3-105; T:106-210CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX
1JE6A:184-272STRUCTURE OF THE MHC CLASS I HOMOLOG MICB
1JF1B:0-99; A:182-270CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH A DECAMERIC ALTERED PEPTIDE LIGAND FROM THE MART-1/MELAN-A
1JGDB:0-99; A:182-276HLA-B*2709 BOUND TO DECA-PEPTIDE S10R
1JGEB:0-99; A:182-276HLA-B*2705 BOUND TO NONA-PEPTIDE M9
1JHTB:0-99; A:182-270CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH A NONAMERIC ALTERED PEPTIDE LIGAND (ALGIGILTV) FROM THE MART-1/MELAN-A.
1JK8A:82-181; B:93-192CRYSTAL STRUCTURE OF A HUMAN INSULIN PEPTIDE-HLA-DQ8 COMPLEX
1JNJA:0-99NMR SOLUTION STRUCTURE OF THE HUMAN BETA2-MICROGLOBULIN
1JPSL:109-211; H:118-216; T:5-105; T:106-210; H:1-117; L:1-108CRYSTAL STRUCTURE OF TISSUE FACTOR IN COMPLEX WITH HUMANIZED FAB D3H44
1JPTL:109-211; H:118-216; H:1-117; L:1-108CRYSTAL STRUCTURE OF FAB D3H44
1JV5A:1-107; B:301-417ANTI-BLOOD GROUP A FV
1JVKA:2-112; B:2-112; A:113-213; B:113-213THREE-DIMENSIONAL STRUCTURE OF AN IMMUNOGLOBULIN LIGHT CHAIN DIMER ACTING AS A LETHAL AMYLOID PRECURSOR
1JWMA:82-181; B:93-190CRYSTAL STRUCTURE OF THE COMPLEX OF THE MHC CLASS II MOLECULE HLA-DR1(HA PEPTIDE 306-318) WITH THE SUPERANTIGEN SEC3
1JWSA:82-181; B:93-190CRYSTAL STRUCTURE OF THE COMPLEX OF THE MHC CLASS II MOLECULE HLA-DR1 (HA PEPTIDE 306-318) WITH THE SUPERANTIGEN SEC3 VARIANT 3B1
1JWUA:82-181; B:93-190CRYSTAL STRUCTURE OF THE COMPLEX OF THE MHC CLASS II MOLECULE HLA-DR1 (HA PEPTIDE 306-318) WITH THE SUPERANTIGEN SEC3 VARIANT 3B2
1K5NB:0-99; A:182-276HLA-B*2709 BOUND TO NONA-PEPTIDE M9
1KF9B:332-432; E:1332-1432; F:1632-1732; C:632-731; E:1233-1331; B:233-331; F:1533-1631; C:533-631PHAGE DISPLAY DERIVED VARIANT OF HUMAN GROWTH HORMONE COMPLEXED WITH TWO COPIES OF THE EXTRACELLULAR DOMAIN OF ITS RECEPTOR
1KFAL:114-215; H:127-225; I:127-224; L:1-113; M:1-113; I:3-121; H:2-121; M:114-213CRYSTAL STRUCTURE OF FAB FRAGMENT COMPLEXED WITH GIBBERELLIN A4
1KG0A:82-181; B:93-190STRUCTURE OF THE EPSTEIN-BARR VIRUS GP42 PROTEIN BOUND TO THE MHC CLASS II RECEPTOR HLA-DR1
1KGCD:2-116; E:3-118; D:117-206; E:119-247IMMUNE RECEPTOR
1KLGA:82-180; B:93-190CRYSTAL STRUCTURE OF HLA-DR1/TPI(23-37, THR28-->ILE MUTANT) COMPLEXED WITH STAPHYLOCOCCAL ENTEROTOXIN C3 VARIANT 3B2 (SEC3-3B2)
1KLUA:82-181; B:93-190CRYSTAL STRUCTURE OF HLA-DR1/TPI(23-37) COMPLEXED WITH STAPHYLOCOCCAL ENTEROTOXIN C3 VARIANT 3B2 (SEC3-3B2)
1KPRB:1-99; A:182-272; C:182-272; D:1-99THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
1KTLB:1-99; A:182-272; C:182-272; D:1-99THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
1KV3A:588-685; B:588-685; C:588-685; D:588-685; E:588-685; F:588-685; A:15-147; B:15-147; C:15-147; D:15-147; E:15-147; F:15-147; A:471-587; B:471-587; C:471-587; D:471-587; E:471-587; F:471-587HUMAN TISSUE TRANSGLUTAMINASE IN GDP BOUND FORM
1L6XA:338-443; A:238-337FC FRAGMENT OF RITUXIMAB BOUND TO A MINIMIZED VERSION OF THE B-DOMAIN FROM PROTEIN A CALLED Z34C
1L7IL:109-211; H:114-213; H:1-113; L:1-108CRYSTAL STRUCTURE OF THE ANTI-ERBB2 FAB2C4
1L9MA:595-691; B:595-691; A:480-594; B:478-594; A:1-142; B:1-142THREE-DIMENSIONAL STRUCTURE OF THE HUMAN TRANSGLUTAMINASE 3 ENZYME: BINDING OF CALCIUM IONS CHANGE STRUCTURE FOR ACTIVATION
1L9NA:595-691; B:595-691; A:481-594; B:481-594; A:1-142; B:1-142THREE-DIMENSIONAL STRUCTURE OF THE HUMAN TRANSGLUTAMINASE 3 ENZYME: BINDING OF CALCIUM IONS CHANGE STRUCTURE FOR ACTIVATION
1LDSA:0-96CRYSTAL STRUCTURE OF MONOMERIC HUMAN BETA-2-MICROGLOBULIN
1LGVA:2-112; B:2-112; A:113-213; B:113-213STRUCTURE OF A HUMAN BENCE-JONES DIMER CRYSTALLIZED IN U.S. SPACE SHUTTLE MISSION STS-95: 100K
1LHZA:2-112; B:2-112; A:113-213; B:113-213STRUCTURE OF A HUMAN BENCE-JONES DIMER CRYSTALLIZED IN U.S. SPACE SHUTTLE MISSION STS-95: 293K
1LILA:2-107; B:2-107; A:108-211; B:108-211BENCE JONES PROTEIN CLE, A LAMBDA III IMMUNOGLOBULIN LIGHT-CHAIN DIMER
1LK3L:108-210; I:120-218; H:120-217; L:1-107; M:1-107; H:1-119; I:1-119; M:108-210ENGINEERED HUMAN INTERLEUKIN-10 MONOMER COMPLEXED TO 9D7 FAB FRAGMENT
1LO5A:82-181; B:93-190CRYSTAL STRUCTURE OF THE D227A VARIANT OF STAPHYLOCOCCAL ENTEROTOXIN A IN COMPLEX WITH HUMAN MHC CLASS II
1LP9B:0-99; A:182-270; H:182-270; I:0-99; F:3-117; M:3-117; E:117-198; L:117-198; F:118-245; M:118-245; E:1-116; L:1-116XENOREACTIVE COMPLEX AHIII 12.2 TCR BOUND TO P1049/HLA-A2.1
1LQSR:104-206; S:104-206; R:2-103; S:2-103CRYSTAL STRUCTURE OF HUMAN CYTOMEGALOVIRUS IL-10 BOUND TO SOLUBLE HUMAN IL-10R1
1LVEA:1-108STRUCTURE OF THE VARIABLE DOMAIN OF HUMAN IMMUNOGLOBULIN K-4 LIGHT CHAIN LEN
1M05B:1-99; D:1-99; A:182-272; C:182-272HLA B8 IN COMPLEX WITH AN EPSTEIN BARR VIRUS DETERMINANT
1M4KA:103-200; A:8-102CRYSTAL STRUCTURE OF THE HUMAN NATURAL KILLER CELL ACTIVATOR RECEPTOR KIR2DS2 (CD158J)
1M6OB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4402 IN COMPLEX WITH HLA DPA*0201 PEPTIDE
1MCCA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCDA:1-111; B:1-111; B:112-216; A:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCEB:2-111; A:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCFA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCHA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCIA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCJA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCKA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCNA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCOH:120-221; H:328-428; L:1-111; H:1-118; L:112-212; H:223-326THREE-DIMENSIONAL STRUCTURE OF A HUMAN IMMUNOGLOBULIN WITH A HINGE DELETION
1MCQA:1-111; B:1-111; A:112-216; B:112-216PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCRA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCSA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCWM:2-111; W:2-112; M:112-216; W:113-216THREE-DIMENSIONAL STRUCTURE OF A HYBRID LIGHT CHAIN DIMER. PROTEIN ENGINEERING OF A BINDING CAVITY
1MHEB:1-99; A:182-272; C:182-272; D:1-99THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
1MI5B:1-99; D:2-116; E:3-118; D:117-206; E:119-247; A:182-272THE CRYSTAL STRUCTURE OF LC13 TCR IN COMPLEX WITH HLAB8-EBV PEPTIDE COMPLEX
1MQ8A:84-184; C:84-184; A:1-83; C:1-83CRYSTAL STRUCTURE OF ALPHAL I DOMAIN IN COMPLEX WITH ICAM-1
1N0XL:108-211; L:1-107; M:1-107; K:110-230; H:110-228; H:1-109; K:1-109; M:108-211CRYSTAL STRUCTURE OF A BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY IN COMPLEX WITH A PEPTIDE MIMOTOPE
1N26A:196-299; A:2-9,A:94-192; A:14-91CRYSTAL STRUCTURE OF THE EXTRA-CELLULAR DOMAINS OF HUMAN INTERLEUKIN-6 RECEPTOR ALPHA CHAIN
1N2RB:1-99; A:182-272A NATURAL SELECTED DIMORPHISM IN HLA B*44 ALTERS SELF, PEPTIDE REPORTOIRE AND T CELL RECOGNITION.
1N6UA:1-106; A:107-212NMR STRUCTURE OF THE INTERFERON-BINDING ECTODOMAIN OF THE HUMAN INTERFERON RECEPTOR
1N6VA:1-106; A:107-212AVERAGE STRUCTURE OF THE INTERFERON-BINDING ECTODOMAIN OF THE HUMAN TYPE I INTERFERON RECEPTOR
1N8ZA:109-211; B:121-220; B:1-120; A:1-108CRYSTAL STRUCTURE OF EXTRACELLULAR DOMAIN OF HUMAN HER2 COMPLEXED WITH HERCEPTIN FAB
1NBQA:129-233; B:129-233; A:25-128; B:26-128CRYSTAL STRUCTURE OF HUMAN JUNCTIONAL ADHESION MOLECULE TYPE 1
1NCNA:0-109; B:0-109THE RECEPTOR-BINDING DOMAIN OF HUMAN B7-2
1NCTA:-6-91TITIN MODULE M5, N-TERMINALLY EXTENDED, NMR
1NCUA:-6-91TITIN MODULE M5, N-TERMINALLY EXTENDED, NMR
1NFIA:190-292; C:190-292; B:249-355; D:249-355I-KAPPA-B-ALPHA/NF-KAPPA-B COMPLEX
1NKOA:21-147ENERGETIC AND STRUCTURAL BASIS OF SIALYLATED OLIGOSACCHARIDE RECOGNITION BY THE NATURAL KILLER CELL INHIBITORY RECEPTOR P75/AIRM1 OR SIGLEC-7
1NKRA:103-200; A:6-102INHIBITORY RECEPTOR (P58-CL42) FOR HUMAN NATURAL KILLER CELLS
1NL0H:114-214; L:1-108; L:109-209; H:1-113CRYSTAL STRUCTURE OF HUMAN FACTOR IX GLA DOMAIN IN COMPLEX OF AN INHIBITORY ANTIBODY, 10C12
1NUDA:595-691; B:595-691; A:481-594; B:481-594; A:1-142; B:1-142ROLE OF CALCIUM IONS IN THE ACTIVATION AND ACTIVITY OF THE TRANSGLUTAMINASE 3 ENZYME (3 CALCIUMS, ACTIVE FORM)
1NUFA:595-691; A:480-594; A:1-142ROLE OF CALCIUM IONS IN THE ACTIVATION AND ACTIVITY OF THE TRANSGLUTAMINASE 3 ENZYME
1NUGA:595-691; B:595-691; A:480-594; B:478-594; A:1-142; B:1-142ROLE OF CALCIUM IONS IN THE ACTIVATION AND ACTIVITY OF THE TRANSGLUTAMINASE 3 ENZYME (2 CALCIUMS, 1 MG, INACTIVE FORM)
1NUNB:151-250; B:251-355CRYSTAL STRUCTURE ANALYSIS OF THE FGF10-FGFR2B COMPLEX
1O0VB:436-545; A:436-545; A:329-435; B:329-435; A:228-328; B:228-328THE CRYSTAL STRUCTURE OF IGE FC REVEALS AN ASYMMETRICALLY BENT CONFORMATION
1O5DT:6-205DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O7SA:24-144HIGH RESOLUTION STRUCTURE OF SIGLEC-7
1O7VA:18-144HIGH RESOLUTION STRUCTURE OF SIGLEC-7
1OF2B:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
1OGAB:0-99; D:3-111; E:5-115; D:112-201; E:116-244; A:182-270A STRUCTURAL BASIS FOR IMMUNODOMINANT HUMAN T-CELL RECEPTOR RECOGNITION.
1OGTB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
1OHQB:1-119; A:1-120CRYSTAL STRUCTURE OF HEL4, A SOLUBLE HUMAN VH ANTIBODY DOMAIN RESISTANT TO AGGREGATION
1OL0A:1-121; B:1-121CRYSTAL STRUCTURE OF A CAMELISED HUMAN VH
1OLZA:539-628; B:539-628THE LIGAND-BINDING FACE OF THE SEMAPHORINS REVEALED BY THE HIGH RESOLUTION CRYSTAL STRUCTURE OF SEMA4D
1OM3M:109-211; H:114-227; K:114-226; H:1-113; K:1-113; L:108-211; L:2-107; M:2-108FAB 2G12 UNLIGANDED
1ONQB:1-99; D:1-99; A:183-278; C:183-278CRYSTAL STRUCTURE OF CD1A IN COMPLEX WITH A SULFATIDE
1OP3L:109-211; H:114-222; M:114-222; H:1-113; M:1-113; K:108-211; K:2-107; L:2-108CRYSTAL STRUCTURE OF FAB 2G12 BOUND TO MAN1->2MAN
1OP5K:109-208; H:114-226; M:114-226; H:1-113; M:1-113; L:108-211; L:2-107; K:2-108CRYSTAL STRUCTURE OF FAB 2G12 BOUND TO MAN9GLCNAC2
1OPGL:108-211; H:126-223; H:1-125; L:1-107OPG2 FAB FRAGMENT
1OQOA:338-443; B:338-443; A:238-337; B:238-337COMPLEX BETWEEN G0 VERSION OF AN FC BOUND TO A MINIMIZED VERSION OF PROTEIN A CALLED MINI-Z
1OQXA:338-443; B:338-443; A:238-337; B:238-337G-2 GLYCOVARIANT OF HUMAN IGG FC BOUND TO MINIMIZED VERSION OF PROTEIN A CALLED Z34C
1OVZA:100-198; B:100-192; B:5-99; A:6-99CRYSTAL STRUCTURE OF HUMAN FCARI
1OW0C:100-195; D:100-195; C:6-99; D:6-99; A:342-450; B:342-450; A:242-341; B:242-341CRYSTAL STRUCTURE OF HUMAN FCARI BOUND TO IGA1-FC
1OWWA:1-93SOLUTION STRUCTURE OF THE FIRST TYPE III MODULE OF HUMAN FIBRONECTIN DETERMINED BY 1H, 15N NMR SPECTROSCOPY
1P53A:185-282; B:185-282; A:368-450; B:368-450; A:283-367; B:283-367THE CRYSTAL STRUCTURE OF ICAM-1 D3-D5 FRAGMENT
1P6FA:99-191; A:4-98STRUCTURE OF THE HUMAN NATURAL CYTOTOXICITY RECEPTOR NKP46
1P7QB:1-99; A:182-270; D:97-198; D:4-96CRYSTAL STRUCTURE OF HLA-A2 BOUND TO LIR-1, A HOST AND VIRAL MHC RECEPTOR
1P9MA:202-299; A:102-201; C:196-296; C:96-195; A:2-101CRYSTAL STRUCTURE OF THE HEXAMERIC HUMAN IL-6/IL-6 ALPHA RECEPTOR/GP130 COMPLEX
1PD6A:208-301THE NMR STRUCTURE OF DOMAIN C2 OF HUMAN CARDIAC MYOSIN BINDING PROTEIN C
1PEWA:1-108; B:1-108HIGH RESOLUTION CRYSTAL STRUCTURE OF JTO2, A MUTANT OF THE NON-AMYLOIDOGENIC LAMBA6 LIGHT CHAIN, JTO
1PGRB:1-108; F:1-108; D:3-108; H:3-108; F:109-213; B:109-213; D:109-213; H:109-2132:2 COMPLEX OF G-CSF WITH ITS RECEPTOR
1PVHA:201-301; C:201-301; A:101-200; C:101-200CRYSTAL STRUCTURE OF LEUKEMIA INHIBITORY FACTOR IN COMPLEX WITH GP130
1PW3A:1-108; B:1-108CRYSTAL STRUCTURE OF JTOR68S
1PY4A:0-97; B:1-97; D:1-97; C:2-97BETA2 MICROGLOBULIN MUTANT H31Y DISPLAYS HINTS FOR AMYLOID FORMATIONS
1PYWA:82-181; B:93-190HUMAN CLASS II MHC PROTEIN HLA-DR1 BOUND TO A DESIGNED PEPTIDE RELATED TO INFLUENZA VIRUS HEMAGGLUTININ, FVKQNA(MAA)AL, IN COMPLEX WITH STAPHYLOCOCCAL ENTEROTOXIN C3 VARIANT 3B2 (SEC3-3B2)
1Q1JH:114-223; I:114-223; L:2-107; M:2-107; L:108-211; M:108-211; H:1-113; I:1-113CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 FAB 447-52D IN COMPLEX WITH V3 PEPTIDE
1Q38A:1-89ANASTELLIN
1Q8MA:16-136; B:16-136; C:16-136; D:16-136CRYSTAL STRUCTURE OF THE HUMAN MYELOID CELL ACTIVATING RECEPTOR TREM-1
1Q94B:0-99; E:0-99; A:182-275; D:182-275STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE
1QA9B:1-95; D:1-95; A:4-105; C:4-105STRUCTURE OF A HETEROPHILIC ADHESION COMPLEX BETWEEN THE HUMAN CD2 AND CD58(LFA-3) COUNTER-RECEPTORS
1QACA:1-108; B:301-408CHANGE IN DIMERIZATION MODE BY REMOVAL OF A SINGLE UNSATISFIED POLAR RESIDUE
1QEWB:0-99; A:182-270HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) COMPLEX WITH A NONAMERIC PEPTIDE FROM MELANOMA-ASSOCIATED ANTIGEN 3 (RESIDUES 271-279)
1QFWH:3-117; L:1-114; M:201-308; I:201-321TERNARY COMPLEX OF HUMAN CHORIONIC GONADOTROPIN WITH FV ANTI ALPHA SUBUNIT AND FV ANTI BETA SUBUNIT
1QG3A:1217-1320; B:1217-1319; A:1126-1216; B:1127-1216CRYSTAL STRUCTURE OF A TANDEM PAIR OF FIBRONECTIN TYPE III DOMAINS FROM THE CYTOPLASMIC TAIL OF INTEGRIN ALPHA6 BETA4
1QLRA:109-211; A:1-108; C:1-108; B:1-120; D:1-120; D:121-223; B:121-222; C:109-211CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF A HUMAN MONOCLONAL IGM COLD AGGLUTININ
1QP1A:1-107; B:1-107; C:1-107KAPPA VARIABLE LIGHT CHAIN
1QQDB:0-98; A:182-272CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER CELL INHIBITORY RECEPTOR
1QR1B:0-99; A:182-270; D:182-270; E:0-99POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE
1QRKA:518-630; B:517-630; A:631-724; B:631-724; A:9-192; B:10-192HUMAN FACTOR XIII WITH STRONTIUM BOUND IN THE ION SITE
1QRNB:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A
1QSEB:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116STRUCTURE OF HUMAN A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R
1QSFB:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A
1QSVA:129-229THE VEGF-BINDING DOMAIN OF FLT-1, 20 NMR STRUCTURES
1QSZA:129-229THE VEGF-BINDING DOMAIN OF FLT-1 (MINIMIZED MEAN)
1QTYT:132-225; U:132-225; X:132-225; Y:132-225VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH DOMAIN 2 OF THE FLT-1 RECEPTOR
1QVOB:0-99; E:0-99; A:182-275; D:182-275STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE
1R5IA:82-181; E:82-181; B:93-190; F:93-190CRYSTAL STRUCTURE OF THE MAM-MHC COMPLEX
1REIA:1-107; B:1-107THE MOLECULAR STRUCTURE OF A DIMER COMPOSED OF THE VARIABLE PORTIONS OF THE BENCE-JONES PROTEIN REI REFINED AT 2.0 ANGSTROMS RESOLUTION
1RHFA:7-97; B:7-97; A:98-182; B:98-182CRYSTAL STRUCTURE OF HUMAN TYRO3-D1D2
1RHHA:108-210; A:1-107; C:1-107; B:114-213; D:114-213; D:4-113; B:3-113; C:108-210CRYSTAL STRUCTURE OF THE BROADLY HIV-1 NEUTRALIZING FAB X5 AT 1.90 ANGSTROM RESOLUTION
1RPQD:4-84; C:4-84; A:4-84; B:4-84; A:85-171; B:85-171; C:85-171; D:85-171HIGH AFFINITY IGE RECEPTOR (ALPHA CHAIN) COMPLEXED WITH TIGHT-BINDING E131 'ZETA' PEPTIDE FROM PHAGE DISPLAY
1RSFA:19-144NMR STRUCTURE OF MONOMERIC CAR D1 DOMAIN
1RV6X:133-224; Y:133-224CRYSTAL STRUCTURE OF PLGF IN COMPLEX WITH DOMAIN 2 OF VEGFR1
1RY7B:150-247; B:248-362CRYSTAL STRUCTURE OF THE 3 IG FORM OF FGFR3C IN COMPLEX WITH FGF1
1RZ7L:108-211; H:110-213; H:1-109; L:2-107CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 48D
1RZ8A:109-211; A:1-108; C:1-108; B:114-213; D:114-213; B:1-113; D:1-113; C:109-211CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 17B
1RZFH:111-214; L:3-108; H:2-110; L:109-209CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY E51
1RZGB:110-211; A:110-214; C:110-213; C:2-109; A:1-109; D:110-211; B:1-108; D:1-108CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120 REACTIVE ANTIBODY 412D
1RZIA:108-211; F:114-214; B:114-213; D:114-213; H:114-213; J:114-213; L:114-213; N:114-213; P:114-213; L:1-113; B:1-113; D:1-113; F:1-113; H:1-113; J:1-113; N:1-113; P:1-113; C:108-211; E:108-211; G:108-211; I:108-211; K:108-211; M:108-211; O:108-211; A:2-107; E:2-107; G:2-107; I:2-107; K:2-107; M:2-107; O:2-107; C:1-107CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 47E FAB
1S78C:109-211; D:114-213; F:114-213; D:1-113; F:1-113; E:109-211; C:1-108; E:1-108INSIGHTS INTO ERBB SIGNALING FROM THE STRUCTURE OF THE ERBB2-PERTUZUMAB COMPLEX
1S8DB:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-3A
1S9VA:82-180; D:82-178; B:93-190; E:93-190CRYSTAL STRUCTURE OF HLA-DQ2 COMPLEXED WITH DEAMIDATED GLIADIN PEPTIDE
1S9WB:0-99; A:182-270CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE, SLLMWITQC, IN COMPLEX WITH HLA-A2
1S9XB:0-99; A:182-270CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE ANALOGUE, SLLMWITQA, IN COMPLEX WITH HLA-A2
1S9YB:0-99; A:182-270CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE ANALOGUE, SLLMWITQS, IN COMPLEX WITH HLA-A2
1SEBA:82-181; E:82-181; B:93-192; F:93-192COMPLEX OF THE HUMAN MHC CLASS II GLYCOPROTEIN HLA-DR1 AND THE BACTERIAL SUPERANTIGEN SEB
1SJEA:82-181; B:93-190HLA-DR1 COMPLEXED WITH A 16 RESIDUE HIV CAPSID PEPTIDE BOUND IN A HAIRPIN CONFORMATION
1SJHA:82-181; B:93-190HLA-DR1 COMPLEXED WITH A 13 RESIDUE HIV CAPSID PEPTIDE
1SMOB:26-135; A:21-133CRYSTAL STRUCTURE OF HUMAN TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 (TREM-1) AT 1.47 .
1SYSB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA, B*4403, AND PEPTIDE EEPTVIKKY
1SYVB:1-99; A:182-272HLA-B*4405 COMPLEXED TO THE DOMINANT SELF LIGAND EEFGRAYGF
1T04A:108-211; B:2-117; D:2-117; B:118-217; D:118-217; C:108-211; A:1-107; C:1-107THREE DIMENSIONAL STRUCTURE OF A HUMANIZED ANTI-IFN-GAMMA FAB IN C2 SPACE GROUP
1T0PB:1-86STRUCTURAL BASIS OF ICAM RECOGNITION BY INTEGRIN ALPAHLBETA2 REVEALED IN THE COMPLEX STRUCTURE OF BINDING DOMAINS OF ICAM-3 AND ALPHALBETA2 AT 1.65 A
1T1WB:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-3F6I8V
1T1XB:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-4L
1T1YB:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-5V
1T1ZB:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-6A
1T20B:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-6I
1T21B:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9, MONOCLINIC CRYSTAL
1T22B:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9, ORTHORHOMBIC CRYSTAL
1T2JA:1-113CRYSTAL STRUCTURE OF A HUMAN VH DOMAIN
1T3FA:108-211; B:2-117; B:118-217; A:1-107THREE DIMENSIONAL STRUCTURE OF A HUMANIZED ANTI-IFN-GAMMA FAB (HUZAF) IN P21 21 21 SPACE GROUP
1T5WA:82-181; D:82-181; B:93-190; E:93-190HLA-DR1 IN COMPLEX WITH A SYNTHETIC PEPTIDE (AAYSDQATPLLLSPR)
1T5XA:82-181; B:93-190HLA-DR1 IN COMPLEX WITH A SYNTHETIC PEPTIDE (AAYSDQATPLLLSPR) AND THE SUPERANTIGEN SEC3-3B2
1T7VA:184-273ZN-ALPHA-2-GLYCOPROTEIN; BACULO-ZAG PEG 200
1T7WA:184-273ZN-ALPHA-2-GLYCOPROTEIN; CHO-ZAG PEG 400
1T7XA:184-273ZN-ALPHA-2-GLYCOPROTEIN; REFOLDED CHO-ZAG PEG 400
1T7YA:184-273ZN-ALPHA-2-GLYCOPROTEIN; BACULO-ZAG PEG 200, NO GLYCEROL
1T7ZA:184-273ZN-ALPHA-2-GLYCOPROTEIN; BACULO-ZAG NO PEG, NO GLYCEROL
1T80A:184-273ZN-ALPHA-2-GLYCOPROTEIN; CHO-ZAG PEG 200
1T83A:338-443; B:338-443; A:238-337; B:238-337; C:90-171; C:5-89CRYSTAL STRUCTURE OF A HUMAN TYPE III FC GAMMA RECEPTOR IN COMPLEX WITH AN FC FRAGMENT OF IGG1 (ORTHORHOMBIC)
1T89A:338-443; B:338-443; A:238-337; B:238-337; C:90-171; C:5-89CRYSTAL STRUCTURE OF A HUMAN TYPE III FC GAMMA RECEPTOR IN COMPLEX WITH AN FC FRAGMENT OF IGG1 (HEXAGONAL)
1TENA:802-891STRUCTURE OF A FIBRONECTIN TYPE III DOMAIN FROM TENASCIN PHASED BY MAD ANALYSIS OF THE SELENOMETHIONYL PROTEIN
1TFHA:5-105; B:5-105; A:106-210; B:106-205EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR
1TITA:1-89TITIN, IG REPEAT 27, NMR, MINIMIZED AVERAGE STRUCTURE
1TIUA:1-89TITIN, IG REPEAT 27, NMR, 24 STRUCTURES
1TJGL:108-211; H:114-213; H:1-113; L:1-107CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY 2F5 IN COMPLEX WITH A GP41 7MER EPITOPE
1TJHL:108-211; H:114-213; H:1-113; L:1-107CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY 2F5 IN COMPLEX WITH A GP41 11MER EPITOPE
1TJIL:108-211; H:114-213; H:1-113; L:1-107CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY 2F5 IN COMPLEX WITH A GP41 17MER EPITOPE
1TMCB:1-99THE THREE-DIMENSIONAL STRUCTURE OF A CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE MISSING THE ALPHA3 DOMAIN OF THE HEAVY CHAIN
1TNMA:1-91TERTIARY STRUCTURE OF AN IMMUNOGLOBULIN-LIKE DOMAIN FROM THE GIANT MUSCLE PROTEIN TITIN: A NEW MEMBER OF THE I SET
1TNNA:1-91TERTIARY STRUCTURE OF AN IMMUNOGLOBULIN-LIKE DOMAIN FROM THE GIANT MUSCLE PROTEIN TITIN: A NEW MEMBER OF THE I SET
1TTFA:1-94THE THREE-DIMENSIONAL STRUCTURE OF THE TENTH TYPE III MODULE OF FIBRONECTIN: AN INSIGHT INTO RGD-MEDIATED INTERACTIONS
1TTGA:1-94THE THREE-DIMENSIONAL STRUCTURE OF THE TENTH TYPE III MODULE OF FIBRONECTIN: AN INSIGHT INTO RGD-MEDIATED INTERACTIONS
1TVBB:0-99; E:0-99; A:182-270; D:182-270CRYSTAL STRUCTURE OF MELANOMA ANTIGEN GP100(209-217) BOUND TO HUMAN CLASS I MHC HLA-A2
1TVDA:1-116; B:1-116VARIABLE DOMAIN OF T CELL RECEPTOR DELTA CHAIN
1TVHB:0-99; E:0-99; A:182-270; D:182-270CRYSTAL STRUCTURE OF MODIFIED MELANOMA ANTIGEN GP100(209-T2M) BOUND TO HUMAN CLASS I MHC HLA-A2
1TZGL:109-211; L:1-108; M:1-108; I:110-228; H:110-232; H:1-109; I:1-109; M:109-211CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A 13-RESIDUE PEPTIDE CONTAINING THE 4E10 EPITOPE ON GP41
1TZHA:109-211; B:114-213; H:114-213; B:1-113; H:1-113; L:109-211; A:1-108; L:1-108CRYSTAL STRUCTURE OF THE FAB YADS1 COMPLEXED WITH H-VEGF
1U2HA:17-112X-RAY STRUCTURE OF THE N-TERMINALLY TRUNCATED HUMAN APEP-1
1U6AL:109-211; L:1-108; H:114-212; H:2-113CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV FAB F105
1U8HA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ALDKWAS
1U8IA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWAN
1U8JA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWAG
1U8KA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE LELDKWASL
1U8LA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE DLDRWAS
1U8MA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKYAS
1U8NA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKFAS
1U8OA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKHAS
1U8PA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ECDKWCS
1U8QA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELEKWAS
1U91A:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ANALOG ENDKW-[DAP]-S (CYCLIC)
1U92A:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ANALOG E-[DAP]-DKWQS (CYCLIC)
1U93A:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ANALOG EQDKW-[DAP]-S (CYCLIC)
1U95A:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDHWAS
1UADC:4-95; D:4-95CRYSTAL STRUCTURE OF THE RALA-GPPNHP-SEC5 RAL-BINDING DOMAIN COMPLEX
1UC6A:1-109SOLUTION STRUCTURE OF THE CARBOXYL TERMINAL DOMAIN OF THE CILIARY NEUROTROPHIC FACTOR RECEPTOR
1UCTA:101-195; A:6-100CRYSTAL STRUCTURE OF THE EXTRACELLULAR FRAGMENT OF FC ALPHA RECEPTOR I (CD89)
1UEMA:1-117SOLUTION STRUCTURE OF THE FIRST FIBRONECTIN TYPE III DOMAIN OF HUMAN KIAA1568 PROTEIN
1UENA:1-125SOLUTION STRUCTURE OF THE THIRD FIBRONECTIN III DOMAIN OF HUMAN KIAA0343 PROTEIN
1UEYA:1-127SOLUTION STRUCTURE OF THE FIRST FIBRONECTIN TYPE III DOMAIN OF HUMAN KIAA0343 PROTEIN
1UFUA:97-195; A:2-96CRYSTAL STRUCTURE OF LIGAND BINDING DOMAIN OF IMMUNOGLOBULIN-LIKE TRANSCRIPT 2 (ILT2; LIR-1)
1UGNA:97-198; A:2-96CRYSTAL STRUCTURE OF LIR1.02, ONE OF THE ALLELES OF LIR1
1UJ3A:109-211; B:418-517; C:606-705; C:706-810; B:301-417; A:1-108CRYSTAL STRUCTURE OF A HUMANIZED FAB FRAGMENT OF ANTI-TISSUE-FACTOR ANTIBODY IN COMPLEX WITH TISSUE FACTOR
1UJTA:1-120SOLUTION STRUCTURE OF THE SECOND FIBRONECTIN TYPE III DOMAIN OF HUMAN KIAA1568 PROTEIN
1UQSB:0-99; A:183-278THE CRYSTAL STRUCTURE OF HUMAN CD1B WITH A BOUND BACTERIAL GLYCOLIPID
1UVQA:85-183; B:93-191CRYSTAL STRUCTURE OF HLA-DQ0602 IN COMPLEX WITH A HYPOCRETIN PEPTIDE
1UXSB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTEIN-BARR VIRUS
1UXWB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS
1V05A:-3-2725DIMERIZATION OF HUMAN FILAMIN C: CRYSTAL STRUCTURE OF THE DOMAIN 24
1V5JA:1-108SOLUTION STRUCTURE OF RSGI RUH-008, FN3 DOMAIN IN HUMAN CDNA
1VCAA:90-199; B:90-199; A:1-89; B:1-89CRYSTAL STRUCTURE OF AN INTEGRIN-BINDING FRAGMENT OF VASCULAR CELL ADHESION MOLECULE-1 AT 1.8 ANGSTROMS RESOLUTION
1VDGA:97-197; B:97-197; B:2-96; A:2-96CRYSTAL STRUCTURE OF LIR1.01, ONE OF THE ALLELES OF LIR1
1VGEL:109-211; H:123-222; H:2-122; L:1-108TR1.9 FAB FRAGMENT OF A HUMAN IGG1 KAPPA AUTOANTIBODY
1VHPA:1-117VH-P8, NMR
1VSCA:90-196; B:90-196; A:1-89; B:1-89VCAM-1
1W0VB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1
1W0WB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1
1W0YT:6-105; T:106-210TF7A_3771 COMPLEX
1W2KT:6-105; T:106-210TF7A_4380 COMPLEX
1W72B:0-99; H:114-228; I:114-228; E:0-99; L:1-107; M:1-107; L:108-211; M:108-211; H:1-113; I:1-113; A:182-274; D:182-274CRYSTAL STRUCTURE OF HLA-A1:MAGE-A1 IN COMPLEX WITH FAB-HYB3
1WAAC:-3-89; D:-3-89; A:-2-89; B:1-89; F:-3-89; E:-3-88IG27 PROTEIN DOMAIN
1WIOA:1-98; B:1-98; A:181-291; B:181-291; A:99-180; B:99-180; A:292-363; B:292-363STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, TETRAGONAL CRYSTAL FORM
1WIPA:1-98; B:1-98; A:181-291; B:181-291; A:99-180; B:99-180; A:292-363; B:292-363STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, MONOCLINIC CRYSTAL FORM
1WQVT:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D-THR-MET-P-AMINOBENZAMIDINE
1WSST:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4
1WT5C:1-111; D:1-111; A:1-115; B:1-115THE CRYSTAL STRUCTURE OF A HUMANIZED ANTIBODY FV 528
1WTGT:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE
1WTLA:1-108; B:1-108COMPARISON OF CRYSTAL STRUCTURES OF TWO HOMOLOGOUS PROTEINS: STRUCTURAL ORIGIN OF ALTERED DOMAIN INTERACTIONS IN IMMUNOGLOBULIN LIGHT CHAIN DIMERS
1WUNT:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE
1WV7T:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE
1WVZA:9-104SOLUTION STRUCTURE OF THE D2 DOMAIN OF THE FIBROBLAST GROWTH FACTOR
1WWAX:282-386; Y:278-382NGF BINDING DOMAIN OF HUMAN TRKA RECEPTOR
1WWBX:283-385LIGAND BINDING DOMAIN OF HUMAN TRKB RECEPTOR
1WWCA:300-404NT3 BINDING DOMAIN OF HUMAN TRKC RECEPTOR
1WWWX:282-382; Y:282-382NGF IN COMPLEX WITH DOMAIN 5 OF THE TRKA RECEPTOR
1X7QB:1-99; A:182-275CRYSTAL STRUCTURE OF HLA-A*1101 WITH SARS NUCLEOCAPSID PEPTIDE
1X9QA:14-124; A:149-2684M5.3 ANTI-FLUORESCEIN SINGLE CHAIN ANTIBODY FRAGMENT (SCFV)
1XH3B:1-99; A:182-272CONFORMATIONAL RESTRAINTS AND FLEXIBILITY OF 14-MERIC PEPTIDES IN COMPLEX WITH HLA-B*3501
1XIWC:1-107; D:1-122; H:1-122; A:12-102; E:12-98; B:1-74; F:2-72; G:1-107CRYSTAL STRUCTURE OF HUMAN CD3-E/D DIMER IN COMPLEX WITH A UCHT1 SINGLE-CHAIN ANTIBODY FRAGMENT
1XR8B:1-99; A:182-272CRYSTAL STRUCTURES OF HLA-B*1501 IN COMPLEX WITH PEPTIDES FROM HUMAN UBCH6 AND EPSTEIN-BARR VIRUS EBNA-3
1XR9B:1-99; A:182-272CRYSTAL STRUCTURES OF HLA-B*1501 IN COMPLEX WITH PEPTIDES FROM HUMAN UBCH6 AND EPSTEIN-BARR VIRUS EBNA-3
1XZ0B:1-98; A:183-277; C:183-277; D:1-98CRYSTAL STRUCTURE OF CD1A IN COMPLEX WITH A SYNTHETIC MYCOBACTIN LIPOPEPTIDE
1Y6KR:104-206; R:2-103CRYSTAL STRUCTURE OF HUMAN IL-10 COMPLEXED WITH THE SOLUBLE IL-10R1 CHAIN
1YA5A:1-98; B:1-98; A:99-198; B:99-197CRYSTAL STRUCTURE OF THE TITIN DOMAINS Z1Z2 IN COMPLEX WITH TELETHONIN
1YDPB:1A-99; A:182-2721.9A CRYSTAL STRUCTURE OF HLA-G
1YMMD:9-104; A:82-183; E:120-246; B:92-189; E:3-119TCR/HLA-DR2B/MBP-PEPTIDE COMPLEX
1YY9C:109-211; D:122-219; D:1-118; C:1-108STRUCTURE OF THE EXTRACELLULAR DOMAIN OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN COMPLEX WITH THE FAB FRAGMENT OF CETUXIMAB/ERBITUX/IMC-C225
1Z6JT:3-105; T:106-211CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR
1ZA6A:114-217; B:116-218; D:116-218; F:116-218; H:116-218; B:239-344; D:239-344; F:239-344; H:239-344; A:1-113; C:1-113; E:1-113; G:1-113; C:114-217; E:114-217; G:114-217; B:1-115; D:1-115; F:1-115; H:1-115THE STRUCTURE OF AN ANTITUMOR CH2-DOMAIN-DELETED HUMANIZED ANTIBODY
1ZAGA:184-273; B:184-273; C:184-273; D:184-273HUMAN ZINC-ALPHA-2-GLYCOPROTEIN
1ZGLR:0-118; V:0-118; P:-1-118; T:-1-118; A:82-181; D:82-181; G:82-181; J:82-181; T:119-247; R:119-240; P:119-244; V:119-244; K:93-189; E:93-189; B:93-189; H:93-189; M:1-115; S:1-115; Q:0-115; U:0-115CRYSTAL STRUCTURE OF 3A6 TCR BOUND TO MBP/HLA-DR2A
1ZHKB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING 13-MER EBV ANTIGEN LPEPLPQGQLTAY
1ZHLB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*3508 PRESENTING 13-MER EBV ANTIGEN LPEPLPQGQLTAY
1ZLSL:108-210; H:114-227; H:1-113; L:2-107FAB 2G12 + MAN4
1ZLUL:108-211; H:114-227; M:114-227; H:1-113; M:1-113; K:108-211; K:2-107; L:2-107FAB 2G12 + MAN5
1ZLVK:108-212; M:114-227; H:114-227; H:1-113; M:1-113; L:108-212; K:2-107; L:2-107FAB 2G12 + MAN7
1ZLWL:108-210; H:114-228; M:114-227; H:1-113; M:1-113; K:108-211; K:2-107; L:2-107FAB 2G12 + MAN8
1ZSDB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING AN 11-MER EBV ANTIGEN EPLPQGQLTAY
1ZT4B:0-99; C:183-281; A:183-277; D:0-99THE CRYSTAL STRUCTURE OF HUMAN CD1D WITH AND WITHOUT ALPHA-GALACTOSYLCERAMIDE
1ZXQA:86-192; A:1-85THE CRYSTAL STRUCTURE OF ICAM-2
2A2QT:6-105; T:106-210COMPLEX OF ACTIVE-SITE INHIBITED HUMAN COAGULATION FACTOR VIIA WITH HUMAN SOLUBLE TISSUE FACTOR IN THE PRESENCE OF CA2+, MG2+, NA+, AND ZN2+
2A38B:1-99; C:1-99; A:1-98; A:99-194; B:100-194; C:100-194CRYSTAL STRUCTURE OF THE N-TERMINUS OF TITIN
2A83B:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE GLUCAGON RECEPTOR (GR) PEPTIDE (RESIDUES 412-420)
2A9ML:3-147; M:2-148; H:1-148; I:1-148STRUCTURAL ANALYSIS OF A TIGHT-BINDING FLUORESCEIN-SCFV; APO FORM
2A9NL:3-149; M:2-148; H:1-148; I:1-148A MUTATION DESIGNED TO ALTER CRYSTAL PACKING PERMITS STRUCTURAL ANALYSIS OF A TIGHT-BINDING FLUORESCEIN-SCFV COMPLEX
2AAVA:-4-1956SOLUTION NMR STRUCTURE OF FILAMIN A DOMAIN 17
2ADFL:108-209; H:120-218; H:1-119; L:1-107CRYSTAL STRUCTURE AND PARATOPE DETERMINATION OF 82D6A3, AN ANTITHROMBOTIC ANTIBODY DIRECTED AGAINST THE VON WILLEBRAND FACTOR A3-DOMAIN
2AEIT:5-105; T:106-211CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR AND 2-[[6-[3-(AMINOIMINOMETHYL)PHENOXY]-3,5-DIFLURO-4-[(1-METHYL-3-PHENYLPROPYL)AMINO]-2-PYRIDINYL]OXY]-BENZOIC ACID
2AERT:5-105; T:106-206CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX.
2AEWB:132-233; A:132-233; A:29-131; B:31-131A MODEL FOR GROWTH HORMONE RECEPTOR ACTIVATION BASED ON SUBUNIT ROTATION WITHIN A RECEPTOR DIMER
2AGJL:110-212; L:1-109; H:2-120; H:121-221CRYSTAL STRUCTURE OF A GLYCOSYLATED FAB FROM AN IGM CRYOGLOBULIN WITH PROPERTIES OF A NATURAL PROTEOLYTIC ANTIBODY
2AJ3A:110-211; B:114-212; D:114-212; F:114-212; B:2-113; D:2-113; F:2-113; C:110-211; E:110-211; A:2-108; C:2-108; E:2-108CRYSTAL STRUCTURE OF A CROSS-REACTIVE HIV-1 NEUTRALIZING CD4-BINDING SITE ANTIBODY FAB M18
2AK4B:1-99; U:3-118; E:3-118; J:3-118; P:3-118; G:1-99; L:1-99; R:1-99; E:119-244; J:119-244; P:119-244; U:119-244; D:1-116; I:1-116; N:1-116; T:1-116; A:182-272; F:182-272; K:182-272; Q:182-272CRYSTAL STRUCTURE OF SB27 TCR IN COMPLEX WITH HLA-B*3508-13MER PEPTIDE
2ARWA:1-103THE SOLUTION STRUCTURE OF THE MEMBRANE PROXIMAL CYTOKINE RECEPTOR DOMAIN OF THE HUMAN INTERLEUKIN-6 RECEPTOR
2AV1B:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF HTLV-1 TAX PEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2 WITH THE E63Q AND K66A MUTATIONS IN THE HEAVY CHAIN.
2AV7B:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF HTLV-1 TAX PEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2 WITH THE K66A MUTATION IN THE HEAVY CHAIN.
2AW2X:34-140; A:34-143CRYSTAL STRUCTURE OF THE HUMAN BTLA-HVEM COMPLEX
2AXFB:1-99; A:182-272THE IMMUNOGENICITY OF A VIRAL CYTOTOXIC T CELL EPITOPE IS CONTROLLED BY ITS MHC-BOUND CONFORMATION
2AXGB:1-99; A:182-272THE IMMUNOGENICITY OF A VIRAL CYTOTOXIC T CELL EPITOPE IS CONTROLLED BY ITS MHC-BOUND CONFORMATION
2AXHA:3-115; B:3-115; A:116-244; B:116-244CRYSTAL STRUCTURES OF T CELL RECEPTOR BETA CHAINS RELATED TO RHEUMATOID ARTHRITIS
2AXJA:3-115; B:3-115; A:116-244; B:116-244CRYSTAL STRUCTURES OF T CELL RECEPTOR BETA CHAINS RELATED TO RHEUMATOID ARTHRITIS
2B0SH:114-225; L:2-107; H:1-113; L:108-211CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3 FAB 2219 IN COMPLEX WITH MN PEPTIDE
2B1AH:114-225; L:2-107; H:1-113; L:108-211CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3 FAB 2219 IN COMPLEX WITH UG1033 PEPTIDE
2B1HH:114-225; L:2-107; H:1-113; L:108-211CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3 FAB 2219 IN COMPLEX WITH UG29 PEPTIDE
2B7DT:6-205FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION, PRECLINICAL PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN A BABOON THROMBOSIS MODEL
2B8OT:6-105; T:106-210CRYSTAL STRUCTURE OF GLU-GLY-ARG-CHLOROMETHYL KETONE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX
2BC4D:93-199; B:93-193; A:92-200; C:92-206CRYSTAL STRUCTURE OF HLA-DM
2BCKB:0-99; E:0-99; A:182-272; D:182-272CRYSTAL STRUCTURE OF HLA-A*2402 COMPLEXED WITH A TELOMERASE PEPTIDE
2BK8A:0-96M1 DOMAIN FROM TITIN
2BNQB:0-99; D:2-114; E:2-113; D:115-204; E:114-239; A:182-270STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
2BNRB:0-99; A:182-270; D:2-114; E:2-113; D:115-204; E:114-239STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
2BNUA:2-114; B:2-113; A:115-204; B:114-239STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
2BP3A:-1-1955; B:1865-1955CRYSTAL STRUCTURE OF FILAMIN A DOMAIN 17 AND GPIB ALPHA CYTOPLASMIC DOMAIN COMPLEX
2BRQA:2236-2329; B:2236-2329CRYSTAL STRUCTURE OF THE FILAMIN A REPEAT 21 COMPLEXED WITH THE INTEGRIN BETA7 CYTOPLASMIC TAIL PEPTIDE
2BSRB:0-99; A:182-276CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2BSSB:0-99; A:182-276CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2BSTB:0-99; A:182-276CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2BVOB:1-99; A:182-272STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION
2BVPB:1-99; A:182-272STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION
2BVQB:1-99; A:182-272STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION
2C5DC:131-218; D:131-218; C:27-130; D:27-130STRUCTURE OF A MINIMAL GAS6-AXL COMPLEX
2C7UB:0-99; A:182-270; D:182-270; E:0-99CONFLICTING SELECTIVE FORCES AFFECT CD8 T-CELL RECEPTOR CONTACT SITES IN AN HLA-A2 IMMUNODOMINANT HIV EPITOPE.
2CD0A:1-108; B:1-108STRUCTURE OF HUMAN LAMBDA-6 LIGHT CHAIN DIMER WIL
2CDEA:2-114; C:2-114; E:2-114; B:2-116; D:2-116; F:2-116; B:117-242; D:117-242; F:117-242STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE SPECIFIC T CELL RECEPTORS - INKT-TCR
2CDFA:3-114; B:2-116; B:117-242STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE-SPECIFIC T CELL RECEPTORS (TCR 5E)
2CDGA:10-114; B:3-117; B:118-243STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE-SPECIFIC T CELL RECEPTORS (TCR 5B)
2CIKB:1-99; A:182-272INSIGHTS INTO CROSSREACTIVITY IN HUMAN ALLORECOGNITION: THE STRUCTURE OF HLA-B35011 PRESENTING AN EPITOPE DERIVED FROM CYTOCHROME P450.
2CK2B:1-96; A:1-96STRUCTURE OF CORE-SWAPPED MUTANT OF FIBRONECTIN
2CLRB:0-99; E:0-99; A:182-275; D:182-275THREE DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING OUT ONE END OF A CLASS I MHC BINDING SITE
2CMRL:108-207; H:114-211; H:3-113; L:1-107CRYSTAL STRUCTURE OF THE HIV-1 NEUTRALIZING ANTIBODY D5 FAB BOUND TO THE GP41 INNER-CORE MIMETIC 5-HELIX
2CQVA:1-114SOLUTION STRUCTURE OF THE EIGHTH IG-LIKE DOMAIN OF HUMAN MYOSIN LIGHT CHAIN KINASE
2CUMA:1-105THE SOLUTION STRUCTURE OF THE 33RD FIBRONECTIN TYPE III DOMAIN OF HUMAN TENASCIN-X
2D31B:1-99; A:182-272; D:182-272; E:1-99CRYSTAL STRUCTURE OF DISULFIDE-LINKED HLA-G DIMER
2D3VA:96-195; A:3-95CRYSTAL STRUCTURE OF LEUKOCYTE IG-LIKE RECEPTOR A5 (LILRA5/LIR9/ILT11)
2D4DA:0-95THE CRYSTAL STRUCTURE OF HUMAN BETA2-MICROGLOBULIN, L39W W60F W95F MUTANT
2D4FA:0-97THE CRYSTAL STRUCTURE OF HUMAN BETA2-MICROGLOBULIN
2D7TL:1-110; H:1-116CRYSTAL STRUCTURE OF HUMAN ANTI POLYHYDROXYBUTYRATE ANTIBODY FV
2D9QB:97-204; B:205-308CRYSTAL STRUCTURE OF THE HUMAN GCSF-RECEPTOR SIGNALING COMPLEX
2DBJA:16-124SOLUTION STRUCTURES OF THE FN3 DOMAIN OF HUMAN PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER PRECURSOR
2DD8H:114-216; L:2-108; H:2-113; L:109-213CRYSTAL STRUCTURE OF SARS-COV SPIKE RECEPTOR-BINDING DOMAIN COMPLEXED WITH NEUTRALIZING ANTIBODY
2DF3A:24-144THE STRUCTURE OF SIGLEC-7 IN COMPLEX WITH ALPHA(2,3)/ALPHA(2,6) DISIALYL LACTOTETRAOSYL 2-(TRIMETHYLSILYL)ETHYL
2DICA:7-100SOLUTION STRUCTURE OF THE 12TH FILAMIN DOMAIN FROM HUMAN FILAMIN-B
2DJ4A:7-103SOLUTION STRUCTURE OF THE 13TH FILAMIN DOMAIN FROM HUMAN FILAMIN-B
2DJSA:13-100SOLUTION STRUCTURES OF THE FN3 DOMAIN OF HUMAN EPHRIN TYPE-B RECEPTOR 1
2DKSA:1-130SOLUTION STRUCTURE OF THE FIRST IG-LIKE DOMAIN OF HUMAN CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 8
2DL2A:103-200; A:5-102KILLER IMMUNOGLOBULIN RECEPTOR 2DL2
2DLIA:103-200; A:5-102KILLER IMMUNOGLOBULIN RECEPTOR 2DL2,TRIGONAL FORM
2DM2A:1-110SOLUTION STRUCTURE OF THE FIRST IG DOMAIN OF HUMAN PALLADIN
2DTQ  [entry was replaced by entry 3AVE without any CATH domain information]
2DTSA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE DEFUCOSYLATED FC FRAGMENT FROM HUMAN IMMUNOGLOBULIN G1
2DYPB:0-99; A:182-272; D:96-195; D:3-95CRYSTAL STRUCTURE OF LILRB2(LIR2/ILT4/CD85D) COMPLEXED WITH HLA-G
2E7HA:13-101SOLUTION STRUCTURE OF THE SECOND FN3 DOMAIN FROM HUMAN EPHRIN TYPE-B RECEPTOR 4
2E9WA:208-310; B:208-310; A:311-412; B:311-412; A:117-207; B:117-207; B:413-507; A:413-507; A:33-116; B:33-116CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF KIT IN COMPLEX WITH STEM CELL FACTOR (SCF)
2EC8A:208-311; A:312-411; A:11-116; A:117-207; A:412-508CRYSTAL STRUCTURE OF THE EXCTRACELLULAR DOMAIN OF THE RECEPTOR TYROSINE KINASE, KIT
2EC9U:91-210; T:6-80CRYSTAL STRUCTURE ANALYSIS OF HUMAN FACTOR VIIA , SOULUBLE TISSUE FACTOR COMPLEXED WITH BCX-3607
2EEDA:1-101SOLUTION STRUCTURE OF THE 24TH FILAMIN DOMAIN FROM HUMAN FILAMIN-B
2EIZA:1-107; B:1-113CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV MUTANT(HW47Y)-HEN LYSOZYME COMPLEX
2EKSA:1-107; B:1-113CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV-HEN LYSOZYME COMPLEX
2ESVB:0-99; A:182-272; D:4-115; E:3-118; E:119-247STRUCTURE OF THE HLA-E-VMAPRTLIL/KK50.4 TCR COMPLEX
2EYRA:1-116; B:3-118; B:119-244A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION
2EYSA:1-116; B:3-118; B:119-244A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION
2EYTA:1-116; C:1-116; B:3-118; D:3-118; B:119-244; D:119-244A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION
2F53B:0-99; A:182-270; D:-1-113; E:-1-112; E:113-238DIRECTED EVOLUTION OF HUMAN T-CELL RECEPTOR CDR2 RESIDUES BY PHAGE DISPLAY DRAMATICALLY ENHANCES AFFINITY FOR COGNATE PEPTIDE-MHC WITHOUT APPARENT CROSS-REACTIVITY
2F54B:0-99; A:182-270; F:182-270; D:1-113; K:0-113; E:1-112; L:1-112; E:113-238; L:113-238; G:0-99DIRECTED EVOLUTION OF HUMAN T CELL RECEPTOR CDR2 RESIDUES BY PHAGE DISPLAY DRAMATICALLY ENHANCES AFFINITY FOR COGNATE PEPTIDE-MHC WITHOUT INCREASING APPARENT CROSS-REACTIVITY
2F5AL:108-211; H:133-231; H:1-132; L:1-107CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5
2F5BL:108-211; H:133-232; H:1-132; L:1-107CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH ITS GP41 EPITOPE
2F8OA:4-97; B:4-97A NATIVE TO AMYLOIDOGENIC TRANSITION REGULATED BY A BACKBONE TRIGGER
2F8VB:1-98; A:2-98; D:2-98; C:4-98; B:99-197; A:99-195; C:99-194; D:99-194STRUCTURE OF FULL LENGTH TELETHONIN IN COMPLEX WITH THE N-TERMINUS OF TITIN
2F9BT:6-205DISCOVERY OF NOVEL HETEROCYCLIC FACTOR VIIA INHIBITORS
2FB4H:119-218; L:1-109; L:110-210; H:1-118DIR PRIMAERSTRUKTUR DES KRISTALLISIERBAREN MONOKLONALEN IMMUNOGLOBULINS IGG1 KOL. II. AMINOSAEURESEQUENZ DER L-KETTE, LAMBDA-TYP, SUBGRUPPE I (GERMAN)
2FCBA:92-178; A:6-91HUMAN FC GAMMA RECEPTOR IIB ECTODOMAIN (CD32)
2FD6L:108-210; H:115-208; H:1-114; L:1-107STRUCTURE OF HUMAN UROKINASE PLASMINOGEN ACTIVATOR IN COMPLEX WITH UROKINASE RECEPTOR AND AN ANTI-UPAR ANTIBODY AT 1.9 A
2FDBP:2151-2250; R:3151-3250; P:2251-2357; R:3251-3357CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR (FGF)8B IN COMPLEX WITH FGF RECEPTOR (FGFR) 2C
2FIRT:6-105; T:106-210CRYSTAL STRUCTURE OF DFPR-VIIA/STF
2FJFA:109-211; B:121-223; D:121-223; F:121-223; H:121-223; I:121-223; K:121-223; N:121-223; P:121-223; R:121-223; T:121-223; V:121-223; X:121-223; B:1-120; D:1-120; F:1-120; H:1-120; I:1-120; K:1-120; N:1-120; P:1-120; R:1-120; T:1-120; V:1-120; X:1-120; C:109-211; E:109-211; G:109-211; J:109-211; L:109-211; M:109-211; O:109-211; Q:109-211; S:109-211; U:109-211; W:109-211; A:1-108; C:1-108; E:1-108; G:1-108; J:1-108; L:1-108; M:1-108; O:1-108; Q:1-108; S:1-108; U:1-108; W:1-108STRUCTURE OF THE G6 FAB, A PHAGE DERIVED VEGF BINDING FAB
2FJGA:109-211; B:121-223; H:121-223; B:1-120; H:1-120; L:109-211; A:1-108; L:1-108STRUCTURE OF THE G6 FAB, A PHAGE DERIVED FAB FRAGMENT, IN COMPLEX WITH VEGF
2FJHL:109-214; B:122-224; H:122-224; B:1-121; H:1-121; A:109-211; A:1-108; L:1-108STRUCTURE OF THE B20-4 FAB, A PHAGE DERIVED FAB FRAGMENT, IN COMPLEX WITH VEGF
2FL5B:114-225; D:114-225; F:114-225; H:114-225; A:1-107; C:1-107; E:1-107; L:1-107; A:108-212; C:108-212; E:108-212; L:108-212; B:1-113; D:1-113; F:1-113; H:1-113COFACTOR-CONTAINING ANTIBODIES: CRYSTAL STRUCTURE OF THE ORIGINAL YELLOW ANTIBODY
2FLBT:6-205DISCOVERY OF A NOVEL HYDROXY PYRAZOLE BASED FACTOR IXA INHIBITOR
2FLRT:6-205NOVEL 5-AZAINDOLE FACTOR VIIA INHIBITORS
2FNBA:1-95NMR STRUCTURE OF THE FIBRONECTIN ED-B DOMAIN, NMR, 20 STRUCTURES
2FSEA:82-181; C:82-180; B:93-190; D:93-189CRYSTALLOGRAPHIC STRUCTURE OF A RHEUMATOID ARTHRITIS MHC SUSCEPTIBILITY ALLELE, HLA-DR1 (DRB1*0101), COMPLEXED WITH THE IMMUNODOMINANT DETERMINANT OF HUMAN TYPE II COLLAGEN
2FX7L:109-211; L:1-108; H:110-228; H:1-109CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A 16-RESIDUE PEPTIDE ENCOMPASSING THE 4E10 EPITOPE ON GP41
2FX8L:109-211; L:1-108; M:1-108; N:1-108; O:1-108; H:110-227; I:110-227; J:110-227; K:110-227; H:1-109; I:1-109; J:1-109; K:1-109; M:109-211; N:109-211; O:109-211CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH AN AIB-INDUCED PEPTIDE ENCOMPASSING THE 4E10 EPITOPE ON GP41
2FX9L:109-211; L:1-108; M:1-108; H:110-227; I:110-227; H:1-109; I:1-109; M:109-211CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A THIOETHER-LINKED PEPTIDE ENCOMPASSING THE 4E10 EPITOPE ON GP41
2FYYB:1-99; A:182-272THE ROLE OF T CELL RECEPTOR ALPHA GENES IN DIRECTING HUMAN MHC RESTRICTION
2FZ3B:1-99; A:182-272THE ROLE OF T CELL RECEPTOR ALPHA GENES IN DIRECTING HUMAN MHC RESTRICTION
2G5RA:24-144CRYSTAL STRUCTURE OF SIGLEC-7 IN COMPLEX WITH METHYL-9-(AMINOOXALYL-AMINO)-9-DEOXYNEU5AC (OXAMIDO-NEU5AC)
2G75A:114-214; C:114-214; B:2-108; D:2-108; A:2-113; C:2-113; B:109-211; D:109-211CRYSTAL STRUCTURE OF ANTI-SARS M396 ANTIBODY
2G9HA:82-181; B:93-190CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN I (SEI) IN COMPLEX WITH A HUMAN MHC CLASS II MOLECULE
2GI7A:89-183; B:89-183; B:0-88; A:2-88CRYSTAL STRUCTURE OF HUMAN PLATELET GLYCOPROTEIN VI (GPVI)
2GITB:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE MODIFIED HTLV-1 TAX (Y5K-4-[3-INDOLYL]-BUTYRIC ACID) PEPTIDE
2GJ6B:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE MODIFIED HTLV-1 TAX (Y5K-4-[3-INDOLYL]-BUTYRIC ACID) PEPTIDE
2GK2A:1-107; B:1-107CRYSTAL STRUCTURE OF THE N TERMINAL DOMAIN OF HUMAN CEACAM1
2GT9B:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE DECAMERIC MELAN-A/MART-1(26-35) PEPTIDE
2GTWB:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE NONAMERIC MELAN-A/MART-1(27-35) PEPTIDE HAVING A27L SUBSTITUTION
2GTZB:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE NONAMERIC MELAN-A/MART-1(27-35) PEPTIDE HAVING A28L SUBSTITUTION
2GUOB:0-99; A:182-270; D:182-270; E:0-99HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE NATIVE NONAMERIC MELAN-A/MART-1(27-35) PEPTIDE
2GW5A:97-198; A:3-96CRYSTAL STRUCTURE OF LIR-2 (ILT4) AT 1.8 : DIFFERENCES FROM LIR-1 (ILT2) IN REGIONS IMPLICATED IN THE BINDING OF THE CYTOMEGALOVIRUS CLASS I MHC HOMOLOG UL18
2GY5A:23-121; A:347-445; A:122-211TIE2 LIGAND-BINDING DOMAIN CRYSTAL STRUCTURE
2GY7B:23-121; B:347-445; B:122-211ANGIOPOIETIN-2/TIE2 COMPLEX CRYSTAL STRUCTURE
2GYSA:109-215; B:109-215; B:320-418; A:320-418; A:1-95; B:1-95; A:218-308; B:218-3082.7 A STRUCTURE OF THE EXTRACELLULAR DOMAINS OF THE HUMAN BETA COMMON RECEPTOR INVOLVED IN IL-3, IL-5, AND GM-CSF SIGNALLING
2H26B:1-99; A:183-278HUMAN CD1B IN COMPLEX WITH ENDOGENOUS PHOSPHATIDYLCHOLINE AND SPACER
2H32H:1-119; H:120-221; A:1-111CRYSTAL STRUCTURE OF THE PRE-B CELL RECEPTOR
2H3NA:2-100; C:1-99CRYSTAL STRUCTURE OF A SURROGATE LIGHT CHAIN (LAMBDA5 AND VPREB) HOMODIMER
2H6PB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING THE HUMAN CYTOCHROME P450 DERIVED PEPTIDE, KPIVVLHGY
2H9GA:109-211; B:114-213; H:114-213; B:1-113; H:1-113; L:109-211; A:1-108; L:1-108CRYSTAL STRUCTURE OF PHAGE DERIVED FAB BDF1 WITH HUMAN DEATH RECEPTOR 5 (DR5)
2HFFA:108-213; B:114-214; H:114-213; H:1-113; B:1-113; L:108-210; A:2-107; L:1-107CRYSTAL STRUCTURE OF CB2 FAB
2HFGL:108-212; H:114-214; H:1-113; L:1-107CRYSTAL STRUCTURE OF HBR3 BOUND TO CB3S-FAB
2HFTA:1-107; A:108-211THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR AT 1.7 ANGSTROMS RESOLUTION
2HJKB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B5703 AND HIV-1 PEPTIDE
2HJLB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B5703 AND HIV-1 PEPTIDE
2HLAB:1-99; A:182-270SPECIFICITY POCKETS FOR THE SIDE CHAINS OF PEPTIDE ANTIGENS IN HLA-AW68
2HN7B:1-99; A:182-274HLA-A*1101 IN COMPLEX WITH HBV PEPTIDE HOMOLOGUE
2HP4A:1-114; B:1-114COMPUTATIONAL DESIGN AND CRYSTAL STRUCTURE OF AN ENHANCED AFFINITY MUTANT HUMAN CD8-ALPHA-ALPHA CO-RECEPTOR
2HRLA:25-144SIGLEC-7 IN COMPLEX WITH GT1B
2HYMA:1-106; A:107-212NMR BASED DOCKING MODEL OF THE COMPLEX BETWEEN THE HUMAN TYPE I INTERFERON RECEPTOR AND HUMAN INTERFERON ALPHA-2
2IALB:2-111; D:2-111; A:1-108; C:1-108; B:112-237; D:112-237STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR
2IAMD:2-111; A:82-181; C:1-108; D:112-237; B:93-190STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR
2IANE:3-111; O:3-111; T:3-111; J:2-111; A:82-181; F:82-181; K:82-181; P:82-181; D:1-108; I:1-108; N:1-108; S:1-108; E:112-237; J:112-237; O:112-237; T:112-237; L:93-190; Q:93-190; B:93-190; G:93-190STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR
2ICWL:3-113; J:1-113; A:82-181; D:82-181; E:93-190; B:93-190; K:2-110; I:1-110CRYSTAL STRUCTURE OF A COMPLETE TERNARY COMPLEX BETWEEN TCR, SUPERANTIGEN, AND PEPTIDE-MHC CLASS II MOLECULE
2IFGA:283-381; B:283-381; A:193-282; B:193-282STRUCTURE OF THE EXTRACELLULAR SEGMENT OF HUMAN TRKA IN COMPLEX WITH NERVE GROWTH FACTOR
2IG2H:119-221; L:1-109; L:110-210; H:1-118DIR PRIMAERSTRUKTUR DES KRISTALLISIERBAREN MONOKLONALEN IMMUNOGLOBULINS IGG1 KOL. II. AMINOSAEURESEQUENZ DER L-KETTE, LAMBDA-TYP, SUBGRUPPE I (GERMAN)
2ILLA:98-195; A:1-97ANOMALOUS SUBSTRUCTURE OF TITIN-A168169
2IPKA:82-181; B:93-190CRYSTAL STRUCTURE OF THE MHC CLASS II MOLECULE HLA-DR1 IN COMPLEX WITH THE FLUOROGENIC PEPTIDE, ACPKXVKQNTLKLAT (X=3-[5-(DIMETHYLAMINO)-1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL]-L-ALANINE) AND THE SUPERANTIGEN, SEC3 VARIANT 3B2
2IWGA:338-443; D:338-443; A:238-337; D:238-337COMPLEX BETWEEN THE PRYSPRY DOMAIN OF TRIM21 AND IGG FC
2J6EA:338-443; B:338-443; L:1-108; M:1-108; H:1-113; I:1-113; L:109-208; M:109-208; A:238-337; B:238-337; I:114-214; H:114-214CRYSTAL STRUCTURE OF AN AUTOIMMUNE COMPLEX BETWEEN A HUMAN IGM RHEUMATOID FACTOR AND IGG1 FC REVEALS A NOVEL FC EPITOPE AND EVIDENCE FOR AFFINITY MATURATION
2J8HA:98-195; A:1-97STRUCTURE OF THE IMMUNOGLOBULIN TANDEM REPEAT A168-A169 OF TITIN
2J8OA:98-195; B:98-195; A:0-97; B:1-97STRUCTURE OF THE IMMUNOGLOBULIN TANDEM REPEAT OF TITIN A168-A169
2JB5H:121-222; L:3-112; H:3-120; L:113-214FAB FRAGMENT IN COMPLEX WITH SMALL MOLECULE HAPTEN, CRYSTAL FORM-1
2JB6B:121-221; H:121-221; L:4-112; A:3-112; H:3-120; B:3-120; A:113-214; L:113-214FAB FRAGMENT IN COMPLEX WITH SMALL MOLECULE HAPTEN, CRYSTAL FORM-2
2JCCB:0-99; A:182-270; H:182-270; F:3-117; M:3-117; I:0-99; F:118-245; M:118-245; E:1-116; L:1-116AH3 RECOGNITION OF MUTANT HLA-A2 W167A
2JLLA:593-689CRYSTAL STRUCTURE OF NCAM2 IGIV-FN3II
2K7PA:1866-1956FILAMIN A IG-LIKE DOMAINS 16-17
2K7QA:-3-1968,A:2047-2141FILAMIN A IG-LIKE DOMAINS 18-19
2KBGA:1-102SOLUTION STRUCTURE OF THE SECOND FIBRONECTIN TYPE-III MODULE OF NCAM2
2KH2B:130-248SOLUTION STRUCTURE OF A SCFV-IL-1B COMPLEX
2KZ1B:11-106; B:107-206INTER-MOLECULAR INTERACTIONS IN A 44 KDA INTERFERON-RECEPTOR COMPLEX DETECTED BY ASYMMETRIC BACK-PROTONATION AND 2D NOESY
2LVEA:1-107RECOMBINANT LEN
2MCG1:2-111; 2:2-111; 1:112-216; 2:112-212THREE-DIMENSIONAL STRUCTURE OF A LIGHT CHAIN DIMER CRYSTALLIZED IN WATER. CONFORMATIONAL FLEXIBILITY OF A MOLECULE IN TWO CRYSTAL FORMS
2NMSA:18-129THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF THE INHIBITOR RECEPTOR EXPRESSED ON MYELOID CELLS IREM-1
2NNAA:82-180; B:93-190STRUCTURE OF THE MHC CLASS II MOLECULE HLA-DQ8 BOUND WITH A DEAMIDATED GLUTEN PEPTIDE
2NQCA:2482-2578CRYSTAL STRUCTURE OF IG-LIKE DOMAIN 23 FROM HUMAN FILAMIN C
2NTSP:3-118; P:119-245CRYSTAL STRUCTURE OF SEK-HVB5.1
2NW2A:1-116; B:1-118; B:119-244CRYSTAL STRUCTURE OF ELS4 TCR AT 1.4A
2NW3B:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*3508 PRESENTING EBV PEPTIDE EPLPQGQLTAY AT 1.7A
2NX5B:1-99; D:1-116; I:1-116; N:1-116; T:1-116; E:1-118; J:1-118; P:1-118; U:1-118; E:119-244; J:119-244; P:119-244; G:1-99; U:119-244; L:1-99; R:1-99; A:182-272; F:182-272; K:182-272; Q:182-272CRYSTAL STRUCTURE OF ELS4 TCR BOUND TO HLA-B*3501 PRESENTING EBV PEPTIDE EPLPQGQLTAY AT 1.7A
2NZIA:95-194; B:95-194; A:-1-93; B:-1-93; A:196-289; B:196-289CRYSTAL STRUCTURE OF DOMAINS A168-A170 FROM TITIN
2OCFD:2-94HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND THE E2#23 FN3 MONOBODY
2OJEA:82-181; E:82-181; B:93-190; F:93-190MYCOPLASMA ARTHRITIDIS-DERIVED MITOGEN COMPLEXED WITH CLASS II MHC MOLECULE HLA-DR1/HA COMPLEX IN THE PRESENCE OF EDTA
2OLDA:2-112; B:2-112; A:113-213; B:113-213BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P3(2)21 CRYSTAL FORM
2OM5A:101-205; A:4-100; A:295-384; A:206-294N-TERMINAL FRAGMENT OF HUMAN TAX1
2OMBA:2-112; B:2-112; C:2-112; D:2-112; D:113-214; A:113-213; B:113-213; C:113-213BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P3(1)21 CRYSTAL FORM
2OMNA:2-112; B:2-112; A:113-213; B:113-213BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P4(3)2(1)2 CRYSTAL FORM
2OQJA:108-212; B:114-228; E:114-228; H:114-228; K:114-228; B:1-113; E:1-113; H:1-113; K:1-113; D:108-212; G:108-212; J:108-212; A:2-107; D:2-107; G:2-107; J:2-107CRYSTAL STRUCTURE ANALYSIS OF FAB 2G12 IN COMPLEX WITH PEPTIDE 2G12.1
2OZ4L:109-211; H:115-214; H:1-114; L:1-108STRUCTURAL PLASTICITY IN IGSF DOMAIN 4 OF ICAM-1 MEDIATES CELL SURFACE DIMERIZATION
2P5EB:0-99; D:0-114; E:1-112; E:113-238; A:182-270CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEAL NATIVE DIAGONAL BINDING GEOMETRY
2P5WB:0-99; A:182-270; D:1-114; E:0-112; E:113-238CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEAL NATIVE DIAGONAL BINDING GEOMETRY
2P8LA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELLELDKWASLWN
2P8MA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELLELDKWASLWN IN NEW CRYSTAL FORM
2P8PA:108-211; B:114-214; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE LELDKWASLW[N-AC]
2PO6B:1-99; C:1-116; G:1-116; D:2-118; H:2-118; D:119-244; H:119-244; A:183-280; E:183-277; F:2-99CRYSTAL STRUCTURE OF CD1D-LIPID-ANTIGEN COMPLEXED WITH BETA-2-MICROGLOBULIN, NKT15 ALPHA-CHAIN AND NKT15 BETA-CHAIN
2PR4L:108-211; H:133-232; H:1-132; L:1-107CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5
2PUQT:6-105; T:106-209CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA IN COMPLEX WITH SOLUBLE TISSUE FACTOR
2PW1A:108-211; B:114-214; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWNSL
2PW2A:108-211; B:114-214; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWKSL
2PYEB:0-99; A:182-270; D:0-114; E:0-112; E:113-238CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEALNATIVE DIAGONAL BINDING GEOMETRY TCR CLONE C5C1 COMPLEXED WITH MHC
2PYFA:1-114; B:1-112; B:113-238CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEALNATIVE DIAGONAL BINDING GEOMETRY UNBOUND TCR CLONE 5-1
2Q1EA:-1-107; B:-1-107; C:-1-107; D:-1-107ALTERED DIMER INTERFACE DECREASES STABILITY IN AN AMYLOIDOGENIC KAPPA1 BENCE JONES PROTEIN.
2Q20A:0-107; B:-1-107STRUCTURE OF THE GERMLINE VK1 O18/O8 LIGHT CHAIN VARIABLE DOMAIN HOMODIMER
2Q6WA:82-182; D:82-182; B:94-190; E:94-190THE STRUCTURE OF HLA-DRA, DRB3*0101 (DR52A) WITH BOUND PLATELET INTEGRIN PEPTIDE ASSOCIATED WITH FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
2Q87C:5-110; A:2-108; B:5-111THE CRYSTAL STRUCTURE OF THE HUMAN IRP60 ECTODOMAIN
2QEJA:342-450; B:342-450; A:240-341; B:242-341CRYSTAL STRUCTURE OF A STAPHYLOCOCCUS AUREUS PROTEIN (SSL7) IN COMPLEX WITH FC OF HUMAN IGA1
2QL1A:338-443; A:238-337STRUCTURAL CHARACTERIZATION OF A MUTATED, ADCC-ENHANCED HUMAN FC FRAGMENT
2QQKL:109-211; H:114-220; H:1-113; L:1-108NEUROPILIN-2 A1A2B1B2 DOMAINS IN COMPLEX WITH A SEMAPHORIN-BLOCKING FAB
2QQLL:109-214; H:114-216; H:1-113; L:1-108NEUROPILIN-2 A1A2B1B2 DOMAINS IN COMPLEX WITH A SEMAPHORIN-BLOCKING FAB
2QQNL:108-211; H:114-220; H:1-113; L:1-107NEUROPILIN-1 B1 DOMAIN IN COMPLEX WITH A VEGF-BLOCKING FAB
2QR0A:109-211; B:114-213; F:114-213; H:114-213; L:114-213; N:114-213; R:114-213; T:114-213; X:114-213; B:1-113; F:1-113; H:1-113; L:1-113; N:1-113; R:1-113; T:1-113; X:1-113; E:109-211; G:109-211; K:109-211; M:109-211; Q:109-211; S:109-211; W:109-211; A:1-108; E:1-108; G:1-108; K:1-108; M:1-108; Q:1-108; S:1-108; W:1-108STRUCTURE OF VEGF COMPLEXED TO A FAB CONTAINING TYR AND SER IN THE CDRS
2QSCL:108-211; H:114-226; H:1-113; L:1-107CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3-FAB F425-B4E8 IN COMPLEX WITH A V3-PEPTIDE
2QSQB:1-108; A:1-110CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAIN OF CARCINOEMBRYONIC ANTIGEN (CEA)
2QSTA:1-110; B:1-110CRYSTAL STRUCTURE OF THE V39C MUTANT OF THE N-TERMINAL DOMAIN OF CARCINOEMBRYONIC ANTIGEN (CEA)
2R0KL:109-214; H:114-216; H:1-113; L:1-108PROTEASE DOMAIN OF HGFA WITH INHIBITOR FAB58
2R4RL:109-211; H:115-217; H:1-114; L:1-108CRYSTAL STRUCTURE OF THE HUMAN BETA2 ADRENOCEPTOR
2R4SL:109-211; H:115-217; H:1-114; L:1-108CRYSTAL STRUCTURE OF THE HUMAN BETA2 ADRENOCEPTOR
2RB8A:801-893HIGH RESOLUTION DESIGN OF A PROTEIN LOOP
2RFXB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*5701, PRESENTING THE SELF PEPTIDE, LSSPVTKSF
2RHEA:1-114STRUCTURE OF A NOVEL BENCE-JONES PROTEIN (RHE) FRAGMENT AT 1.6 ANGSTROMS RESOLUTION
2RQ8A:0-97SOLUTION NMR STRUCTURE OF TITIN I27 DOMAIN MUTANT
2SEBA:82-180; B:92-190X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH A PEPTIDE FROM HUMAN COLLAGEN II
2UWEB:0-99; A:182-270; H:182-270; F:3-117; M:3-117; I:0-99; F:118-245; M:118-245; E:1-116; L:1-116LARGE CDR3A LOOP ALTERATION AS A FUNCTION OF MHC MUTATION
2UZIL:4-107; H:1-114CRYSTAL STRUCTURE OF HRAS(G12V) - ANTI-RAS FV COMPLEX
2V17L:109-211; H:124-222; H:1-123; L:1-108STRUCTURE OF THE COMPLEX OF ANTIBODY MN423 WITH A FRAGMENT OF TAU PROTEIN
2V2WB:0-99; E:0-99; A:182-270; D:182-270T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT
2V2XB:0-99; E:0-99; A:182-270; D:182-270T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT.
2V44  [entry was replaced by entry 2XY2 without any CATH domain information]
2VAJA:1-93CRYSTAL STRUCTURE OF NCAM2 IG1 (I4122 CELL UNIT)
2VB5A:0-99SOLUTION STRUCTURE OF W60G MUTANT OF HUMAN BETA2-MICROGLOBULIN
2VC2L:108-211; H:120-216; H:1-119; L:1-107RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST L-739758
2VDKL:108-211; H:120-216; H:1-119; L:1-107RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE
2VDLL:108-211; H:120-216; H:1-119; L:1-107RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE
2VDML:108-211; H:120-216; H:1-119; L:1-107RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST TIROFIBAN
2VDNL:108-211; H:120-216; H:1-119; L:1-107RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST EPTIFIBATIDE
2VDOL:108-211; H:120-216; H:1-119; L:1-107INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO FIBRINOGEN GAMMA CHAIN PEPTIDE, HHLGGAKQAGDV
2VDPL:108-211; H:120-216; H:1-119; L:1-107INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO FIBRINOGEN GAMMA CHAIN PEPTIDE,LGGAKQAGDV
2VDQL:108-211; H:120-216; H:1-119; L:1-107INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO A CHIMERIC FIBRINOGEN GAMMA CHAIN PEPTIDE, HHLGGAKQRGDV
2VDRL:108-211; H:120-216; H:1-119; L:1-107INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO A CHIMERIC FIBRINOGEN GAMMA CHAIN PEPTIDE, LGGAKQRGDV
2VH5L:4-107; H:1-114CRYSTAL STRUCTURE OF HRAS(G12V) - ANTI-RAS FV (DISULFIDE FREE MUTANT) COMPLEX
2VLJB:0-99; A:182-270; D:3-111; E:5-115; E:116-244THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2VLKB:0-99; A:182-270; D:3-111; E:5-115; E:116-244THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2VLLB:0-99; E:0-99; A:182-270; D:182-270THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2VLMD:3-111; E:5-115; E:116-244THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2VLRB:0-99; A:182-270; F:182-270; D:3-111; I:3-111; E:5-115; J:5-115; G:0-99; E:116-244; J:116-244THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2VWEC:107-210; E:114-212; L:114-212; J:107-210; E:1-113; L:1-113; C:1-106A; J:1-106ACRYSTAL STRUCTURE OF VASCULAR ENDOTHELIAL GROWTH FACTOR-B IN COMPLEX WITH A NEUTRALIZING ANTIBODY FAB FRAGMENT
2VXSI:114-216; K:114-215; H:114-216; J:114-213; O:109-209; H:1-113; I:1-113; J:1-113; K:1-113STRUCTURE OF IL-17A IN COMPLEX WITH A POTENT, FULLY HUMAN NEUTRALISING ANTIBODY
2VXVL:109-211; H:114-214; H:1-113CRYSTAL STRUCTURE OF HUMAN IGG ABT-325 FAB FRAGMENT
2VYRG:1-123; E:1-124; F:1-124; I:1-124; J:1-124; K:1-124; L:1-124; H:1-125STRUCTURE OF HUMAN MDM4 N-TERMINAL DOMAIN BOUND TO A SINGLE DOMAIN ANTIBODY
2W9EL:108-210; H:117-215; H:1-116STRUCTURE OF ICSM 18 (ANTI-PRP THERAPEUTIC ANTIBODY) FAB FRAGMENT COMPLEXED WITH HUMAN PRP FRAGMENT 119-231
2WAHA:338-444; B:338-445; B:237-337; A:238-337CRYSTAL STRUCTURE OF AN IGG1 FC GLYCOFORM (MAN9GLCNAC2)
2WBJC:8-112; G:10-112; A:82-180; E:82-180; H:142-268; D:142-269; F:92-190; B:92-188; H:1-141; D:-1-141TCR COMPLEX
2WIMA:19-112; B:19-112; A:113-208; B:113-208; A:209-298; B:209-294CRYSTAL STRUCTURE OF NCAM2 IG1-3
2WUBL:109-214; H:114-217; R:114-209; H:1-113; R:1-113; Q:109-214CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP
2WUCL:109-214; H:114-217; H:1-113CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP AND AC-KQLR-CHLOROMETHYLKETONE
2X4NB:0-99; A:182-270; D:181-269; E:0-99CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO RESIDUAL FRAGMENTS OF A PHOTOCLEAVABLE PEPTIDE THAT IS CLEAVED UPON UV-LIGHT TREATMENT
2X4OB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO HIV-1 ENVELOPE PEPTIDE ENV120-128
2X4PB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PHOTOCLEAVABLE PEPTIDE
2X4QB:1-98; A:182-270; D:182-270; E:1-98CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PHOTOCLEAVABLE PEPTIDE
2X4RB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO CYTOMEGALOVIRUS (CMV) PP65 EPITOPE
2X4SB:1-98; A:182-270; D:182-270; E:1-98CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PEPTIDE REPRESENTING THE EPITOPE OF THE H5N1 (AVIAN FLU) NUCLEOPROTEIN
2X4TB:1-98; A:182-270; D:182-270; E:1-98CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PEIODATE-CLEAVABLE PEPTIDE
2X4UB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO HIV-1 PEPTIDE RT468-476
2XACC:129-226; X:132-226STRUCTURAL INSIGHTS INTO THE BINDING OF VEGF-B BY VEGFR-1D2: RECOGNITION AND SPECIFICITY
2YR3A:1-99SOLUTION STRUCTURE OF THE FOURTH IG-LIKE DOMAIN FROM MYOSIN LIGHT CHAIN KINASE, SMOOTH MUSCLE
2YSSA:1-107; B:1-113CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV MUTANT(HQ39KW47Y)-HEN LYSOZYME COMPLEX
2YXFA:0-98THE HIGH RESOLUTION CRYSTAL STRUCTURE OF BETA2-MICROGLOBULIN UNDER PHYSIOLOGICAL CONDITIONS
2Z9TA:0-99CRYSTAL STRUCTURE OF THE HUMAN BETA-2 MICROGLOBULIN MUTANT W60G
2ZCHL:109-211; L:1-108; H:114-212; H:1-113CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
2ZCKL:109-214; L:1-108; H:114-212; H:1-113CRYSTAL STRUCTURE OF A TERNARY COMPLEX BETWEEN PSA, A SUBSTRAT-ACYL INTERMEDIATE AND AN ACTIVATING ANTIBODY
2ZCLL:109-214; L:1-108; H:114-212; H:1-113CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
2ZKHL:108-209; H:117-205; H:1-116HUMAN THROMBOPOIETIN NEUTRALIZING ANTIBODY TN1 FAB
2ZP0T:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D-ILE-GLN-P-AMINOBENZAMIDINE
2ZWLT:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH HIGHLY SELECTIVE PEPTIDE INHIBITOR
2ZZUT:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-(3-CARBOXYBENZYLOXY)-TRP-GLN-P-AMINOBENZAMIDINE
3AAZB:113-216; A:126-224; H:126-224; A:1-125; H:1-125; L:113-216CRYSTAL STRUCTURE OF THE HUMANIZED RECOMBINANT FAB FRAGMENT OF A MURINE; ANTIBODY
3B2UD:109-211; D:1-108; G:1-108; K:1-108; L:1-108; O:1-108; R:1-108; U:1-108; X:1-108; H:122-219; J:122-219; N:122-219; Q:122-219; F:122-219; T:122-219; W:122-219; C:122-219; C:1-121; F:1-121; H:1-121; J:1-121; N:1-121; Q:1-121; T:1-121; W:1-121; G:109-211; K:109-211; L:109-211; O:109-211; R:109-211; U:109-211; X:109-211CRYSTAL STRUCTURE OF ISOLATED DOMAIN III OF THE EXTRACELLULAR REGION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN COMPLEX WITH THE FAB FRAGMENT OF IMC-11F8
3B2VL:109-211; L:1-108; H:122-220; H:1-121CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN COMPLEX WITH THE FAB FRAGMENT OF IMC-11F8
3B3IB:0-99; A:182-276CITRULLINATION-DEPENDENT DIFFERENTIAL PRESENTATION OF A SELF-PEPTIDE BY HLA-B27 SUBTYPES
3B5GA:1-111; B:1-111CRYSTAL STRUCTURE OF THE UNSTABLE AND HIGHLY FIBRILLOGENIC PRO7SER MUTANT OF THE RECOMBINANT VARIABLE DOMAIN 6AJL2
3B6SB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE CITRULLINATED VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
3B9VB:1-112; D:1-112; A:1-112; C:1-112CRYSTAL STRUCTURE OF AN AUTONOMOUS VH DOMAIN
3BDXA:1-111; B:1-111; C:1-111CRYSTAL STRUCTURE OF THE UNSTABLE AND HIGHLY FIBRILLOGENIC PRO7SER MUTANT OF THE RECOMBINANT VARIABLE DOMAIN 6AJL2
3BDYL:109-213; H:116-215; H:0-115; L:1-108DUAL SPECIFIC BH1 FAB IN COMPLEX WITH VEGF
3BE1L:109-212; H:116-215; H:1-115; L:1-108DUAL SPECIFIC BH1 FAB IN COMPLEX WITH THE EXTRACELLULAR DOMAIN OF HER2/ERBB-2
3BFOA:225-309; B:225-309; C:225-309; D:225-309CRYSTAL STRUCTURE OF IG-LIKE C2-TYPE 2 DOMAIN OF THE HUMAN MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATION PROTEIN 1
3BGMB:0-99; A:182-270CRYSTAL STRUCTURE OF PKD2 PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2
3BH8B:0-99; A:182-270CRYSTAL STRUCTURE OF RQA_M PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2
3BH9B:0-99; A:182-270CRYSTAL STRUCTURE OF RTY PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2
3BHBB:2-99; A:182-270CRYSTAL STRUCTURE OF KMD PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2
3BIKB:33-148; C:30-147CRYSTAL STRUCTURE OF THE PD-1/PD-L1 COMPLEX
3BJ91:3-118CRYSTAL STRUCTURE OF THE SURROGATE LIGHT CHAIN VARIABLE DOMAIN VPREBJ
3BJLA:2-111; B:2-111; A:112-212; B:112-212LOC, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN AMMONIUM SULFATE
3BN3B:87-196CRYSTAL STRUCTURE OF ICAM-5 IN COMPLEX WITH AL I DOMAIN
3BN9E:108-211; F:114-213; D:114-213; D:1-113; F:1-113; C:108-210; C:1-107; E:1-107CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH FAB INHIBITOR E2
3BO8B:0-99; A:182-274THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-A1 COMPLEXED WITH THE MAGE-A1 PEPTIDE
3BP4B:0-99; A:182-276THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*2705 IN COMPLEX WITH A CATHEPSIN A SIGNAL SEQUENCE PEPTIDE PCATA
3BP7B:0-99; A:182-276THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*2709 IN COMPLEX WITH A CATHEPSIN A SIGNAL SEQUENCE PEPTIDE, PCATA
3BPLB:-2-96; B:97-199CRYSTAL STRUCTURE OF THE IL4-IL4R-COMMON GAMMA TERNARY COMPLEX
3BPNB:0-96; B:97-198CRYSTAL STRUCTURE OF THE IL4-IL4R-IL13RA TERNARY COMPLEX
3BPOB:-1-96; B:97-196CRYSTAL STRUCTURE OF THE IL13-IL4R-IL13RA TERNARY COMPLEX
3BSZL:113-215; L:1-112; M:1-112; H:119-215; N:119-215; M:113-215; H:1-118; N:1-118CRYSTAL STRUCTURE OF THE TRANSTHYRETIN-RETINOL BINDING PROTEIN-FAB COMPLEX
3BT2L:108-210; H:115-208; H:1-114; L:1-107STRUCTURE OF UROKINASE RECEPTOR, UROKINASE AND VITRONECTIN COMPLEX
3BVNB:1-99; E:1-99; A:182-272; D:182-272HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*1402 IN COMPLEX WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS
3BW9B:0-99; A:182-272CRYSTAL STRUCTURE OF HLA B*3508 IN COMPLEX WITH A HCMV 12-MER PEPTIDE FROM THE PP65 PROTEIN
3BWAB:0-99; A:182-272CRYSTAL STRUCTURE OF HLA B*3508 IN COMPLEX WITH A HCMV 8-MER PEPTIDE FROM THE PP65 PROTEIN
3BX7C:3-122ENGINEERED HUMAN LIPOCALIN 2 (LCN2) IN COMPLEX WITH THE EXTRACELLULAR DOMAIN OF HUMAN CTLA-4
3BXNB:1-99; A:182-272THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*1402 COMPLEXED WITH A CATHEPSIN A SIGNAL SEQUENCE PEPTIDE, PCATA
3BZEB:0-99; A:182-272; C:182-272; G:182-272; E:182-272; D:0-99; F:0-99; H:0-99THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
3BZFB:3-99; A:182-272; C:182-272; D:3-99THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
3C2AH:114-223; I:114-223; L:2-107; M:2-107; L:108-211; M:108-211; H:1-113; I:1-113ANTIBODY FAB FRAGMENT 447-52D IN COMPLEX WITH UG1033 PEPTIDE
3C2SA:338-443; A:238-337STRUCTURAL CHARACTERIZATION OF A HUMAN FC FRAGMENT ENGINEERED FOR LACK OF EFFECTOR FUNCTIONS
3C5JA:82-180; B:94-190CRYSTAL STRUCTURE OF HLA DR52C
3C9NB:1-99; A:182-272CRYSTAL STRUCTURE OF A SARS CORONA VIRUS DERIVED PEPTIDE BOUND TO THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I MOLECULE HLA-B*1501
3CAFA:154-249CRYSTAL STRUCTURE OF HFGFR2 D2 DOMAIN
3CD4A:1-98; A:99-173REFINEMENT AND ANALYSIS OF THE FIRST TWO DOMAINS OF HUMAN CD4
3CDGB:0-99; A:182-272; C:182-272; D:0-99HUMAN CD94/NKG2A IN COMPLEX WITH HLA-E
3CDYA:0-107; B:0-107AL-09 H87Y, IMMUNOGLOBULIN LIGHT CHAIN VARIABLE DOMAIN
3CIQG:0-98; A:0-97; B:0-97; C:0-97; D:0-97; E:0-97; F:0-97; I:0-97; J:0-97; K:0-97; L:0-97; H:0-97A REGULATABLE SWITCH MEDIATES SELF-ASSOCIATION IN AN IMMUNOGLOBULIN FOLD
3CNKA:2559-2647; B:2559-2647CRYSTAL STRUCTURE OF THE DIMERIZATION DOMAIN OF HUMAN FILAMIN A
3CSYB:108-211; A:114-228; C:114-228; E:114-228; G:114-228; B:1-107; D:1-107; F:1-107; H:1-107; A:1-113; C:1-113; E:1-113; G:1-113; D:108-211; F:108-211; H:108-211CRYSTAL STRUCTURE OF THE TRIMERIC PREFUSION EBOLA VIRUS GLYCOPROTEIN IN COMPLEX WITH A NEUTRALIZING ANTIBODY FROM A HUMAN SURVIVOR
3CU1A:154-249; C:154-249CRYSTAL STRUCTURE OF 2:2:2 FGFR2D2:FGF1:SOS COMPLEX
3CXE  [entry was replaced by entry 4NKQ without any CATH domain information]
3D0LA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 BROADLY NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH THE GP41 FP-MPER HYB3K CONSTRUCT 514GIGALFLGFLGAAGS528KK-AHX-655KNEQELLELDKWASLWN671
3D0VA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE LLELDKWASLW
3D18B:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH A VARIANT OF THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2(L)) OF EPSTEIN-BARR VIRUS
3D25B:2-99; A:182-270CRYSTAL STRUCTURE OF HA-1 MINOR HISTOCOMPATIBILITY ANTIGEN BOUND TO HUMAN CLASS I MHC HLA-A2
3D48R:2-101; R:102-204CRYSTAL STRUCTURE OF A PROLACTIN RECEPTOR ANTAGONIST BOUND TO THE EXTRACELLULAR DOMAIN OF THE PROLACTIN RECEPTOR
3D5OF:87-171; F:1-86STRUCTURAL RECOGNITION AND FUNCTIONAL ACTIVATION OF FCRR BY INNATE PENTRAXINS
3D6GA:338-443; B:338-443; A:238-337; B:238-337FC FRAGMENT OF IGG1 (HERCEPTIN) WITH PROTEIN-A MIMETIC PEPTIDE DENDRIMER LIGAND.
3D85A:109-213; B:116-215; B:1-115; D:103-210; D:1-84; D:214-304; A:1-108CRYSTAL STRUCTURE OF IL-23 IN COMPLEX WITH NEUTRALIZING FAB
3D87B:103-210; D:103-210; B:1-84; D:1-84; B:214-304; D:214-304CRYSTAL STRUCTURE OF INTERLEUKIN-23
3DARA:154-249; B:154-249CRYSTAL STRUCTURE OF D2 DOMAIN FROM HUMAN FGFR2
3DHJA:0-99BETA 2 MICROGLOBULIN MUTANT W60C
3DHMA:0-99BETA 2 MICROGLOBULIN MUTANT D59P
3DI2B:109-211; D:109-209CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN INTERLEUKIN-7 WITH UNGLYCOSYLATED HUMAN INTERLEUKIN-7 RECEPTOR ALPHA ECTODOMAIN
3DI3B:109-209CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN INTERLEUKIN-7 WITH GLYCOSYLATED HUMAN INTERLEUKIN-7 RECEPTOR ALPHA ECTODOMAIN
3DJ9A:236-342CRYSTAL STRUCTURE OF AN ISOLATED, UNGLYCOSYLATED ANTIBODY CH2 DOMAIN
3DROA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELLELDKWASLWN GROWN IN AMMONIUM SULFATE
3DRQA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 BROADLY NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH THE GP41 FP-MPER HYB3K CONSTRUCT 514GIGALFLGFLGAAGS528KK-AHX-655KNEQELLELDKWASLWN671 SOAKED IN PEG/2-PROPANOL SOLUTION
3DRTA:108-211; B:114-213; B:1-113CRYSTAL STRUCTURE OF THE HIV-1 BROADLY NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH THE GP41 SCRAMBLEDFP-MPER SCRHYB3K CONSTRUCT GIGAFGLLGFLAAGSKK-AHX-K656NEQELLELDKWASLWN671
3DTXB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE DOUBLE CITRULLINATED VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
3DUHB:103-210; A:103-210; B:-1-84; A:0-84; A:214-304; B:214-304STRUCTURE OF INTERLEUKIN-23
3DVGA:111-214; B:121-221; B:1-120; A:5-110CRYSTAL STRUCTURE OF K63-SPECIFIC FAB APU.3A8 BOUND TO K63-LINKED DI-UBIQUITIN
3DVNA:111-216; B:121-221; H:121-221; B:1-120; H:1-120; L:111-216; A:5-110; L:5-110CRYSTAL STRUCTURE OF K63-SPECIFIC FAB APU2.16 BOUND TO K63-LINKED DI-UBIQUITIN
3DX6B:1-99; A:182-272CRYSTAL STRUCTURE OF B*4402 PRESENTING A 10MER EBV EPITOPE
3DX7B:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4403 PRESENTING 10MER EBV ANTIGEN
3DX8B:1-99; A:182-272CRYSTAL STRUCTURE OF B*4405 PRESENTING A 10MER EBV EPITOPE
3DX9A:2-125; C:2-125; B:2-128; D:2-128; B:129-257; D:129-257CRYSTAL STRUCTURE OF THE DM1 TCR AT 2.75A
3DXAB:1-99; D:2-125; I:2-125; N:2-125; E:2-128; J:2-128; O:2-128; E:129-257; J:129-257; O:129-257; G:1-99; L:1-99; A:182-272; F:182-272; K:182-272CRYSTAL STRUCTURE OF THE DM1 TCR IN COMPLEX WITH HLA-B*4405 AND DECAMER EBV ANTIGEN
3EKCA:0-99STRUCTURE OF W60V BETA-2 MICROGLOBULIN MUTANT
3ELAT:6-105; T:106-209CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA MUTANT IN COMPLEX WITH SOLUBLE TISSUE FACTOR
3ES6A:184-273CRYSTAL STRUCTURE OF THE NOVEL COMPLEX FORMED BETWEEN ZINC 2-GLYCOPROTEIN (ZAG) AND PROLACTIN INDUCIBLE PROTEIN (PIP) FROM HUMAN SEMINAL PLASMA
3EUUA:154-249; B:154-249CRYSTAL STRUCTURE OF THE FGFR2 D2 DOMAIN
3EW3B:0-101; C:4-101; B:102-202; C:102-201THE 1:2 COMPLEX BETWEEN A NTERMINAL ELONGATED PROLACTIN AND THE EXTRA CELLULAR DOMAIN OF THE RAT PROLACTIN RECEPTOR
3F7PC:1217-1330; C:1127-1216CRYSTAL STRUCTURE OF A COMPLEX BETWEEN INTEGRIN BETA4 AND PLECTIN
3FCTC:109-211; B:115-214; D:115-214; A:109-213; A:1-108; C:1-108; B:1-114; D:1-114MATURE METAL CHELATASE CATALYTIC ANTIBODY WITH HAPTEN
3FFCB:0-99; E:2-131; J:2-131; E:132-260; J:132-260; G:0-99; D:3-122; I:3-122; A:182-272; F:182-272CRYSTAL STRUCTURE OF CF34 TCR IN COMPLEX WITH HLA-B8/FLR
3FJTA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF A HUMAN FC FRAGMENT ENGINEERED FOR EXTENDED SERUM HALF-LIFE
3FQNB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FQRB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FQTB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FQUB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FQWB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FQXB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FT2B:0-99; A:182-270CRYSTAL STRUCTURE OF A CITRULLINE PEPTIDE VARIANT OF THE MINOR HISTOCOMPATIBILITY PEPTIDE HA-1 IN COMPLEX WITH HLA-A2
3FT3B:0-99; A:182-270CRYSTAL STRUCTURE OF THE MINOR HISTOCOMPATIBILITY PEPTIDE HA-1HIS IN COMPLEX WITH HLA-A2
3FT4B:0-99; A:182-270CRYSTAL STRUCTURE OF THE MINOR HISTOCOMPATIBILITY PEPTIDE HA-1ARG IN COMPLEX WITH HLA-A2
3FZUD:108-211; H:119-219; C:119-219; C:1-118; H:1-118; L:108-211IGG1 FAB CHARACTERIZED BY H/D EXCHANGE
3G04B:114-213; B:1-113; A:108-208CRYSTAL STRUCTURE OF THE TSH RECEPTOR IN COMPLEX WITH A THYROID-STIMULATING AUTOANTIBODY
3G6AB:123-222; H:123-222; B:1-122; H:1-122CRYSTAL STRUCTURE OF ANTI-IL-13 ANTIBODY CNTO607
3G6DH:123-223; H:1-122CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN CNTO607 FAB AND IL-13
3G6JE:109-214; F:114-213; H:114-213; F:1-113; H:1-113; G:109-214C3B IN COMPLEX WITH A C3B SPECIFIC FAB
3GHBH:114-211; I:114-211; H:1-113; I:1-113CRYSTAL STRUCTURE OF ANTI-HIV-1 FAB 447-52D IN COMPLEX WITH V3 PEPTIDE W2RW020
3GHEH:114-211; H:1-113CRYSTAL STRUCTURE OF ANTI-HIV-1 FAB 537-10D IN COMPLEX WITH V3 PEPTIDE MN
3GIVB:0-99; A:182-270; D:182-270; E:0-99ANTIGEN PROCESSING INFLUENCES HIV-SPECIFIC CYTOTOXIC T LYMPHOCYTE IMMUNODOMINANCE
3GIZL:109-211; H:123-222; H:1-122CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ANTI-CD20 ANTIBODY OFATUMUMAB
3GJEB:120-219; H:120-219; B:1-119; H:1-119RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES
3GJFB:0-99; A:182-270; D:182-270; H:120-219; M:120-219; H:1-119; M:1-119; E:0-99RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES
3GKWL:109-207; H:108-212; H:6-107CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF NIMOTUZUMAB. AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY
3GRWL:109-214; H:114-216; H:1-113FGFR3 IN COMPLEX WITH A FAB
3GSNL:0-99; H:182-270CRYSTAL STRUCTURE OF THE PUBLIC RA14 TCR IN COMPLEX WITH THE HCMV DOMINANT NLV/HLA-A2 EPITOPE
3GSOB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV PEPTIDE
3GSQB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5S PEPTIDE VARIANT
3GSRB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5V PEPTIDE VARIANT
3GSUB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5T PEPTIDE VARIANT
3GSVB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5Q PEPTIDE VARIANT
3GSWB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-T8A PEPTIDE VARIANT
3GSXB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-T8V PEPTIDE VARIANT
3H0TB:123-220; B:1-122HEPCIDIN-FAB COMPLEX
3H3BC:138-244; D:138-244CRYSTAL STRUCTURE OF THE SINGLE-CHAIN FV (SCFV) FRAGMENT OF AN ANTI-ERBB2 ANTIBODY CHA21 IN COMPLEX WITH RESIDUES 1-192 OF ERBB2 EXTRACELLULAR DOMAIN
3H42H:124-224; H:1-123CRYSTAL STRUCTURE OF PCSK9 IN COMPLEX WITH FAB FROM LDLR COMPETITIVE ANTIBODY
3H7BB:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE TEL1P PEPTIDE
3H8NA:103-200; A:6-102CRYSTAL STRUCTURE ANALYSIS OF KIR2DS4
3H9HB:0-99; D:182-270; A:183-270; E:0-99HUMAN CLASS I MHC HLA-A2(A150P) IN COMPLEX WITH THE TEL1P PEPTIDE
3H9SB:0-99; A:182-270; D:1-116THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND TEL1P PEPTIDE
3H9YA:436-543; B:436-543; E:436-543; B:335-435; A:336-435; E:336-435CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS
3H9ZA:436-543; B:436-543; C:436-543; D:436-543; A:336-435; B:336-435; C:336-435; D:336-435CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS
3HA0A:436-543; B:436-543; C:436-543; D:436-543; E:436-543; F:436-543; A:336-435; B:336-435; C:336-435; D:336-435; E:336-435; F:336-435CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS
3HAEB:0-99; A:182-270; D:182-270; J:182-270; P:182-270; H:120-219; I:120-219; O:120-219; T:120-219; G:111-211; L:111-211; N:111-211; S:111-211; H:1-119; I:1-119; O:1-119; T:1-119; E:0-99; K:0-99; Q:0-99RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES
3HC0B:109-211; H:117-217; A:117-216; A:1-116; H:1-116; L:109-211BHA10 IGG1 WILD-TYPE FAB - ANTIBODY DIRECTED AT HUMAN LTBR
3HC3L:109-211; H:117-217; H:1-116BHA10 IGG1 FAB DOUBLE MUTANT VARIANT - ANTIBODY DIRECTED AT HUMAN LTBR
3HC4L:109-211; H:117-217; H:1-116BHA10 IGG1 FAB QUADRUPLE MUTANT VARIANT - ANTIBODY DIRECTED AT HUMAN LTBR
3HCVB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE DOUBLE CITRULLINATED VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
3HG1B:0-99; A:182-270; D:2-109GERMLINE-GOVERNED RECOGNITION OF A CANCER EPITOPE BY AN IMMUNODOMINANT HUMAN T CELL RECEPTOR
3HHRB:132-234; C:132-232; B:32-131; C:32-131HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX
3HI5L:107-210; H:121-220; H:2-120CRYSTAL STRUCTURE OF FAB FRAGMENT OF AL-57
3HI6L:107-210; X:121-220; H:121-220; H:1-120; X:1-120; Y:107-210CRYSTAL STRUCTURE OF INTERMEDIATE AFFINITY I DOMAIN OF INTEGRIN LFA-1 WITH THE FAB FRAGMENT OF ITS ANTIBODY AL-57
3HLAB:1-99; A:182-270HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2.1
3HMWL:108-214; H:120-221; H:1-119CRYSTAL STRUCTURE OF USTEKINUMAB FAB
3HMXL:108-214; H:120-220; H:1-119; A:103-210; A:1-84; A:214-304CRYSTAL STRUCTURE OF USTEKINUMAB FAB/IL-12 COMPLEX
3HUJD:1-99; E:1-116; G:1-116; B:1-97; A:183-280; C:183-278CRYSTAL STRUCTURE OF HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE IN COMPLEX WITH SEMI-INVARIANT NKT CELL RECEPTOR
3I6GB:0-99; A:182-270; D:182-270; E:0-99NEWLY IDENTIFIED EPITOPE MN2 FROM SARS-COV M PROTEIN COMPLEXED WITHHLA-A*0201
3I6KB:0-99; A:182-270; E:182-270; F:0-99NEWLY IDENTIFIED EPITOPE FROM SARS-COV MEMBRANE PROTEIN COMPLEXED WITH HLA-A*0201
3IXAB:0-99; A:183-270; D:183-270; E:0-99HUMAN CLASS I MHC HLA-A2(A150P) IN COMPLEX WITH THE TAX PEPTIDE
3JUYA:1-126; C:1-127; D:1-127; E:1-127; F:1-127; B:1-130CRYSTAL STRUCTURE OF A 3B3 VARIANT, A BROADLY NEUTRALIZING HIV-1 SCFV ANTIBODY
3K2MC:1-101; D:1-101CRYSTAL STRUCTURE OF MONOBODY HA4/ABL1 SH2 DOMAIN COMPLEX
3K2UL:109-214; H:114-216; H:1-113CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC INHIBITORY ANTIBODY FAB40
3KJ6L:109-211; H:115-217; H:1-114CRYSTAL STRUCTURE OF A METHYLATED BETA2 ADRENERGIC RECEPTOR-FAB COMPLEX
3KLAB:0-99; E:0-99; A:182-270; D:182-270CA2+ RELEASE FROM THE ENDOPLASMIC RETICULUM OF NY-ESO-1 SPECIFIC T CELLS IS MODULATED BY THE AFFINITY OF T CELL RECEPTOR AND BY THE USE OF THE CD8 CO-RECEPTOR
3KPLB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4402 IN COMPLEX WITH EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN
3KPMB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4402 IN COMPLEX WITH EEYLKAWTF, A MIMOTOPE
3KPNB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4403 IN COMPLEX WITH EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN
3KPOB:0-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4403 IN COMPLEX WITH EEYLKAWTF, A MIMOTOPE
3KPPB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4405 IN COMPLEX WITH EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN
3KPQB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4405 IN COMPLEX WITH EEYLKAWTF, A MIMOTOPE
3KPRB:1-99; D:2-116; I:2-116; G:1-99; A:182-272; F:182-272CRYSTAL STRUCTURE OF THE LC13 TCR IN COMPLEX WITH HLA B*4405 BOUND TO EEYLKAWTF A MIMOTOPE
3KPSB:1-99; D:2-116; A:182-272CRYSTAL STRUCTURE OF THE LC13 TCR IN COMPLEX WITH HLA B*4405 BOUND TO EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN
3KR3L:109-212; H:123-222; H:1-122CRYSTAL STRUCTURE OF IGF-II ANTIBODY COMPLEX
3KWWB:1-99; A:182-272CRYSTAL STRUCTURE OF THE 'RESTRICTION TRIAD' MUTANT OF HLA B*3508, BETA-2-MICROGLOBULIN AND EBV PEPTIDE
3KXFB:1-99; F:1-99; J:1-99; L:1-99; D:1-114; G:1-114; M:1-114; N:1-114; A:182-272; C:182-272; I:182-272; K:182-272CRYSTAL STRUCTURE OF SB27 TCR IN COMPLEX WITH THE 'RESTRICTION TRIAD' MUTANT HLA-B*3508-13MER
3KYKL:109-211; H:120-220; H:1-119CRYSTAL STRUCTURE OF LI33 IGG1 FAB
3KYNB:0-99; A:182-272CRYSTAL STRUCTURE OF HLA-G PRESENTING KGPPAALTL PEPTIDE
3KYOB:0-99; A:182-272; C:182-272; D:0-99CRYSTAL STRUCTURE OF HLA-G PRESENTING KLPAQFYIL PEPTIDE
3L3DB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE F3A MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201
3L3GB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE R5A MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201
3L3IB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE F7A MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201
3L3JB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE F3A/R5A DOUBLE MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201
3L3KB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE R5A/F7A DOUBLE MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201
3L5XL:109-214; H:122-220; H:2-121CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN IL-13 AND H2L6 FAB
3L5Y  [entry was replaced by entry 4PS4 without any CATH domain information]
3L6FA:82-180; B:93-190STRUCTURE OF MHC CLASS II MOLECULE HLA-DR1 COMPLEXED WITH PHOSPHOPEPTIDE MART-1
3LVEA:1-108LEN Q38E MUTANT: A DOMAIN FLIP FROM A SINGLE AMINO ACID SUBSTITUTION
3MCG1:2-111; 2:2-111; 1:112-216; 2:112-212THREE-DIMENSIONAL STRUCTURE OF A LIGHT CHAIN DIMER CRYSTALLIZED IN WATER. CONFORMATIONAL FLEXIBILITY OF A MOLECULE IN TWO CRYSTAL FORMS
4BJLA:2-111; B:2-111; A:112-212; B:112-210LOCW, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN DISTILLED WATER
4LVEB:301-407; A:1-108LEN K30T MUTANT: A DOMAIN FLIP AS A RESULT OF A SINGLE AMINO ACID SUBSTITUTION
5LVEA:1-108STRUCTURE OF THE VARIABLE DOMAIN OF HUMAN IMMUNOGLOBULIN K-4 LIGHT CHAIN LEN
7FABH:118-216; L:1-103; H:1-117; L:104-204CRYSTAL STRUCTURE OF HUMAN IMMUNOGLOBULIN FRAGMENT FAB NEW REFINED AT 2.0 ANGSTROMS RESOLUTION
8FABD:122-221; B:122-222; A:3-107; C:3-107; A:108-208; C:108-208; B:1-121; D:1-121CRYSTAL STRUCTURE OF THE FAB FRAGMENT FROM THE HUMAN MYELOMA IMMUNOGLOBULIN IGG HIL AT 1.8 ANGSTROMS RESOLUTION
(-)
Human (homo sapiens) (4)
1AXSA:109-211; B:114-213; H:114-213; L:109-211; B:1-113; H:1-113; A:1-108; L:1-108MATURE OXY-COPE CATALYTIC ANTIBODY WITH HAPTEN
1CLYL:109-211; L:3-108; H:114-227; H:1-113IGG FAB (HUMAN IGG1, KAPPA) CHIMERIC FRAGMENT (CBR96) COMPLEXED WITH LEWIS Y NONOATE METHYL ESTER
1MIML:106-208; L:1-105; H:116-215; H:1-115IGG FAB FRAGMENT (CD25-BINDING)
1UCBL:109-211; L:4-108; H:114-227; H:1-113STRUCTURE OF UNCOMPLEXED FAB COMPARED TO COMPLEX (1CLY, 1CLZ)
(-)
Human (Homo sapiens, undefined) (2)
2ZNWA:126-225; B:126-225CRYSTAL STRUCTURE OF SCFV10 IN COMPLEX WITH HEN EGG LYSOZYME
2ZNXA:126-224; B:126-2245-FLUOROTRYPTOPHAN INCORPORATED SCFV10 COMPLEXED TO HEN EGG LYSOZYME
(-)
Human (homosapiens) (2)
1GAFL:109-211; H:1-114; L:1-108; H:115-21448G7 HYBRIDOMA LINE FAB COMPLEXED WITH HAPTEN 5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID
1HKLL:109-211; H:1-113; L:1-108; H:114-213FREE AND LIGANDED FORM OF AN ESTEROLYTIC CATALYTIC ANTIBODY
(-)
Human adenovirus 12. Organism_taxid: 28282. (2)
1P69B:23-146STRUCTURAL BASIS FOR VARIATION IN ADENOVIRUS AFFINITY FOR THE CELLULAR RECEPTOR CAR (P417S MUTANT)
1P6AB:23-146STRUCTURAL BASIS FOR VARIATION IN ASDENOVIRUS AFFINITY FOR THE CELLULAR RECEPTOR CAR (S489Y MUTANT)
(-)
Human adenovirus 12. Organism_taxid: 28282. Variant: serotype 12. (1)
1KACB:23-146KNOB DOMAIN FROM ADENOVIRUS SEROTYPE 12 IN COMPLEX WITH DOMAIN 1 OF ITS CELLULAR RECEPTOR CAR
(-)
Human adenovirus 37. Organism_taxid: 52275. (1)
2WBWB:19-138AD37 FIBRE HEAD IN COMPLEX WITH CAR D1 AND SIALIC ACID
(-)
Human adenovirus. Organism_taxid: 52275. Strain: type 37. (1)
2J12B:19-138AD37 FIBRE HEAD IN COMPLEX WITH CAR D1
(-)
Human cytomegalovirus (Human herpesvirus 5) (1)
3D2UB:1-99; F:1-99STRUCTURE OF UL18, A PEPTIDE-BINDING VIRAL MHC MIMIC, BOUND TO A HOST INHIBITORY RECEPTOR
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. (3)
1YYLL:109-211; H:114-213; R:1114-1213; H:1-113; R:1001-1113; Q:1109-1211; L:1-108; Q:1001-1108CRYSTAL STRUCTURE OF CD4M33, A SCORPION-TOXIN MIMIC OF CD4, IN COMPLEX WITH HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN AND ANTI-HIV-1 ANTIBODY 17B
1YYML:109-211; Q:1109-1211; H:114-213; R:1114-1213; H:1-113; R:1001-1113; L:1-108; Q:1001-1108CRYSTAL STRUCTURE OF F23, A SCORPION-TOXIN MIMIC OF CD4, IN COMPLEX WITH HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN AND ANTI-HIV-1 ANTIBODY 17B
2B4CL:109-211; H:114-213; H:2-113; C:1-98; C:99-173; L:1-108CRYSTAL STRUCTURE OF HIV-1 JR-FL GP120 CORE PROTEIN CONTAINING THE THIRD VARIABLE REGION (V3) COMPLEXED WITH CD4 AND THE X5 ANTIBODY
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: c-12. Cell_line: bl21. (1)
1AFVL:113-210; M:113-210; H:121-219; K:121-219; L:1-112; M:1-112; H:1-120; K:1-120HIV-1 CAPSID PROTEIN (P24) COMPLEX WITH FAB25.3
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: clade b. Variant: hxbc2. (1)
1GC1L:111-213; L:1-110; H:129-228; H:1-128; C:1-98; C:99-173HIV-1 GP120 CORE COMPLEXED WITH CD4 AND A NEUTRALIZING HUMAN ANTIBODY
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: clade b. Variant: laboratory-adapted isolate hxbc2. (3)
1G9ML:111-213; H:1-128; C:1-98; C:99-173; L:1-110; H:129-228HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
1RZJL:109-211; C:1-98; C:99-173; L:1-108; H:114-213; H:1-113HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
1RZKL:109-211; H:1-113; C:1-98; C:99-173; L:1-108; H:114-213HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: clade b. Variant: primary isolate yu2. (1)
1G9NL:111-213; L:1-110; H:129-228; H:1-128; C:1-98; C:99-173HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: hxbc2. (13)
2NXYC:2111-2213; C:2001-2110; D:3129-3228; D:3001-3128; B:1001-1098; B:1099-1173HIV-1 GP120 ENVELOPE GLYCOPROTEIN(S334A) COMPLEXED WITH CD4 AND ANTIBODY 17B
2NXZC:2111-2213; C:2001-2110; D:3129-3228; D:3001-3128; B:1001-1098; B:1099-1173HIV-1 GP120 ENVELOPE GLYCOPROTEIN (T257S, S334A, S375W) COMPLEXED WITH CD4 AND ANTIBODY 17B
2NY0C:2111-2213; C:2001-2110; D:3129-3228; D:3001-3128; B:1001-1098; B:1099-1173HIV-1 GP120 ENVELOPE GLYCOPROTEIN (M95W, W96C, T257S, V275C, S334A, S375W, A433M) COMPLEXED WITH CD4 AND ANTIBODY 17B
2NY1C:2111-2213; C:2001-2110; D:3129-3228; D:3001-3128; B:1001-1098; B:1099-1173HIV-1 GP120 ENVELOPE GLYCOPROTEIN (I109C, T257S, S334A, S375W, Q428C) COMPLEXED WITH CD4 AND ANTIBODY 17B
2NY2C:2111-2213; C:2001-2110; D:3129-3228; D:3001-3128; B:1001-1098; B:1099-1173HIV-1 GP120 ENVELOPE GLYCOPROTEIN (T123C, T257S, S334A, S375W, G431C) COMPLEXED WITH CD4 AND ANTIBODY 17B
2NY3C:2111-2213; C:2001-2110; D:3129-3228; D:3001-3128; B:1001-1098; B:1099-1173HIV-1 GP120 ENVELOPE GLYCOPROTEIN (K231C, T257S, E267C, S334A, S375W) COMPLEXED WITH CD4 AND ANTIBODY 17B
2NY4C:2111-2213; C:2001-2110; D:3129-3228; D:3001-3128; B:1001-1098; B:1099-1173HIV-1 GP120 ENVELOPE GLYCOPROTEIN (K231C, T257S, E268C, S334A, S375W) COMPLEXED WITH CD4 AND ANTIBODY 17B
2NY5L:2111-2213; L:2001-2110; H:3129-3228; H:3001-3128; C:1001-1098; C:1099-1173HIV-1 GP120 ENVELOPE GLYCOPROTEIN (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) COMPLEXED WITH CD4 AND ANTIBODY 17B
2NY6C:2111-2213; C:2001-2110; D:3129-3228; D:3001-3128; B:1001-1098; B:1099-1173HIV-1 GP120 ENVELOPE GLYCOPROTEIN (M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, G431C) COMPLEXED WITH CD4 AND ANTIBODY 17B
2NY7L:108-211; L:1-107; H:110-230; H:1-109HIV-1 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH THE BROADLY NEUTRALIZING CD4-BINDING-SITE ANTIBODY B12
3IDXL:108-211; H:114-216; H:1-113CRYSTAL STRUCTURE OF HIV-GP120 CORE IN COMPLEX WITH CD4-BINDING SITE ANTIBODY B13, SPACE GROUP C222
3IDYC:108-211; L:108-211; B:114-216; H:114-216; B:1-113; H:1-113CRYSTAL STRUCTURE OF HIV-GP120 CORE IN COMPLEX WITH CD4-BINDING SITE ANTIBODY B13, SPACE GROUP C2221
3JWDL:108-211; O:108-211; H:110-214; P:110-213; H:1-109; P:1-109; C:1000-1098; D:1001-1098; C:1099-1173; D:1099-1173STRUCTURE OF HIV-1 GP120 WITH GP41-INTERACTIVE REGION: LAYERED ARCHITECTURE AND BASIS OF CONFORMATIONAL MOBILITY
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: yu2. (2)
2I60L:109-211; Q:109-211; H:2-113; R:1-113; L:1-108; Q:1-108; H:114-213; R:114-213CRYSTAL STRUCTURE OF [PHE23]M47, A SCORPION-TOXIN MIMIC OF CD4, IN COMPLEX WITH HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN AND ANTI-HIV-1 ANTIBODY 17B
2QADC:110-211; D:110-214; H:110-214; D:1-109; H:1-109; B:1-98; F:1-98; B:99-173; F:99-173; G:110-211; C:1-108; G:1-108STRUCTURE OF TYROSINE-SULFATED 412D ANTIBODY COMPLEXED WITH HIV-1 YU2 GP120 AND CD4
(-)
Human immunodeficiency virus. Organism_taxid: 12721. Strain: yu2. (1)
2I5YL:109-211; Q:109-211; L:1-108; Q:1-108; H:114-213; R:114-213; H:1-113; R:1-113CRYSTAL STRUCTURE OF CD4M47, A SCORPION-TOXIN MIMIC OF CD4, IN COMPLEX WITH HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN AND ANTI-HIV-1 ANTIBODY 17B
(-)
Human poliovirus 1 mahoney. Organism_taxid: 12081. Strain: mahoney. Mus musculus. House mouse. Organism_taxid: 10090. (1)
1FPTL:109-211; H:1-113; H:114-227; L:1-108THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN THE FAB FRAGMENT OF AN NEUTRALIZING ANTIBODY FOR TYPE 1 POLIOVIRUS AND ITS VIRAL EPITOPE
(-)
Human rhinovirus 14. Organism_taxid: 12131. Strain: serotype 14. Humanrhinovirus 14. Organism_taxid: 12131. Strain: serotype 14. Human rhinovirus 14. Organism_taxid: 12131. Strain: serotype 14. Human rhinovirus sp.. Organism_taxid: 169066. Strain: serotype 14. Mus musculus. House mouse. Organism_taxid: 10090. (1)
1RVFH:1-113; L:1-111FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS
(-)
Human, house mouse (Homo sapiens, mus musculus) (6)
1BVLB:1-108; D:1-108; A:1-116; C:1-116HUMANIZED ANTI-LYSOZYME FV
1S3KL:114-216; L:1-113; H:120-219; H:1-119CRYSTAL STRUCTURE OF A HUMANIZED FAB (HU3S193) IN COMPLEX WITH THE LEWIS Y TETRASACCHARIDE
2OSLB:108-210; B:1-107; L:1-107; H:122-224; A:122-221; L:108-210; A:1-121; H:1-121CRYSTAL STRUCTURE OF RITUXIMAB FAB IN COMPLEX WITH AN EPITOPE PEPTIDE
3BKYL:108-210; L:1-107; H:123-222; H:1-122CRYSTAL STRUCTURE OF CHIMERIC ANTIBODY C2H7 FAB IN COMPLEX WITH A CD20 PEPTIDE
3C08L:108-211; L:4-107; H:118-223; H:1-117CRYSTAL STRUCTURE THE FAB FRAGMENT OF MATUZUMAB/EMD72000 (FAB72000)
3C09L:108-211; B:1-107; L:1-107; H:118-222; C:118-218; C:1-117; H:1-117; B:108-206CRYSTAL STRUCTURE THE FAB FRAGMENT OF MATUZUMAB (FAB72000) IN COMPLEX WITH DOMAIN III OF THE EXTRACELLULAR REGION OF EGFR
(-)
Hypomyces rosellus. Organism_taxid: 5132 (3)
1GOFA:542-639NOVEL THIOETHER BOND REVEALED BY A 1.7 ANGSTROMS CRYSTAL STRUCTURE OF GALACTOSE OXIDASE
1GOGA:542-639NOVEL THIOETHER BOND REVEALED BY A 1.7 ANGSTROMS CRYSTAL STRUCTURE OF GALACTOSE OXIDASE
1GOHA:542-639NOVEL THIOETHER BOND REVEALED BY A 1.7 ANGSTROMS CRYSTAL STRUCTURE OF GALACTOSE OXIDASE
(-)
Im6501 (Thermus sp) (1)
1SMAA:1-125; B:1-125CRYSTAL STRUCTURE OF A MALTOGENIC AMYLASE
(-)
Influenza a virus (a/tern/australia/g70c/1975(h11n9)). Organism_taxid:384509. Strain: (a/tern/australia/g70c/1975(h11n9)). Mus musculus. House mouse. Organism_taxid: 10090. (3)
1NCAL:109-211; H:1-114; L:1-108; H:115-227REFINED CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS N9 NEURAMINIDASE-NC41 FAB COMPLEX
1NCBL:109-211; L:1-108; H:114-225; H:1-113CRYSTAL STRUCTURES OF TWO MUTANT NEURAMINIDASE-ANTIBODY COMPLEXES WITH AMINO ACID SUBSTITUTIONS IN THE INTERFACE
1NCCL:109-211; H:1-113; L:1-108; H:114-225CRYSTAL STRUCTURES OF TWO MUTANT NEURAMINIDASE-ANTIBODY COMPLEXES WITH AMINO ACID SUBSTITUTIONS IN THE INTERFACE
(-)
Influenza a virus (a/whale/maine/1/84(h13n9)). Organism_taxid: 11484.Strain: (a/whale/maine/1/84(h13n9)). Mus musculus. House mouse. Organism_taxid: 10090. (1)
1NCDL:109-211; L:1-108; H:114-218; H:1-113REFINED CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS N9 NEURAMINIDASE-NC41 FAB COMPLEX
(-)
Influenza a virus (a/x-31(h3n2)). Organism_taxid: 132504. Strain: x31. (1)
1QFUL:108-210; H:114-212; H:1-113; L:1-107INFLUENZA VIRUS HEMAGGLUTININ COMPLEXED WITH A NEUTRALIZING ANTIBODY
(-)
Influenza a virus (a/x-31(h3n2)). Organism_taxid: 132504. Strain: x31.Influenza a virus (a/x-31(h3n2)). Organism_taxid: 132504. Strain: x31. Mus musculus. House mouse. Organism_taxid: 10090. (1)
1KENL:110-212; U:110-212; L:1-109; U:1-109; H:121-219; T:121-219; H:1-120; T:1-120INFLUENZA VIRUS HEMAGGLUTININ COMPLEXED WITH AN ANTIBODY THAT PREVENTS THE HEMAGGLUTININ LOW PH FUSOGENIC TRANSITION
(-)
Influenza a virus (a/x-31(h3n2)). Organism_taxid: 132504. Strain: x31.Influenza a virus (a/x-31(h3n2)). Organism_taxid: 132504. Strain: x31. Mus musculus. House mouse. Organism_taxid: 10090. Strain: balb/c. (1)
1EO8L:108-211; H:1-113; L:1-107; H:114-212INFLUENZA VIRUS HEMAGGLUTININ COMPLEXED WITH A NEUTRALIZING ANTIBODY
(-)
Influenza a virus (strain a/south carolina/1/1918 h1n1) (Influenza a virus (a/brevig mission/1/1918(h1n1))) (1)
3GBNH:1-113CRYSTAL STRUCTURE OF FAB CR6261 IN COMPLEX WITH THE 1918 H1N1 INFLUENZA VIRUS HEMAGGLUTININ
(-)
Influenza a virus. Organism_taxid: 11320. Mus musculus. House mouse. Organism_taxid: 10090. (2)
1NMAH:1-113; L:1-109N9 NEURAMINIDASE COMPLEXES WITH ANTIBODIES NC41 AND NC10: EMPIRICAL FREE-ENERGY CALCULATIONS CAPTURE SPECIFICITY TRENDS OBSERVED WITH MUTANT BINDING DATA
1NMBH:1-113; L:1-109THE STRUCTURE OF A COMPLEX BETWEEN THE NC10 ANTIBODY AND INFLUENZA VIRUS NEURAMINIDASE AND COMPARISON WITH THE OVERLAPPING BINDING SITE OF THE NC41 ANTIBODY
(-)
Influenza a virus. Organism_taxid: 11320. Strain: a-memphis-31-98. Musmusculus. House mouse. Organism_taxid: 10090. (1)
2AEQL:1-107; H:1-116AN EPIDEMIOLOGICALLY SIGNIFICANT EPITOPE OF A 1998 INFLUENZA VIRUS NEURAMINIDASE FORMS A HIGHLY HYDRATED INTERFACE IN THE NA-ANTIBODY COMPLEX.
(-)
Influenza a virus. Organism_taxid: 11320. Strain: n9, a/tern/australia/g70c/75. Mus musculus. House mouse. Organism_taxid: 10090. (1)
1A14H:1-111; L:1-104COMPLEX BETWEEN NC10 ANTI-INFLUENZA VIRUS NEURAMINIDASE SINGLE CHAIN ANTIBODY WITH A 5 RESIDUE LINKER AND INFLUENZA VIRUS NEURAMINIDASE
(-)
Influenza a virus. Organism_taxid: 11320. Strain: n9. Variant: a/tern/australia/g70c/75. (1)
1NMCB:1-113; H:1-113; C:1-109; L:1-109COMPLEX BETWEEN NC10 ANTI-INFLUENZA VIRUS NEURAMINIDASE SINGLE CHAIN ANTIBODY WITH A 15 RESIDUE LINKER AND INFLUENZA VIRUS NEURAMINIDASE
(-)
Influenza a virus. Organism_taxid: 228928. Strain: a/memphis/31/98(h3n2). Mus musculus. House mouse. Organism_taxid: 10090. (1)
2AEPH:1-113; L:1-141AN EPIDEMIOLOGICALLY SIGNIFICANT EPITOPE OF A 1998 INFLUENZA VIRUS NEURAMINIDASE FORMS A HIGHLY HYDRATED INTERFACE IN THE NA-ANTIBODY COMPLEX.
(-)
Influenza a virus. Organism_taxid: 284218. Strain: h5n1. (1)
3FKUS:140-242; T:140-242; Y:1-139; Z:1-139; U:140-242; X:140-242; Y:140-242; Z:140-242; S:1-139; T:1-139; U:1-139; X:1-139CRYSTAL STRUCTURE OF INFLUENZA HEMAGGLUTININ (H5) IN COMPLEX WITH A BROADLY NEUTRALIZING ANTIBODY F10
(-)
Jellyfish (Aequorea victoria) (1)
3G9AB:2-112GREEN FLUORESCENT PROTEIN BOUND TO MINIMIZER NANOBODY
(-)
Lactococcus lactis phage p2. Organism_taxid: 100641. (1)
2BSED:2-123; E:2-123; F:2-123STRUCTURE OF LACTOCOCCAL BACTERIOPHAGE P2 RECEPTOR BINDING PROTEIN IN COMPLEX WITH A LLAMA VHH DOMAIN
(-)
Lactococcus phage p2. Organism_taxid: 254252. (1)
2WZPD:2-123; E:2-123; F:2-123; J:2-123; K:2-123; L:2-123STRUCTURES OF LACTOCOCCAL PHAGE P2 BASEPLATE SHED LIGHT ON A NOVEL MECHANISM OF HOST ATTACHMENT AND ACTIVATION IN SIPHOVIRIDAE
(-)
Lama glama. Organism_taxid: 9844. (1)
3K3QA:4-140CRYSTAL STRUCTURE OF A LLAMA ANTIBODY COMPLEXED WITH THE C. BOTULINUM NEUROTOXIN SEROTYPE A CATALYTIC DOMAIN
(-)
Listeria monocytogenes. Organism_taxid: 169963. Strain: egd-e. Variant: serovar 12a. (2)
2UZXB:532-658; D:532-658STRUCTURE OF THE HUMAN RECEPTOR TYROSINE KINASE MET IN COMPLEX WITH THE LISTERIA MONOCYTOGENES INVASION PROTEIN INLB: CRYSTAL FORM I
2UZYB:562-654; D:562-654; B:655-741; D:655-741STRUCTURE OF THE HUMAN RECEPTOR TYROSINE KINASE MET IN COMPLEX WITH THE LISTERIA MONOCYTOGENES INVASION PROTEIN INLB: LOW RESOLUTION, CRYSTAL FORM II
(-)
Llama (Lama glama) (11)
1G9EA:1-117SOLUTION STRUCTURE AND RELAXATION MEASUREMENTS OF AN ANTIGEN-FREE HEAVY CHAIN VARIABLE DOMAIN (VHH) FROM LLAMA
1HCVA:2-113LLAMA HEAVY CHAIN VARIABLE DOMAIN AGAINST ALPHA SUBUNIT OF HCG (HUMAN CHORIONIC GONADOTROPIN)
1I3UA:2-127THREE-DIMENSIONAL STRUCTURE OF A LLAMA VHH DOMAIN COMPLEXED WITH THE DYE RR1
1I3VA:1-129; B:1-129THREE-DIMENSIONAL STRUCTURE OF A LAMA VHH DOMAIN UNLIGANDED
1IEHA:1-135SOLUTION STRUCTURE OF A SOLUBLE SINGLE-DOMAIN ANTIBODY WITH HYDROPHOBIC RESIDUES TYPICAL OF A VL/VH INTERFACE
1QD0A:1-128CAMELID HEAVY CHAIN VARIABLE DOMAINS PROVIDE EFFICIENT COMBINING SITES TO HAPTENS
1SHMD:2-113; B:2-113; A:2-113; E:2-113CONVERGENT SOLUTIONS TO VHH DOMAIN STABILIZATION FROM NATURAL AND IN VITRO EVOLUTION
1SJVA:8-110THREE-DIMENSIONAL STRUCTURE OF A LLAMA VHH DOMAIN SWAPPING
1SJXA:801-919THREE-DIMENSIONAL STRUCTURE OF A LLAMA VHH DOMAIN OE7 BINDING THE CELL WALL PROTEIN MALF1
1U0QA:2-113; B:202-313STRUCTURE OF A LLAMA VHH DOMAIN RAISED AGAINST A CARBAZOLE MOLECULE
2XA3A:1-113CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING LLAMA VHH D7 AND ITS MODE OF HIV-1 GP120 INTERACTION
(-)
Man (Homo sapiens) (1)
3DNKA:338-443; B:1338-1443; A:238-337; B:1238-1337ENZYME DEGLYCOSYLATED HUMAN IGG1 FC FRAGMENT
(-)
Methanococcus jannaschii (Methanocaldococcus jannaschii) (1)
3GI8H:1-124; H:125-220CRYSTAL STRUCTURE OF APCT K158A TRANSPORTER BOUND TO 7F11 MONOCLONAL FAB FRAGMENT
(-)
Micromonospora viridifaciens. Organism_taxid: 1881. (7)
1EUTA:401-502SIALIDASE, LARGE 68KD FORM, COMPLEXED WITH GALACTOSE
1EUUA:401-502SIALIDASE OR NEURAMINIDASE, LARGE 68KD FORM
1W8NA:401-502CONTRIBUTION OF THE ACTIVE SITE ASPARTIC ACID TO CATALYSIS IN THE BACTERIAL NEURAMINIDASE FROM MICROMONOSPORA VIRIDIFACIENS.
1W8OA:401-502CONTRIBUTION OF THE ACTIVE SITE ASPARTIC ACID TO CATALYSIS IN THE BACTERIAL NEURAMINIDASE FROM MICROMONOSPORA VIRIDIFACIENS
1WCQA:401-502; B:401-502; C:401-502MUTAGENESIS OF THE NUCLEOPHILIC TYROSINE IN A BACTERIAL SIALIDASE TO PHENYLALANINE.
2BERA:401-502Y370G ACTIVE SITE MUTANT OF THE SIALIDASE FROM MICROMONOSPORA VIRIDIFACIENS IN COMPLEX WITH BETA-NEU5AC (SIALIC ACID).
2BZDA:401-502; B:401-502; C:401-502GALACTOSE RECOGNITION BY THE CARBOHYDRATE-BINDING MODULE OF A BACTERIAL SIALIDASE.
(-)
Mouse (Mus musculus) (152)
1GL4B:1769-1857NIDOGEN-1 G2/PERLECAN IG3 COMPLEX
1H3PL:109-211; H:114-213; L:1-108; H:1-113STRUCTURAL CHARACTERISATION OF A MONOCLONAL ANTIBODY SPECIFIC FOR THE PRES1 REGION OF THE HEPATITIS B VIRUS
1H5BB:1-111; D:1-111; A:1-113; C:1-113T CELL RECEPTOR VALPHA11 (AV11S5) DOMAIN
1HK6A:3-97RAL BINDING DOMAIN FROM SEC5
1OB1A:108-210; D:108-210; A:1-107; D:1-107; B:114-212; E:114-212; B:1-113; E:1-113CRYSTAL STRUCTURE OF A FAB COMPLEX WHITH PLASMODIUM FALCIPARUM MSP1-19
1OD7A:1-119N-TERMINAL OF SIALOADHESIN IN COMPLEX WITH ME-A-9-N-(NAPHTHYL-2-CARBONYL)-AMINO-9-DEOXY-NEU5AC (NAP COMPOUND)
1OD9A:1-119N-TERMINAL OF SIALOADHESIN IN COMPLEX WITH ME-A-9-N-BENZOYL-AMINO-9-DEOXY-NEU5AC (BENZ COMPOUND)
1ODAA:1-119N-TERMINAL OF SIALOADHESIN IN COMPLEX WITH ME-A-9-N-(BIPHENYL-4-CARBONYL)-AMINO-9-DEOXY-NEU5AC (BIP COMPOUND)
1QKZL:109-211; H:114-212; L:1-108; H:1-113FAB FRAGMENT (MN14C11.6) IN COMPLEX WITH A PEPTIDE ANTIGEN DERIVED FROM NEISSERIA MENINGITIDIS P1.7 SEROSUBTYPE ANTIGEN AND DOMAIN II FROM STREPTOCOCCAL PROTEIN G
1QLFB:1-99; A:182-272MHC CLASS I H-2DB COMPLEXED WITH GLYCOPEPTIDE K3G
1QNZH:113-231; L:1-112NMR STRUCTURE OF THE 0.5B ANTI-HIV ANTIBODY COMPLEX WITH THE GP120 V3 PEPTIDE
1QO3B:0-99; A:182-272COMPLEX BETWEEN NK CELL RECEPTOR LY49A AND ITS MHC CLASS I LIGAND H-2DD
1QOKA:27-146; A:162-260MFE-23 AN ANTI-CARCINOEMBRYONIC ANTIGEN SINGLE-CHAIN FV ANTIBODY
1URLA:1-118N-TERMINAL DOMAIN OF SIALOADHESIN (MOUSE) IN COMPLEX WITH GLYCOPEPTIDE
1UWXK:110-213; L:110-213; K:3-109; L:3-109; H:115-215; M:115-215; H:2-114; M:2-114P1.2 SEROSUBTYPE ANTIGEN DERIVED FROM N. MENINGITIDIS PORA IN COMPLEX WITH FAB FRAGMENT
1UYWL:109-211; L:1-108; N:1-108; H:114-212; M:114-212; H:2-113; M:2-113; N:109-211CRYSTAL STRUCTURE OF THE ANTIFLAVIVIRUS FAB4G2
1UZ6E:108-210; L:108-210; M:108-210; V:108-210; P:114-213; W:114-213; H:114-213; F:114-213; E:1-107; L:1-107; M:1-107; V:1-107; F:1-112; H:1-112; P:1-112; W:1-112ANTI-LEWIS X FAB FRAGMENT UNCOMPLEXED
1UZ8A:108-210; B:114-213; H:114-213; A:1-107; L:1-107; B:1-112; H:1-112; L:108-210ANTI-LEWIS X FAB FRAGMENT IN COMPLEX WITH LEWIS X
1WBXB:1-99; A:182-272CRYSTAL STRUCTURES OF MURINE MHC CLASS I H-2 DB AND KB MOLECULES IN COMPLEX WITH CTL EPITOPES FROM INFLUENZA A VIRUS: IMPLICATIONS FOR TCR REPERTOIRE SELECTION AND IMMUNODOMINANCE
1WBYB:1-99; A:182-272CRYSTAL STRUCTURES OF MURINE MHC CLASS I H-2 DB AND KB MOLECULES IN COMPLEX WITH CTL EPITOPES FROM INFLUENZA A VIRUS: IMPLICATIONS FOR TCR REPERTOIRE SELECTION AND IMMUNODOMINANCE
1WBZB:1-99; D:1-99; C:182-275; A:182-274CRYSTAL STRUCTURES OF MURINE MHC CLASS I H-2 DB AND KB MOLECULES IN COMPLEX WITH CTL EPITOPES FROM INFLUENZA A VIRUS: IMPLICATIONS FOR TCR REPERTOIRE SELECTION AND IMMUNODOMINANCE
1WC7A:109-214; L:109-210; A:1-108; L:1-108; B:114-214; H:114-212; B:1-113; H:1-113FAB FRAGMENT OF PLP-DEPENDENT CATALYTIC ANTIBODY 15A9 IN COMPLEX WITH PHOSPHOPYRIDOXYL-L-ALANINE
1WCBA:109-214; L:109-214; A:1-108; L:1-108; B:114-214; H:114-213; B:1-113; H:1-113PLP-DEPENDENT CATALYTIC ANTIBODY 15A9 IN COMPLEX WITH ITS HAPTEN
2BMKA:109-214; L:109-214; A:1-108; L:1-108; B:114-214; H:114-214; B:1-113; H:1-113FAB FRAGMENT OF PLP-DEPENDENT CATALYTIC ANTIBODY 15A9 IN COMPLEX WITH PHOSPHOPYRIDOXYL-D-ALANINE
2BOBB:109-211; B:1-108; A:119-217; A:1-118POTASSIUM CHANNEL KCSA-FAB COMPLEX IN THALLIUM WITH TETRABUTYLAMMONIUM (TBA)
2BOCB:109-211; B:1-108; A:119-217; A:1-118POTASSIUM CHANNEL KCSA-FAB COMPLEX IN THALLIUM WITH TETRAETHYLARSONIUM (TEAS)
2BRRL:109-211; X:2-108; L:1-108; H:114-215; Y:114-215; H:2-113; Y:1-113; X:109-211COMPLEX OF THE NEISSERIAL PORA P1.4 EPITOPE PEPTIDE AND TWO FAB-FRAGMENTS (ANTIBODY MN20B9.34)
2BVEA:1-119; B:1-119STRUCTURE OF THE N-TERMINAL OF SIALOADHESIN IN COMPLEX WITH 2-PHENYL-PROP5AC
2C1PA:109-213; L:2-108; A:1-108; B:114-215; H:114-214; B:2-113; H:2-113; L:109-213FAB-FRAGMENT OF ENANTIOSELECTIVE ANTIBODY COMPLEXED WITH FINROZOLE
2CIIB:1-99; A:182-272THE CRYSTAL STRUCTURE OF H-2DB COMPLEXED WITH A PARTIAL PEPTIDE EPITOPE SUGGESTS AN MHC CLASS I ASSEMBLY-INTERMEDIATE
2CJUL:1-107; H:1-113CRYSTAL STRUCTURE OF THE TEPC15-VK45.1 ANTI-2-PHENYL-5-OXAZOLONE NQ16-113.8 SCFV IN COMPLEX WITH PHOXGABA
2CLVB:1-99; A:182-274; H:182-274; P:1-99MHC CLASS I NATURAL MUTANT H-2KBM8 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND PBM8 PEPTIDE
2CLZB:1-99; A:182-274; H:182-274; P:1-99MHC CLASS I NATURAL MUTANT H-2KBM8 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND PBM1 PEPTIDE
2FATL:108-210; H:1-114; L:1-107; H:115-209AN ANTI-UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR) ANTIBODY: CRYSTAL STRUCTURE AND BINDING EPITOPE
2JK5B:109-211; A:119-217; A:1-118POTASSIUM CHANNEL KCSA IN COMPLEX WITH TETRABUTYLAMMONIUM IN HIGH K
2R1WA:108-210; B:112-210; A:1-107; B:1-111CRYSTAL STRUCTURE OF S25-2 FAB IN COMPLEX WITH KDO ANALOGUES
2R1XA:108-210; B:112-210; A:1-107; B:1-111CRYSTAL STRUCTURE OF S25-2 FAB IN COMPLEX WITH KDO ANALOGUES
2R1YA:108-210; B:112-210; A:1-107; B:1-111CRYSTAL STRUCTURE OF S25-2 FAB IN COMPLEX WITH KDO ANALOGUES
2R23A:108-210; B:112-210; A:1-107; B:1-111CRYSTAL STRUCTURE OF S25-2 FAB IN COMPLEX WITH KDO ANALOGUES
2R2BA:108-210; B:112-210; A:1-107; B:1-111CRYSTAL STRUCTURE OF S25-2 FAB IN COMPLEX WITH KDO ANALOGUES
2R2EA:108-210; B:112-210; A:1-107; B:1-111CRYSTAL STRUCTURE OF S25-2 FAB IN COMPLEX WITH KDO ANALOGUES
2R2HA:108-210; B:112-210; A:1-107; B:1-111STRUCTURE OF S25-2 IN COMPLEX WITH KO
2RGSA:338-442; B:338-443; A:238-337; B:238-337FC-FRAGMENT OF MONOCLONAL ANTIBODY IGG2B FROM MUS MUSCULUS
2UUDK:1-107; L:1-107; H:1-113; J:1-113CRYSTAL STRUCTURE OF THE TEPC15-VK45.1 ANTI-2-PHENYL-5-OXAZOLONE NQ10-1.12 SCFV IN COMPLEX WITH THE HAPTEN
2UYLA:115-214; M:115-214; V:115-214; X:115-214; A:1-113; M:1-113; V:1-113; X:1-113; B:120-218; N:120-218; W:120-218; Y:120-218; B:1-119; N:1-119; W:1-119; Y:1-119CRYSTAL STRUCTURE OF A MONOCLONAL ANTIBODY DIRECTED AGAINST AN ANTIGENIC DETERMINANT COMMON TO OGAWA AND INABA SEROTYPES OF VIBRIO CHOLERAE O1
2V2TA:278-372; B:246-350X-RAY STRUCTURE OF A NF-KB P50-RELB-DNA COMPLEX
2V7HA:108-211; L:108-211; B:1-121; H:1-121; A:1-107; L:1-107; H:122-220; B:122-220CRYSTAL STRUCTURE OF AN IMMUNOGEN SPECIFIC ANTI-MANNOPYRANOSIDE MONOCLONAL ANTIBODY FAB FRAGMENT
2VE6B:1-99; A:182-272; D:182-272; G:182-272; J:182-272; E:1-99; H:1-99; K:1-99CRYSTAL STRUCTURE OF A MURINE MHC CLASS I H2-DB MOLECULE IN COMPLEX WITH A PHOTOCLEAVABLE PEPTIDE
2VL5B:113-217; B:1-112; D:1-112; A:120-218; C:120-218; A:1-119; C:1-119; D:113-216STRUCTURE OF ANTI-COLLAGEN TYPE II FAB CIIC1
2VOL  [entry was replaced by entry 3ZO0 without any CATH domain information]
2VQ1A:109-212; E:109-212; B:114-213; F:114-213; B:1-113; F:1-113ANTI TRIMERIC LEWIS X FAB54-5C10-A
2VXTL:109-211; H:114-212; H:1-113CRYSTAL STRUCTURE OF HUMAN IL-18 COMPLEXED TO MURINE REFERENCE ANTIBODY 125-2H FAB
2VXUL:109-211; M:109-211; H:114-212; I:114-212; H:1-113; I:1-113CRYSTAL STRUCTURE OF MURINE REFERENCE ANTIBODY 125-2H FAB FRAGMENT
2W0FB:109-211; A:119-217; A:1-118POTASSIUM CHANNEL KCSA-FAB COMPLEX WITH TETRAOCTYLAMMONIUM
2W60B:114-217; A:119-215; A:1-118ANTI CITRULLINATED COLLAGEN TYPE 2 ANTIBODY ACC4
2W65B:114-217; D:114-217; A:119-215; C:119-215; A:1-118; C:1-118ANTI CITRULLINATED COLLAGEN TYPE 2 ANTIBODY ACC4 IN COMPLEX WITH A CITRULLINATED PEPTIDE
2Z91B:109-211; D:109-211; B:1-108; D:1-108; A:114-212; C:114-212; A:3-113; C:3-113CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ANTI-CIGUATOXIN ANTIBODY 10C9
2Z92B:109-211; B:1-108; A:114-212; A:3-113CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ANTI-CIGUATOXIN ANTIBODY 10C9 IN COMPLEX WITH CTX3C_ABCDE
2Z93D:109-205; D:1-108; C:114-213; C:3-113CRYSTAL STRUCTURE OF FAB FRAGMENT OF ANTI-CIGUATOXIN ANTIBODY 10C9 IN COMPLEX WITH CTX3C-ABCD
2ZOKB:1-99; D:1-99; F:1-99; H:1-99; C:182-275; G:182-274; E:182-276; A:182-276CRYSTAL STRUCTURE OF H-2DB IN COMPLEX WITH JHMV EPITOPE S510
2ZOLB:2-99; A:182-274; C:182-274; D:2-99CRYSTAL STRUCTURE OF H-2DB IN COMPLEX WITH THE W513S VARIANT OF JHMV EPITOPE S510
2ZPKI:114-210; H:114-210; L:2-108; M:2-109; H:2-113; I:2-113; L:109-210; M:110-208CRYSTAL STRUCTURE OF P20.1 FAB FRAGMENT IN COMPLEX WITH ITS ANTIGEN PEPTIDE
2ZSVB:1-99; A:182-274; C:182-274; D:1-99CRYSTAL STRUCTURE OF H-2KB IN COMPLEX WITH JHMV EPITOPE S598
2ZSWB:2-99; A:182-274; C:182-274; E:182-274; G:182-274; D:2-99; F:2-99; H:2-99CRYSTAL STRUCTURE OF H-2KB IN COMPLEX WITH THE Q600Y VARIANT OF JHMV EPITOPE S598
3BP5A:1-114CRYSTAL STRUCTURE OF THE MOUSE PD-1 AND PD-L2 COMPLEX
3BP6A:1-112CRYSTAL STRUCTURE OF THE MOUSE PD-1 MUTANT AND PD-L2 COMPLEX
3BPCA:108-210; B:112-210; A:1-107; B:1-111CO-CRYSTAL STRUCTURE OF S25-2 FAB IN COMPLEX WITH 5-DEOXY-4-EPI-2,3-DEHYDRO KDO (4.8) KDO
3BYTA:2-110; C:2-117; E:2-117; G:2-117A COMPLEX BETWEEN A VARIANT OF STAPHYLOCOCCAL ENTEROTOXIN C3 AND THE VARIABLE DOMAIN OF THE MURINE T CELL RECEPTOR BETA CHAIN 8.2
3BYYA:2-117MANIPULATING THE COUPLED FOLDING AND BINDING PROCESS DRIVES AFFINITY MATURATION IN A PROTEIN-PROTEIN COMPLEX
3BZ4C:109-213; B:114-215; D:114-215; F:114-215; H:114-215; A:1-108; C:1-108; E:1-108; G:1-108; B:1-113; D:1-113; F:1-113; H:1-113; A:109-211; E:109-211; G:109-211CRYSTAL STRUCTURE OF FAB F22-4 IN COMPLEX WITH A SHIGELLA FLEXNERI 2A O-AG DECASACCHARIDE
3C5SA:109-213; B:114-215; D:114-215; A:1-108; C:1-108; B:1-113; D:1-113; C:109-212CRYSTAL STRUCTURE OF MONOCLONAL FAB F22-4 SPECIFIC FOR SHIGELLA FLEXNERI 2A O-AG
3C6SC:109-213; B:114-215; D:114-215; F:114-215; H:114-215; A:1-108; C:1-108; E:1-108; G:1-108; B:1-113; D:1-113; F:1-113; H:1-113; A:109-211; E:109-211; G:109-211CRYSTAL STRUCTURE OF FAB F22-4 IN COMPLEX WITH A SHIGELLA FLEXNERI 2A O-AG PENTADECASACCHARIDE
3CC5B:1-99; E:1-99; A:182-272; D:182-272H-2DB COMPLEX WITH HUMAN GP100
3CCHB:1-99; A:182-272; D:182-272; G:182-272; J:182-272; E:1-99; H:1-99; K:1-99H-2DB COMPLEX WITH MURINE GP100
3CH1B:1-99; E:1-99; H:1-99; A:182-272; D:182-272; K:1-99; G:182-272; J:182-272CRYSTAL STRUCTURE OF H-2DB IN COMPLEX WITH CHIMERIC GP100
3CPLB:1-99; A:182-272; C:182-272; D:1-99CRYSTAL STRUCTURE OF H-2DB IN COMPLEX WITH A VARIANT M6A OF THE NP366 PEPTIDE FROM INFLUENZA A VIRUS
3CUPA:82-181; B:94-188CRYSTAL STRUCTURE OF THE MHC CLASS II MOLECULE I-AG7 IN COMPLEX WITH THE PEPTIDE GAD221-235
3CVHB:1-99; L:108-209; R:108-209; L:1-107; R:1-107; A:182-272; M:182-272; H:121-219; Q:121-219; N:1-99; H:1-120; Q:1-120HOW TCR-LIKE ANTIBODY RECOGNIZES MHC-BOUND PEPTIDE
3CVIL:108-209; L:1-107; H:121-219; H:1-120HOW TCR-LIKE ANTIBODY RECOGNIZES MHC-BOUND PEPTIDE
3CXDL:109-211; L:1-108; H:117-214; H:1-116CRYSTAL STRUCTURE OF ANTI-OSTEOPONTIN ANTIBODY 23C3 IN COMPLEX WITH ITS EPITOPE PEPTIDE
3D69B:114-214; H:114-214; B:1-113; H:1-113CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF AN ANTI-FACTOR IX ANTIBODY 10C12
3DO7A:279-383; B:225-322X-RAY STRUCTURE OF A NF-KB P52/RELB/DNA COMPLEX
3DSFL:109-211; L:1-108; H:117-214; H:1-116CRYSTAL STRUCTURE OF ANTI-OSTEOPONTIN ANTIBODY 23C3 IN COMPLEX WITH W43A MUTATED EPITOPE PEPTIDE
3DURA:1-106; C:1-106; B:1-111; D:1-111CRYSTAL STRUCTURE OF SAG173-04
3DUSA:1-106; C:1-106; B:1-113; D:1-113CRYSTAL STRUCTURE OF SAG506-01, ORTHORHOMBIC, TWINNED, CRYSTAL 1
3DUUA:1-106; C:1-106; B:1-113; D:1-113CRYSTAL STRUCTURE OF SAG506-01, ORTHORHOMBIC, TWINNED, CRYSTAL 2
3DV4A:1-106; B:1-113CRYSTAL STRUCTURE OF SAG506-01, TETRAGONAL, CRYSTAL 1
3DV6A:1-106; B:1-113CRYSTAL STRUCTURE OF SAG506-01, TETRAGONAL, CRYSTAL 2
3E2HC:2-118; B:2-115STRUCTURE OF THE M67 HIGH-AFFINITY MUTANT OF THE 2C TCR IN COMPLEX WITH LD/QL9
3E3QE:1-118; F:1-118; J:1-118; N:1-118; S:1-118; W:1-118; a:1-118; e:1-118; C:2-115; D:2-115; I:2-115; M:2-115; R:2-115; V:2-115; Z:2-115; d:2-115STRUCTURE OF THE 3ALPHAM13 HIGH-AFFINITY MUTANT OF THE 2C TCR IN COMPLEX WITH LD/QL9
3E6FB:1-99; A:182-272MHC CLASS I H-2DD HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND A VARIANT PEPTIDE, PA9, FROM THE HUMAN IMMUNODEFICIENCY VIRUS (BAL) ENVELOPE GLYCOPROTEIN 120
3E6HB:1-99; A:182-272MHC CLASS I H-2DD HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND A VARIANT PEPTIDE, PI10, FROM THE HUMAN IMMUNODEFICIENCY VIRUS (BAL) ENVELOPE GLYCOPROTEIN 120
3ECBB:1-99; A:182-272CRYSTAL STRUCTURE OF MOUSE H-2DD IN COMPLEX WITH PEPTIDE P18-I10 DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEIN 120
3EOTL:110-214; H:119-216; H:1-118CRYSTAL STRUCTURE OF LAC031, AN ENGINEERED ANTI-VLA1 FAB
3ESUF:1004-1103CRYSTAL STRUCTURE OF ANTHRAX-NEUTRALIZING SINGLE-CHAIN ANTIBODY 14B7
3ESVF:1004-1103; G:1004-1103CRYSTAL STRUCTURE OF THE ENGINEERED NEUTRALIZING ANTIBODY M18
3ET9F:1004-1103CRYSTAL STRUCTURE OF THE ENGINEERED NEUTRALIZING ANTIBODY 1H
3ETBF:1004-1103; G:1004-1103; H:1004-1103; I:1004-1103CRYSTAL STRUCTURE OF THE ENGINEERED NEUTRALIZING ANTIBODY M18 COMPLEXED WITH ANTHRAX PROTECTIVE ANTIGEN DOMAIN 4
3EYSH:124-222; H:1-123PFA1 FAB FRAGMENT COMPLEXED WITH PYRO-GLU3-A-BETA (3-8)
3EYUH:124-226; H:1-123PFA1 FAB FRAGMENT COMPLEXED WITH ROR2(518-525)
3FFDA:119-217; A:1-118STRUCTURE OF PARATHYROID HORMONE-RELATED PROTEIN COMPLEXED TO A NEUTRALIZING MONOCLONAL ANTIBODY
3FO9A:109-214; B:114-227; H:114-227; B:1-113; H:1-113; L:109-214CRYSTAL STRUCTURE OF ALDOLASE ANTIBODY 33F12 FAB' IN COMPLEX WITH HAPTEN 1,3-DIKETONE
3FOLB:0-99; A:182-272CRYSTAL STRUCTURE OF THE CLASS I MHC MOLECULE H-2KWM7 WITH A SINGLE SELF PEPTIDE VNDIFERI
3FOMB:0-99; A:182-272CRYSTAL STRUCTURE OF THE CLASS I MHC MOLECULE H-2KWM7 WITH A SINGLE SELF PEPTIDE IQQSIERL
3FONB:0-99; D:0-99; A:182-272; C:182-272CRYSTAL STRUCTURE OF THE CLASS I MHC MOLECULE H-2KWM7 WITH A SINGLE SELF PEPTIDE VNDIFEAI
3FTGB:0-99; A:182-272CRYSTAL STRUCTURE OF H2DB IN COMPLEX WITH NP366-N3A VARIANT PEPTIDE FROM INFLUENZA
3G08B:2-98; A:185-279CRYSTAL STRUCTURE OF THE ALPHA-GALACTOSYLCERAMIDE ANALOG OCH IN COMPLEX WITH MOUSE CD1D
3G5VA:108-211; B:117-213; B:1-116ANTIBODIES SPECIFICALLY TARGETING A LOCALLY MISFOLDED REGION OF TUMOR ASSOCIATED EGFR
3G5XA:108-211; C:108-211; B:115-213; D:115-213; B:1-114; D:1-114ANTIBODIES SPECIFICALLY TARGETING A LOCALLY MISFOLDED REGION OF TUMOR ASSOCIATED EGFR
3G5YA:108-211; B:117-215; B:1-116ANTIBODIES SPECIFICALLY TARGETING A LOCALLY MISFOLDED REGION OF TUMOR ASSOCIATED EGFR
3G5ZA:108-211; B:117-215; B:1-116ANTIBODIES SPECIFICALLY TARGETING A LOCALLY MISFOLDED REGION OF TUMOR ASSOCIATED EGFR
3GGWA:109-213; D:114-215; B:114-214; B:1-113; D:1-113; C:109-214CRYSTAL STRUCTURE OF FAB F22-4 IN COMPLEX WITH A CARBOHYDRATE-MIMETIC PEPTIDE
3GK8L:109-211; H:1-120; H:121-220X-RAY CRYSTAL STRUCTURE OF THE FAB FROM MAB 14, MOUSE ANTIBODY AGAINST CANINE PARVOVIRUS
3GKZA:9-138CRYSTAL STRUCTURES OF A THERAPEUTIC SINGLE CHAIN ANTIBODY IN COMPLEX METHAMPHETAMINE
3GM0A:9-138ANTI-METHAMPHETAMINE SINGLE CHAIN FV IN COMPLEX WITH MDMA
3GMLB:1-99; A:185-281STRUCTURE OF MOUSE CD1D IN COMPLEX WITH C6PH
3GMMB:1-99; A:185-281STRUCTURE OF MOUSE CD1D IN COMPLEX WITH C8PH
3GMNB:1-99; A:185-281STRUCTURE OF MOUSE CD1D IN COMPLEX WITH C10PH
3GMOB:1-99; A:185-281STRUCTURE OF MOUSE CD1D IN COMPLEX WITH C8PHF
3GMPB:1-99; A:185-281STRUCTURE OF MOUSE CD1D IN COMPLEX WITH PBS-25
3GMQB:1-99; A:185-281STRUCTURE OF MOUSE CD1D EXPRESSED IN SF9 CELLS, NO LIGAND ADDED
3GMRB:1-99; A:185-279STRUCTURE OF MOUSE CD1D IN COMPLEX WITH C8PH, DIFFERENT SPACE GROUP
3GNMH:1-118; H:119-218THE CRYSTAL STRUCTURE OF THE JAA-F11 MONOCLONAL ANTIBODY FAB FRAGMENT
3HE6B:1-99; C:1-116; A:185-280CRYSTAL STRUCTURE OF MOUSE CD1D-ALPHA-GALACTOSYLCERAMIDE WITH MOUSE VALPHA14-VBETA8.2 NKT TCR
3HE7B:2-99; C:1-116; A:185-280CRYSTAL STRUCTURE OF MOUSE CD1D-ALPHA-GALACTOSYLCERAMIDE WITH MOUSE VALPHA14-VBETA7 NKT TCR
3HKFA:341-445; A:241-340MURINE UNGLYCOSYLATED IGG FC FRAGMENT
3HNSL:108-211; H:1-118; H:119-220CS-35 FAB COMPLEX WITH OLIGOARABINOFURANOSYL HEXASACCHARIDE
3HNTL:108-211; H:1-118; H:119-220CS-35 FAB COMPLEX WITH A LINEAR, TERMINAL OLIGOARABINOFURANOSYL TETRASACCHARIDE FROM LIPOARABINOMANNAN
3HNVL:108-211; H:1-118; H:119-220CS-35 FAB COMPLEX WITH OLIGOARABINOFURANOSYL TETRASACCHARIDE (BRANCH PART OF HEXASACCHARIDE)
3HZKA:108-210; B:114-211; B:1-113CRYSTAL STRUCTURE OF S73-2 ANTIBODY IN COMPLEX WITH ANTIGEN KDO(2.4)KDO
3HZMA:108-210; B:114-211; B:1-113CRYSTAL STRUCTURE OF S73-2 ANTIBODY IN COMPLEX WITH ANTIGEN KDO
3HZVA:108-210; B:114-211; B:1-113CRYSTAL STRUCTURE OF S73-2 ANTIBODY IN COMPLEX WITH ANTIGEN KDO(2.8) KDO(2.4)KDO
3HZYA:108-210; B:114-211; B:1-113CRYSTAL STRUCTURE OF S73-2 ANTIBODY IN COMPLEX WITH ANTIGEN KDO(2.4)KDO(2.4)KDO
3I02A:108-213; C:108-207; B:114-212; D:114-212; B:1-113; D:1-113CRYSTAL STRUCTURE OF S54-10 ANTIBODY IN COMPLEX WITH ANTIGEN KDO(2.4)KDO(2.4)KDO
3I2CL:112-215; H:121-218; H:1-120CRYSTAL STRUCTURE OF ANTI-IL-23 ANTIBODY CNTO4088
3IFLH:1-120X-RAY STRUCTURE OF AMYLOID BETA PEPTIDE:ANTIBODY (ABETA1-7:12A11) COMPLEX
3IFNH:1-120X-RAY STRUCTURE OF AMYLOID BETA PEPTIDE:ANTIBODY (ABETA1-40:12A11) COMPLEX
3IFOA:1-123; H:1-123X-RAY STRUCTURE OF AMYLOID BETA PEPTIDE:ANTIBODY (ABETA1-7:10D5) COMPLEX
3IFPA:2-123; C:2-123; E:2-123; H:2-123X-RAY STRUCTURE OF AMYLOID BETA PEPTIDE:ANTIBODY (ABETA1-7:12B4) COMPLEX
3IGAB:109-211; A:119-217; A:1-118POTASSIUM CHANNEL KCSA-FAB COMPLEX IN LI+ AND K+
3IJHA:108-210; C:108-210; B:114-213; D:114-213; B:1-113; D:1-113STRUCTURE OF S67-27 IN COMPLEX WITH KO
3IJSA:108-210; C:108-210; B:114-213; D:114-213; B:1-113; D:1-113STRUCTURE OF S67-27 IN COMPLEX WITH TSBP
3IJYC:108-210; A:108-210; B:114-213; D:114-213; B:1-113; D:1-113STRUCTURE OF S67-27 IN COMPLEX WITH KDO(2.8)KDO
3IKCA:108-210; C:108-210; B:114-213; D:114-213; B:1-113; D:1-113STRUCTURE OF S67-27 IN COMPLEX WITH KDO(2.8)-7-O-METHYL-KDO
3ILPB:1-99; A:185-279STRUCTURE OF MCD1D WITH BOUND GLYCOLIPID BBGL-2F FROM BORRELIA BURGDORFERI
3ILQD:2-99; C:185-279STRUCTURE OF MCD1D WITH BOUND GLYCOLIPID BBGL-2C FROM BORRELIA BURGDORFERI
3IXTL:109-212; B:109-211; H:114-212; A:114-212; A:1-113; H:1-113CRYSTAL STRUCTURE OF MOTAVIZUMAB FAB BOUND TO PEPTIDE EPITOPE
3JXAA:120-221; B:120-221; B:22-119; A:22-119; A:222-313; B:222-313IMMUNOGLOBULIN DOMAINS 1-4 OF MOUSE CNTN4
3KLDA:120-221; A:23-119; A:222-313PTPRG CNTN4 COMPLEX
3KS0H:118-213; K:118-213; H:1-117; K:1-117CRYSTAL STRUCTURE OF THE HEME DOMAIN OF FLAVOCYTOCHROME B2 IN COMPLEX WITH FAB B2B4
3L1OL:109-211; H:124-227; H:1-123CRYSTAL STRUCTURE OF MONOCLONAL ANTIBODY MN423 FAB FRAGMENT WITH FREE COMBINING SITE, CRYSTALLIZED IN THE PRESENCE OF ZINC
3L3HB:1-99; A:182-272X-RAY CRYSTAL STRUCTURE OF THE F6A MUTANT OF INFLUENZA A ACID POLYMERASE EPITOPE PA224 BOUND TO MURINE H2-DB MHC
(-)
Mouse, human (Mus musculus, homo sapiens) (6)
1UWGL:109-213; X:109-213; L:1-108; X:1-108; H:114-215; Y:114-215; H:3-113; Y:3-113MOLECULAR MECHANISM OF ENANTIOSELECTIVE PROTON TRANSFER TO CARBON IN CATALYTIC ANTIBODY 14D9
3CFJA:109-213; L:109-213; B:114-228; D:114-228; F:114-228; H:114-228; A:1-108; C:1-108; E:1-108; L:1-108; B:1-113; D:1-113; F:1-113; H:1-113; C:109-213; E:109-213CRYSTAL STRUCTURE OF CATALYTIC ELIMINATION ANTIBODY 34E4, ORTHORHOMBIC CRYSTAL FORM
3EYVA:114-219; B:120-222; H:120-219; B:1-119; H:1-119; L:114-216ANTI-LEWIS Y FAB FRAGMENT WITH LEWIS Y ANTIGEN IN THE PRESENCE OF ZINC IONS
3FO0L:114-216; H:124-221; H:1-120CRYSTAL STRUCTURE OF HAPTEN COMPLEX OF CATALYTIC ELIMINATION ANTIBODY 13G5 (WILD-TYPE)
3FO1A:114-216; H:124-221; B:124-221; L:114-216; B:1-120; H:1-120CRYSTAL STRUCTURE OF HAPTEN COMPLEX OF CATALYTIC ELIMINATION ANTIBODY 13G5 (GLU(L39)ALA MUTANT)
3FO2A:114-216; L:114-216; B:124-221; H:124-221; B:1-120; H:1-120CRYSTAL STRUCTURE OF HAPTEN COMPLEX OF CATALYTIC ELIMINATION ANTIBODY 13G5 (GLU(L39)GLN MUTANT)
(-)
Murine cytomegalovirus (Murid herpesvirus 1) (2)
1PQZB:1-99; A:142-242MURINE CYTOMEGALOVIRUS IMMUNOMODULATORY PROTEIN M144
1U58B:1-98; A:143-242CRYSTAL STRUCTURE OF THE MURINE CYTOMEGALOVIRUS MHC-I HOMOLOG M144
(-)
Mus musculus (Yes) (2)
1XF2A:109-213; B:1-113; H:1-113; L:109-213; A:1-108; L:1-108; B:114-212; H:114-212STRUCTURE OF FAB DNA-1 COMPLEXED WITH DT3
2OK0L:110-209; H:1-114; H:115-228; L:1-108FAB ED10-DNA COMPLEX
(-)
Mus musculus, homo sapiens. Organism_taxid: 10090, 9606. (1)
1UWEL:109-212; U:109-212; V:4-113; Y:4-113; X:109-212; L:1A-108; U:1A-108; X:1A-108; H:114-214; V:114-212; Y:114-212; H:4-113MOLECULAR MECHANISM OF ENANTIOSELECTIVE PROTON TRANSFER TO CARBON IN CATALYTIC ANTIBODY 14D9
(-)
Mus musculus, homo sapiens. Organism_taxid: 10090, 9606. Strain: balb/c. (1)
3IU4L:109-213; H:116-213; H:2-112ANTI NEUGCGM3 GANGLIOSIDE CHIMERIC ANTIBODY CHP3
(-)
Mus musculus, homo sapiens. Organism_taxid: 10090,9606. (1)
3L5WA:109-213; L:109-213; B:122-220; H:122-220; B:1-121; H:1-121CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN IL-13 AND C836 FAB
(-)
Mus musculus. Organism_taxid: 10090 (2)
1H8OB:4-111; A:4-132; A:133-235; B:133-231THREE-DIMENSIONAL STRUCTURE OF ANTI-AMPICILLIN SINGLE CHAIN FV FRAGMENT.
1H8SB:4-111; A:4-132; A:133-231; B:133-231THREE-DIMENSIONAL STRUCTURE OF ANTI-AMPICILLIN SINGLE CHAIN FV FRAGMENT COMPLEXED WITH THE HAPTEN.
(-)
Mus musculus. Organism_taxid: 10090. (1)
2W9DL:108-210; H:117-215; H:1-116STRUCTURE OF FAB FRAGMENT OF THE ICSM 18 - ANTI-PRP THERAPEUTIC ANTIBODY AT 1.57 A RESOLUTION.
(-)
Mus musculus. Organism_taxid: 10090. (3)
3DMMB:0-99; A:182-272; C:4-121CRYSTAL STRUCTURE OF THE CD8 ALPHA BETA/H-2DD COMPLEX
3FMGL:109-211; H:1-123; H:124-237STRUCTURE OF ROTAVIRUS OUTER CAPSID PROTEIN VP7 TRIMER IN COMPLEX WITH A NEUTRALIZING FAB
3I9GL:108-211; H:114-214; H:1-113CRYSTAL STRUCTURE OF THE LT1009 (SONEPCIZUMAB) ANTIBODY FAB FRAGMENT IN COMPLEX WITH SPHINGOSINE-1-PHOSPHATE
(-)
Mus musculus. Organism_taxid: 10090. (7)
1H8NA:4-134; A:135-233THREE-DIMENSIONAL STRUCTURE OF ANTI-AMPICILLIN SINGLE CHAIN FV FRAGMENT FROM PHAGE-DISPLAYED MURINE ANTIBODY LIBRARIES
2C1OA:109-212; L:109-212; A:1-108; L:1-108; B:114-213; H:114-213; B:1-113; H:1-113ENAIIHIS FAB FRAGMENT IN THE FREE FORM
3BZDA:2-117MANIPULATING THE COUPLED FOLDING AND BINDING PROCESS DRIVES AFFINITY MATURATION IN A PROTEIN-PROTEIN COMPLEX
3EO0A:110-213; A:1-109; C:1-109; C:110-213; B:121-220; D:121-220; B:1-120; D:1-120STRUCTURE OF THE TRANSFORMING GROWTH FACTOR-BETA NEUTRALIZING ANTIBODY GC-1008
3EO1A:110-213; G:110-213; J:110-213; A:1-109; D:1-109; G:1-109; J:1-109; B:121-220; E:121-220; H:121-220; K:121-220; B:1-120; E:1-120; H:1-120; K:1-120; D:110-213STRUCTURE OF THE FAB FRAGMENT OF GC-1008 IN COMPLEX WITH TRANSFORMING GROWTH FACTOR-BETA 3
3HR5A:114-219; B:118-220; H:118-220; I:118-220; J:118-220; B:1-117; H:1-117; I:1-117; L:114-219; J:1-117; P:114-219; Q:114-219M1PRIME PEPTIDE FROM IGE BOUND BY HUMANIZED ANTIBODY 47H4 FAB
3IVKB:110-213; L:110-213; A:126-225; H:126-225; A:3-125; H:3-125CRYSTAL STRUCTURE OF THE CATALYTIC CORE OF AN RNA POLYMERASE RIBOZYME COMPLEXED WITH AN ANTIGEN BINDING ANTIBODY FRAGMENT
(-)
Mus musculus. Organism_taxid: 10090. Mus musculus. Organism_taxid: 10090. (10)
3E8UL:109-212; H:114-213; H:1-113CRYSTAL STRUCTURE AND THERMODYNAMIC ANALYSIS OF DIAGNOSTIC FAB 106.3 COMPLEXED WITH BNP 5-13 (C10A) REVEAL BASIS OF SELECTIVE MOLECULAR RECOGNITION
3EFDL:109-211; H:123-225; H:1-122THE CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF KCSA
3EFFA:111-215; B:125-223; D:125-223; B:1-124; D:1-124; C:111-215THE CRYSTAL STRUCTURE OF FULL-LENGTH KCSA IN ITS CLOSED CONFORMATION
3F5WB:109-211; A:119-217; A:1-118KCSA POTASSIUM CHANNEL IN THE OPEN-INACTIVATED STATE WITH 32 A OPENING AT T112
3F7VB:109-211; A:119-217; A:1-118KCSA POTASSIUM CHANNEL IN THE OPEN-INACTIVATED STATE WITH 23 A OPENING AT T112
3F7YB:109-211; A:119-217; A:1-118KCSA POTASSIUM CHANNEL IN THE PARTIALLY OPEN STATE WITH 17 A OPENING AT T112
3FB5B:109-211; A:119-217; A:1-118KCSA POTASSIUM CHANNEL IN THE PARTIALLY OPEN STATE WITH 14.5 A OPENING AT T112
3FB6B:109-211; A:119-217; A:1-118KCSA POTASSIUM CHANNEL IN THE PARTIALLY OPEN STATE WITH 16 A OPENING AT T112
3FB8B:109-211; A:119-217; A:1-118KCSA POTASSIUM CHANNEL IN THE OPEN-CONDUCTIVE STATE WITH 20 A OPENING AT T112 IN THE PRESENCE OF RB+ ION
3GB7B:109-211; A:119-217; A:1-118POTASSIUM CHANNEL KCSA-FAB COMPLEX IN LI+
(-)
Mus musculus. Organism_taxid: 10090. Strain: murine hybridoma. (1)
3GI9H:1-124; H:125-220CRYSTAL STRUCTURE OF APCT TRANSPORTER BOUND TO 7F11 MONOCLONAL FAB FRAGMENT
(-)
Mus musculus. Strain: hybridoma. (1)
3CMOL:108-211; X:108-211; H:1-113; Y:1-113; X:2-107; L:1-107; H:114-222; Y:114-222HIV NEUTRALIZING MONOCLONAL ANTIBODY YZ18
(-)
Norway rat (Rattus norvegicus) (32)
1A64A:4-99; B:4-99ENGINEERING A MISFOLDED FORM OF RAT CD2
1A6PA:4-99; B:4-99ENGINEERING OF A MISFOLDED FORM OF CD2
1A7BA:5-99; B:5-99; C:5-99; D:5-99ENGINEERING A MISFOLDED FORM OF CD2
1C5DA:108-210; L:108-210; A:1-107; L:1-107; B:118-214; H:118-214; B:1-117; H:1-117THE CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF A RAT MONOCLONAL ANTIBODY AGAINST THE MAIN IMMUNOGENIC REGION OF THE HUMAN MUSCLE ACETYLCHOLINE RECEPTOR
1CDCA:4-99; B:4-99CD2, N-TERMINAL DOMAIN (1-99), TRUNCATED FORM
1CIDA:1-106; A:107-177CRYSTAL STRUCTURE OF DOMAINS 3 & 4 OF RAT CD4 AND THEIR RELATIONSHIP TO THE NH2-TERMINAL DOMAINS
1ED3B:1-99; A:182-272; D:182-272; E:1-99CRYSTAL STRUCTURE OF RAT MINOR HISTOCOMPATIBILITY ANTIGEN COMPLEX RT1-AA/MTF-E.
1EPFA:1-96; B:1-96; C:1-96; D:1-96; A:97-189; B:97-189; C:97-189; D:97-189CRYSTAL STRUCTURE OF THE TWO N-TERMINAL IMMUNOGLOBULIN DOMAINS OF THE NEURAL CELL ADHESION MOLECULE (NCAM)
1FN4A:108-208; C:108-208; A:1-107; C:1-107; B:107-205; D:107-205; B:1-106; D:1-106CRYSTAL STRUCTURE OF FAB198, AN EFFICIENT PROTECTOR OF ACETYLCHOLINE RECEPTOR AGAINST MYASTHENOGENIC ANTIBODIES
1I1AB:1-99; A:178-269; D:338-443; C:338-443; D:239-337; C:239-337CRYSTAL STRUCTURE OF THE NEONATAL FC RECEPTOR COMPLEXED WITH A HETERODIMERIC FC
1I1CA:338-443; B:338-443; A:239-337; B:239-337NON-FCRN BINDING FC FRAGMENT OF RAT IGG2A
1KJMB:1-99; A:182-272TAP-A-ASSOCIATED RAT MHC CLASS I MOLECULE
1KJVB:0-99; A:182-272TAP-B-ASSOCIATED RAT MHC CLASS I MOLECULE
1LWRA:1-96SOLUTION STRUCTURE OF THE NCAM FIBRONECTIN TYPE III MODULE 2
1MHPL:108-210; Y:2-106; L:2-107; H:119-218; H:1-118; X:1-118CRYSTAL STRUCTURE OF A CHIMERIC ALPHA1 INTEGRIN I-DOMAIN IN COMPLEX WITH THE FAB FRAGMENT OF A HUMANIZED NEUTRALIZING ANTIBODY
1NEUA:1-119STRUCTURE OF MYELIN MEMBRANE ADHESION MOLECULE P0
1PKOA:1-126MYELIN OLIGODENDROCYTE GLYCOPROTEIN (MOG)
1QZ1A:-1-96; A:97-192; A:193-289CRYSTAL STRUCTURE OF THE IG 1-2-3 FRAGMENT OF NCAM
1T6WA:1-99RATIONAL DESIGN OF A CALCIUM-BINDING ADHESION PROTEIN NMR, 20 STRUCTURES
1TDQA:1-94; A:95-184; A:185-271STRUCTURAL BASIS FOR THE INTERACTIONS BETWEEN TENASCINS AND THE C-TYPE LECTIN DOMAINS FROM LECTICANS: EVIDENCE FOR A CROSS-LINKING ROLE FOR TENASCINS
1ZANL:110-212; L:1-109; H:114-212; H:1-113CRYSTAL STRUCTURE OF ANTI-NGF AD11 FAB
2APBA:1-117CRYSTAL STRUCTURE OF THE S54N VARIANT OF MURINE T CELL RECEPTOR VBETA 8.2 DOMAIN
2APFA:-1-117CRYSTAL STRUCTURE OF THE A52V/S54N/K66E VARIANT OF THE MURINE T CELL RECEPTOR V BETA 8.2 DOMAIN
2APTA:2-117; B:2-117CRYSTAL STRUCTURE OF THE G17E/S54N/K66E/Q72H/E80V/L81S/T87S/G96V VARIANT OF THE MURINE T CELL RECEPTOR V BETA 8.2 DOMAIN
2APVA:2-117CRYSTAL STRUCTURE OF THE G17E/A52V/S54N/Q72H/E80V/L81S/T87S/G96V VARIANT OF THE MURINE T CELL RECEPTOR V BETA 8.2 DOMAIN
2APWA:2-117CRYSTAL STRUCTURE OF THE G17E/A52V/S54N/K66E/E80V/L81S/T87S/G96V VARIANT OF THE MURINE T CELL RECEPTOR V BETA 8.2 DOMAIN
2APXA:2-117CRYSTAL STRUCTURE OF THE G17E/A52V/S54N/K66E/Q72H/E80V/L81S/T87S/G96V VARIANT OF THE MURINE T CELL RECEPTOR V BETA 8.2 DOMAIN
2ARJA:109-211; L:109-211; A:1-108; L:1-108; B:114-227; H:114-227; B:1-113; H:1-113; Q:4-122; R:4-123CD8ALPHA-ALPHA IN COMPLEX WITH YTS 105.18 FAB
2B2XL:113-215; L:1-107; M:1-107; H:119-216; I:119-216; H:1-118; I:1-118; M:113-215VLA1 RDELTAH I-DOMAIN COMPLEXED WITH A QUADRUPLE MUTANT OF THE AQC2 FAB
2DRUA:104-180CRYSTAL STRUCTURE AND BINDING PROPERTIES OF THE CD2 AND CD244 (2B4) BINDING PROTEIN, CD48
3FRUB:1-99; D:1-99; F:1-99; A:178-269; C:178-269; E:178-269NEONATAL FC RECEPTOR, PH 6.5
3NCMA:1-92NEURAL CELL ADHESION MOLECULE, MODULE 2, NMR, 20 STRUCTURES
(-)
Paracoccus denitrificans. Organism_taxid: 266. (3)
1AR1D:1-108; C:1-118STRUCTURE AT 2.7 ANGSTROM RESOLUTION OF THE PARACOCCUS DENITRIFICANS TWO-SUBUNIT CYTOCHROME C OXIDASE COMPLEXED WITH AN ANTIBODY FV FRAGMENT
1QLEL:1-108; H:1-119CRYO-STRUCTURE OF THE PARACOCCUS DENITRIFICANS FOUR-SUBUNIT CYTOCHROME C OXIDASE IN THE COMPLETELY OXIDIZED STATE COMPLEXED WITH AN ANTIBODY FV FRAGMENT
3HB3C:1-118HIGH RESOLUTION CRYSTAL STRUCTURE OF PARACOCCUS DENITRIFICANS CYTOCHROME C OXIDASE
(-)
Paracoccus denitrificans. Organism_taxid: 266. (2)
1PBYA:351-481; A:275-350STRUCTURE OF THE PHENYLHYDRAZINE ADDUCT OF THE QUINOHEMOPROTEIN AMINE DEHYDROGENASE FROM PARACOCCUS DENITRIFICANS AT 1.7 A RESOLUTION
3EHBD:1-109; C:1-119A D-PATHWAY MUTATION DECOUPLES THE PARACOCCUS DENITRIFICANS CYTOCHROME C OXIDASE BY ALTERING THE SIDE CHAIN ORIENTATION OF A DISTANT, CONSERVED GLUTAMATE
(-)
Paracoccus denitrificans. Organism_taxid: 266. Strain: ifo12442. Paracoccus denitrificans. Organism_taxid: 266. Strain: ifo12442. (1)
1JJUA:351-481; A:275-350STRUCTURE OF A QUINOHEMOPROTEIN AMINE DEHYDROGENASE WITH A UNIQUE REDOX COFACTOR AND HIGHLY UNUSUAL CROSSLINKING
(-)
Pig (Sus scrofa) (3)
1KXQE:1-120; F:1-120; G:1-120; H:1-120CAMELID VHH DOMAIN IN COMPLEX WITH PORCINE PANCREATIC ALPHA-AMYLASE
1KXTB:1-111; D:1-111; F:1-111CAMELID VHH DOMAINS IN COMPLEX WITH PORCINE PANCREATIC ALPHA-AMYLASE
1KXVC:2-120; D:1-121CAMELID VHH DOMAINS IN COMPLEX WITH PORCINE PANCREATIC ALPHA-AMYLASE
(-)
Plasmodium falciparum 3d7. Organism_taxid: 36329. Strain: 3d7. (2)
2Q8AL:109-211; H:113-208; L:1-108; H:1-112STRUCTURE OF THE MALARIA ANTIGEN AMA1 IN COMPLEX WITH A GROWTH-INHIBITORY ANTIBODY
2Q8BL:109-211; H:113-208; L:1-108; H:1-112STRUCTURE OF THE MALARIA ANTIGEN AMA1 IN COMPLEX WITH A GROWTH-INHIBITORY ANTIBODY
(-)
Plasmodium falciparum. Organism_taxid: 5833. Strain: fvo. (1)
2J5LB:109-214; B:2-108; C:114-227; C:1-113STRUCTURE OF A PLASMODIUM FALCIPARUM APICAL MEMBRANE ANTIGEN 1-FAB F8.12.19 COMPLEX
(-)
Plasmodium vivax. Organism_taxid: 5855. Strain: sal i. (1)
2J4WL:109-214; L:2-108; H:114-227; H:1-113STRUCTURE OF A PLASMODIUM VIVAX APICAL MEMBRANE ANTIGEN 1-FAB F8.12.19 COMPLEX
(-)
Porphyromonas gingivalis. Organism_taxid: 837. (1)
1CVRA:350-432CRYSTAL STRUCTURE OF THE ARG SPECIFIC CYSTEINE PROTEINASE GINGIPAIN R (RGPB)
(-)
Pseudomonas amyloderamosa. Organism_taxid: 32043 (1)
1BF2A:1-162STRUCTURE OF PSEUDOMONAS ISOAMYLASE
(-)
Pseudomonas putida. Organism_taxid: 303. Pseudomonas putida. Organism_taxid: 303. (2)
1JMXA:363-486; A:284-362CRYSTAL STRUCTURE OF A QUINOHEMOPROTEIN AMINE DEHYDROGENASE FROM PSEUDOMONAS PUTIDA
1JMZA:364-486; A:284-363CRYSTAL STRUCTURE OF A QUINOHEMOPROTEIN AMINE DEHYDROGENASE FROM PSEUDOMONAS PUTIDA WITH INHIBITOR
(-)
Rabbit (Oryctolagus cuniculus) (5)
1A21A:4-103; B:4-103; B:104-206; A:104-205TISSUE FACTOR (TF) FROM RABBIT
2RIKA:-2-93; A:94-188; A:189-280I-BAND FRAGMENT I67-I69 FROM TITIN
2RJMA:-2-93; A:94-188; A:189-2803IG STRUCTURE OF TITIN DOMAINS I67-I69 E-TO-A MUTATED VARIANT
2VUOA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE RABBIT IGG FC FRAGMENT
3B43A:189-282; A:-2-91; A:283-380; A:472-566; A:381-471; A:92-188I-BAND FRAGMENT I65-I70 FROM TITIN
(-)
Rat (Rattus norvegicus) (1)
3CSPA:1-121CRYSTAL STRUCTURE OF THE DM2 MUTANT OF MYELIN OLIGODENDROCYTE GLYCOPROTEIN
(-)
Rat (Rattus rattus) (1)
3B9KC:109-211; L:109-211; C:1-108; L:1-108; D:114-230; H:114-230; D:1-113; H:1-113; A:4-121; E:4-121CRYSTAL STRUCTURE OF CD8ALPHA-BETA IN COMPLEX WITH YTS 156.7 FAB
(-)
Rattus rattus. Organism_taxid: 10117. (1)
2BJMH:1-120; L:1-110SPE7:ANTHRONE COMPLEX
(-)
Red seabream (Pagrus major) (1)
1G0DA:473-585; A:586-682; A:6-142CRYSTAL STRUCTURE OF RED SEA BREAM TRANSGLUTAMINASE
(-)
Reovirus sp.. Organism_taxid: 10891. Strain: reassortant f18. Reovirussp.. Organism_taxid: 10891. Strain: reassortant f18. (1)
1EJ6A:1027-1121REOVIRUS CORE
(-)
Rhesus monkey (Macaca mulatta) (2)
1ZVSB:1-99; E:1-99; A:182-272; D:182-272CRYSTAL STRUCTURE OF THE FIRST CLASS MHC MAMU AND TAT-TL8 COMPLEX
2Q3AB:1-114; A:1-117CRYSTAL STRUCTURE OF RHESUS MACAQUE CD8 ALPHA-ALPHA HOMODIMER
(-)
Sars coronavirus. Organism_taxid: 227859. (1)
2GHWB:132-232; D:1-117; B:1-119CRYSTAL STRUCTURE OF SARS SPIKE PROTEIN RECEPTOR BINDING DOMAIN IN COMPLEX WITH A NEUTRALIZING ANTIBODY, 80R
(-)
Sars-cov (Sars coronavirus) (1)
3BGFL:109-212; C:109-211; C:1-108; L:1-108; B:114-213; H:114-213; B:1-113; H:1-113X-RAY CRYSTAL STRUCTURE OF THE SARS CORONAVIRUS SPIKE RECEPTOR BINDING DOMAIN IN COMPLEX WITH F26G19 FAB
(-)
Serratia marcescens. (1)
1K9TA:24-130CHITINASE A COMPLEXED WITH TETRA-N-ACETYLCHITOTRIOSE
(-)
Serratia marcescens. Organism_taxid: 615. (6)
1RD6A:24-130CRYSTAL STRUCTURE OF S. MARCESCENS CHITINASE A MUTANT W167A
1X6LA:24-130CRYSTAL STRUCTURE OF S. MARCESCENS CHITINASE A MUTANT W167A
1X6NA:24-130CRYSTAL STRUCTURE OF S. MARCESCENS CHITINASE A MUTANT W167A IN COMPLEX WITH ALLOSAMIDIN
2WK2A:24-130CHITINASE A FROM SERRATIA MARCESCENS ATCC990 IN COMPLEX WITH CHITOTRIO-THIAZOLINE DITHIOAMIDE.
2WLZA:24-130CHITINASE A FROM SERRATIA MARCESCENS ATCC990 IN COMPLEX WITH CHITOBIO-THIAZOLINE.
2WM0A:24-130CHITINASE A FROM SERRATIA MARCESCENS ATCC990 IN COMPLEX WITH CHITOBIO-THIAZOLINE THIOAMIDE.
(-)
Serratia marcescens. Organism_taxid: 615. (4)
1EDQA:24-130CRYSTAL STRUCTURE OF CHITINASE A FROM S. MARCESCENS AT 1.55 ANGSTROMS
1EHNA:24-130CRYSTAL STRUCTURE OF CHITINASE A MUTANT E315Q COMPLEXED WITH OCTA-N-ACETYLCHITOOCTAOSE (NAG)8.
1EIBA:24-130CRYSTAL STRUCTURE OF CHITINASE A MUTANT D313A COMPLEXED WITH OCTA-N-ACETYLCHITOOCTAOSE (NAG)8.
1NH6A:24-130STRUCTURE OF S. MARCESCENS CHITINASE A, E315L, COMPLEX WITH HEXASACCHARIDE
(-)
Serratia marcescens. Organism_taxid: 615. Expression_system_vector_type: bacterial. (1)
1CTNA:24-130CRYSTAL STRUCTURE OF A BACTERIAL CHITINASE AT 2.3 ANGSTROMS RESOLUTION
(-)
Serratia marcescens. Organism_taxid: 615. Strain: 2170. (2)
1FFQA:24-130CRYSTAL STRUCTURE OF CHITINASE A COMPLEXED WITH ALLOSAMIDIN
1FFRA:24-130CRYSTAL STRUCTURE OF CHITINASE A MUTANT Y390F COMPLEXED WITH HEXA-N-ACETYLCHITOHEXAOSE (NAG)6
(-)
Sheep (Ovis aries) (4)
1F6FB:5-101; C:6-101; B:102-202; C:102-199CRYSTAL STRUCTURE OF THE TERNARY COMPLEX BETWEEN OVINE PLACENTAL LACTOGEN AND THE EXTRACELLULAR DOMAIN OF THE RAT PROLACTIN RECEPTOR
1TPXC:109-214; B:1-113; C:1-108; B:114-223OVINE RECOMBINANT PRP(114-234), ARQ VARIANT IN COMPLEX WITH THE FAB OF THE VRQ14 ANTIBODY
1TQBC:109-214; C:1-108; B:114-223; B:1-113OVINE RECOMBINANT PRP(114-234), VRQ VARIANT IN COMPLEX WITH THE FAB OF THE VRQ14 ANTIBODY
1TQCC:109-214; B:1-113; C:1-108; B:114-223OVINE RECOMBINANT PRP(114-234), ARR VARIANT IN COMPLEX WITH THE VRQ14 FAB FRAGMENT (IGG2A)
(-)
Staphylococcus aureus. Organism_taxid: 1280. (1)
2IJ0C:1-117; E:1-117STRUCTURAL BASIS OF T CELL SPECIFICITY AND ACTIVATION BY THE BACTERIAL SUPERANTIGEN TOXIC SHOCK SYNDROME TOXIN-1
(-)
Streptococcus pyogenes. Organism_taxid: 1314. (1)
1KTKE:119-246; F:4-116; E:3-118; F:124-240COMPLEX OF STREPTOCOCCAL PYROGENIC ENTEROTOXIN C (SPEC) WITH A HUMAN T CELL RECEPTOR BETA CHAIN (VBETA2.1)
(-)
Sulfolobus solfataricus. Organism_taxid: 2287. (2)
1EH9A:1-87CRYSTAL STRUCTURE OF SULFOLOBUS SOLFATARICUS GLYCOSYLTREHALOSE TREHALOHYDROLASE
1EHAA:1-87CRYSTAL STRUCTURE OF GLYCOSYLTREHALOSE TREHALOHYDROLASE FROM SULFOLOBUS SOLFATARICUS
(-)
Synthetic construct. Organism_taxid: 32630 (1)
1IVLA:1-107; B:1-107THE DE NOVO DESIGN OF AN ANTIBODY COMBINING SITE: CRYSTALLOGRAPHIC ANALYSIS OF THE VL DOMAIN CONFIRMS THE STRUCTURAL MODEL
(-)
Synthetic construct. Organism_taxid: 32630. (1)
1PG7L:109-211; M:109-211; X:1-113; Z:1-113; W:109-206; Y:109-206; H:1-113; I:1-113; L:1-108; M:1-108; X:114-212; Z:114-212; H:114-212; I:114-212; W:1-108; Y:1-108MURINE 6A6 FAB IN COMPLEX WITH HUMANIZED ANTI-TISSUE FACTOR D3H44 FAB
(-)
Thermoactinomyces vulgaris. Organism_taxid: 2026. (2)
1BVZA:1-121; B:1-121ALPHA-AMYLASE II (TVAII) FROM THERMOACTINOMYCES VULGARIS R-47
1JIBA:1-121; B:1-121COMPLEX OF ALPHA-AMYLASE II (TVA II) FROM THERMOACTINOMYCES VULGARIS R-47 WITH MALTOTETRAOSE BASED ON A CRYSTAL SOAKED WITH MALTOHEXAOSE.
(-)
Thermoactinomyces vulgaris. Organism_taxid: 2026. Strain: r-47. (23)
1G1YA:1-121; B:1-121CRYSTAL STRUCTURE OF ALPHA-AMYLASE II (TVAII) FROM THERMOACTINOMYCES VULGARIS R-47 AND BETA-CYCLODEXTRIN COMPLEX
1IZJA:1-124THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 1 MUTANT ENZYME F313A
1IZKA:1-124THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 1 MUTANT ENZYME W398V
1JF5A:1-121; B:1-121CRYSTAL STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 2 MUTANT F286A
1JF6A:1-121; B:1-121CRYSTAL STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE MUTANT F286Y
1JI1A:1-124; B:1-124CRYSTAL STRUCTURE ANALYSIS OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 1
1JI2A:1-121; B:1-121IMPROVED X-RAY STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 2
1JL8A:1-121; B:1-121COMPLEX OF ALPHA-AMYLASE II (TVA II) FROM THERMOACTINOMYCES VULGARIS R-47 WITH BETA-CYCLODEXTRIN BASED ON A CO-CRYSTALLIZATION WITH METHYL BETA-CYCLODEXTRIN
1UH2A:1-124THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE/MALTO-HEXAOSE COMPLEX
1UH3A:1-124THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE/ACARBOSE COMPLEX
1UH4A:1-124THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 1/MALTO-TRIDECAOSE COMPLEX
1VB9A:1-121; B:1-121CRYSTAL STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE II (TVA II) COMPLEXED WITH TRANSGLYCOSYLATED PRODUCT
1VFK  [entry was replaced by entry 3A6O without any CATH domain information]
1VFMA:1-121; B:1-121CRYSTAL STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 2/ALPHA-CYCLODEXTRIN COMPLEX
1VFOA:1-121; B:1-121CRYSTAL STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 2/BETA-CYCLODEXTRIN COMPLEX
1VFUA:1-121; B:1-121CRYSTAL STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 AMYLASE 2/GAMMA-CYCLODEXTRIN COMPLEX
1WZKA:1-121; B:1-121THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE II (TVA II) MUTATNT D465N
1WZLA:1-121; B:1-121THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE II (TVA II) MUTATNT R469L
1WZMA:1-121; B:1-121THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE II (TVA II) MUTATNT R469K
2D0FA:1-124CRYSTAL STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 1 (TVAI) MUTANT D356N COMPLEXED WITH P2, A PULLULAN MODEL OLIGOSACCHARIDE
2D0GA:1-124CRYSTAL STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 1 (TVAI) MUTANT D356N/E396Q COMPLEXED WITH P5, A PULLULAN MODEL OLIGOSACCHARIDE
2D0HA:1-124CRYSTAL STRUCTURE OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 1 (TVAI) MUTANT D356N/E396Q COMPLEXED WITH P2, A PULLULAN MODEL OLIGOSACCHARIDE
2D2OA:1-121; B:1-121STRUCTURE OF A COMPLEX OF THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE 2 WITH MALTOHEXAOSE DEMONSTRATES THE IMPORTANT ROLE OF AROMATIC RESIDUES AT THE REDUCING END OF THE SUBSTRATE BINDING CLEFT
(-)
Thermoanaerobacterium thermosulfurigenes. Organism_taxid: 33950 (1)
1CIUA:580-682; A:496-579THERMOSTABLE CGTASE FROM THERMOANAEROBACTERIUM THERMOSULFURIGENES EM1 AT PH 8.0.
(-)
Thermoanaerobacterium thermosulfurigenes. Organism_taxid: 33950. Strain: em1. (3)
1A47A:580-682; A:496-579CGTASE FROM THERMOANAEROBACTERIUM THERMOSULFURIGENES EM1 IN COMPLEX WITH A MALTOHEXAOSE INHIBITOR
3BMVA:580-682; A:496-579CYCLODEXTRIN GLYCOSYL TRANSFERASE FROM THERMOANEROBACTERIUM THERMOSULFURIGENES EM1 MUTANT S77P
3BMWA:580-682; A:496-579CYCLODEXTRIN GLYCOSYL TRANSFERASE FROM THERMOANEROBACTERIUM THERMOSULFURIGENES EM1 MUTANT S77P COMPLEXED WITH A MALTOHEPTAOSE INHIBITOR
(-)
Thermus aquaticus. Organism_taxid: 271. (1)
1BGXL:109-211; L:1-108; H:116-208; H:5-115TAQ POLYMERASE IN COMPLEX WITH TP7, AN INHIBITORY FAB
(-)
Thermus sp.. Organism_taxid: 275. (1)
1GVIA:1-125; B:1-125THERMUS MALTOGENIC AMYLASE IN COMPLEX WITH BETA-CD
(-)
Thermus thermophilus. Organism_taxid: 274. (1)
2ZJSL:108-211; H:1-119; L:1-107; H:120-218CRYSTAL STRUCTURE OF SECYE TRANSLOCON FROM THERMUS THERMOPHILUS WITH A FAB FRAGMENT
(-)
Turkey (Meleagris gallopavo) (2)
1FHGA:34-135HIGH RESOLUTION REFINEMENT OF TELOKIN
1TLKA:33-135X-RAY STRUCTURE DETERMINATION OF TELOKIN, THE C-TERMINAL DOMAIN OF MYOSIN LIGHT CHAIN KINASE, AT 2.8 ANGSTROMS RESOLUTION
(-)
Unclassified. Organism_taxid: 32644. (1)
2X7LB:112-214; D:112-214; H:118-221; J:118-221; A:1-117; C:1-117; E:1-117; G:1-117; H:1-117; J:1-117; F:112-214; I:112-214; K:112-214; L:112-214; A:118-221; C:118-221; E:118-221; G:118-221IMPLICATIONS OF THE HIV-1 REV DIMER STRUCTURE AT 3.2A RESOLUTION FOR MULTIMERIC BINDING TO THE REV RESPONSE ELEMENT
(-)
Vibrio harveyi. Organism_taxid: 669. Strain: lmg7890. (4)
3B8SA:22-132; B:22-132CRYSTAL STRUCTURE OF WILD-TYPE CHITINASE A FROM VIBRIO HARVEYI
3B9AA:22-132CRYSTAL STRUCTURE OF VIBRIO HARVEYI CHITINASE A COMPLEXED WITH HEXASACCHARIDE
3B9DA:22-132CRYSTAL STRUCTURE OF VIBRIO HARVEYI CHITINASE A COMPLEXED WITH PENTASACCHARIDE
3B9EA:22-131CRYSTAL STRUCTURE OF INACTIVE MUTANT E315M CHITINASE A FROM VIBRIO HARVEYI
(-)
Vibrio parahaemolyticus rimd 2210633. Organism_taxid: 223926. Strain:rimd 2210633. (1)
2R39A:377-487CRYSTAL STRUCTURE OF FIXG-RELATED PROTEIN FROM VIBRIO PARAHAEMOLYTICUS
(-)
Vibrio vulnificus. Organism_taxid: 672. (1)
3CFIL:3-113; F:2-115; C:2-116; I:1-116NANOBODY-AIDED STRUCTURE DETERMINATION OF THE EPSI:EPSJ PSEUDOPILIN HETERDIMER FROM VIBRIO VULNIFICUS
(-)
West nile virus. Organism_taxid: 11082. (1)
1ZTXL:109-211; L:1-108; H:1-113; H:114-228WEST NILE VIRUS ENVELOPE PROTEIN DIII IN COMPLEX WITH NEUTRALIZING E16 ANTIBODY FAB
(-)
West nile virus. Organism_taxid: 11082. Strain: ny 1999. (1)
3I50H:114-211; H:1-113CRYSTAL STRUCTURE OF THE WEST NILE VIRUS ENVELOPE GLYCOPROTEIN IN COMPLEX WITH THE E53 ANTIBODY FAB
(-)
Yeast (Saccharomyces cerevisiae) (2)
3CX5K:1-107; V:1-107; J:1-127; U:1-127STRUCTURE OF COMPLEX III WITH BOUND CYTOCHROME C IN REDUCED STATE AND DEFINITION OF A MINIMAL CORE INTERFACE FOR ELECTRON TRANSFER.
3CXHK:1-107; V:1-107; J:1-127; U:1-127STRUCTURE OF YEAST COMPLEX III WITH ISOFORM-2 CYTOCHROME C BOUND AND DEFINITION OF A MINIMAL CORE INTERFACE FOR ELECTRON TRANSFER.